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1. PREAMBLE
It is important that the medical profession play a significant
role in critically evaluating the use of diagnostic procedures
and therapies in the detection, management, or prevention of
disease states. Rigorous and expert analysis of the available
data documenting relative benefits and risks of those proce-
dures and therapies can produce helpful guidelines that
improve the effectiveness of care, optimize patient outcomes,
and generally have a favorable impact on the overall cost of
care by focusing resources on the most effective strategies. 
The American College of Cardiology (ACC) and the
American Heart Association (AHA) have jointly engaged in
the production of such guidelines in the area of cardiovascu-
lar disease since 1980. This effort is directed by the
ACC/AHA Task Force on Practice Guidelines, whose charge
is to develop and revise practice guidelines for important car-
diovascular diseases and procedures. Experts in the subject
under consideration are selected from both organizations to
examine subject-specific data and write guidelines. The
process includes additional representatives from other med-
ical practitioner and specialty groups where appropriate.
Writing groups are specifically charged to perform a formal
literature review, weigh the strength of evidence for or
against a particular treatment or procedure, and include esti-
mates of expected health outcomes where data exist. Patient-
specific modifiers, comorbidities and issues of patient pref-
erence that might influence the choice of particular tests or
therapies are considered as well as frequency of follow-up.
When available, information from studies on cost will be
considered, however review of data on efficacy and clinical
outcomes will be the primary basis for preparing recommen-
dations in these guidelines.
The ACC/AHA Task Force on Practice Guidelines makes
every effort to avoid any actual or potential conflicts of inter-
est that might arise as a result of an outside relationship or
personal interest of a member of the writing panel.
Specifically, all members of the writing panel are asked to
provide disclosure statements of all such relationships that
might be perceived as real or potential conflicts of interest.
These statements are reviewed by the parent task force,
reported orally to all members of the writing panel at the first
meeting, and updated and reviewed by the writing committee
as changes occur. 
These practice guidelines are intended to assist healthcare
providers in clinical decision making by describing a range
of generally acceptable approaches for the diagnosis, man-
agement, and prevention of specific diseases or conditions.
These guidelines attempt to define practices that meet the
needs of most patients in most circumstances. These guide-
line recommendations reflect a consensus of expert opinion
after a thorough review of the available, current scientific
evidence and are intended to improve patient care. If these
guidelines are used as the basis for regulatory/payer deci-
sions, the ultimate goal is quality of care and serving the
patient’s best interests. The ultimate judgment regarding care
of a particular patient must be made by the healthcare
provider and patient in light of all of the circumstances pre-
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Figure 1. Evolution of ACC/AHA guidelines for management of patients with acute MI. The first guideline published by the ACC/AHA
described the management of patients with acute myocardial infarction (AMI). The subsequent three documents were the Agency for
Healthcare and Quality/National Heart, Lung and Blood Institute sponsored guideline on management of unstable angina (UA), the
revised/updated ACC/AHA guideline on AMI, and the revised/updated ACC/AHA guideline on unstable angina/non–ST-segment
myocardial infarction (UA/NSTEMI). The present guideline is a revision and deals strictly with the management of patients present-
ing with ST-elevation myocardial infarction (STEMI). The names of the chairs of the writing committees for each of the guidelines are
shown at the bottom of each box.
sented by that patient. There are circumstances where devia-
tions from these guidelines are appropriate.
The executive summary and recommendations are pub-
lished in the August 4, 2004, issue of the Journal of the
American College of Cardiology and August 3, 2004, issue
of Circulation. The full text is published on the ACC and
AHA World Wide Web sites. Copies of the full text and the
executive summary are available from both organizations. 
Elliott M. Antman, MD, FACC, FAHA
Chair, ACC/AHA Task Force on Practice Guidelines
1.1. Introduction
The process of guideline development for management of
patients with acute myocardial infarction (AMI) has under-
gone substantial evolution since the inaugural publication
entitled “Guidelines for the Early Management of Patients
with Acute Myocardial Infarction” in 1990 under the aus-
pices of the ACC/AHA Task Force on Assessment of
Diagnostic and Therapeutic Cardiovascular Procedures
(Chairman, Dr. Rolf Gunnar; Figure 1) (1). Subsequently, the
ACC/AHA Task Force on Practice Guidelines convened a
committee (Chairman, Dr. Thomas J. Ryan) in 1994 to revise
the 1990 guidelines. In the 1996 guideline publication,
“ACC/AHA Guidelines for the Management of Patients with
Acute Myocardial Infarction,” the term acute coronary syn-
drome was used, reflecting the emerging overarching con-
cept that disruption of a vulnerable or high-risk plaque caus-
es an episode of ischemic discomfort (2). Emphasis was
placed on the 12-lead electrocardiogram (ECG) that was
used to categorize patients into 2 broad cohorts: those pre-
senting with ST elevation and those presenting without ST
elevation (ultimately diagnosed as unstable angina or non–Q-
wave myocardial infarction (MI) depending on whether a
biomarker of necrosis was detected in the patient’s blood).
The 1996 guidelines discussed the management of both the
ST-elevation and non–ST-elevation presentations of the acute
coronary syndromes. The same approach was taken in the
1999 update of the guideline (also chaired by Dr. Ryan) that
was posted as an electronic update on the ACC and AHA
World Wide Web sites (3). 
In parallel to the above efforts, in 1994, the Agency for
Health Care Policy and Research and the National Heart,
Lung, and Blood Institute jointly published guidelines for the
diagnosis and management of patients with unstable angina
(Chairman, Dr. Eugene Braunwald). In recognition of rapid
advances in the understanding and management of patients
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• Level of Evidence B: Data derived from a single random-
ized trial, or nonrandomized studies.
• Level of Evidence C: Only consensus opinion of experts,
case studies, or standard-of-care.
The schema for classification of recommendations and
level of evidence is summarized in Table 1, which also illus-
trates how the grading system provides an estimate of the
size of the treatment effect and an estimate of the certainty of
the treatment effect. 
The committee recognizes the importance of timely reper-
fusion for patients with STEMI and spent considerable effort
reviewing the literature published since 1999 when formulat-
ing recommendations. Along with reperfusion by pharmaco-
logical and catheter-based means, the committee emphasized
the use of established therapies such as aspirin, beta-adreno-
ceptor–blocking agents, vasodilator therapy, angiotensin
converting enzyme (ACE) inhibitors, and cholesterol-lower-
ing therapy. To provide clinicians with a set of recommenda-
tions that can easily be translated into the practice of caring
for patients with STEMI, this guideline is organized around
the chronology of the interface between the patient and the
clinician (Figure 2) (8-10). Thus, readers will find material
on prevention of STEMI, patient education, prehospital
issues, initial recognition and management in the emergency
department (ED), hospital management, and long-term man-
agement after treatment for the index STEMI event. The
reorganization of the material in this guideline along the
timeline noted above necessitated considerable modification
of the sequence of text presented in the 1996 and 1999 guide-
lines on AMI. Whenever possible, the writing committee
used the term STEMI rather than AMI. Given the reorgani-
zation of the guideline along the chronology of clinical care
of patients with STEMI and the anticipated desire of readers
to search the guideline for specific advice on management of
patients with STEMI at different phases of their illness, in a
few selected instances, recommendations and, to a lesser
extent, some portions of the text are repeated.
Although these guidelines on STEMI have been shaped
largely within the context of evidence-based medical prac-
tice, the committee clearly understands that variations in
inclusion and exclusion criteria from one randomized trial to
another impose some limitation on the generalizability of
their findings. Likewise, in its efforts to reconcile conflicting
data, the committee emphasized the importance of properly
characterizing the population under study. 
Writing committee members were selected with attention
to cardiovascular subspecialties, broad geographical repre-
sentation, and involvement in academic medicine and pri-
mary practice, including neurology, emergency medicine,
and nursing. The Writing Committee on the Management of
Patients with ST-Elevation Myocardial Infarction also
included members of the ACCF Board of Governors, the
American Academy of Family Physicians (AAFP), and the
Canadian Cardiovascular Society (CCS).
with acute coronary syndromes, the ACC/AHA Task Force
on Practice Guidelines convened a committee (also chaired
by Dr. Braunwald) to revise the 1994 unstable angina guide-
line. That committee focused on patients presenting without
ST elevation and introduced the nomenclature of unstable
angina/non–ST-elevation MI (UA/NSTEMI). The “ACC/
AHA Guidelines for the Management of Patients with
UA/NSTEMI” were published in 2000 and were updated in
electronic form in 2002 (4).
Although considerable improvement has occurred in the
process of care for patients with ST-elevation MI (STEMI),
room for improvement exists (5-7). The purpose of the pres-
ent guideline is to focus on the numerous advances in the
diagnosis and management of patients with STEMI since
1999. This is reflected in the changed name of the guideline:
“ACC/AHA Guidelines for the Management of Patients With
ST-Elevation Myocardial Infarction” (Figure 1). It is recog-
nized that there are areas of overlap among this guideline on
patients with STEMI, the guideline on patients with
UA/NSTEMI, and other guidelines. The committee has han-
dled this overlap by reiterating important concepts and rec-
ommendations in this guideline and by providing cross-ref-
erences to other guidelines.
The final recommendations for indications for a diagnostic
procedure, a particular therapy, or an intervention in patients
with STEMI summarize both clinical evidence and expert
opinion. Once recommendations were written, a Classi-
fication of Recommendation and Level of Evidence grade
was assigned to each recommendation. Classification of
Recommendations and Level of Evidence are expressed in
the ACC/AHA format as follows:
Classification of Recommendations
Class I: Conditions for which there is evidence and/or
general agreement that a given procedure or 
treatment is beneficial, useful, and effective.
Class II: Conditions for which there is conflicting evi-
dence and/or a divergence of opinion about
the usefulness/efficacy of a procedure or treat-
ment.
Class IIa: Weight of evidence/opinion is in
favor of usefulness/efficacy.
Class IIb: Usefulness/efficacy is less well
established by evidence/opinion.
Class III: Conditions for which there is evidence and/or
general agreement that a procedure/treat-
ment is not useful/effective and in some cases
may be harmful.
Level of Evidence
• Level of Evidence A: Data derived from multiple random-
ized clinical trials or meta-analyses.
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Figure 2. Acute coronary syndromes. The top half of the figure illustrates the chronology of the interface between the patient and the clinician through the pro-
gression of plaque formation, onset and complications of STEMI along with relevant management considerations at each stage. The longitudinal section of an
artery depicts the "timeline" of atherogenesis from a normal artery (1) to (2) lesion initiation and accumulation of extracellular lipid in the intima, to (3) the evolu-
tion to the fibrofatty stage, to (4) lesion progression with procoagulant expression and weakening of the fibrous cap. An acute coronary syndrome develops when
the vulnerable or high risk plaque undergoes disruption of the fibrous cap (5); disruption of the plaque is the stimulus for thrombogenesis. Thrombus resorption
may be followed by collagen accumulation and smooth muscle cell growth (6). Following disruption of a vulnerable or high-risk plaque, patients experience
ischemic discomfort resulting from a reduction of flow through the affected epicardial coronary artery. The flow reduction may be caused by a completely occlu-
sive thrombus (bottom half, right side) or subtotally occlusive thrombus (bottom half, left side). Patients with ischemic discomfort may present with or without ST-
segment elevation on the ECG. Of patients with ST-segment elevation, most (large red arrow in bottom panel) ultimately develop a Q-wave MI (QwMI), while a
few (small red arrow) develop a non–Q-wave MI (NQMI). Patients who present without ST-segment elevation are suffering from either unstable angina or a non–ST-
segment elevation MI (NSTEMI) (large open arrows), a distinction that is ultimately made on the presence or absence of a serum cardiac marker such as CK-MB
or a cardiac troponin detected in the blood. Most patients presenting with NSTEMI ultimately develop a NQMI on the ECG; a few may develop a QwMI. The spec-
trum of clinical presentations ranging from unstable angina through NSTEMI and STEMI are referred to as the acute coronary syndromes. This STEMI guideline
is arranged along the chronologic interface of the clinician with the patient, as diagrammed in the upper panel, and includes sections on management prior to
STEMI, at the onset of STEMI, and during the hospital phase. Secondary prevention and plans for long-term management begin early during the hospital phase
of treatment. Dx = diagnosis; NQMI, non–Q-wave myocardial infarction; QwMI = Q-wave myocardial infarction; CK-MB = MB isoenzyme of creatine kinase. Modified
with permission from Libby. Circulation 2001;104:365-72 (8), Hamm, Bertrand, Braunwald. The Lancet 2001;358:1533-8 (9), and Davies. Heart 2000;83:361-6
(10) with permission from the BMJ Publishing Group.
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The committee conducted comprehensive searching of the
scientific and medical literature on AMI, with special empha-
sis on STEMI. Literature searching was limited to publica-
tions on humans and in English from 1990 to 2004. In addi-
tion to broad-based searching on MI, specific targeted
searches were performed on MI and the following subtopics:
9-1-1, patient delays, emergency medical services (EMS),
prehospital fibrinolysis, prehospital ECG, ED, supplemental
oxygen, nitroglycerin, ASA, clopidogrel, arrhythmia, reper-
fusion, fibrinolysis/fibrinolytic therapy, angioplasty, stent,
coronary artery bypass graft surgery (CABG), glycoprotein
(GP) IIb/IIIa, pericarditis, beta-blockers, ischemia, intra-
arterial pressure monitoring, ACE inhibitors, amiodarone,
procainamide, lidocaine, electrical cardioversion, atropine,
temporary pacing, transvenous pacing, permanent pacing,
cardiac repair, heparin, low-molecular-weight heparin
(LMWH), unfractionated heparin (UFH), ramipril, calcium
channel blockers, verapamil, nifedipine, magnesium, stress
ECG, invasive strategy, secondary prevention, statins, and
cholesterol. The complete list of keywords is beyond the
scope of this section. The committee reviewed all compiled
reports from computerized searches and conducted addition-
al searching by hand. Literature citations were generally
restricted to published manuscripts appearing in journals list-
ed in Index Medicus. Because of the scope and importance of
certain ongoing clinical trials and other emerging informa-
tion, published abstracts were cited when they were the only
published information available.
This document was reviewed by 3 outside reviewers nomi-
nated by the ACC and 3 outside reviewers nominated by the
AHA, as well as 1 reviewer each from the AAFP and the
CCS, and 58 individual content reviewers. (See Appendix 2
for details.)
This document was approved for publication by the gov-
erning bodies of the American College of Cardiology
Foundation and the American Heart Association and
endorsed by the Canadian Cardiovascular Society. These
guidelines will be reviewed annually by the ACC/AHA Task
Force on Practice Guidelines and will be considered current
unless they are revised or withdrawn from distribution.
2. PATHOLOGY
2.1. Role of Acute Plaque Change
Slowly accruing high-grade stenoses of epicardial coronary
arteries may progress to complete occlusion but do not usu-
ally precipitate STEMI, probably because of the develop-
ment over time of a rich collateral network. However, during
the natural evolution of atherosclerotic plaques, especially
those that are lipid laden, an abrupt and catastrophic transi-
tion may occur, characterized by plaque disruption by rup-
ture of the fibrous cap or erosion of the surface of the fibrous
cap (Figure 2) (8-10). Plaques that are prone to disruption are
usually nonobstructive, are characterized by abundant
macrophages and other inflammatory cells, and are often
located at branch points or bends in the arterial tree (11-15).
They are referred to as vulnerable or high-risk plaques. After
plaque disruption, there is exposure of substances that pro-
mote platelet activation, adhesion, and aggregation, thrombin
generation, and ultimately thrombus formation (16,17). The
resultant thrombus can completely occlude the epicardial
infarct artery. If there is an insufficient collateral supply, a
wave front of myocardial necrosis begins within 15 minutes
and spreads from the endocardium toward the epicardium
(18). This may be modulated by the extent of collateral flow
and determinants of myocardial oxygen consumption,
affording opportunity for significant myocardial salvage
(19). Of note, intravascular ultrasound studies suggest that in
addition to the disruptured plaque, several other vulnerable
or high-risk plaques may coexist throughout the coronary
vasculature.
2.2. Acute Coronary Syndromes
Disruption of vulnerable or high-risk plaques is the common
pathophysiological substrate of the acute coronary syn-
dromes that comprise a spectrum of myocardial ischemia.
Patients with an acute coronary syndrome include those
whose clinical presentations cover the following range of
diagnoses: unstable angina, MI without ST elevation (NSTE-
MI), and MI with ST elevation (STEMI) (Figure 2) (8-10).
Patients with STEMI have a high likelihood of a coronary
thrombus occluding the infarct artery (20,21). Angiographic
evidence of coronary thrombus formation may be seen in
more than 90% of patients with STEMI but in only 1% of
patients with stable angina and about 35% to 75% of patients
with unstable angina or NSTEMI (20-24). However, not
every STEMI evolves into a Q-wave MI; likewise, a patient
with NSTEMI may develop Q waves. The acute coronary
syndrome spectrum concept is a useful framework for devel-
oping therapeutic strategies. Antithrombin therapy and
antiplatelet therapy should be administered to all patients
with an acute coronary syndrome regardless of the presence
or absence of ST-segment elevation. Patients presenting with
persistent ST-segment elevation are candidates for reperfu-
sion therapy (either pharmacological or catheter-based) to
restore flow promptly in the occluded epicardial infarct-relat-
ed artery and are the subject of this guideline (Figure 3) (24-
40). Patients presenting without ST-segment elevation are not
candidates for immediate pharmacological reperfusion but
should receive anti-ischemic therapy and catheter-based ther-
apy where applicable as discussed in the ACC/AHA
Guidelines for Management of Patients with UA/NSTEMI
(4).
2.3. Pathophysiology
A key concept in the pathophysiology of STEMI is ventricu-
lar remodeling, a term that refers to changes in size, shape,
and thickness of the left ventricle involving both the infarct-
ed and noninfarcted segments of the ventricle (41,42). Acute
dilatation and thinning of the area of infarction that is not due
to additional myocardial necrosis is referred to as infarct
expansion (43). An extra load is placed on the residual func-
tioning myocardium, which results in compensatory hyper-
trophy. Inhibition of the renin-angiotensin-aldosterone sys-
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exact incidence is difficult to ascertain, using first-listed and
secondary hospital discharge data, there were 1 680 000
unique discharges for ACS in 2001 (46). Applying the con-
servative estimate of 30% of the ACS patients who have
STEMI from the National Registry of Myocardial Infarction
[NRMI-4] (46a), we estimate 500000 STEMI events per year
in the U.S. However, there has been a steady decline in the
mortality rate from STEMI over the last several decades.
This appears to be due to a combination of a fall in the inci-
dence of MI (replaced in part by an increase in the incidence
of unstable angina) and a reduction in the case fatality rate
once an MI has occurred (47-49). There has been a progres-
sive increase in the proportion of patients who present with
NSTEMI compared with STEMI. 
The committee strongly endorses several public health
campaigns that are likely to contribute to a reduction in the
incidence of and fatality from STEMI in the future. These
tem is a key therapeutic maneuver in patients with STEMI
(44). Additional important pathophysiological concepts in
patients with STEMI that form the basis for recommenda-
tions in this guideline include cardiac arrhythmias such as
those that result from electrical instability, pump
failure/excessive sympathetic stimulation, and conduction
disturbances. Mechanical problems that result from dysfunc-
tion or disruption of critical myocardial structures (e.g.,
mitral regurgitation [MR], rupture of the interventricular sep-
tum, ventricular aneurysm formation, and free wall rupture)
may require a combination of pharmacological, catheter-
based, and surgical treatments.
2.4. Epidemiology
STEMI continues to be a significant public health problem in
industrialized countries and is becoming an increasingly sig-
nificant problem in developing countries (45). Although the
Figure 3. Relative treatment effect associated with several acute reperfusion modalities in patients presenting with STEMI. Data are
odds ratios and 95% confidence intervals. UFH = unfractionated heparin; PCI = percutaneous coronary intervention; Exp = experi-
mental group; Ctrl = control group. *Data for myocardial reinfarction as a single end point were not available for meta-3; in this case
the figure presents odds ratios for the composite of death or myocardial reinfarction. †Intracranial hemorrhage was not reported in
meta-1-data were derived from the HERO-1, HIT-4, TIMI9b, and GUSTO2b trials that were included in this meta-analysis. Modified with
permission from Elsevier (Boersma et al. The Lancet 2003;361:847-58) (24).
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Major risk factors for developing CHD (i.e., smoking, fam-
ily history, adverse lipid profiles, and elevated blood pres-
sure) have been established from large long-term epidemio-
logical studies (59,60). These risk factors are predictive for
most populations in the United States. Primary prevention
interventions aimed at these risk factors are effective when
used properly. They can also be costly in terms of primary
care physician time, diversion of attention from other com-
peting and important healthcare needs, and expense, and they
may not be effective unless targeted at higher-risk patients
(61). It is therefore important for primary care providers to
make identifying patients at risk, who are most likely to ben-
efit from primary prevention, a routine part of everyone’s
health care. The Third Report of the NCEP provides guid-
ance on identifying such patients (59). 
Patients with 2 or more risk factors who are at increased
10-year risk will have the greatest benefit from primary pre-
vention, but any individual with a single elevated risk factor
is a candidate for primary prevention. Waiting until the
patient develops multiple risk factors and increased 10-year
risk contributes to the high prevalence of CHD in the United
States (59,62). Such patients should have their risk specifi-
cally calculated, by any of the several available valid prog-
nostic tools available in print (59,63), on the internet (64), or
for use on a personal computer or PDA (Personal Digital
Assistant) (59). Patients’ specific risk levels determine the
absolute risk reductions they can obtain from preventive
interventions and guide selection and prioritization of those
interventions. For example, target levels for lipid lowering
and for antihypertensive therapy vary by patients’ baseline
risk. A specific risk number can also serve as a powerful edu-
cational intervention to motivate lifestyle changes (65).
3.2. Interventions to Reduce Risk of STEMI
The benefits of prevention of STEMI in patients with CHD
are well documented and of large magnitude (62,66-68).
Patients with established CHD should be identified for sec-
ondary prevention, and patients with a CHD risk equivalent
(e.g., diabetes mellitus, chronic kidney disease, or 10-year
risk greater than 20% as calculated by Framingham equa-
tions) should receive equally intensive risk factor interven-
tion for high-risk primary prevention regardless of sex (69).
Patients with diabetes and peripheral vascular disease have
baseline risks of STEMI similar to patients with known
CHD, as do patients with multiple risk factors predicting cal-
culated risk of greater than 20% over 10 years as estimated
by the Framingham equations (59). Such patients should be
considered to have the risk equivalents of CHD, and they can
be expected to have an absolute benefit similar to those with
established CHD.
All patients who smoke should be encouraged to quit and
should be provided with help in quitting at every opportuni-
ty. Even a single recommendation by a clinician to quit
smoking can have a meaningful impact on the rate of cessa-
tion of smoking. The most effective strategies for encourag-
ing quitting are those that identify patients’ level or stage of
readiness and provide information, support, and, if necessary,
include the following: 1) recognition of diabetes mellitus and
chronic kidney disease as “risk equivalents” to coronary
heart disease (CHD) and therefore recommendation for more
aggressive attempts at control of other risk factors (50,51); 
2) recognition of the importance of dyslipidemia as a major
risk factor for CHD and recommendation for aggressive
attempts at cholesterol reduction and treatment of the meta-
bolic syndrome (50); 3) aggressive primary prevention
efforts at smoking cessation as emphasized by the World
Health Organization; 4) patient education campaigns regard-
ing the signs and symptoms of MI and the appropriate cours-
es of action to be taken (52,53); and 5) implementation at a
professional level of quality assurance projects such as the
ACC’s “Guidelines Applied in Practice” (54) and the AHA’s
“Get with the Guidelines” (55) to improve compliance with
established treatment strategies when caring for patients with
MI. A proposal that holds great promise for reducing the
morbidity and mortality associated with STEMI is the
regionalization of care for patients with acute coronary syn-
dromes using centers of excellence (56-58).
3. MANAGEMENT BEFORE STEMI
One third of patients who experience STEMI will die within
24 hours of the onset of ischemia, and many of the survivors
will suffer significant morbidity (24). For many patients, the
first manifestation of CHD will be sudden death. The major
risk factors for development of CHD and STEMI are well
established. Clinical trials have demonstrated that modifica-
tion of those risk factors can prevent the development of
CHD (primary prevention) or reduce the risk of experiencing
STEMI in patients who have CHD (secondary prevention).
All practitioners should emphasize prevention and refer
patients to primary care providers for appropriate long-term
preventive care. In addition to internists and family physi-
cians, cardiologists have an important leadership role in pri-
mary (and secondary) prevention efforts.
3.1. Identification of Patients at Risk of STEMI
Class I
1. Primary care providers should evaluate the presence
and status of control of major risk factors for CHD for
all patients at regular intervals (approximately every
3 to 5 years). (Level of Evidence: C)
2. Ten-year risk (National Cholesterol Education
Program [NCEP] global risk) of developing sympto-
matic CHD should be calculated for all patients who
have 2 or more major risk factors to assess the need
for primary prevention strategies (59). (Level of
Evidence: B)
3. Patients with established CHD should be identified for
secondary prevention, and patients with a CHD risk
equivalent (e.g., diabetes mellitus, chronic kidney dis-
ease, or 10-year risk greater than 20% as calculated
by Framingham equations) should receive equally
intensive risk factor intervention as those with clini-
cally apparent CHD. (Level of Evidence: A)
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pharmacotherapy targeted at the individual’s readiness and
specific needs (66,70). Pharmacotherapy may include nico-
tine replacement or withdrawal-relieving medication such as
bupropion. Most patients require several attempts before
succeeding in quitting permanently. Additional discussion in
this area can be found in the ACC/AHA 2002 Guideline
Update for the Management of Patients With Chronic Stable
Angina (71).
All patients should be instructed in and encouraged to
maintain appropriate low-saturated-fat and low-cholesterol
diets high in soluble (viscous) fiber and rich in vegetables,
fruits, and whole grains. The statin drugs have the best out-
come evidence supporting their use and should be the main-
stay of pharmacological intervention (62). The appropriate
levels for lipid management are dependent on baseline risk;
the reader is referred to the NCEP report for details (59). 
Primary prevention patients with high blood pressure
should be treated according to the recommendations of the
Seventh Joint National Committee on High Blood Pressure
(JNC-7) (72,73). Specific treatment recommendations are
based on the level of hypertension and the patient’s other risk
factors. A diet low in salt and rich in vegetables, fruits, and
low-fat dairy products should be encouraged for all hyper-
tensive patients, as should a regular aerobic exercise pro-
gram. Most patients will require more than 1 medication to
achieve blood pressure control, and pharmacotherapy should
begin with known outcome-improving medications (primari-
ly thiazide diuretics as first choice, with the addition of beta-
blockers, ACE inhibitors, angiotensin receptor blockers, and
long-acting calcium channel blockers) (72,74). Systolic
hypertension is a powerful predictor of adverse outcome,
particularly among the elderly, and should be treated even if
diastolic pressures are normal (75).
Aspirin prophylaxis can uncommonly result in hemorrhag-
ic complications and should only be used in primary preven-
tion when the level of risk justifies it. Patients whose 10-year
risk of CHD is 6% or more are most likely to benefit, and
aspirin 75 to 162 mg/d as primary prophylaxis should be dis-
cussed with such patients (76-79).
3.3. Patient Education for Early Recognition and
Response to STEMI
Class I
1. Patients with symptoms of STEMI (chest discomfort
with or without radiation to the arms[s], back, neck,
jaw, or epigastrium; shortness of breath; weakness;
diaphoresis; nausea; lightheadedness) should be
transported to the hospital by ambulance rather than
by friends or relatives. (Level of Evidence: B)
2. Healthcare providers should actively address the fol-
lowing issues regarding STEMI with patients and
their families:
a. The patient’s heart attack risk (Level of Evidence: C)
b. How to recognize symptoms of STEMI (Level of
Evidence: C)
c. The advisability of calling 9-1-1 if symptoms are
unimproved or worsening after 5 minutes, despite
feelings of uncertainty about the symptoms and
fear of potential embarrassment (Level of
Evidence: C)
d. A plan for appropriate recognition and response to
a potential acute cardiac event, including the phone
number to access EMS, generally 9-1-1 (80) (Level
of Evidence: C)
3. Healthcare providers should instruct patients for
whom nitroglycerin has been prescribed previously to
take ONE nitroglycerin dose sublingually in response
to chest discomfort/pain. If chest discomfort/pain is
unimproved or worsening 5 minutes after 1 nitroglyc-
erin dose has been taken, it is recommended that the
patient or family member/friend call 9-1-1 immedi-
ately to access EMS. (Level of Evidence: C)
Morbidity and mortality from STEMI can be reduced sig-
nificantly if patients and bystanders recognize symptoms
early, activate the EMS system, and thereby shorten the time
to definitive treatment. Patients with possible symptoms of
STEMI should be transported to the hospital by ambulance
rather than by friends or relatives, because there is a signifi-
cant association between arrival at the ED by ambulance and
early reperfusion therapy (81-84). In addition, emergency
medical technicians (EMTs) and paramedics can provide
life-saving interventions (e.g., early cardiopulmonary resus-
citation [CPR] and defibrillation) if the patient develops car-
diac arrest. Approximately 1 in every 300 patients with chest
pain transported to the ED by private vehicle goes into car-
diac arrest en route (85). 
Several studies have confirmed that patients with STEMI
usually do not call 9-1-1 and are not transported to the hos-
pital by ambulance. A follow-up survey of chest pain patients
presenting to participating EDs in 20 US communities who
were either released or admitted to the hospital with a con-
firmed coronary event revealed that the average proportion of
patients who used EMS was 23%, with significant geograph-
ic difference (range 10% to 48%). Most patients were driven
by someone else (60%) or drove themselves to the hospital
(16%) (86). In the National Registry of Myocardial
Infarction 2, just over half (53%) of patients with STEMI
were transported to the hospital by ambulance (82). 
Even in areas of the country that have undertaken substan-
tial public education on warning signs of STEMI and the
need to activate the EMS system rapidly, either there were no
increases in EMS use (87-91) or EMS use increased (as a
secondary outcome measure) but was still suboptimal, with a
20% increase from a baseline of 33% in all 20 communities
in the Rapid Early Action for Coronary Treatment (REACT)
study (92) and an increase from 27% to 41% in southern
Minnesota after a community campaign (93). Given the
importance of patients using EMS for possible acute cardiac
symptoms, communities, including medical providers, EMS
systems, healthcare insurers, hospitals, and policy makers at
the state and local level, need to have agreed-upon emer-
gency protocols to ensure patients with possible heart attack
symptoms will be able to access 9-1-1 without barriers, to
secure their timely evaluation and treatment (94).
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In September 2001, the NHAAP and the AHA launched a
campaign urging patients and providers to “Act in Time to
Heart Attack Signs” (101). The campaign urges both men
and women who feel heart attack symptoms or observe the
signs in others to wait no more than a few minutes, 5 minutes
at most, before calling 9-1-1 (101,102). Campaign materials
point out that patients can increase their chance of surviving
a STEMI by learning the symptoms and filling out a survival
plan. They also are advised to talk with their doctor about
heart attack and how to reduce their risk of having one. The
patient materials include a free brochure about symptoms
and recommended actions for survival, in English (103) and
Spanish (104), as well as a free wallet card that can be filled
in with emergency medical information (105). Materials
geared directly to providers include a Patient Action Plan
Tablet (106), which contains the heart attack warning symp-
toms and steps for developing a survival plan individualized
with the patient’s name; a quick reference card for address-
ing common patient questions about seeking early treatment
to survive a heart attack (107), including a palm pilot version
(108); and a warning signs wall chart (109). These materials
and others are available on the “Act in Time” Web page
(www.nhlbi.nih.gov/actintime) (51,101) (Figure 5).
4. ONSET OF STEMI
4.1. Recognition of Symptoms by Patient
Early recognition of symptoms of STEMI by the patient or
someone with the patient is the first step that must occur
before evaluation and life-saving treatment can be obtained.
Although many lay persons are generally aware that chest
pain is a presenting symptom of STEMI, they are unaware of
the common associated symptoms, such as arm pain, lower
jaw pain, shortness of breath, and diaphoresis (111) or angi-
nal equivalents. The average patient with STEMI does not
seek medical care for approximately 2 hours after symptom
onset, and this pattern appears unchanged over the last
decade (45,87,112). Average and median delays for patients
with STEMI were 4.7 and 2.3 hours, respectively, from the
14-country Global Registry of Acute Coronary Events
(GRACE) project. Approximately 41% of patients with
STEMI presented to the 94 study hospitals within 2 hours of
acute cardiac ischemia symptom onset (113).
A baseline analysis from the REACT research program
demonstrated longer delay times among non-Hispanic
blacks, older patients, and Medicaid-only recipients and
shorter delay times among Medicare recipients (compared
with privately insured patients) and among patients who
came to the hospital by ambulance (87). In the majority of
studies examined to date, women in both univariate and mul-
tivariate adjusted analyses (in which age and other potential-
ly confounding variables have been controlled) exhibit more
prolonged delay patterns than men (113). 
A number of studies have provided insight into why
patients delay in seeking early care for heart symptoms
(Table 2) (114). Focus groups conducted for the REACT
research program (92,115) revealed that patients commonly
As part of making a plan with the patient for timely recog-
nition and response to an acute event, providers should
review instructions for taking nitroglycerin in response to
chest discomfort/pain. If a patient has previously been pre-
scribed nitroglycerin, it is recommended that the patient be
advised to take ONE nitroglycerin dose sublingually prompt-
ly for chest discomfort/pain. If symptoms are unimproved or
worsening 5 minutes after ONE nitroglycerin dose has been
taken, it is also recommended that the patient be instructed to
call 9-1-1 immediately to access EMS. Although the tradi-
tional recommendation is for patients to take 1 nitroglycerin
dose sublingually, 5 minutes apart, for up to 3 doses before
calling for emergency evaluation, this recommendation has
been modified by the writing committee to encourage earlier
contacting of EMS by patients with symptoms suggestive of
STEMI. Self-treatment with prescription medication, includ-
ing nitrates, and with nonprescription medication (e.g.,
antacids) has been documented as a frequent cause of delay
among patients with STEMI, including those with a history
of MI or angina (95,96). Both the rate of use of these med-
ications and the number of doses taken were positively cor-
related with delay time to hospital arrival (95). 
Family members, close friends, or advocates should be
included in these discussions and enlisted as reinforcement
for rapid action when the patient experiences symptoms of a
possible STEMI (3,80,97) (Figure 4). For patients known to
their providers to have frequent angina, physicians may con-
sider a selected, more tailored message that takes into
account the frequency and character of the patient’s angina
and their typical time course of response to nitroglycerin.
Avoidance of patient delay associated with self-medication
and prolonged re-evaluation of symptoms is paramount.
Taking an aspirin in response to acute symptoms by
patients has been reported to be associated with a delay in
calling EMS (86). Patients should focus on calling 9-1-1,
which activates the EMS system, where they may receive
instructions from emergency medical dispatchers to chew
aspirin (162 to 325 mg) while emergency personnel are en
route, or emergency personnel can give an aspirin while
transporting the patient to the hospital (98). Alternatively,
patients may receive an aspirin as part of their early treat-
ment once they arrive at the hospital if it has not been given
in the prehospital setting (3).
Providers should target those patients at increased risk for
STEMI, focusing on patients with known CHD, peripheral
vascular disease, or cerebral vascular disease, those with dia-
betes, and patients with 10-year Framingham risk of CHD of
greater than 20% (99). They should stress that the chest dis-
comfort will usually not be dramatic, such as is commonly
misrepresented on television or in the movies as a
“Hollywood heart attack.” Providers should also describe
anginal equivalents and the commonly associated symptoms
of STEMI (e.g., shortness of breath, a cold sweat, nausea, or
lightheadedness) in both men and women (83), as well as the
increased frequency of atypical symptoms in elderly patients
(100). 
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hold a pre-existing expectation that a heart attack would
present dramatically with severe, crushing chest pain, such
that there would be no doubt that one was occurring. This
was in contrast to their actual reported symptom experience
of a gradual onset of discomfort involving midsternal chest
pressure or tightness, with other associated symptoms often
increasing in intensity. The ambiguity of these symptoms,
due to this disconnect between prior expectations and actual
experience, resulted in uncertainty about the origin of symp-
toms and thus a “wait-and-see” posture by patients and those
around them (114). Other reported reasons for delay were
that patients thought the symptoms were self-limited and
would go away or were not serious (95,116,117); that they
attributed symptoms to other pre-existing chronic conditions,
especially among the elderly with multiple chronic condi-
tions (e.g., arthritis), or sometimes to a common illness such
as influenza; that they were afraid of being embarrassed if
symptoms turned out to be a “false alarm”; that they were
reluctant to trouble others (e.g., providers, EMS) unless they
were “really sick” (95,116,117); that they held stereotypes of
who is at risk for a heart attack; and that they lacked aware-
ness of the importance of rapid action, knowledge of reper-
fusion treatment, or knowledge of the benefits of calling
EMS/9-1-1 to ensure earlier treatment (Table 2) (Figure 5)
(51,114) . Notably, women did not perceive themselves to be
at risk (53). 
4.1.1. Silent and Unrecognized Events
Patients experiencing STEMI do not always present with
chest discomfort (118). The Framingham Study was the first
to show that as many as half of all MIs may be clinically
silent and unrecognized by the patient (119). Canto et al.
(100) found that one third of the 434 877 patients with con-
firmed MI in the National Registry of Myocardial Infarction
(NRMI) (100) presented to the hospital with symptoms other
than chest discomfort. Compared with MI patients with chest
discomfort, MI patients without chest discomfort were more
likely to be older (74.2 versus 66.9 years), women (49.0%
versus 38.0%), diabetic (32.6% versus 25.4%), and/or have
prior heart failure (26.4% versus 12.3%). MI patients without
chest discomfort delayed longer before they went to the hos-
pital (mean 7.9 versus 5.3 hours) and were less likely to be
diagnosed as having an MI when admitted (22.2% versus
50.3%). They also were less likely to receive fibrinolysis or
primary percutaneous coronary intervention (PCI) (25.3%
versus 74.0%), aspirin (60.4% versus 84.5%), beta-blockers
(28.0% versus 48.0%), or heparin (53.4% versus 83.2%).
Silent MI patients were 2.2 times (95% confidence interval
[CI] 2.17 to 2.26) more likely to die during the hospitaliza-
tion (in-hospital mortality rate 23.3% versus 9.3%).
Healthcare providers should maintain a high index of suspi-
cion for MI when evaluating women, diabetics, older
patients, and those with a history of heart failure, as well as
those patients complaining of chest discomfort but who have
a permanent pacemaker that may confound recognition of
STEMI on their 12-lead ECG (120).
4.2. Out-of-Hospital Cardiac Arrest
Class I
1. All communities should create and maintain a strong
“Chain of Survival” for out-of-hospital cardiac arrest
that includes early access (recognition of the problem
and activation of the EMS system by a bystander),
early CPR, early defibrillation for patients who need
it, and early advanced cardiac life support (ACLS).
(Level of Evidence: C)
2. Family members of patients experiencing STEMI
should be advised to take CPR training and familiar-
ize themselves with the use of an automated external
defibrillator (AED). In addition, they should be
referred to a CPR training program that has a social
support component for family members of post-
STEMI patients. (Level of Evidence: B)
The majority of deaths from STEMI occur within the first
1 to 2 hours after symptom onset, usually from ventricular
fibrillation (VF). Survival from VF is inversely related to the
time interval between its onset and termination. For each
minute that a patient remains in VF, the odds of survival
decrease by 7% to 10% (121). Survival is optimal when both
CPR and ACLS, including defibrillation and drug therapy,
are provided early. 
The AHA has introduced the “chain of survival” concept to
represent a sequence of events that ideally should occur to
maximize the odds of successful resuscitation from cardiac
arrest (121). The links in the chain include early access
(recognition of the problem and activation of the EMS sys-
Table 2. Reasons Patients Delay Seeking Medical Attention for
Symptoms of ST-Elevation Myocardial Infarction
Expected a dramatic presentation
Thought symptoms were not serious/would go away
Took a “wait and see” approach to the initial symptoms that included
self-evaluation, self-treatment, and reassessment until “certain”
Tended to attribute symptoms to other chronic conditions (e.g.,
arthritis, muscle strain) or common illnesses (e.g., influenza)
Lacked awareness of the benefits of rapid action, reperfusion treat-
ment, or of the importance of calling EMS/9-1-1 for acute MI 
symptoms
Expressed fear of embarrassment if symptoms turned out to be a 
false alarm; reluctant to “bother” physicians or EMS unless “really
sick”; need “permission” from others such as healthcare providers,
spouses, family to take rapid action
Few ever discussed symptoms, responses, or actions for a heart 
attack in advance with family or providers
Stereotypes of who is at risk for a heart attack
Not perceived at risk if:
Young and healthy (especially men)
A woman
Under a doctor’s care or making lifestyle changes (especially 
men with risk factors)
Based on findings from Finnegan et al. Preventive Medicine 2000;31:205-13 (114).
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5. PREHOSPITAL ISSUES
5.1. Emergency Medical Services Systems
Class I
1. All EMS first responders who respond to patients with
chest pain and/or suspected cardiac arrest should be
trained and equipped to provide early defibrillation.
(Level of Evidence: A)
2. All public safety first responders who respond to
patients with chest pain and/or suspected cardiac
arrest should be trained and equipped to provide
early defibrillation with AEDs. (Provision of early
defibrillation with AEDs by non–public safety first
responders is a promising new strategy, but further
study is needed to determine its safety and efficacy.)
(Level of Evidence: B)
3. Dispatchers staffing 9-1-1 center emergency medical
calls should have medical training, should use nation-
ally developed and maintained protocols, and should
have a quality-improvement system in place to ensure
compliance with protocols. (Level of Evidence: C)
EMS systems vary considerably among communities in
their ability to evaluate and treat suspected patients with
STEMI, with some providing little beyond first aid and early
defibrillation, whereas others have highly trained paramedics
with sophisticated technology and advanced protocols. 
EMS systems have 3 traditional components: emergency
medical dispatch, first response, and EMS ambulance
response. 
Emergency Medical Dispatch. Early access to EMS is pro-
moted by a 9-1-1 system currently available to more than
90% of the United States population. Enhanced 9-1-1 sys-
tems provide the caller’s location to the dispatcher, which
permits rapid dispatch of prehospital personnel to locations
even if the caller is not capable of verbalizing or the dis-
patcher cannot understand the location of the emergency. A
major challenge is the widespread proliferation and use of
cell phones. Current cell phone technology does not provide
the location of the caller to an enhanced 9-1-1 center.
Instead, such calls are usually answered by the state police,
who then attempt to determine the location of the emergency
and forward the call to the appropriate 9-1-1 center. Such
additional steps often result in substantial delays in the dis-
patch of emergency units to the scene. Several technological
solutions to this problem exist but have not yet been imple-
mented by the cell phone industry. EMS healthcare workers
should encourage enhanced cell phone technology to identi-
fy caller location on 9-1-1 systems. 
In most communities, law enforcement or public safety
officials are responsible for operating 9-1-1 centers, because
in most locations, 85% of calls are for police assistance, 10%
are for EMS, and 5% are for fire-related emergencies.
Dispatchers who staff 9-1-1 centers typically have only min-
imal medical background and training and usually operate by
following written cards and protocols that in many cases are
tem by a bystander), early CPR, early defibrillation for
patients who need it, and early ACLS. 
Although estimates of overall survival from out-of-hospital
cardiac arrest in the United States are as low as 5%, survival
in patients who are in VF initially can be much higher. The
percentage of patients who are found in VF and the likeli-
hood of survival are higher if the patient’s collapse is wit-
nessed, bystander CPR is performed, and a monitor/defibril-
lator can be applied quickly. For example, 27% of patients
with witnessed out-of-hospital cardiac arrest in Seattle, WA,
survived to leave the hospital when bystanders performed
CPR (122). Only 13% survived without bystander CPR.
Emerging data suggest that treatment of VF with immediate
defibrillation, irrespective of “down time,” may not be opti-
mal for all patients and that as the duration of cardiac arrest
increases, different interventions may take priority over
defibrillation, such as a period of chest compressions (with
associated tissue oxygen delivery) after 3 minutes of VF
before defibrillation (123).
There is often a long delay from the recognition of cardiac
arrest to defibrillation in rural areas where travel time is long
and in densely populated urban areas. Survival rates are often
extremely low in such settings (124-126). In Seattle, WA, the
majority of out-of-hospital cardiac arrest victims receive
defibrillation within 5 to 7 minutes after the recognition of
out-of-hospital cardiac arrest. In Rochester, MN, the addition
of a police defibrillation program to conventional EMS serv-
ices resulted in a median time to first shock of 5.9 minutes
for patients in VF and a 49% rate of survival to discharge
(127). Total cumulative survival experience at 7 years in this
community was 40% (128). Outcomes data on all Rochester,
MN, patients who had an out-of-hospital cardiac arrest with
VF from 1990 to 2000 who received defibrillation from
emergency personnel showed that 72% survived to hospital
admission and 40% were neurologically intact at discharge,
with a mean follow-up of 4.8 years (129).
The key to improved survival appears to be the availability
of early defibrillation. In the Ontario Pre-hospital Advanced
Life Support (OPALS) study, which involved 19 suburban
and urban communities, improving the proportion of out-of-
hospital cardiac arrest patients who were reached by a defib-
rillation-equipped ambulance within 8 minutes from 77% to
93% increased survival to hospital discharge from 3.9% to
5.2% (130). A 2-year prospective study at 3 Chicago, IL, air-
ports of readily accessible AEDs in well-marked areas of the
airport reported successful resuscitation in 11 of 18 patients
with VF. Ten of the 18 were alive and neurologically intact at
1 year of follow-up (131).
Family members of patients with STEMI should be
referred to a CPR program that combines CPR training with
social support (132,133) (see Section 7.12.1). One study of
the impact of in-home defibrillators on post-MI patients and
their significant others reported that AEDs were valued by
the participants and increased their perception of control over
their heart disease, notably for those who believed their risk
of cardiac arrest to be high (134). Research is under way to
test the safety and effectiveness of home use of AEDs by
family members of patients after MI (135).
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designed and updated locally. High-performance centers
employ EMTs and/or paramedics who are specially trained
and certified as emergency medical dispatchers. They, too,
operate under written protocols, but such protocols are usu-
ally developed and upgraded at the national level. Such cen-
ters typically have intense quality-assurance programs to
ensure that emergency medical dispatchers follow protocols
and procedures correctly and consistently. This is particular-
ly true for the prearrival instructions that are given to cardiac
arrest bystanders to instruct them on how to perform CPR
while awaiting arrival of emergency personnel (phone CPR)
(136). Efforts to shorten the time for contact of the STEMI
patient with the medical system are likely to require expan-
sion of the number of trained emergency response personnel
and consideration of streamlining methods for distinguishing
emergency calls for medical assistance from other emergen-
cies using separate phone numbers, as is the practice cur-
rently in some European countries.
First Response. To minimize time to treatment, particularly
for cardiopulmonary arrest, many communities allow volun-
teer and/or paid firefighters and other first-aid providers to
function as first responders, providing CPR and, increasing-
ly, early defibrillation using AEDs until EMTs and para-
medics arrive. AEDs have been shown to be safe and effec-
tive when used by trained first responders with a duty to act
(137-139). Systems that incorporate AEDs to shorten
response times are highly desirable. Ideally, there should be
a sufficient number of trained personnel so that a trained first
responder can be at the victim’s side within 5 minutes of the
call. 
Another popular community approach to increase the num-
ber of out-of-hospital VF patients who receive early defibril-
lation is public access defibrillation (PAD), so named
because the intent is to have laypersons perform early defib-
rillation. Experience thus far has been favorable in terms of
efficacy and safety when trained public safety laypersons
(e.g., flight attendants or security officers) have been allowed
to use AEDs to treat cardiac arrest victims (131,140,141).
Provision of early defibrillation with AEDs by non–public
safety first responders is a promising new strategy to prevent
sudden cardiac death after the onset of STEMI, but further
study is needed to determine its safety and efficacy (142-147)
(Ornato JP; oral presentation, American Heart Association
2003 Annual Scientific Sessions, November 2003, Orlando,
FL). 
EMS Ambulance Response. Most cities and larger suburban
areas provide EMS ambulance services with providers from
the fire department, a private ambulance company, and/or
volunteers. The most common pattern is a tiered system in
which some of the ambulances are staffed and equipped at
the basic EMT level (which includes first aid and early defib-
rillation with AEDs) and other units (either transporting or
nontransporting) are staffed by paramedics or other interme-
diate-level EMTs (who can, in addition to basic care, start
intravenous [IV] drips, intubate, and administer medica-
tions). In some systems, the advanced providers can also per-
form 12-lead ECGs, provide external pacing for sympto-
matic bradycardia, and utilize other techniques. Some high-
performance EMS systems have only advanced life sup-
port–staffed ambulances (all-ALS systems). Advantages of
such systems are that they provide a uniform standard of care
and, surprisingly, can actually lower cost by eliminating the
need to dispatch 2 units in response to calls in which it is not
clear to dispatchers initially that the patient needs advanced
life support (149). The potential disadvantage of such mod-
els is that they typically have a relatively large number of
paramedics, each of whom gets to perform their advanced
skills less frequently than the smaller number of paramedics
typically found in tiered systems (150).
Rural areas typically provide primarily basic life support
ambulance services, usually by volunteers supplemented by
a relatively small number of ALS units. In some cases, ALS
is provided by paramedics or helicopter personnel who
respond to the scene in addition to the basic life support
ambulance.
5.2. Prehospital Chest Pain Evaluation 
and Treatment
Class I
Prehospital EMS providers should administer 162 to
325 mg of aspirin (chewed) to chest pain patients sus-
pected of having STEMI unless contraindicated or
already taken by the patient. Although some trials have
used enteric-coated aspirin for initial dosing, more
rapid buccal absorption occurs with non–enteric-
coated formulations. (Level of Evidence: C)
Class IIa 
1. It is reasonable for all 9-1-1 dispatchers to advise
patients without a history of aspirin allergy who have
symptoms of STEMI to chew aspirin (162 to 325 mg)
while awaiting arrival of prehospital EMS providers.
Although some trials have used enteric-coated aspirin
for initial dosing, more rapid buccal absorption
occurs with non–enteric-coated formulations. (Level
of Evidence: C)
2. It is reasonable that all ACLS providers perform and
evaluate 12-lead ECGs routinely on chest pain
patients suspected of STEMI. (Level of Evidence: B)
3. If the ECG shows evidence of STEMI, it is reasonable
that prehospital ACLS providers review a reperfusion
“checklist” and relay the ECG and checklist findings
to a predetermined medical control facility and/or
receiving hospital. (Level of Evidence: C)
Because the potential benefits of early aspirin use are great
and the risks and costs are low, it is reasonable for physicians
to encourage the prehospital administration of aspirin via
EMS personnel (i.e., EMS dispatchers and providers) to
patients with symptoms suggestive of STEMI unless its use
is contraindicated (151). The AHA chest pain algorithm can
be adapted for use by prehospital emergency personnel. This
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The selection of reperfusion strategy is discussed in
Section 6.3.1.6.2 and involves assessment of the time from
onset of symptoms, risk of STEMI, risk of bleeding, and the
time required for transport to a skilled PCI lab. This section
discusses issues related to prehospital fibrinolysis, which
may bear on the timing and selection of reperfusion therapy.
Randomized controlled trials of fibrinolytic therapy have
demonstrated the benefit of initiating fibrinolytic therapy as
early as possible after onset of ischemic-type chest discom-
fort (155-157) (Figure 6). It seems reasonable to expect that
if fibrinolytic therapy could be started at the time of prehos-
pital evaluation, a greater number of lives could be saved. In
Assessment of the Safety and Efficacy of a New
Thrombolytic Regimen (ASSENT)-3, 53% of patients
received prehospital fibrinolysis within 2 hours after symp-
tom onset (158). The value of reducing delay until treatment
depends not only on the amount of time saved but also on
when it occurs. Available data suggest that time saved with-
in the first 1 to 2 hours has greater biological importance than
time saved during the later stages of STEMI (156,157,159-
164). Several randomized trials of prehospital-initiated fibri-
nolysis have advanced our understanding of the impact of
early treatment (Table 4) (159,165-174). Acquisition of 12-
lead ECGs in the field and use of a reperfusion checklist
(Table 3) lead to more rapid prehospital and hospital care
(159,175). Although none of the individual trials showed a
reduction in mortality with prehospital-initiated fibrinolytic
therapy, a meta-analysis of all available trials (before the
Comparison of Angioplasty and Prehospital Thrombolysis in
Acute Myocardial Infarction trial [CAPTIM], which was
performed after the meta-analysis) (173) demonstrated a
17% relative improvement in outcome associated with pre-
hospital fibrinolytic therapy compared with in-hospital fibri-
nolytic therapy (95% CI 2% to 29%) (171). In the CAPTIM
trial, patients randomized less than 2 hours after symptom
onset had a strong trend toward lower 30-day mortality with
prehospital fibrinolysis than did those randomized to primary
PCI (2.2% versus 5.7%, p equals 0.058) (176). Similarly,
patients in PRimary Angioplasty in patients transferred from
General community hospitals to specialized PTCA Units
with or without Emergency thrombolysis (PRAGUE-2) who
were randomized within 3 hours of symptom onset (n equals
551) had no difference in mortality whether treated by fibri-
nolysis (7.4%) or transferred for PCI (7.3%) (177). Systems
that have extensive experience with prehospital fibrinolysis
with physician attendance in the ambulance and a well-inte-
grated mechanism for obtaining and transmitting a 12-lead
ECG continue to show excellent short- and long-term mor-
tality results with prehospital fibrinolysis. Using data from a
national registry, investigators in France reported 1-year
mortality from STEMI of 6% in patients receiving prehospi-
tal fibrinolysis compared with 11% in patients receiving in-
hospital fibrinolysis or primary PCI; the survival difference
in favor of prehospital fibrinolysis persisted after adjustment
for baseline characteristics (Danchin N; oral presentation,
American Heart Association 2003 Annual Scientific
Sessions, November 2003, Orlando, FL).
protocol recommends empirical treatment of patients with
suspected STEMI with Morphine, Oxygen, Nitroglycerin,
and Aspirin (MONA) (102). Although short-acting nitroglyc-
erin is often administered for temporary symptomatic relief,
it can precipitate hypotension (especially if right ventricular
[RV] infarction is present), and long-term nitrates have not
been shown to decrease mortality in patients with STEMI
(152). To facilitate earlier aspirin administration, it is reason-
able that 9-1-1 dispatchers advise non–aspirin-allergic
patients with symptoms of STEMI to chew 162 to 325 mg of
aspirin while awaiting arrival of prehospital EMS providers.
In the absence of instructions by emergency medical dis-
patchers, prehospital EMS providers (under medical direc-
tion) should administer an aspirin en route to the hospital as
noted above. Although some trials have used enteric-coated
aspirin for initial dosing, more rapid buccal absorption
occurs with non–enteric-coated formulations.
The AHA (102), the 31st Bethesda Conference of the
American College of Cardiology (153), and a technology
review supported by the NHLBI’s NHAAP (154) strongly
encourage the use of 12-lead ECGs by paramedics to evalu-
ate all patients with chest discomfort suspected to be of
ischemic origin in the prehospital setting (Figure 6) (Table 3)
(155). This requires providing training and 12-lead ECG
equipment to all ACLS personnel.
For patients who have ECG evidence of STEMI, it is rea-
sonable that paramedics review a reperfusion checklist and
relay the ECG and checklist findings to a predetermined
medical control facility and/or receiving hospital (Table 3).
The checklist should be designed to determine the presence
or absence of comorbid conditions and underlying conditions
in which fibrinolytic therapy may be hazardous. The check-
list should also facilitate detection of patients with suspected
STEMI who are at especially high risk (see Table 3), includ-
ing those with severe heart failure or cardiogenic shock, for
whom primary PCI is generally the preferred reperfusion
strategy. (See Section 6.3.1.6.4.2.)
Active involvement of local healthcare providers, particu-
larly cardiologists and emergency physicians, is needed to
formulate local EMS protocols for patients with suspected
STEMI, provide training, and secure equipment. In the
future, regional centers of excellence for care of patients with
STEMI may facilitate improvement of EMS protocols (56-
58).
5.3. Prehospital Fibrinolysis
Class IIa
Establishment of a prehospital fibrinolysis protocol is
reasonable in 1) settings in which physicians are pres-
ent in the ambulance or 2) well-organized EMS sys-
tems with full-time paramedics who have 12-lead
ECGs in the field with transmission capability, para-
medic initial and ongoing training in ECG interpreta-
tion and STEMI treatment, on-line medical com-
mand, a medical director with training/experience in
STEMI management, and an ongoing continuous
quality-improvement program. (Level of Evidence: B)
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Figure 6. Options for transportation of patients with STEMI and initial reperfusion treatment. Panel A: Patient transported by EMS after calling 9-1-
1: Reperfusion in patients with STEMI can be accomplished by the pharmacologic (fibrinolysis) or catheter-based (primary PCI) approaches.
Implementation of these strategies varies based on the mode of transportation of the patient and capabilities at the receiving hospital. Transport time
to the hospital is variable from case to case, but the goal is to keep total ischemic time within 120 min. There are 3 possibilities: 1) If EMS has fibri-
nolytic capability and the patient qualifies for therapy, prehospital fibrinolysis should be started within 30 min of EMS arrival on scene; 2) If EMS is not
capable of administering prehospital fibrinolysis and the patient is transported to a non–PCI-capable hospital, the hospital door-needle time should
within 30 minutes for patients in whom fibrinolysis is indicated; 3) If EMS is not capable of administering prehospital fibrinolysis and the patient is trans-
ported to a PCI-capable hospital, the hospital door-to-balloon time should be within 90 min. Interhospital transfer: It is also appropriate to consider
emergency interhospital transfer of the patient to a PCI-capable hospital for mechanical revascularization if: 1) there is a contraindication to fibrinoly-
sis; 2) PCI can be initiated promptly (within 90 minutes after the patient presented to the initial receiving hospital or within 60 minutes compared to
when fibrinolysis with a fibrin-specific agent could be initiated at the initial receiving hospital); 3) fibrinolysis is administered and is unsuccessful (i.e.,
"rescue PCI"). Secondary non-emergency interhospital transfer can be considered for recurrent ischemia. Patient self transport: Patient self-trans-
portation is discouraged. If the patient arrives at a non-PCI capable hospital, the door-to-needle time should within 30 min. If the patient arrives at PCI-
capable hospital, the door-to-balloon time should be within 90 min. The treatment options and time recommended after first hospital arrival are the
same. Panel B: For patients who receive fibrinolysis, noninvasive risk stratification is recommended to identify the need for rescue PCI (failed fibrinol-
ysis) or ischemia driven PCI. See Sections 6.3.1.6.4.5 and 6.3.1.6.7 in the full-text guidelines. Regardless of the initial method of reperfusion treatment,
all patients should receive late hospital care and secondary prevention of STEMI. †The medical system goal is to facilitate rapid recognition and treat-
ment of patients with STEMI such that door-to-needle (or medical contact–to-needle) for initiation of fibrinolytic therapy can be achieved within 30 min-
utes or that door-to-balloon (or medical contact–to-balloon) for PCI can be achieved within 90 minutes. These goals should not be understood as 'ideal'
times, but rather the longest times that should be considered acceptable for a given system. Systems that are able to achieve even more rapid times
for treatment of patients with STEMI should be encouraged. Modified with permission from Armstrong et al. Circulation 2003;107:2533-7 (155).
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The difference between time to fibrinolytic therapy in the
prehospital setting versus the hospital setting can be mini-
mized by improved hospital triage with a decrease in door-
to-needle time to within 30 minutes (179) (Figure 7) (180).
However, only a small percentage (5% to 10%) of patients
with chest pain in the prehospital setting have STEMI and
are eligible for fibrinolytic therapy (159,181,182). Ensuring
proper selection of patients for therapy can be difficult, and
administration of therapy when it is contraindicated has
important medical, legal, and economic implications. For
these reasons, a general national policy of prehospital fibri-
nolytic therapy cannot currently be advocated. Prehospital
fibrinolysis is reasonable in those settings in which physi-
cians are present in the ambulance or prehospital transport
times are more than 60 minutes in high-volume (more than
25 000 runs per year) EMS systems (102).
Other considerations for implementing a prehospital fibri-
nolytic service include the ability to transmit ECGs, para-
medic initial and ongoing training in ECG interpretation and
MI treatment, online medical command, and the presence of
a medical director with training/experience in management
of STEMI and full-time paramedics (183). An example of the
time saved by prehospital fibrinolysis is illustrated in a report
from Scotland. The National Health Service in the United
Kingdom established the standard that patients thought to be
suffering from STEMI should receive fibrinolysis within 60
minutes of calling for medical assistance (http://
www.doh.gov.uk/nsf/coronarych3.htm). Three groups of
patients in Scotland were studied: group 1 consisted of
patients (n equals 107) within an urban area who received
fibrinolytic therapy in the hospital, group 2 consisted of
patients (n equals 43) from rural areas who received fibri-
nolytic therapy in the hospital, and group 3 consisted of
patients (n equals 28) in a rural area who received fibrinolyt-
ic therapy (tenecteplase) in the ambulance by trained para-
medics who were supervised by a medical control officer
(183). Administration of prehospital fibrinolytic therapy
resulted in a median time savings of 73 minutes compared
with patients from rural areas and 28 minutes compared with
patients from urban areas (p less than 0.001). A greater pro-
portion of patients who received prehospital fibrinolytic ther-
Figure 7. Major components of time delay between onset of symptoms from ST-elevation MI and restoration of flow in the infarct
artery. Plotted sequentially from left to right are shown the time for patients to recognize symptoms and seek medical attention,
transportation to the hospital, in-hospital decision-making, and implementation of reperfusion strategy, in time for restoration of flow
once the reperfusion strategy has been initiated. The time to initiate fibrinolytic therapy is the "door-to-needle" (D-N) time; this is
followed by the period of time required for pharmacologic restoration of flow. More time is required to move the patient to the
catheterization laboratory for a percutaneous coronary interventional (PCI) procedure, referred to as the "door-to-balloon" (D-B)
time, but restoration of flow in the epicardial infarct artery occurs promptly after PCI. At the bottom are shown a variety of methods
for speeding the time to reperfusion along with the goals for the time intervals for the various components of the time delay. Cath
= catheterization; PCI = percutaneous coronary intervention; min = minutes; ECG = electrocardiogram; MI = myocardial infarction;
Rx = therapy. *These bar graphs are meant to be semiquantitative and not to scale. Modified with permission from Cannon et al. J
Thromb Thrombol 1994;1:27-34 (180).
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Class IIa
1. It is reasonable that patients with STEMI who have
cardiogenic shock and are 75 years of age or older be
considered for immediate or prompt secondary trans-
fer to facilities capable of cardiac catheterization and
rapid revascularization (PCI or CABG) if it can be
performed within 18 hours of onset of shock. (Level of
Evidence: B)
2. It is reasonable that patients with STEMI who are at
especially high risk of dying, including those with
severe congestive heart failure (CHF), be considered
for immediate or prompt secondary transfer (i.e., pri-
mary-receiving hospital door-to-departure time less
than 30 minutes) to facilities capable of cardiac
catheterization and rapid revascularization (PCI or
CABG). (Level of Evidence: B)
Every community should have a written protocol that
guides EMS system personnel in determining where to take
patients with suspected or confirmed STEMI. Active involve-
ment of local healthcare providers, particularly cardiologists
and emergency physicians, is needed to formulate local EMS
destination protocols for these patients. In general, patients
apy were in compliance with the National Health Service
standard of “call-to-needle” of 60 minutes (Figure 8) (183).
5.4. Prehospital Destination Protocols
Class I
1. Patients with STEMI who have cardiogenic shock and
are less than 75 years of age should be brought imme-
diately or secondarily transferred to facilities capable
of cardiac catheterization and rapid revascularization
(PCI or CABG) if it can be performed within 18 hours
of onset of shock. (Level of Evidence: A)
2. Patients with STEMI who have contraindications to
fibrinolytic therapy should be brought immediately or
secondarily transferred promptly (i.e., primary-
receiving hospital door-to-departure time less than 30
minutes) to facilities capable of cardiac catheteriza-
tion and rapid revascularization (PCI or CABG).
(Level of Evidence: B)
3. Every community should have a written protocol that
guides EMS system personnel in determining where to
take patients with suspected or confirmed STEMI.
(Level of Evidence: C)
Figure 8. Cumulative distribution of call-to-needle time. Group 1 refers to patients from an urban area receiving fibrinolysis in the
hospital. Group 2 are patients from rural areas who received fibrinolysis in the hospital. Group 3 are patients from the study area
who received prehospital fibrinolysis. Modified from Pedley et al. BMJ 2003;327:22-6 (183) with permission from the BMJ Publishing
Group.
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with suspected STEMI should be taken to the nearest appro-
priate hospital. However, patients with STEMI and shock are
an exception to this general rule (Table 3).
Emergency revascularization improves 1-year survival in
patients with STEMI complicated by cardiogenic shock
(184). Subgroup analysis suggested a differential treatment
effect, with the clearest benefit for those under 75 years of
age. Therefore, whenever possible, patients with STEMI less
than 75 years of age with shock should be transferred to
facilities capable of cardiac catheterization and rapid revas-
cularization (PCI or CABG). On the basis of observations in
the SHOCK Trial Registry and other registries, it is reason-
able to extend such considerations of transfer to invasive cen-
ters for elderly patients with shock (see Section 7.6.5).
Patients with STEMI who have contraindications to fibri-
nolytic therapy and an especially high risk of dying, includ-
ing severe CHF or cardiogenic shock, should be brought
immediately or secondarily transferred promptly (i.e., pri-
mary-receiving hospital door-to-departure time less than 30
minutes) to facilities capable of cardiac catheterization and
rapid revascularization (PCI or CABG). Given the impor-
tance of avoiding delays in time to reperfusion (see Section
6.3.1.6.3.1), direct transport to a facility capable of rapid
revascularization is strongly preferred to interhospital trans-
fer. 
6. INITIAL RECOGNITION AND
MANAGEMENT IN THE 
EMERGENCY DEPARTMENT
A variety of treatment options (Figure 3) (24-40) are avail-
able that can reduce mortality and morbidity in patients with
STEMI, but the effectiveness of these therapies diminishes
rapidly within the first several hours after symptoms onset
(162,185). The traditional ED evaluation of patients with
chest pain relies heavily on the patient’s history, physical
examination, and the ECG. This approach not infrequently
fails to identify patients who are actually suffering from
STEMI, which results in an inappropriate discharge home
from the ED (186). Such missed MI patients are at relatively
high risk of death or complications for the next 4 to 6 weeks
after ED discharge (187-192).
In a large study on this subject, Pope et al. (188) found that
889 of 10 689 patients who presented to 10 US hospital EDs
with chest pain or other symptoms that suggested acute car-
diac ischemia had STEMI; 19 patients (2.1%, 95% CI 1.1%
to 3.1%) were discharged from the ED. Patients with STEMI
were more likely not to be hospitalized if they were nonwhite
(odds ratio [OR] for discharge 4.5; 95% CI 1.8 to 11.8) or
had a normal or nondiagnostic ECG (OR 7.7; 95% CI 2.9 to
20.2). The risk-adjusted mortality ratio for MI patients who
were not hospitalized compared with those who were hospi-
talized was 1.9 (95% CI 0.7 to 5.2).
6.1. Optimal Strategies for Emergency
Department Triage
Class I
Hospitals should establish multidisciplinary teams
(including primary care physicians, emergency medi-
cine physicians, cardiologists, nurses, and laboratori-
ans) to develop guideline-based, institution-specific
written protocols for triaging and managing patients
who are seen in the prehospital setting or present to
the ED with symptoms suggestive of STEMI. (Level of
Evidence: B)
The advent of highly effective, time-dependent treatment
for STEMI coupled with the need to reduce healthcare costs
adds further incentive for clinicians to get the right answer
quickly and to reduce unnecessary admissions and length of
hospital stay. Investigators have tried various diagnostic tools
such as clinical decision algorithms, cardiac biomarkers,
echocardiography, and myocardial perfusion imaging in an
attempt to avoid missing patients with MI or unstable angi-
na. The most successful strategies to emerge thus far are
designed to identify MI patients and, when clinically appro-
priate, screen for unstable angina and underlying coronary
artery disease. Most strategies use a combination of cardiac
biomarkers, short-term observation, diagnostic imaging, and
provocative stress testing. An increasing number of high-
quality centers now use structured protocols, checklists, or
critical pathways to screen patients with suspected MI or
unstable angina (193-205). It does not appear to matter
whether the institution designates itself a chest pain center.
Rather, it is the multifaceted, structured approach to the
problem that appears to provide clinical, cost-effective bene-
fit (206,207). One randomized trial has confirmed the safety,
efficacy, and cost-effectiveness of the structured decision-
making approach compared with standard, unstructured care
(208).
6.2. Initial Patient Evaluation
Class I
1. The delay from patient contact with the healthcare
system (arrival at the ED or contact with paramedics)
to initiation of fibrinolytic therapy should be less than
30 minutes. Alternatively, if PCI is chosen, the delay
from patient contact with the healthcare system (typi-
cally, arrival at the ED, or contact with paramedics) to
balloon inflation should be less than 90 minutes.
(Level of Evidence: B)
2. The choice of initial STEMI treatment should be
made by the emergency medicine physician on duty
based on a predetermined, institution-specific, written
protocol that is a collaborative effort of cardiologists
(both those involved in coronary care unit manage-
ment and interventionalists), emergency physicians,
primary care physicians, nurses, and other appropri-
ate personnel. For cases in which the initial diagnosis
and treatment plan are unclear to the emergency
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revascularization to the nearest appropriate interventional
facility (Figure 6) (155). The protocol should also include the
level of training and certification of personnel required to
accompany the patient during transfer, the minimum equip-
ment requirements, and the type(s) of transport vehicles (e.g.,
standard ground ambulance, mobile intensive care unit, heli-
copter, or fixed-wing aircraft) that can be used on the basis of
patient condition. For cases in which the initial diagnosis and
treatment plan are unclear to the emergency medicine physi-
cian or are not covered directly by the agreed-upon protocol,
immediate cardiology consultation is advisable. 
6.2.1. History
Class I
The targeted history of STEMI patients taken in the
ED should ascertain whether the patient has had
prior episodes of myocardial ischemia, such as stable
or unstable angina, MI, coronary bypass surgery, or
PCI. Evaluation of the patient’s complaints should
focus on chest discomfort, associated symptoms, sex-
and age-related differences in presentation, hyperten-
sion, diabetes mellitus, possibility of aortic dissection,
risk of bleeding, and clinical cerebrovascular disease
(amaurosis fugax, face/limb weakness or clumsiness,
face/limb numbness or sensory loss, ataxia, or verti-
go). (Level of Evidence: C)
The history taken in the ED must be concise and detailed
enough to establish the probability of STEMI but should be
obtained expeditiously so as not to delay implementation of
reperfusion therapy. 
Chest Discomfort. The severity of discomfort varies and is
typically graded on a scale of 1 to 10, with 10 being the most
physician or are not covered directly by the agreed-
upon protocol, immediate cardiology consultation is
advisable. (Level of Evidence: C)
Regardless of the approach used, all patients presenting to
the ED with chest discomfort or other symptoms suggestive
of STEMI or unstable angina should be considered high-pri-
ority triage cases and should be evaluated and treated on the
basis of a predetermined, institution-specific chest pain pro-
tocol. The protocol should include several diagnostic possi-
bilities (Figure 9) (4). The patient should be placed on a car-
diac monitor immediately, with emergency resuscitation
equipment, including a defibrillator, nearby. An ECG should
be performed and shown to an experienced emergency med-
icine physician within 10 minutes of ED arrival. If STEMI is
present, the decision as to whether the patient will be treated
with fibrinolytic therapy or primary PCI should be made
within the next 10 minutes (Figure 7) (180). The goal for
patients with STEMI should be to achieve a door-to-needle
time of within 30 minutes and a door-to-balloon time of
within 90 minutes (Figure 6) (155). If the initial ECG is not
diagnostic, the patient remains symptomatic, and there is a
high clinical suspicion for STEMI, serial ECGs at 5- to 10-
minute intervals or continuous ST-segment monitoring
should be performed.
Ideally, such decisions should be made by the emergency
medicine physician on duty in the ED based on a predeter-
mined, institution-specific, written protocol that has been
developed with input from cardiologists (both those involved
in coronary care unit management and interventionalists),
emergency medicine physicians, primary care physicians,
nurses, and other appropriate personnel. For noninterven-
tional hospitals, this will usually require formal, written
transfer agreements and protocols that will permit expedi-
tious transfer of patients who require urgent mechanical
Figure 9. Algorithm for evaluation and management of patients suspected of having acute coronary syndrome. STEMI = ST-elevation
myocardial infarction. Modified from Braunwald et al. J Am Coll Cardiol 2000;36:970-1062 (4).
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severe pain. It is important to keep in mind that many
patients will not admit having chest “pain” but will acknowl-
edge the presence of chest “discomfort,” because of their def-
inition of pain. The chest discomfort is often described as a
crushing, vice-like constriction, a feeling equivalent to an
“elephant sitting on the chest,” or heartburn. Usually, the dis-
comfort is substernal but may originate in or radiate to areas
such as the neck, jaw, interscapular area, upper extremities,
and epigastrium. The duration of the discomfort, which typ-
ically lasts longer than 30 minutes, may wax and wane and
may be remitting. It may be described as “indigestion in the
chest” and occasionally may be relieved with belching. The
possibility of precipitation of STEMI by use of illicit drugs
such as cocaine should be considered.
The targeted history of patients with STEMI taken in the
ED should ascertain whether the patient has had prior
episodes of myocardial ischemia such as stable or unstable
angina, MI, coronary bypass surgery, or PCI. Evaluation of
the patient’s complaints should focus on chest discomfort,
associated symptoms, sex- and age-related differences in
presentation, hypertension, diabetes mellitus, possibility of
aortic dissection, risk of bleeding, and clinical cerebrovascu-
lar disease (amaurosis fugax, face/limb weakness or clumsi-
ness, face/limb numbness or sensory loss, ataxia, or vertigo).
Associated Symptoms. Other symptoms to be aware of when
taking a patient’s history include nausea and vomiting.
Diaphoresis associated with a pale complexion may also
appear, as well as weakness or profound fatigue. Dizziness,
lightheadedness, syncope, and paresthesia may occur
because of pain and hyperventilation.
Hypertension. Hypertension should be assessed, because
chronic, severe, poorly controlled hypertension or severe
uncontrolled hypertension on presentation is a relative con-
traindication to fibrinolytic therapy (see Section 6.3.1.6.3.2).
Sex- and Age-Related Differences in Presentation. It has
been noted in studies that women present with STEMI at an
older age and later after the onset of symptoms than men
(53,210). There must be an elevated index of suspicion dur-
ing the evaluation of women for STEMI. Although some
variation exists, when large databases of MI patients are
examined, symptom profiles for STEMI by sex generally
appear more similar than different between men and women
(211-215). Elderly patients with STEMI are significantly less
likely than younger patients to complain of chest discomfort.
However, elderly patients with STEMI are more likely to
complain of shortness of breath, as well as other atypical
symptoms such as syncope or unexplained nausea. (181). 
Diabetes Mellitus. Diabetics may have impaired angina
(pain) recognition, especially in the presence of autonomic
neuropathy. A diabetic may misinterpret dyspnea, nausea,
vomiting, fatigue, and diaphoresis as disturbance of diabetic
control. Up to 50% of diabetic individuals with type 2 dia-
betes for longer than 10 years will have autonomic nervous
system dysfunction manifested by impaired heart rate vari-
ability. Diabetics with STEMI should be evaluated for renal
dysfunction (216).
Possibility of Aortic Dissection. Severe tearing pain radiating
directly to the back associated with dyspnea or syncope and
without ECG changes indicative of STEMI should raise the
suspicion for aortic dissection, and appropriate studies
should be undertaken. Clinicians should have a heightened
index of suspicion for aortic dissection in elderly hyperten-
sive patients. However, it must be kept in mind that the dis-
section may extend to the pericardial sac and produce cardiac
tamponade or disrupt the origin of a coronary artery. 
Risk of Bleeding. Patients should be questioned about previ-
ous bleeding problems, e.g., during surgery or dental proce-
dures, history of ulcer disease, cerebral vascular accidents,
unexplained anemia, or melena. The use of antiplatelet,
antithrombin, and fibrinolytic agents as part of the treatment
for STEMI will exacerbate any underlying bleeding risks.
Clinical Cerebrovascular Disease. The patient with STEMI
frequently has medical conditions that are risk factors for
both MI and stroke. Evidence for prior episodes suggestive
of clinical cerebrovascular disease should be sought. For
example, the patient should be asked whether he/she has ever
had symptoms of transient retinal or cerebral ischemia such
as amaurosis fugax, face/limb weakness or clumsiness,
face/limb numbness or sensory loss, ataxia, or vertigo.
Transient ischemic attacks (TIAs) typically last less than 30
minutes, whereas symptoms that last more than 60 to 90
minutes are more likely to indicate the presence of a stroke
(217). In addition, the patient should be asked whether he/she
has ever had an ischemic stroke, intracerebral hemorrhage
[ICH], or subarachnoid hemorrhage. A brief summary of the
details for diagnosis of the different stroke subtypes is avail-
able (218). Finally, a history of cognitive decline/dementia
may indicate the presence of cerebral amyloid angiopathy
and increased risk of ICH, and information regarding head
and facial trauma should be obtained. 
6.2.2. Physical Examination
Class I
1. A physical examination should be performed to aid in
the diagnosis and assessment of the extent, location,
and presence of complications of STEMI. (Level of
Evidence: C)
2. A brief, focused, and limited neurological examination
to look for evidence of prior stroke or cognitive
deficits should be performed on STEMI patients
before administration of fibrinolytic therapy. (Level of
Evidence: C)
A brief physical examination may promote rapid triage
(Table 5), whereas a more detailed physical examination aids
in the differential diagnosis and is useful for assessing the
extent, location, and presence of complications of STEMI
(Tables 6 and 7) (219). 
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anginal equivalent) or other symptoms suggestive of
STEMI. (Level of Evidence: C)
2. If the initial ECG is not diagnostic of STEMI but the
patient remains symptomatic, and there is a high clin-
ical suspicion for STEMI, serial ECGs at 5- to 10-
minute intervals or continuous 12-lead ST-segment
monitoring should be performed to detect the potential
development of ST elevation. (Level of Evidence: C)
3. In patients with inferior STEMI, right-sided ECG
leads should be obtained to screen for ST elevation
suggestive of RV infarction. (See Section 7.6.6 and the
ACC/AHA/ASE 2003 Guideline Update for the Clini-
cal Application of Echocardiography) (Level of
Evidence: B)
The 12-lead ECG in the ED is at the center of the thera-
peutic decision pathway because of the strong evidence that
Evidence of prior stroke or dementia may be suggested by
the finding on examination of focal neurological or cognitive
deficits (Table 6). A brief but focused examination can iden-
tify focal neurological or cognitive deficits. 
6.2.2.1. Differential Diagnosis
The differential diagnosis of STEMI includes conditions that
can be exacerbated by fibrinolysis and anticoagulation (Table
8). The pain of aortic dissection is typically described as
searing, ripping, or tearing and frequently radiates to the
back or lower extremities. The pain is worse at onset and
lasts for hours. Major pulses may be absent, and a murmur of
aortic regurgitation may be present. A transesophageal
echocardiogram, computed tomography (CT) scan, or mag-
netic resonance imaging scan is useful for establishing the
diagnosis of aortic dissection. Active peptic ulcer disease can
be present with chest or epigastric pain, sometimes radiating
posteriorly, and may be associated with syncope, hemateme-
sis, or melena. Free subdiaphragmatic air may be seen on
upright chest X-ray in perforations. Acute pericarditis may
show PR-segment depression and ST-segment elevation on
the ECG but without reciprocal ST-segment depression
(220). Pain from pericarditis is usually pleuritic and can radi-
ate to the shoulder and trapezius ridge and is often relieved
by sitting up and leaning forward, characteristics not found
in STEMI. A rub is often present. Pulmonary embolus, with
or without infarction, presents with dyspnea and knifelike
pleuritic pain, sometimes with hemoptysis. Pulmonary
embolism can present with chest pain similar to that of
STEMI. Costochondral pain is described as sharp or sticking,
with associated localized tenderness. Pneumothorax may
present with acute dyspnea, pleuritic pain, and differential
decrease in breath sounds with hyperresonance over 1 lung
field. Acute cholecystitis may mimic STEMI, and right-
upper-quadrant abdominal tenderness should be sought on
physical examination.
6.2.3. Electrocardiogram
Class I
1. A 12-lead ECG should be performed and shown to an
experienced emergency physician within 10 minutes
of ED arrival on all patients with chest discomfort (or
Table 6. Physical Findings and Possible Implications in Complicated
and Uncomplicated ST-Elevation Myocardial Infarction Patients
Cardiovascular
General: Restless agitated, anguished facies, clenched fist 
(Levine’s sign) 
Skin: Cool, clammy, pale, ashen
Low-grade fever: Nonspecific response to myocardial necrosis
Hypertension, tachycardia: High sympathetic tone (anterior MI)
Hypotension, bradycardia: High vagal tone (inferior-posterior MI)
Small-volume pulses: Low cardiac output
Fast, slow, or irregular pulse: Atrial or ventricular arrhythmias,
heart block
Paradoxical “ectopic” systolic impulse: LV dyskinesis, ventricular
aneurysm (anterior MI)
Soft S1: Decreased LV contractility; first-degree AV block (inferi-
or MI)
S4 gallop: Decreased LV compliance
Paradoxically split S2: Severe LV dysfunction, LBBB
S3 gallop, pulmonary rales, pulsus alternans: LV systolic dysfunc-
tion (signs of CHF – greater than 25% of myocardium)
Hypotension: Skin – cool, clammy, cyanotic; CNS – altered men-
tal status; kidneys – oliguria (signs of cardiogenic shock)
Jugular venous distension: with Kussmaul’s sign, hypotension,
RV S4 and S3 gallops, clear lungs (RV infarction)
Systolic murmur of VSR: VSR (LSB, palpable thrill common)
Differentiate from systolic murmur of MR: papillary muscle rup-
ture
Pericardial friction rub: Pericarditis (accompanies transmural MI) 
– late post-MI (Dressler’s) syndrome
Signs of cardiac tamponade, EM dissociation: Cardiac rupture
Absent pulses and murmur of aortic regurgitation: Aortic dissec-
tion
Screening Neurological Examination
Cognitive disorientation: memory loss, dysarthria, aphasia, hemi-
spatial neglect
Motor: facial asymmetry, pronator drift, reflex symmetry, limb 
dysmetria
Sensory: loss of sensation of pinprick
MI = myocardial infarction; LV = left ventricular; AV = atrioventricular; LBBB = left bun-
dle-branch block; CHF = congestive heart failure; CNS = central nervous system; RV =
right ventricular; VSR = ventricular septal rupture; LSB = left sternal border; mitral regur-
gitation; EM = electromechanical.
Table 5. Brief Physical Examination in the Emergency Department
1. Airway, Breathing, Circulation (ABC)  
2. Vital signs, general observation  
3. Presence or absence of jugular venous distension  
4. Pulmonary auscultation for rales  
5. Cardiac auscultation for murmurs and gallops  
6. Presence or absence of stroke  
7. Presence or absence of pulses  
8. Presence or absence of systemic hypoperfusion (cool, clammy,
pale, ashen)
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In the absence of ST elevation, there is no evidence of ben-
efit of fibrinolytic therapy for patients with normal ECG or
nonspecific changes, and there is some suggestion of harm
(including increased bleeding risk) for patients with ST-seg-
ment depression only (221,224). Notwithstanding this, fibri-
nolytic therapy may be appropriate when there is marked ST-
segment depression confined to leads V1 through V4 and
accompanied by tall R waves in the right precordial leads and
upright T waves indicative of a true posterior injury current
and circumflex coronary occlusion. In circumstances where
there is a suggestive clinical history and suggestive evidence
of true posterior infarction, confirmatory data from posterior
leads (i.e., V7 and V8) as well as 2-dimensional echocardiog-
raphy may be especially helpful; this latter investigation has
a high negative predictive value (225,226). Primary PCI is
another reperfusion strategy that may be effective in patients
with true posterior MI (see Section 6.3.1.6.4.2).
Initial errors in ECG interpretation can result in up to 12%
of patients being categorized inappropriately, demonstrating
a potential benefit of accurate computer-interpreted electro-
cardiography and fax transmission to an expert (227). It is
less likely that STEMI is present if the upward-directed ST-
segment changes are concave rather than convex (228). 
Because lethal ventricular arrhythmias may develop
abruptly in patients with STEMI, all patients should be mon-
itored electrocardiographically on arrival in the ED. It is
important to examine serial tracings approximately 5 to 10
minutes apart, or if symptoms recur, during evaluation in the
ED for development of ST elevation if the initial ECG is
nondiagnostic. ST elevation may also be detected by inter-
mittent visual inspection of the oscilloscope or auditory
alarms in systems with continuous ST-segment monitoring
capability.
Although the Fibrinolytic Therapy Trialists’ (FTT)
Collaborative Group overview indicates that patients with
new or presumably new LBBB are at high risk when pre-
senting with presumed MI, this ECG presentation is a fre-
quent cause of delay or lack of reperfusion therapy because
of the concern of the validity of the ECG criteria for MI diag-
nosis and the risk of therapy. This is also a situation in which
direct PCI may be preferable to fibrinolytic therapy (156). It
has been suggested that patients with new or presumably new
LBBB coupled with a typical ischemic history be
approached with a plan to rule in MI using 1 of 3 ECG crite-
ST-segment elevation identifies patients who benefit from
reperfusion therapy (221). Mortality increases with the num-
ber of ECG leads showing ST elevation. Important predictors
of mortality on the initial 12-lead ECG include left bundle-
branch block (LBBB) and anterior location of infarction
(Figure 10) (222,223). Diagnostic criteria of greater than 0.1
mV in leads V1 through V4 may have reduced specificity for
STEMI in patients with early repolarization. Some evidence
exists to support the use of greater than or equal to 0.2 mV
anteroseptal elevation as a preferable threshold for diagnos-
ing STEMI, because a higher proportion of patients are cor-
rectly classified as having STEMI than with a threshold of
greater than 0.1 mV in these leads (221).
Table 7. Percent Mortality by Killip Class*
Fibrinolytic Trials (30 Days)
GISSI-1 (157)Killip Killip and International Study Group: ASSENT-2:
Class Kimball (Inhospital) Placebo Fibrinolytic Fibrinolytic (354) Fibrinolytic (28)
I 6 7 6 5 5
II 17 20 16 18 13
III 38 39 33 32 26 
IV 81 70 70 72 56†
Class I = no rales, no S3; Class II = rales less than 50%; Class III = pulmonary edema; Class IV = cardiogenic shock.
*Values cited are subject to survivor bias.
†Highly selected group of patients.
Modified with permission from Topol. Textbook of Cardiovascular Medicine. 2nd ed. Philadelphia, PA: Lippincott-Williams & Wilkins; 2002:438 (219).
Table 8. Differential Diagnosis of ST-Elevation Myocardial Infarc-
tion
Life-threatening  
Aortic dissection  
Pulmonary embolus
Perforating ulcer 
Tension pneumothorax
Boerhaave syndrome (esophageal rupture with mediastinitis)
Other cardiovascular and nonischemic
Pericarditis
Atypical angina
Early repolarization
Wolff-Parkinson-White syndrome
Deeply inverted T waves suggestive of a central nervous system 
lesion or apical hypertrophic cardiomyopathy
LV hypertrophy with strain
Brugada syndrome
Myocarditis
Hyperkalemia
Bundle-branch blocks
Vasospastic angina
Hypertrophic cardiomyopathy
Other noncardiac
Gastroesophageal reflux (GERD) and spasm
Chest-wall pain
Pleurisy
Peptic ulcer disease
Panic attack
Biliary or pancreatic pain
Cervical disc or neuropathic pain
Somatization and psychogenic pain disorder
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ria that provide independent diagnostic value. These consist
of ST elevation greater than or equal to 0.1 mV in leads with
a positive QRS, ST depression greater than or equal to 0.1
mV in V1 to V3, and ST elevation greater than or equal to 0.5
mV in leads with a negative QRS (229,230).
6.2.4. Laboratory Examinations
Class I
Laboratory examinations should be performed as
part of the management of STEMI patients but should
not delay the implementation of reperfusion therapy.
For specific laboratory examinations, see Table 9.
(Level of Evidence: C)
In addition to serum cardiac biomarkers for cardiac dam-
age, several routine evaluations have important implications
for management of patients with STEMI (Table 9). Although
these studies should be undertaken when the patient is first
examined, therapeutic decisions should not be delayed until
results are obtained because of the crucial role of time to
therapy in STEMI.
6.2.5. Biomarkers of Cardiac Damage
Class I
1. Cardiac-specific troponins should be used as the opti-
mum biomarkers for the evaluation of patients with
STEMI who have coexistent skeletal muscle injury.
(Level of Evidence: C)
2. For patients with ST elevation on the 12-lead ECG
and symptoms of STEMI, reperfusion therapy should
be initiated as soon as possible and is not contingent
on a biomarker assay. (Level of Evidence: C)
Class IIa
Serial biomarker measurements can be useful to pro-
vide supportive noninvasive evidence of reperfusion of
the infarct artery after fibrinolytic therapy in patients
Table 9. Laboratory Evaluations for Management of ST-Elevation
Myocardial Infarction
Serum biomarkers for cardiac damage (do not wait for results before
implementing reperfusion strategy)  
CBC with platelet count 
INR  
aPTT 
Electrolytes and magnesium 
BUN 
Creatinine 
Glucose 
Serum lipids
CBC = complete blood count; INR = international normalized ratio; aPTT = activated
partial thomboplastin time; BUN = blood urea nitrogen.
Figure 10. Risk stratification: electrocardiogram (ECG). This 12-lead ECG was obtained from a middle-aged man admitted with an
extensive anterior acute myocardial infarction. (Note pathological Q waves in the precordial leads and marked repolarization abnor-
malities in the anterior and lateral leads.) A 5-beat salvo of non-sustained VT is seen extending over the transition between leads III
and aVF. Reprinted with permission from Antman and Rutherford. Coronary Care Medicine. Boston, MA: Martinus Nijhoff Publishing;
1986:81 (223).
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not undergoing angiography within the first 24 hours
after fibrinolytic therapy. (Level of Evidence: B)
Class III
Serial biomarker measurements should not be relied
upon to diagnose reinfarction within the first 18 hours
after the onset of STEMI. (Level of Evidence: C)
The nomenclature of acute coronary syndromes is illustrat-
ed in Figure 2 (8-10). The central position of the 12-lead
ECG and initial triage of patients are emphasized. Serum car-
diac biomarkers (creatine kinase [CK], CK-MB, cardiac-spe-
cific troponins, myoglobin) are useful for confirming the
diagnosis of MI and estimating infarct size. Serum cardiac
biomarkers also provide valuable prognostic information.
For patients with ST-segment elevation, the diagnosis of
STEMI is secure; initiation of reperfusion therapy should not
be delayed while awaiting the results of a cardiac biomarker
assay (231,232) (Table 10). Quantitative analysis of cardiac
biomarker measurements provides prognostic information as
well as a noninvasive assessment of the likelihood that the
patient has undergone successful reperfusion when fibri-
nolytic therapy is administered (Figure 11) (233,234). 
Because there are differences in the clinical need for bio-
markers in STEMI versus NSTEMI patients and differences
in the characteristics of the various cardiac biomarkers, pref-
erential use of a particular biomarker should be based on the
clinical syndrome. CK-MB is found in the skeletal muscle
and blood of healthy subjects; therefore, the cutoff value for
an elevated CK-MB is typically set a few units above the
upper end of the reference (normal) range. In contrast,
because cardiac troponin I (cTnI) and cardiac troponin T
(cTnT) are not normally detected in the blood of healthy peo-
ple, the definition of an abnormally increased level is a value
that exceeds that of 99% of a reference control group. Given
the nearly absolute myocardial tissue specificity and high
sensitivity for even microscopic zones of myocardial necro-
sis, the ACC and the European Society of Cardiology subse-
quently declared cardiac troponins to be the preferred bio-
marker for diagnosing MI (233). A single cutoff point was
recommended such that an MI would be diagnosed if, as a
result of myocardial ischemia, cTnI or cTnT were detected at
least once within 24 hours of the index clinical event at a
level exceeding the 99th percentile of the mean value meas-
ured in a normal control population (233). The superior sen-
sitivity makes troponin the preferred marker for patients with
UA/NSTEMI. In contrast, patients with STEMI are recog-
nized on the basis of the 12-lead ECG, and in general, sub-
sequent confirmation of MI can be ascertained by measure-
ment of any of the available cardiac biomarkers.
Occasionally, a very small infarct will be missed by CK-MB;
therefore, troponin should be measured for patients suspect-
ed to have STEMI who have negative serial CK-MBs. 
It should be recognized that in patients with STEMI, cTnT
and cTnI may first begin to rise above the reference limit by
3 to 6 hours from the onset of ischemic symptoms.
Therefore, a significant number of patients will present to the
emergency room with negative biomarkers. Myoglobin, a
low-molecular-weight heme protein found in cardiac and
skeletal muscle, is not cardiac specific but is released more
rapidly from infarcted myocardium than CK-MB and may be
detected as early as 2 hours after STEMI. 
In some patients, cardiac-specific troponins may not be
detectable for up to 6 hours after onset of chest pain. Thus,
when CK-MB, cTnI, or cTnT levels are elevated in less than
6 hours after the onset of discomfort in patients with STEMI,
clinicians should suspect that an antecedent episode of unsta-
ble angina was in fact MI and the patient is exhibiting a stut-
tering course of occlusion and release of the infarct artery.
Data from the Global Utilization of Streptokinase and TPA
for Occluded Arteries (GUSTO) III Study suggest that
patients with STEMI who have elevated cTnT levels and who
are less than 6 hours from the onset of discomfort have an
increased mortality risk (235). 
CK-MB is the preferred, widely available cardiac biomark-
er for most patients with STEMI, for whom the need to diag-
nose reinfarction and noninvasively assess reperfusion is
Table 10. Molecular Biomarkers for the Evaluation of Patients With ST-Elevation Myocardial Infarction
Mean Time to 
Range of Times to Peak Elevations Time to Return to
Biomarker Molecular Weight, Da Initial Elevation, h (Nonreperfused) Normal Range
Frequently used in 
clinical practice
CK-MB 86 000 3-12 h 24 h 48-72 h  
cTnI 23 500 3-12 h 24 h 5-10 d 
cTnT 33 000 3-12 h 12 h–2 d 5-14 d
Infrequently used in 
clinical practice
Myoglobin 17 800 1-4 h 6-7 h 24 h
CK-MB tissue isoform 86 000 2-6 h 18 h Unknown
CK-MM tissue isoform 86 000 1-6 h 12 h 38 h
Da = Daltons; h = hours; CK-MB = MB isoenzyme of creatine kinase; cTnI = cardiac troponin I; cTnT = cardiac troponin T; CK-MM = MM isoenzyme of creatine
kinase.
Modified with permission from Adams et al. Circulation 1993;88:750 (232).
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In addition to monitoring the patient for resolution of
ischemic-type chest discomfort and regression of the magni-
tude of ST-segment elevation on the ECG, clinicians can
obtain serial measurements of serum cardiac markers to but-
tress the noninvasive diagnosis of reperfusion of the infarct-
related artery after fibrinolytic therapy (Figure 11)
(233,234,236). An early peak of CK-MB (12 to 18 hours)
suggests reperfusion. Because of its rapid-release kinetics,
myoglobin is also an attractive marker for the early diagno-
sis of reperfusion. 
CK-MB isoforms are another serum cardiac biomarker less
frequently used for evaluating patients with STEMI. CK-MB
exists in only 1 form in myocardial tissue but in different iso-
forms (or subforms) in the plasma. An absolute level of CK-
MB2 greater than 1 U/L or a ratio of CK-MB2 to CK-MB1
of 1.5 has improved sensitivity and specificity for diagnosis
of MI within the first 6 hours compared with conventional
assays for CK-MB (237). 
greater than the need to make the diagnosis. By mapping the
time course of the rise and fall of a biomarker (typically CK-
MB), clinicians can detect an interruption of the progressive
fall of the biomarker level to a point below the upper refer-
ence limit (Figure 11) (233,234). Re-elevation of the bio-
marker level is evidence of myocardial reinfarction (Figure
12). A more rapidly rising and falling biomarker such as CK-
MB or myoglobin is superior for diagnosing reinfarction. As
a consequence of continuous release from a degenerating
contractile apparatus in necrotic myocytes, elevations of
cTnI may persist for 7 to 10 days after MI, and elevations of
cTnT may persist for up to 10 to 14 days. The more pro-
tracted time course of kinetic release of cTnI and cTnT lim-
its the ability of clinicians to make the diagnosis of reinfarc-
tion within several days after the index STEMI event. An
algorithm illustrating the decision-making process that incor-
porates biomarker measurements, ECG findings, clinical
symptoms, and, if available, autopsy data for making the
diagnosis of reinfarction is shown in Figure 12.
Figure 11. Cardiac biomarkers in ST-elevation myocardial infarction (STEMI).Typical cardiac biomarkers that are used to evaluate patients with
STEMI include the MB isoenzyme of CK (CK-MB) and cardiac specific troponins. The horizontal line depicts the upper reference limit (URL)
for the cardiac biomarker in the clinical chemistry laboratory.The URL is that value representing the 99th percentile of a reference control group
without STEMI. The kinetics of release of CK-MB and cardiac troponin in patients who do not undergo reperfusion are shown in the solid green
and red curves as multiples of the URL. Note that when patients with STEMI undergo reperfusion, as depicted in the dashed green and red
curves, the cardiac biomarkers are detected sooner, rise to a higher peak value, but decline more rapidly, resulting in a smaller area under the
curve and limitation of infarct size. Modified with permission from Alpert et al. J Am Coll Cardiol 2000;36:959 (233) and Wu et al. Clin Chem
1999;45:1104 (234).
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in patients for whom the diagnosis of STEMI is evi-
dent on the ECG. (Level of Evidence: B)
Various forms of imaging are often used to evaluate
patients with symptoms that are suggestive of MI or acute
coronary syndrome. Cardiac imaging can be of value in fur-
ther determining the cause of chest discomfort in patients
suspected of having an acute MI or unstable angina but
whose initial ECG is normal or nondiagnostic. The 2 most
studied techniques thus far have been echocardiography and
radionuclide imaging. 
Bedside echocardiography is useful for diagnosis and risk
stratification of chest pain patients in the ED (226). A high-
quality portable chest X-ray, transthoracic and/or trans-
esophageal echocardiography, and a contrast chest CT scan
can be useful for differentiating acute MI from aortic dissec-
tion in patients for whom this distinction is clinically unclear.
SPECT radionuclide imaging at rest is not routinely indi-
cated to establish the diagnosis of MI in patients with
STEMI, although it can provide valuable, accurate diagnos-
tic and prognostic information in patients who present to the
ED with symptoms suggestive of acute cardiac ischemia and
a normal or nondiagnostic ECG (239). During the recupera-
tive phase of hospitalization for STEMI, SPECT imaging can
be used to study myocardial perfusion and to look for seg-
mental abnormalities of LV wall motion.
6.2.7. Global Risk Assessment Tools 
Global risk assessment provides an opportunity to integrate
various patient characteristics into a single score that can
convey an overall estimate of a patient’s prognosis over a
given period of time. Beyond being informative about prog-
nosis, the general value of these risk assessment tools is that
they can influence clinical strategies. In general, the risk of
the intervention should be commensurate with the underly-
ing risk of the patient without the intervention and the
expected benefit of the intervention. That is, a high-risk inter-
vention should usually not be used for a very low-risk
patient. The expected increase in risk associated with the
intervention would very likely outweigh the expected bene-
fit. 
Several risk assessment tools have been proposed for
patients with STEMI (240-243). One such tool uses clinical
and ECG characteristics to predict risk of mortality for a
patient if and if not treated with fibrinolytic therapy, as well
as the risk of intracranial hemorrhage and major bleeding.
This decision aid suggests that some patients with small
infarctions may not have a substantial benefit from fibri-
nolytic therapy, particularly those who may have a risk fac-
tor for bleeding. These estimates are based on trials and reg-
istries. The use of this aid in clinical practice did not increase
the use of fibrinolytic therapy overall (244). Whether the
widespread application of these tools can improve decision
making is not clear. Nevertheless, they provide estimates of
risk that may be useful in the tailoring of therapy for indi-
vidual patients. In general, however, patients who present
with STEMI require evaluation for rapid reperfusion therapy
6.2.5.1. Bedside Testing for Serum Cardiac
Biomarkers
Class I
1. Although handheld bedside (point-of-care) assays
may be used for a qualitative assessment of the pres-
ence of an elevated level of a serum cardiac biomark-
er, subsequent measurements of cardiac biomarker
levels should be done with a quantitative test. (Level of
Evidence: B)
2. For patients with ST elevation on the 12-lead ECG
and symptoms of STEMI, reperfusion therapy should
be initiated as soon as possible and is not contingent
on a bedside biomarker assay. (Level of Evidence: C)
Handheld rapid bedside assays are clinically available for
measuring cTnI, cTnT, myoglobin, and CK-MB, but in gen-
eral, bedside assays are less sensitive and less precise than
quantitative assays. Small desktop rapid analyzers are also
available for the same purpose. A rapid, high-voltage elec-
trophoretic system is available for measuring CK-MB iso-
forms. Monitoring the timing of the appearance of a positive
bedside assay result may provide clinicians with a tool for a
semiquantitative estimate of a serum cardiac biomarker level
at the patient’s bedside (238). A positive bedside test should
be confirmed by a conventional quantitative test. However,
reperfusion therapy should not be delayed while one awaits
the results of a quantitative assay.
6.2.6. Imaging
Class I
1. Patients with STEMI should have a portable chest
X-ray, but this should not delay implementation of
reperfusion therapy (unless a potential contraindi-
cation is suspected, such as aortic dissection). (Level
of Evidence: C)
2. Imaging studies such as a high-quality portable chest
X-ray, transthoracic and/or transesophageal echocar-
diography, and a contrast chest CT scan or magnetic
resonance imaging scan should be used for differenti-
ating STEMI from aortic dissection in patients for
whom this distinction is initially unclear. (Level of
Evidence: B)
Class IIa
Portable echocardiography is reasonable to clarify the
diagnosis of STEMI and allow risk stratification of
patients with chest pain who present to the ED, espe-
cially if the diagnosis of STEMI is confounded by
LBBB or pacing or if there is suspicion of posterior
STEMI with anterior ST depressions. (See Section
7.6.7, Mechanical Causes of Heart Failure/Low-
Output Syndrome.) (Level of Evidence: B)
Class III
Single-photon emission CT (SPECT) radionuclide
imaging should not be performed to diagnose STEMI
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For patients without complications, excess administration
of oxygen can lead to systemic vasoconstriction, and high
flow rates can be harmful to patients with chronic obstructive
airway disease. In the absence of compelling evidence for
established benefit in uncomplicated cases, and in view of its
expense, there appears to be little justification for continuing
its routine use beyond 6 hours.
6.3.1.2. Nitroglycerin
Class I
1. Patients with ongoing ischemic discomfort should
receive sublingual nitroglycerin (0.4 mg) every 5 min-
utes for a total of 3 doses, after which an assessment
should be made about the need for intravenous nitro-
glycerin. (Level of Evidence: C)
2. Intravenous nitroglycerin is indicated for relief of
ongoing ischemic discomfort, control of hypertension,
or management of pulmonary congestion. (Level of
Evidence: C)
Class III
1. Nitrates should not be administered to patients with
systolic blood pressure less than 90 mm Hg or greater
than or equal to 30 mm Hg below baseline, severe
bradycardia (less than 50 beats per minute [bpm]),
tachycardia (more than 100 bpm), or suspected RV
infarction. (Level of Evidence: C)
2. Nitrates should not be administered to patients who
have received a phosphodiesterase inhibitor for erec-
tile dysfunction within the last 24 hours (48 hours for
tadalafil). (Level of Evidence: B)
The physiological effects of nitrates include reducing pre-
load and afterload through peripheral arterial and venous
dilation, relaxation of epicardial coronary arteries to improve
coronary flow, and dilation of collateral vessels, potentially
creating a more favorable subendocardial to epicardial flow
ratio (252-254). Vasodilation of the coronary arteries, espe-
cially at or adjacent to sites of recent plaque disruption, may
be particularly beneficial for the patient with acute infarc-
tion. Nitrate-induced vasodilatation may also have particular
utility in those rare patients with coronary spasm presenting
as STEMI.
Clinical trial results have suggested only a modest benefit
from nitroglycerin used acutely in STEMI and continued
subsequently. A pooled analysis of more than 80000 patients
treated with nitrate-like preparations intravenously or orally
in 22 trials revealed a mortality rate of 7.7% in the control
group, which was reduced to 7.4% in the nitrate group. These
data are consistent with a possible small treatment effect of
nitrates on mortality such that 3 to 4 fewer deaths would
occur for every 1000 patients treated (152).
Nitroglycerin may be administered to relieve ischemic pain
and is clearly indicated as a vasodilator in patients with STEMI
associated with LV failure. Nitrates in all forms should be
avoided in patients with initial systolic blood pressures less
than 90 mm Hg or greater than or equal to 30 mm Hg below
and treatment with aspirin, beta-blockers, and ACE
inhibitors. Nevertheless, any patient with a risk from the
intervention that exceeds their STEMI risk reduction will, on
average, do better without that treatment. This group will
generally include patients with a higher risk from the inter-
vention or a lower absolute risk reduction (generally because
of a low absolute STEMI risk). This issue may be particular-
ly important for younger patients, who tend to have a lower
absolute risk of mortality (245), and for the elderly, who tend
to have a higher risk from interventions, particularly with
respect to fibrinolytic therapy (246). Precise estimates of
risks and benefits are useful because the low STEMI risk in
younger patients is often accompanied by a lower risk of
interventions. In contrast, in the elderly, the higher interven-
tion risk is accompanied by a higher STEMI risk (and thus a
larger absolute reduction in risk with the intervention) (247).
The use of any risk assessment tool should not contribute to
any delay in providing the time-sensitive assessment and
treatment strategies that patients with STEMI require.
Further research is necessary to determine how these tools
may best contribute to optimizing patient outcomes.
6.3. Management 
6.3.1. Routine Measures
6.3.1.1. Oxygen
Class I
Supplemental oxygen should be administered to
patients with arterial oxygen desaturation (SaO2 less
than 90%). (Level of Evidence: B)
Class IIa
It is reasonable to administer supplemental oxygen to
all patients with uncomplicated STEMI during the
first 6 hours. (Level of Evidence: C)
It has become universal practice to administer oxygen, usu-
ally by nasal prongs, to virtually all patients suspected of
having acute ischemic-type chest discomfort, although it is
not known whether this therapy limits myocardial damage or
reduces morbidity or mortality. If oxygen saturation moni-
toring is used, therapy with supplemental oxygen is indicat-
ed if the saturation is less than 90%. Experimental results
indicate that breathing oxygen may limit ischemic myocar-
dial injury (248), and there is evidence that oxygen adminis-
tration reduces ST-segment elevation (249). The rationale for
use of oxygen is based on the observation that even with
uncomplicated MI, some patients are modestly hypoxemic
initially, presumably because of ventilation-perfusion mis-
match and excessive lung water (250). 
In patients with severe congestive heart failure, pulmonary
edema, or a mechanical complication of STEMI, significant
hypoxemia may not be corrected with supplemental oxygen
alone. Continuous positive-pressure breathing or endotra-
cheal intubation and mechanical ventilation may be required
in such cases (251). 
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baseline, marked bradycardia or tachycardia (256), or known
or suspected RV infarction. Patients with RV infarction are
especially dependent on adequate RV preload to maintain car-
diac output and may experience profound hypotension during
administration of nitrates (257). Phosphodiesterase inhibitors
potentiate the hypotensive effects of nitrates because of their
mechanism of action in releasing nitric oxide and increasing
cyclic guanosine monophosphate (258). Therefore, it is useful
clinical practice to ascertain whether such agents have been
used, and nitrates should not be administered to patients who
have received a phosphodiesterase inhibitor for erectile dys-
function in the prior 24 hours (48 hours for tadalafil). 
Nitroglycerin is commonly given sublingually at doses of
0.4 mg when patients present with STEMI. Arterial pressure
may decline precipitously because of limited control of the
initial dose and rate of absorption. An intravenous infusion of
nitroglycerin allows clinicians to titrate the therapy in
response to the patient’s blood pressure. A useful intravenous
nitroglycerin regimen employs an initial infusion rate of 5 to
10 mcg per minute with increases of 5 to 20 mcg per minute
until symptoms are relieved or mean arterial blood pressure
is reduced by 10% of its baseline level in normotensive
patients and by up to 30% for hypertensive patients, but in no
case below a systolic pressure of 90 mmHg or a drop greater
than 30 mm Hg below baseline. In view of their marginal
treatment benefits, nitrates should not be used if hypotension
limits the administration of beta-blockers, which have more
powerful salutary effects. 
6.3.1.3. Analgesia
Class I
Morphine sulfate (2 to 4 mg IV with increments of 2 to
8 mg IV repeated at 5- to 15-minute intervals) is the
analgesic of choice for management of pain associated
with STEMI. (Level of Evidence: C)
Pain relief is an important element in the early management
of the patient with STEMI. There is a tendency to underdose
patients with STEMI because of the desire to assess the
response to anti-ischemic or reperfusion therapy. This should
be avoided, because patients with STEMI have a hypera-
drenergic state particularly early after the onset of coronary
occlusion. Conversely, it should not be assumed that resolu-
tion of discomfort after administration of analgesics indi-
cates reperfusion has occurred (see Section 6.3.1.6.3.7 for
further discussion). Pain, which is commonly severe in the
acute phase of the event, contributes to increased sympathet-
ic activity. 
Pain management should be directed toward acute relief of
symptoms of ongoing myocardial ischemia and necrosis and
toward general relief of anxiety and apprehension, the latter
of which can heighten pain perception. Surges of cate-
cholamines have been implicated as having a role in plaque
fissuring and thrombus propagation and in reducing the
threshold for ventricular fibrillation (259). Because the pain
of STEMI is related to ongoing ischemia, interventions that
affect the oxygen supply-demand relationship (i.e., by either
increasing supply or decreasing demand) may lessen the pain
of STEMI (260). 
Control of cardiac pain is typically accomplished with a
combination of nitrates, opiate analgesic agents, oxygen, and
beta-adrenergic blockers. Treatment with these agents
extends from the ED to the critical care unit. An important
consideration when using intravenous nitrates is not to lower
blood pressure to a level that would preclude adequate
dosage of morphine sulfate for pain control. Morphine sul-
fate remains the analgesic agent of choice for management of
pain associated with STEMI, except in documented cases of
morphine sensitivity. The dose required for adequate pain
relief varies in relation to age and body size, as well as blood
pressure and heart rate. Anxiety reduction secondary to mor-
phine administration reduces the patient’s restlessness and
the activity of the autonomic nervous system, with a conse-
quent reduction of the heart’s metabolic demands. Morphine
administration for patients with pulmonary edema is clearly
beneficial and may promote peripheral arterial and venous
dilation, reducing the work of breathing and slowing the
heart rate secondary to combined withdrawal of sympathetic
tone and augmentation of vagal tone (259,260).
Side effects of morphine administration such as hypoten-
sion can be minimized by keeping the patient supine and ele-
vating the lower extremities if systolic pressure goes below
100 mmHg systolic, assuming pulmonary edema is not pres-
ent. The concomitant use of atropine in 0.5- to 1.5-mg doses
intravenously may be helpful in reducing the excessive
vagomimetic effects of morphine if significant bradycardia
or hypotension occurs. Although respiratory depression is
relatively uncommon, patients’ respirations should be moni-
tored, particularly as their cardiovascular status improves.
The narcotic reversing agent naloxone, 0.1 to 0.2 mg intra-
venously, can be given initially if indicated and repeated after
15 minutes if necessary. Nausea and vomiting as potential
side effects of large doses of morphine may be treated with a
phenothiazine (260).
See “Hospital Management” (Section 7.2.4) for additional
discussion of analgesia.
6.3.1.4. Aspirin
Class I
Aspirin should be chewed by patients who have not
taken aspirin before presentation with STEMI. The
initial dose should be: 162 mg (Level of Evidence: A) to
325 mg (Level of Evidence: C). Although some trials
have used enteric-coated aspirin for initial dosing,
more rapid buccal absorption occurs with
non–enteric-coated aspirin formulations.
At a dose of 162 mg or more, aspirin produces a rapid clin-
ical antithrombotic effect caused by immediate and near-total
inhibition of thromboxane A2 production. The Second
International Study of Infarct Survival (ISIS-2) has shown
conclusively the efficacy of aspirin alone for treatment of
evolving acute MI, with an absolute risk difference in 35-day
mortality of 2.4% (relative risk reduction [RRR] 23%) (261).
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saved per 1000 treated). The mortality difference between
those receiving and not receiving atenolol was evident by the
end of day 1 and was sustained subsequently. In the
Metoprolol In Acute Myocardial Infarction (MIAMI) trial
(267), more than 5700 subjects with evolving MI were ran-
domly assigned to receive placebo or metoprolol, up to 15
mg IV in 3 divided doses followed by 50 mg orally every 6
hours for 48 hours and then 100 mg twice per day thereafter.
Fifteen-day mortality was reduced with metoprolol from
4.9% to 4.3%. As in ISIS-1, the mortality difference between
those given placebo and those receiving metoprolol was evi-
dent by the end of day 1, after which it was sustained. 
In subjects receiving concomitant fibrinolytic therapy,
intravenously administered beta-blocking drugs diminish the
incidence of subsequent nonfatal reinfarction and recurrent
ischemia. In addition, they may reduce mortality if given par-
ticularly early (i.e., within 2 hours) after onset of symptoms.
In the Thrombolysis In Myocardial Infarction Phase II
(TIMI-II) trial (268), in which all patients received IV
alteplase, those randomly assigned to receive metoprolol, 15
mg IV, followed by oral metoprolol, 50 mg twice per day for
1 day and then 100 mg twice per day thereafter, had a dimin-
ished incidence of subsequent nonfatal reinfarction and
recurrent ischemia compared with those begun on oral meto-
prolol 6 days after the acute event. Among those treated espe-
cially early (i.e., within 2 hours of symptom onset), the com-
posite end point, death or reinfarction, occurred less often in
those given immediate IV metoprolol than in those who did
not receive it. 
The benefits of routine early IV use of beta-blockers in the
fibrinolytic era have been challenged by 2 later randomized
trials of IV beta-blockade (269,270) and by a post hoc analy-
sis of the use of atenolol in the GUSTO-I trial (271). A sub-
sequent systematic review of early beta-blocker therapy in
STEMI found no significant reduction in mortality (67).
Therefore, data on the early use of intravenous beta-blockade
in STEMI are inconclusive, and patterns of use vary.
Beta-blockers should not be administered to patients with
STEMI precipitated by cocaine use because of the risk of
exacerbating coronary spasm (272). If IV beta-blockade
induces an untoward effect, such as atrioventricular (AV)
block, excessive bradycardia, or hypotension, the condition
is quickly reversed by infusion of a beta-adrenergic agonist
(i.e., isoproterenol 1 to 5 mcg/min). The presence of moder-
ate LV failure early in the course of STEMI should preclude
the use of early IV beta-blockade until the heart failure has
been compensated but is a strong indication for the oral use
of beta-blockade before discharge from the hospital. 
The following are relative contraindications to beta-block-
er therapy: heart rate less than 60 bpm, systolic arterial pres-
sure less than 100 mm Hg, moderate or severe LV failure,
signs of peripheral hypoperfusion, shock, PR interval greater
than 0.24 second, second- or third-degree AV block, active
asthma, or reactive airway disease. 
Randomized trials of beta-blocker therapy in patients with
STEMI undergoing PCI without fibrinolytic therapy have not
been performed. However, it seems reasonable pending fur-
ther information to extrapolate data from those receiving
When aspirin was combined with streptokinase, the absolute
risk difference in mortality was 5.2% (RRR 42%). A meta-
analysis demonstrated that aspirin reduced coronary reocclu-
sion and recurrent ischemic events after fibrinolytic therapy
with either streptokinase or alteplase (262). Accordingly,
aspirin now forms part of the early management of all
patients with suspected STEMI and should be given prompt-
ly, certainly within the first 24 hours, at a dose between 162
and 325 mg and continued indefinitely at a daily dose of 75
to 162 mg (263). Although some trials have used enteric-
coated aspirin for initial dosing, more rapid buccal absorp-
tion occurs with non–enteric-coated formulations (264).
Unlike fibrinolytic agents, there is little evidence for a
time-dependent effect of aspirin on early mortality. However,
data do support the contention that a chewable aspirin is
absorbed more quickly than one swallowed in the early hours
after infarction, particularly after opiate therapy. The use of
aspirin is contraindicated in those with a hypersensitivity to
salicylate. Aspirin suppositories (300 mg) can be used safely
and are the recommended route of administration for patients
with severe nausea and vomiting or known upper-gastroin-
testinal disorders. In patients with true aspirin allergy (hives,
nasal polyps, bronchospasm, or anaphylaxis), clopidogrel or
ticlopidine may be substituted.
6.3.1.5. Beta-Blockers
Class I
Oral beta-blocker therapy should be administered
promptly to those patients without a contraindication,
irrespective of concomitant fibrinolytic therapy or
performance of primary PCI. (Level of Evidence: A)
Class IIa
It is reasonable to administer IV beta-blockers
promptly to STEMI patients without contraindica-
tions, especially if a tachyarrhythmia or hypertension
is present. (Level of Evidence: B)
During the first few hours after the onset of STEMI, beta-
blocking agents may diminish myocardial oxygen demand
by reducing heart rate, systemic arterial pressure, and
myocardial contractility. In addition, prolongation of diastole
caused by a reduction in heart rate may augment perfusion to
ischemic myocardium, particularly the subendocardium. As
a result, immediate beta-blocker therapy appears to reduce 1)
the magnitude of infarction and incidence of associated com-
plications in subjects not receiving concomitant fibrinolytic
therapy, 2) the rate of reinfarction in patients receiving fibri-
nolytic therapy, and 3) the frequency of life-threatening ven-
tricular tachyarrhythmias.
In patients not receiving fibrinolytic therapy, intravenously
administered beta-blocking agents exert a modestly favor-
able influence on infarct size (265). Large early trials sug-
gested a mortality benefit as well. In ISIS-1 (266), more than
16 000 patients with suspected acute MI were enrolled with-
in 12 hours of onset of symptoms; immediate atenolol, 5 to
10 mg IV, followed by oral atenolol, 100 mg daily, reduced
7-day mortality from 4.3% to 3.7% (p less than 0.02; 6 lives
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tions from clinical trials of reperfusion to routine practice.
Despite the wealth of reports on reperfusion for STEMI, it is
not possible to produce a simple algorithm given the hetero-
geneity of patient profiles and availability of resources in
various clinical settings at various times of day. This section
introduces the recommendations for an aggressive attempt to
minimize the time from entry into the medical system to
implementation of a reperfusion strategy using the concept of
medical system goals. More detailed discussion of these
goals and the issues to be considered in selecting the type of
reperfusion therapy may be found in Section 6.3.1.6.2, fol-
lowed by a discussion of available resources in Section
6.3.1.6.2.1.
The medical system goal is to facilitate rapid recognition
and treatment of patients with STEMI such that door-to-nee-
dle (or medical contact–to-needle) time for initiation of fib-
rinolytic therapy can be achieved within 30 minutes or that
door-to-balloon (or medical contact–to-balloon) time for PCI
can be kept under 90 minutes. These goals may not be rele-
vant for patients with an appropriate reason for delay, such as
uncertainty about the diagnosis (particularly for the use of
fibrinolytic therapy), need for evaluation and treatment of
other life-threatening conditions (e.g., respiratory failure), or
delays associated with the patient’s informed choice to have
more time to consider the decision. In the absence of such
types of circumstances, the emphasis is on having a system
in place such that when a patient with STEMI presents for
medical care, reperfusion therapy can be provided as soon as
possible within these time periods. Because there is not con-
sidered to be a threshold effect for the benefit of shorter times
to reperfusion, these goals should not be understood as
“ideal” times but rather the longest times that should be con-
sidered acceptable. Systems that are able to achieve even
more rapid times for patients should be encouraged. Also,
this goal should not be perceived as an average performance
standard but as a goal that an early treatment system in every
hospital should seek for every appropriate patient.
A critically important goal of reperfusion is to restore flow
in the infarct artery as quickly and as completely as possible,
but the ultimate goal of reperfusion in STEMI is to improve
myocardial perfusion in the infarct zone. Despite adequate
restoration of flow in the epicardial infarct artery, perfusion
of the infarct zone may still be compromised by a combina-
tion of microvascular damage and reperfusion injury (276-
278). Microvascular damage occurs as a consequence of
downstream embolization of platelet microemboli and
thrombi followed by the release of substances from activated
platelets that promote occlusion or spasm in the microvascu-
lature. Reperfusion injury results in cellular edema, free rad-
ical formation, calcium overload, and acceleration of the
apoptotic process. Cytokine activation in the infarct zone
leads to neutrophil accumulation and inflammatory media-
tors that contribute to tissue injury.
Thus, construction of an ideal reperfusion regimen in
patients with STEMI not only should focus on the primary
means of restoring flow in the epicardial infarct artery (phar-
macological or catheter-based) but should also include
another form of revascularization, fibrinolytic therapy, to the
PCI population. The more contemporary CAPRICORN
(Carvedilol Post-infarct Survival Controlled Evaluation) trial
(273), which includes patients undergoing either form of
revascularization, confirms the benefits of beta-blocker ther-
apy in patients with transient or sustained postinfarction LV
dysfunction.
6.3.1.6. Reperfusion
6.3.1.6.1. GENERAL CONCEPTS
Class I
All STEMI patients should undergo rapid evaluation
for reperfusion therapy and have a reperfusion strat-
egy implemented promptly after contact with the
medical system. (Level of Evidence: A)
Although rapid spontaneous reperfusion of the infarct
artery may occur, in the majority of patients there is persist-
ent occlusion of the infarct artery in the first 6 to 12 hours
while the affected myocardial zone is undergoing necrosis.
Prompt and complete restoration of flow in the infarct artery
can be achieved by pharmacological means (fibrinolysis),
PCI (balloon angioplasty with or without deployment of an
intracoronary stent under the support of pharmacological
measures to prevent thrombosis), or surgical measures
(Figure 3) (24-40). Despite the extensive improvement in
intraoperative preservation with cardioplegia and hypother-
mia and in numerous surgical techniques, it is not logistical-
ly possible to provide surgical reperfusion in a timely fash-
ion, and therefore patients with STEMI who are candidates
for reperfusion routinely receive either fibrinolysis or a
catheter-based treatment. 
Evidence exists that expeditious restoration of flow in the
obstructed infarct artery after the onset of symptoms in
patients with STEMI is a key determinant of short- and long-
term outcomes regardless of whether reperfusion is accom-
plished by fibrinolysis or PCI (24,274,275). As discussed
previously (Section 4.1), efforts should be made to shorten
the time from recognition of symptoms by the patient to con-
tact with the medical system. All healthcare providers caring
for patients with STEMI from the point of entry into the
medical system must recognize the need for rapid triage and
implementation of care in a fashion analogous to the han-
dling of trauma patients. When considering recommenda-
tions for timely reperfusion of patients with STEMI, the
Writing Committee reviewed data from clinical trials, focus-
ing particular attention on enrollment criteria for selection of
patients for randomization, actual times reported in the trial
report rather than simply the allowable window specified in
the trial protocol, treatment effect of the reperfusion strategy
on individual components of a composite primary end point
(e.g., mortality, recurrent nonfatal infarction), ancillary ther-
apies (e.g., antithrombin and antiplatelet agents), and the
interface between fibrinolysis and referral for angiography
and revascularization. When available, data from registries
were also reviewed to assess the generalizability of observa-
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adjunctive and ancillary treatments that minimize the
amount of microvascular damage and protect the jeopard-
ized myocardial infarct zone that contains cells in various
stages of ischemia, necrosis, and apoptosis (279,280). The
Writing Committee endorses further research to identify the
optimum strategies for achieving these goals.
6.3.1.6.2. SELECTION OF REPERFUSION STRATEGY. The litera-
ture provides very strong evidence that among patients with
suspected STEMI and without contraindications, the prompt
use of reperfusion therapy is associated with improved sur-
vival (156). Despite such strong evidence, studies continue
to indicate that reperfusion therapy is underutilized and
often not administered soon after presentation (281-283).
Indecision about the choice of reperfusion therapy should
not deter physicians from using these strategies or delay
them in administering therapy.
There is controversy about which form of reperfusion ther-
apy is superior in various clinical settings. Part of the uncer-
tainty derives from the continual introduction of new agents,
devices, and strategies, which quickly make previous studies
less relevant to contemporary practice. With pharmacologi-
cal reperfusion therapies, there are new agents, dosing regi-
mens, adjunctive treatments, and combined strategies with
procedures that are in a continual process of refinement and
evaluation. Similarly, with catheter-based approaches, there
are new devices, adjunctive therapies, technologies, and
combined strategies with medications that are being intro-
duced and evaluated. As a result, the evidence base regarding
the best approach to reperfusion therapy is quite dynamic.
Several issues should be considered in selecting the type of
reperfusion therapy, as discussed below.
Time From Onset of Symptoms. Time from onset of symp-
toms to fibrinolytic therapy is an important predictor of MI
size and patient outcome (284). The efficacy of fibrinolytic
agents in lysing thrombus diminishes with the passage of
time (279). Fibrinolytic therapy administered within the first
2 hours (especially the first hour) can occasionally abort MI
and dramatically reduces mortality (Figure 13) (156,159).
The National Heart Attack Alert Working Group (179) rec-
ommends that EDs strive to achieve a 30-minute door-to-
needle time to minimize treatment delays. Prehospital fibri-
nolysis reduces treatment delays by up to 1 hour and reduces
mortality by 17% (285).
The amount of myocardium at risk, presence of collateral
blood flow, and duration of coronary occlusion are major
determinants of myocardial infarct size (286-289). In animal
models (18), occlusions persisting greater than 30 minutes
produce myonecrosis. Reperfusion at 90 minutes salvages
approximately half of the myocardium at risk. Myocardial
salvage is minimal after 4 to 6 hours of ischemia unless
ischemic preconditioning and/or collateral flow have modi-
fied the wave front of necrosis.
A time-dependent decrease in efficacy of fibrinolytic ther-
apy may also contribute to the higher mortality rate in
patients with longer symptom duration (279). In contrast, the
ability to produce a patent infarct artery is much less
dependent on symptom duration in patients undergoing PCI.
Several reports claim no influence of time delay on mortali-
ty rates when PCI is performed after 2 to 3 hours of symp-
tom duration (290,291). One study suggests that time to PCI
is only important for patients presenting with shock (292).
Another showed that time was associated with outcome in
higher-risk but not lower-risk patients (293). Conversely,
others have reported increasing mortality rates with increas-
ing door-to-balloon times (294,295). Importantly, after
adjustment for baseline characteristics, time from symptom
onset to balloon inflation is significantly correlated with 1-
year mortality in patients undergoing primary PCI for
STEMI (relative risk [RR] equals 1.08 for each 30-minute
delay from symptom onset to balloon inflation, p equals
0.04) (275,275a). Interestingly, although the CAPTIM (173)
and PRAGUE-2 (177) studies reached different conclusions
about the overall superiority of PCI over fibrinolysis, impor-
tant observations were made in the subset of patients pre-
senting very early after the onset of symptoms. In the subset
of patients presenting within 3 hours of the onset of symp-
toms in PRAGUE-2, mortality was equivalent in those treat-
ed with streptokinase and those transferred with PCI (177).
Patients treated within 2 hours of symptom onset in CAP-
TIM had improved outcomes with prehospital tissue plas-
minogen activator (tPA) versus transfer for PCI (176). (See
Section 6.3.1.6.2.1.) 
It is also possible that time-to-treatment analyses have
been confounded by other variables (293,296). First, higher-
risk patients report later to the hospital and may respond bet-
ter to PCI than to fibrinolytic agents. Second, shorter door-
to-balloon times may be a surrogate for better quality of care
and adherence to treatment guidelines. The Task Force on
the Management of Acute Myocardial Infarction of the
European Society of Cardiology (297) and this Committee
both recommend a target medical contact– or door-to-bal-
loon time of less than 90 minutes. 
Risk of STEMI. Several models have been developed that
assist clinicians in estimating the risk of mortality in patients
with STEMI (240-242,298,299). Although these models
vary somewhat in the factors loaded into the risk prediction
tool and also vary with respect to statistical measures of their
discriminative power (e.g., C statistic), all the models pro-
vide clinicians with a means to assess the continuum of risk
from STEMI. None of the models have been tested prospec-
tively by randomizing patients to a reperfusion strategy
based on estimated mortality at presentation. Retrospective
analyses do suggest that the absolute difference in mortality
at 30 days between PCI and fibrinolysis increases in favor of
PCI as the estimated risk of mortality with fibrinolysis
increases (300). Conversely, as the estimated mortality ben-
efit with fibrinolysis decreases, the absolute mortality bene-
fit of PCI decreases, with equipoise appearing (i.e., similar
30-day mortality rates) when the estimated mortality with
fibrinolysis is approximately 2% to 3% (300). 
When the estimated mortality with fibrinolysis is extreme-
ly high, as is the case in patients with cardiogenic shock,
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Risk of Bleeding. Choice of reperfusion therapy is also affect-
ed by the patient’s risk of bleeding. When both types of
reperfusion are available, the higher the patient’s risk of
bleeding with fibrinolytic therapy, the more strongly the
decision should favor PCI. If PCI is unavailable, then the
benefit of pharmacological reperfusion therapy should be
balanced against the risk. A decision analysis suggested that
fibrinolytic therapy should be favored against no reperfusion
treatment until the risk of a life-threatening bleed exceeds
4% in older patients who have a risk profile similar to those
in the classic randomized trials of fibrinolytic therapy (247).
compelling evidence exists that favors a PCI strategy. The
SHOCK trial (SHould we emergently revascularize
Occluded Coronaries for cardiogenic shocK?) demonstrated
that patients with cardiogenic shock have a better 1-year sur-
vival if they have undergone early coronary revascularization
(184). At 1 year, patients in the early revascularization group
had a mortality rate of 53% compared with 66% for the
group that had initial medical stabilization followed by no or
late revascularization (184,301). Observational data from
NRMI suggest superiority of PCI over fibrinolysis for
patients with Killip class greater than or equal to II (302).
Figure 13. Mortality differences during days 0 through 35 subdivided by presentation features in a collaborative overview of results
from nine trials of fibrinolytic therapy. At center absolute mortality rates are shown for fibrinolytic and control groups for each clinical
feature at presentation listed at left. The odds ratio of death in fibrinolytic group to that in control group is shown for each subdivision
(black square) along with 95% confidence interval (horizontal line). The summary odds ratio at bottom corresponds to an 18% pro-
portional reduction in 35-day mortality and is highly statistically significant. This translates to a reduction of 18 deaths per 1000
patients treated with fibrinolytic agents. O-E indicates observed versus expected ratio; CIs = confidence intervals; ECG = electrocar-
diogram; BBB = bundle-branch block; ST elev = ST-segment elevation; df = degrees of freedom; BP = blood pressure; MI = myocar-
dial infarction; SD = standard deviation. Reprinted with permission from Elsevier (Fibrinolytic Therapy Trialists’ (FTT) Collaborative
Group. The Lancet 1994; 343:311-22) (156).
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The balance of risk/benefit between the transfer of patients
for PCI and more immediate treatment with fibrinolytic ther-
apy remains uncertain. The DANAMI-2 trial (DANish trial
in Acute Myocardial Infarction), conducted in Denmark,
found that patients treated at facilities without interventional
cardiology capabilities had better composite outcomes with
transfer for PCI within 2 hours of presentation than with
pharmacological reperfusion treatment at the local hospital
(306). Whether these results could be replicated elsewhere is
not known. An alternative to transfer is for hospitals without
on-site cardiac surgery to develop the capability to provide
primary mechanical reperfusion therapy. A study by
Aversano and colleagues with 11 hospitals in Massachusetts
and Maryland suggested that this approach may improve
outcomes (307). It can be expected, however, that only a lim-
ited number of hospitals could develop such a program, and
it has yet to be determined whether a certain volume of cases
would be necessary to maintain the effectiveness of the serv-
ice. The economic implications of expansion of the number
of PCI-capable centers that are able to maintain an inventory
of the necessary catheters and other devices and provide 24-
hour coverage, 7 days per week, deserve further evaluation
from the perspectives of individual institutions and the glob-
al healthcare delivery system. See additional discussion in
Section 6.3.1.6.2.1. 
Given the current literature, it is not possible to say defini-
tively that a particular reperfusion approach is superior for all
patients, in all clinical settings, at all times of day
(173,176,177) (Danchin N; oral presentation, American
Heart Association 2003 Annual Scientific Sessions, Orlando,
FL, November 2003). The main point is that some type of
reperfusion therapy should be selected for all appropriate
patients with suspected STEMI. The appropriate and timely
use of some reperfusion therapy is likely more important
than the choice of therapy, given the current literature and the
expanding array of options. Clinical circumstances in which
fibrinolytic therapy is generally preferred or an invasive strat-
egy is generally preferred are shown in Table 11.
6.3.1.6.2.1. Available Resources 
Class I
STEMI patients presenting to a facility without the
capability for expert, prompt intervention with pri-
mary PCI within 90 minutes of first medical contact
should undergo fibrinolysis unless contraindicated.
(Level of Evidence: A)
The preferred reperfusion therapy for STEMI must take
into account the location of the patient, the response time and
expertise of the paramedical/ambulance personnel, their rela-
tionship to the regional healthcare facility(s), and the avail-
ability, capability, and expertise of the medical personnel at
the facility. The most recent NRMI data continue to support
advantages of primary PCI versus fibrinolysis in high-
PCI–volume hospitals but not among those institutions with
low volume (fewer than or equal to 16 procedures per year)
Risk scores for bleeding after fibrinolytic therapy allow for
the calculation of this risk (246). Because they are derived
from less restricted populations, the scores that are most gen-
eralizable are those derived from observational studies (246).
Time Required for Transport to Skilled PCI Laboratory. The
availability of interventional cardiology facilities is a key
determinant of whether PCI can be provided. For facilities
that can offer PCI, the literature suggests that this approach
is superior to pharmacological reperfusion (303). The trials
comparing pharmacological and PCI strategies, however,
were conducted before the advent of more recent pharmaco-
logical and PCI strategies. When a composite end point of
death, nonfatal recurrent MI, or stroke is analyzed, much of
the superiority of a PCI strategy is driven by a reduction in
the rate of nonfatal recurrent MI (Figure 14) (40). The rate of
nonfatal recurrent MI can be influenced both by the adjunc-
tive therapy used (Figure 3) (24-40) and by the proportion of
patients who are referred for PCI when the initial attempt at
fibrinolysis fails or myocardial ischemia recurs after initially
successful pharmacological reperfusion (Figure 14) (155).
The experience and location of the PCI laboratory also
plays a role in the choice of therapy. The trials were per-
formed in centers with highly experienced teams, and their
results may not be generalizable to all PCI laboratories
throughout the country. Not all laboratories can provide
prompt, high-quality primary PCI. Even centers with inter-
ventional cardiology facilities may not be able to provide the
staffing required for 24-hour coverage of the catheterization
laboratory. Despite staffing availability, the volume of cases
in the laboratory may be insufficient for the team to acquire
and maintain skills required for rapid PCI reperfusion strate-
gies. A study from NRMI investigated the effect of volume
on the outcomes of patients treated with PCI versus pharma-
cological reperfusion strategies (303). They studied 446
acute-care hospitals, with 112 classified as low-volume
(fewer than or equal to 16 procedures), 223 as intermediate-
volume (17 to 48 procedures), and 111 as high-volume (49 or
more procedures) based on their annual primary angioplasty
volume. They reported that patients hospitalized at interme-
diate- and high-volume centers had lower mortality with PCI
reperfusion, whereas in the low-volume centers, there was no
significant difference between the 2 reperfusion strategies. In
another article from the NRMI investigators, the volume of
primary PCI procedures, but not pharmacological treatment,
was inversely associated with the mortality rate for patients
with STEMI (304).
A decision must be made when a STEMI patient presents
to a center without interventional cardiology facilities.
Fibrinolytic therapy can generally be provided sooner than
primary PCI (Figure 7) (180). As the time delay for perform-
ing PCI increases, the mortality benefit associated with expe-
ditiously performed primary PCI over fibrinolysis decreases
(305). Compared with a fibrin-specific lytic agent, a PCI
strategy may not reduce mortality when a delay greater than
60 minutes is anticipated versus immediate administration of
a lytic (Figure 15) (305).
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Figure 15. PCI versus lysis with fibrin-specific agents:is timing (almost) everything? RCT = randomized controlled trial; N = Number
of patients; PCI = percutaneous coronary intervention. Modified from Nallamothu and Bates. Am J Cardiol 2003;92:824-6 (305).
Copyright 2003, with permission from Excerpta Medica, Inc.
STEMI = ST-elevation myocardial infarction; PCI = percutaneous coronary intervention; ICH = intracranial hemorrhage.
*Applies to fibrin-specific agents (See Figure 15).
†Operator experience greater than a total of 75 Primary PCI cases/year.
‡Team experience greater than a total of 36 Primary PCI cases/year.
§This calculation implies that the estimated delay to the implementation of the invasive strategy is greater than one hour versus initi-
ation of fibrinolytic therapy immediately with a fibrin-specific agent.
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frequency of this event after 2 hours was similar (i.e., 3.9%
versus 4.4%, respectively) (176). 
The DANAMI-2 study, which compared primary PCI ver-
sus accelerated alteplase, enrolled 1572 patients versus the
2000 patients planned (306). Patients were eligible if they
had a sum of greater than 0.4 mV of ST elevation in 2 con-
tiguous leads on their presenting ECG within 12 hours of
symptom onset; however, patient enrollment consisted of
37% of those screened, and patients deemed to be at high risk
during ambulance transport were excluded (306). Twenty-
nine hospitals, of which 5 conducted primary PCI and were
located a mean of 35 miles from referring hospitals (maxi-
mum 95 miles), participated. The median door-to-needle
time for patients randomized to fibrinolysis was approxi-
mately 50 minutes for patients presenting either to a com-
munity (referral) hospital or an invasive center. For patients
who presented to a community hospital (where 1129 patients
were enrolled), the time from initial presentation to balloon
inflation at an invasive center was 108 minutes; the door-to-
balloon time was 93 minutes for patients presenting to an
invasive center and randomized to PCI. The primary com-
posite end point of death, reinfarction, and stroke through 30
days occurred in 14.2% of the fibrinolysis-treated patients
and 8.5% of the PCI-treated patients (p less than 0.001). The
individual end-point components of death, reinfarction, and
stroke occurred in 7.8%, 6.3%, and 2.0% of the fibrinolysis-
treated patients and 6.6%, 1.6%, and 1.1% of the PCI-treat-
ed patients, respectively. In addition to the exclusion of high-
risk patients for transport, some caveats in DANAMI-2 are
noteworthy: 1) The antithrombotic dosing regimen was in
excess of ACC/AHA guidelines. 2) The protocol specified
that repeat fibrinolysis was to be used for failed reperfusion,
reinfarction, and recurrent ST-elevation ischemia; this strate-
gy was used in 26 patients within 12 hours after randomiza-
tion, and only 1.9% underwent rescue PCI. 3) Patients with
prior stroke were included, and an imbalance in this baseline
characteristic was present, (i.e., 4.0% for fibrinolysis versus
2.7% for PCI ([1-sided p equals 0.06]). 4) The difference in
reinfarction rates between the 2 groups was likely exaggerat-
ed by the exclusion of those patients associated with invasive
procedures (311). 
Hence, on the basis of the data, patients with STEMI pre-
senting to a facility without the capability for expert, prompt
intervention with primary PCI within 90 minutes of first
medical contact should undergo fibrinolysis unless con-
traindicated. (See Sections 6.3.1.6.4.2, Primary PCI, and
6.3.1.6.4.2.4, Interhospital Transfer for Primary PCI.)
6.3.1.6.3. PHARMACOLOGICAL REPERFUSION. RATION-
ALE FOR FIBRINOLYTIC THERAPY. Although the clinical fea-
tures of coronary obstruction were described nearly a centu-
ry ago (312,313), thrombotic obstruction of the infarct artery
as a cause of STEMI was not proven until 1980 (20). The
benefits of fibrinolytic therapy are maximal when there is
prompt, adequate restoration of flow in the epicardial infarct
artery and perfusion of the myocardium in the infarct zone.
Controlled clinical trials have demonstrated the potential for
(303). Approximately 20% of US hospitals have cardiac
catheterization laboratories; and less than that number have
the capacity for primary PCI. The C-PORT study (Atlantic
Cardiovascular Patient Outcomes Research Team), which
randomized 451 fibrinolysis-eligible patients with STEMI
treated in 11 community hospitals with diagnostic catheteri-
zation but not onsite PCI facilities, is of interest. Patients
were randomized within 12 hours of symptom onset to an
accelerated alteplase regimen (median door-to-lytic time was
46 minutes) versus primary PCI (median door-to-balloon
time 101.5 minutes). At 6 months, the incidence of death, re-
MI, and stroke was 12.4% for PCI and 19.9% for fibrinolyt-
ic therapy (p equals 0.03). Because only 18% of the intend-
ed sample size was actually enrolled, this study is signifi-
cantly underpowered, and its conclusion can only be hypoth-
esis-generating rather than definitive (307). Importantly,
most C-PORT patients were randomized between 0800 and
1600 hours, an experience consistent with NRMI data. The
NRMI report also demonstrated a substantially longer door-
to-balloon time when patients with STEMI undergo direct
PCI outside of daylight hours (308). The Zwolle group eval-
uated 1702 consecutive patients and found that the 47% of
patients who presented outside “routine duty hours” (i.e.,
1800 to 0800 hours) had a higher rate of both PCI failure and
30-day mortality than those within the 0800 to 1800 period
(6.9% and 4.2% versus 3.8% and 1.9%, respectively; p less
than 0.01) (309). The reasons for these differences are
unclear but could relate to both patient and process-of-care
factors, including variations in both cognitive function and
manual dexterity in sleep-deprived healthcare providers
(308,310).
Two studies germane to STEMI care and resource utiliza-
tion are noteworthy. The first, CAPTIM, a comparison of
angioplasty and prehospital fibrinolysis (accelerated
alteplase) in STEMI, fell short of its planned 1200-patient
enrollment, and hence was underpowered (173). Eight hun-
dred forty patients were randomized to prehospital fibrinoly-
sis versus primary PCI. The primary end point was the com-
posite of all-cause mortality, nonfatal recurrent MI, and non-
fatal disabling stroke at 30 days, which occurred in 8.2% of
patients assigned fibrinolytic therapy and 6.2% of patients
assigned to PCI (p not significant [NS]). The components for
death, reinfarction, and disabling stroke were 3.8%, 3.7%,
and 1.0% for fibrinolytic therapy and 4.8%, 1.7%, and 0%
for PCI. Unlike C-PORT, this trial liberally used rescue
angioplasty (28%), which probably accounts for the relative-
ly low reinfarction rate in the lytic-treated group. A subse-
quent analysis from CAPTIM of the 55% of patients treated
within 2 hours of symptom onset revealed a mortality trend
in favor of prehospital fibrinolysis versus primary PCI (2.2%
versus 5.7%, p equals 0.058), whereas those patients treated
beyond 2 hours had a 5.9% versus 3.7% (p equals 0.47) 30-
day mortality rate, respectively (176). Interestingly, there
was a significant reduction in the frequency of cardiogenic
shock for patients treated within 2 hours with prehospital fib-
rinolysis (1.3% versus 5.3%, p equals 0.032), whereas the
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2. In the absence of contraindications, fibrinolytic thera-
py should be administered to STEMI patients with
symptom onset within the prior 12 hours and new or
presumably new LBBB. (Level of Evidence: A)
Class IIa
1. In the absence of contraindications, it is reasonable to
administer fibrinolytic therapy to STEMI patients
with symptom onset within the prior 12 hours and 12-
lead ECG findings consistent with a true posterior
MI. (Level of Evidence: C)
2. In the absence of contraindications, it is reasonable to
administer fibrinolytic therapy to patients with symp-
toms of STEMI beginning within the prior 12 to 24
hours who have continuing ischemic symptoms and
ST elevation greater than 0.1 mV in at least 2 contigu-
ous precordial leads or at least 2 adjacent limb leads.
(Level of Evidence: B)
Class III
1. Fibrinolytic therapy should not be administered to
asymptomatic patients whose initial symptoms of
STEMI began more than 24 hours earlier. (Level of
Evidence: C)
2. Fibrinolytic therapy should not be administered to
patients whose 12-lead ECG shows only ST-segment
depression except if a true posterior MI is suspected.
(Level of Evidence: A)
functional, clinical, and mortality benefits only if fibrinolyt-
ic therapy is given within 12 hours. (See additional discus-
sion on the use of antithrombins and antiplatelet agents as
ancillary therapy in Sections 6.3.1.6.8.1 and 6.3.1.6.8.2.)
The reduction in mortality with fibrinolytic therapy is pres-
ent regardless of sex, presence of diabetes, blood pressure (if
less than 180 mmHg systolic) (246,314), heart rate, or histo-
ry of previous MI (156). The mortality benefit is greater in
the setting of anterior STEMI, diabetes, low blood pressure,
(less than 100 mm Hg systolic) or high heart rate (greater
than 100 bpm) (Figure 13) (156). The earlier therapy begins,
the better the outcome, with the greatest benefit decidedly
occurring when therapy is given within the first 3 hours.
Benefit occurs, however, up to at least 12 hours from the
onset of symptoms. The absolute benefit is less with inferior
STEMI, except for the subgroup with associated RV infarc-
tion or anterior ST-segment depression indicative of a greater
territory at risk (Figure 16) (156). 
6.3.1.6.3.1. Indications for Fibrinolytic Therapy
Class I
1. In the absence of contraindications, fibrinolytic thera-
py should be administered to STEMI patients with
symptom onset within the prior 12 hours and ST ele-
vation greater than 0.1 mV in at least 2 contiguous
precordial leads or at least 2 adjacent limb leads.
(Level of Evidence: A)
Figure 16. Effect of fibrinolytic therapy on mortality according to admission electrocardiogram. Patients with bundle-branch block
(BBB) and anterior ST-segment elevation (ANT ST Elevation) derive the most benefit from fibrinolytic therapy. Effects in patients with
inferior ST-segment elevation (INF ST Elevation) are much less, while patients with ST-segment depression (ST DEP) do not bene-
fit. Reprinted with permission from Elsevier (Fibrinolytic Therapy Trialists' Collaborative Group. The Lancet 1994;343:311-22) (156).
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Table 12. Contraindications and Cautions for Fibrinolysis in ST-
Elevation Myocardial Infarction* 
Absolute contraindications
Any prior ICH
Known structural cerebral vascular lesion (e.g., arteriovenous 
malformation)
Known malignant intracranial neoplasm (primary or metastatic)
Ischemic stroke within 3 months EXCEPT acute ischemic stroke 
within 3 hours
Suspected aortic dissection
Active bleeding or bleeding diathesis (excluding menses)
Significant closed-head or facial trauma within 3 months
Relative contraindications
History of chronic, severe, poorly controlled hypertension 
Severe uncontrolled hypertension on presentation (SBP greater 
than 180 mm Hg or DBP greater than 110 mm Hg)†
History of prior ischemic stroke greater than 3 months, dementia,
or known intracranial pathology not covered in contraindica-
tions
Traumatic or prolonged (greater than 10 minutes) CPR or major 
surgery (within less than 3 weeks)
Recent (within 2-4 weeks) internal bleeding 
Noncompressible vascular punctures 
For streptokinase/anistreplase: prior exposure (more than 5 days 
ago) or prior allergic reaction to these agents
Pregnancy
Active peptic ulcer 
Current use of anticoagulants: the higher the INR, the higher the 
risk of bleeding
ICH = intracranial hemorrhage; SBP = systolic blood pressure; DBP = diastolic blood pres-
sure; CPR = cardiopulmonary resuscitation; INR = international normalized ratio; MI =
myocardial infarction.
*Viewed as advisory for clinical decision making and may not be all-inclusive or defini-
tive.
†Could be an absolute contraindication in low-risk patients with MI (see Section
6.3.1.6.3.2).
tant RV infarction (318). Attainment of additional ECG leads
(right sided and/or posterior) or an echocardiogram may help
clarify the location and extent of infarction and anticipated
risk of complications, but it is important that acquisition of
such ancillary information not interfere with the strategy of
providing timely reperfusion in patients with STEMI (319).
6.3.1.6.3.2. Contraindications/Cautions
Class I
1. Healthcare providers should ascertain whether the
patient has neurological contraindications to fibri-
nolytic therapy, including: any history of intracranial
hemorrhage or significant closed head or facial trauma
within the past 3 months, uncontrolled hypertension,
or ischemic stroke within the past 3 months. (See Table
12 for a comprehensive list.) (Level of Evidence: A)
2. STEMI patients at substantial (greater than or equal to
4%) risk of ICH should be treated with PCI rather
than with fibrinolytic therapy. (See Table 11 for further
management considerations.) (Level of Evidence: A)
A detailed list of contraindications and cautions for the use
of fibrinolytic therapy is shown in Table 12. Specific neuro-
logical considerations are addressed below.
Hemorrhage represents the most important risk of fibri-
nolytic therapy, especially ICH, which may be fatal in half to
two thirds of patients. There is both legitimate concern and
confusion surrounding the issue of whether fibrinolytic ther-
apy should be contraindicated in patients with a history of
prior cerebrovascular disease (2,320-322). The 1996
ACC/AHA Guidelines for the Management of Acute
Myocardial Infarction (2) stated that “Previous hemorrhagic
stroke at any time; other strokes or cerebrovascular events
within 1 year” was a contraindication to use of thrombolytic
therapy and that “...history of prior cerebrovascular accident
or known intracerebral pathology not covered in contraindi-
cations” was a caution/relative contraindication. After the
first 627 patients were enrolled in TIMI-II (320), a number of
protocol changes were made: the dose of tPA was reduced
from 150 to 100 mg, use of 80 mg of aspirin was postponed
for 24 hours, patients who had a history of stroke or inter-
mittent cerebral ischemic attacks were excluded, and patients
with blood pressures greater than or equal to 180 mmHg sys-
tolic or greater than or equal to 110 mm Hg diastolic were
excluded. The reduction of ICH frequency by the exclusion
of patients with any history of cerebrovascular disease was
likely confounded by the influence of the other 3 protocol
changes. The basis for the 1996 recommendation for a time
frame of 1 year for ischemic stroke as a contraindication to
coronary fibrinolysis was a consensus opinion without spe-
cific supporting data.
In subsequent trials (26-31,33,323,324), the use of prior
TIA or stroke as an exclusion criterion has varied: stroke
within 2 years (30), stroke within 6 months (323), TIA with-
in 6 months/any history of stroke (33), any stroke
(26,27,324), and any history of prior TIA or stroke
Because the benefit of fibrinolytic therapy is directly relat-
ed to the time from symptom onset, treatment benefit is max-
imized by the earliest possible application of therapy. The
constellation of clinical features that must be present
(although not necessarily at the same time) to serve as an
indication for fibrinolysis includes symptoms of myocardial
ischemia and ST elevation greater than 0.1 mV, in 2 contigu-
ous leads, or new or presumably new LBBB on the present-
ing ECG (156,315). In the very early phase of STEMI, giant
hyperacute T waves may precede ST elevation (316). True
posterior MI may be manifested by tall R waves in the right
precordial leads and ST-segment depression in leads V1
through V4, especially when T waves are upright (317).
Repeat ECGs and incorporation of additional leads such as
V7 through V9 are more specific for the detection of posteri-
or infarction (225). Patients with LBBB or anterior ST ele-
vation are at greater inherent risk from MI and achieve
greater benefit with fibrinolytic therapy. Additional valuable
information may be garnered from concurrent echocardiog-
raphy to identify the location and extent of regional wall-
motion abnormalities. Patients with inferior MI and ST ele-
vation in V1, V4R, or both are more likely to have concomi-
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patients with presumed new LBBB, anterior infarction, and
the greatest area of risk, as exemplified by the number of
ECG leads affected and the extent of ST deviation, derived
maximal benefit from fibrinolytic therapy (Figure 16)
(156,336). 
Elderly patients. Although the elderly constitute a minority
of the general population, they are the fastest-growing seg-
ment of the population and account for the majority of
patients presenting with MI and a disproportionately high
component of death from MI (46,213,338). In persons older
than 75 years, the overall risk of mortality from MI is high
with and without therapy. Although the proportionate reduc-
tion in mortality for patients older than 75 years treated with-
in 12 hours with ST elevation or LBBB is somewhat less for
patients less than or equal to 75 years, the absolute number
of lives saved per 1000 patients treated is actually greater
(i.e., 34 lives saved per 1000 patients treated versus 28 for
those less than 75 years) (339).
Registry observations from the Cooperative Cardiovascular
Project (CCP) database by Thiemann and colleagues of 2673
patients between the age of 75 and 86 years suggested that
the 1607 patients receiving fibrinolytics had a lower 30-day
survival than those not treated with this therapy (340). Some
caution in the interpretation of these observational data is
appropriate because 1) a reversal of this effect toward bene-
fit was seen in women between the ages of 65 and 75 years
derived from a larger sample, and 2) a substantial proportion
of the patients possessed conventional clinical trial fibri-
nolytic exclusion criteria (i.e., 11.8% had systolic blood pres-
sure greater than 180 mm Hg, 18% had a history of recent
trauma or a remote history of peptic ulcer or internal bleed-
ing, and 6.9% had a history of stroke). Twice as many
patients receiving fibrinolysis (i.e., 2.2% versus 0.9%) had
CPR before arrival as opposed to those without fibrinolysis
(340). In contrast to the CCP study by Thiemann et al.,
another CCP analysis in the elderly by Berger et al. indicat-
ed that both fibrinolytic therapy and primary angioplasty
were associated with a survival benefit at 1 year compared
with patients receiving neither (341). Data from the Swedish
National Register on the use of fibrinolysis in 6891 patients
75 years and older with first registry-recorded STEMI also
confirm a 13% adjusted relative risk reduction (95% CI 0.80
to 0.94; p equals 0.001; absolute risk reduction 4%) in the
composite of mortality and cerebral bleeding after 1 year
(Figure 18) (342). 
6.3.1.6.3.4. Effect on LV Function
Early reperfusion of ischemic myocardium within the risk
region of an occluded infarct-related artery interrupts the
wave front of necrosis (18), reduces ultimate infarct size,
preserves regional and global ventricular function, and
improves survival. Clinical evidence for this paradigm was
inconclusive until the GUSTO-I angiographic trial (343-
348). Global LV ejection fraction (LVEF), a load-dependent
measurement, is an imperfect surrogate for infarct size.
Compensatory remote-segment hyperkinesis, the important
(28,29,31) have each been used as exclusion criteria. In
some studies, the frequency of ICH in patients older than 75
years ranged from 0.5% with streptokinase and heparin (33)
to 2.5% with reteplase (26). Giugliano et al. (325) showed
that the higher ICH frequencies with lanoteplase or
tenecteplase may be explained in part by the effect of the
UFH (InTIME-2 [Intravenous NPA for the Treatment of
Infarcting Myocardium Early] equals 1.12%, InTIME-IIb
equals 0.50%) and dose of the UFH infusion (ASSENT-1
and TIMI-10B: higher heparin dose equals 1.83%, lower
heparin dose equals 0.74%). (See discussion on the use of
LMWH in the elderly in Section 6.3.1.6.8.1.2.) In the
Maximal Individual Therapy in Acute Myocardial Infarction
(MITRA) registry (326), previous stroke within 3 months
was the strongest predictor of stroke (OR equals 9.3, 95% CI
6.0 to 14.2) after STEMI. On the basis of these data, it
appears that the effect of prior stroke/TIA per se on the fre-
quency of ICH after fibrinolysis may be influenced by a
number of factors. However, in patients with STEMI with
prior ischemic stroke and other ICH risk factors who have a
substantial risk for ICH, another reperfusion strategy should
be pursued. Additional contraindications to fibrinolytic ther-
apy include a recent history of significant closed head or
facial trauma (327).
Estimation of risk of ICH. Several models have been devel-
oped for estimating the risk of ICH after fibrinolysis
(246,328-330). These models incorporate baseline demo-
graphic features of the patient and also illustrate the impact
of certain therapeutic decisions (e.g., selection of streptoki-
nase versus tPA; dose of tPA used) (Table 13)
(29,246,329,330). Streptokinase without heparin is the regi-
men associated with the lowest ICH rates (Figure 17)
(29,246,329,330). 
6.3.1.6.3.3. Effect on Mortality
Efficacy of intravenous fibrinolytic therapy in STEMI. It has
now been well established that fibrinolytic therapy provides
a survival benefit for patients with STEMI, based on large,
well-controlled clinical trials (157,261,331,332). The mech-
anisms of benefit, which may have different time dependen-
cies, include salvage of myocardium with reduced infarct
size, favorable effect on infarct healing and myocardial
remodeling, and reduced electrical heterogeneity and poten-
tial for life-threatening ventricular arrhythmia (333). An
overview from 9 trials of fibrinolytic therapy (versus con-
trol) for STEMI has shown a highly significant 18% relative
reduction in 35-day mortality (9.6% fibrinolysis versus
11.5% control), which corresponds to a reduction of 18
deaths per 1000 patients treated when data from all patient
groups are pooled (156). In patients with ST elevation, a rel-
ative mortality reduction of 21% occurred. This survival
benefit is maintained over the long term (up to 10 years)
(334,335). Mortality reduction from fibrinolytic therapy is
greatest within the first hour after symptom onset; thereafter,
a decline in benefit of approximately 1.6 lives per 1000
patients treated is seen per 1-hour delay. Additionally,
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Figure 17. Estimation of risk of ICH with fibrinolysis. ICH = intracranial hemorrhage; CCP = Cooperative Cardiovascular Project;
InTIME-2 = Intravenous nPA for treatment of Infracting Myocardium Early-2; *The number of risk factors is the sum of the points based
on the criteria shown in Table 13. †If the overall incidence of ICH is assumed to be 0.75%, patients without risk factors who receive
streptokinase have a 0.26% probability of ICH. The risk is 0.96%, 1.32%, and 2.17% in patients with 1, 2, or 3 risk factors, respec-
tively. See Simoons et al. (329) for further discussion.
Table 13.  Models for Estimating Risk of ICH
Risk Factor* Model
Simoons et al (329) CCP (246) InTIME-2 (29)
Age, y Greater than 65 = 1 point 75 or greater = 1 point 75 or greater = 1 point
Weight 70 kg or less = 1 point 65 kg or less (women) = 1 point
80 kg or less (men) = 1 point 67 kg or less = 1 point
Hypertension SBP: SBP: SBP:
on admission 170 mm Hg or greater = 1 point 160 mm Hg or greater = 1 point 160 mm Hg or greater = 1 point
DBP: 170 mm Hg or greater = 1 point 170 mm Hg or greater = 1 point
95 mm Hg or greater = 1 point
Both SBP and DBP 
above limits = 1 point 
Treatment 
assignment
rtPA 1 point 1 point –
nPA – – 1 point
Female – 1 point –
Black race – 1 point 1 point
Prior stroke – 1 point 1 point
Prior nifedipine use – – 1 point
Excessive anticoagulation – 1 point –
ICH = intracranial hemorrhage; CCP = Cooperative Cardiovascular Project; InTIME-2 = Intravenous nPA for treatment of Infracting Myocardium Early-2; SBP = systolic blood pressure;
DBP = diastolic blood pressure; rtPA = recombinant alteplase; nPA = lanoteplase.
*The sum of the points for each of the models is used for interpretation of the graphs shown in Figure 17.
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6.3.1.6.3.5. Complications of Fibrinolytic Therapy:
Neurological and Other
Class I
1. The occurrence of a change in neurological status dur-
ing or after reperfusion therapy, particularly within
the first 24 hours after initiation of treatment, is con-
sidered to be due to ICH until proven otherwise.
Fibrinolytic, antiplatelet, and anticoagulant therapies
should be discontinued until brain imaging scan
shows no evidence of ICH. (Level of Evidence: A)
2. Neurology and/or neurosurgery or hematology con-
sultations should be obtained for STEMI patients who
have ICH, as dictated by clinical circumstances. (Level
of Evidence: C)
3. In patients with ICH, infusions of cryoprecipitate,
fresh frozen plasma, protamine, and platelets should
be given, as dictated by clinical circumstances. (Level
of Evidence: C)
Class IIa
In patients with ICH it is reasonable to:
a. Optimize blood pressure and blood glucose levels
(Level of Evidence: C)
b. Reduce intracranial pressure with an infusion of
mannitol, endotracheal intubation, and hyperven-
tilation (Level of Evidence: C)
c. Consider neurosurgical evacuation of ICH (Level
of Evidence: C)
prognostic effect of ventricular dilation, and the potential
effects of a patent infarct artery independent of myocardial
salvage confound the relationship between early reperfusion,
global LV function, and survival. Poor perfusion at the
myocardial cellular level due to microvascular obstruction
further confounds the relationship between early reflow in
the epicardial coronary artery, wall-motion improvement,
and survival. In patients with TIMI 3 flow, those with abnor-
mal myocardial tissue perfusion have worse LV function and
survival than those with normal perfusion. Myocardial blush
on angiography, contrast perfusion on echocardiography, and
prompt complete resolution of ST elevation are measures of
tissue perfusion. Poor perfusion at the myocardial cellular
level is associated with increased morbidity and mortality.
However, the mechanism by which poor tissue perfusion
confers an adverse prognosis is not clear. Evidence of poor
tissue perfusion may be the result of extensive transmural
infarction with tissue edema and increased microvascular
resistance (349). Alternatively, poor microvascular flow may
result from distal embolization of atherothrombotic debris
and hence be a target for therapeutic interventions. Flow in
the infarct artery before PCI is associated with smaller infarct
size and better outcome. Infarct size can be measured with
SPECT sestamibi imaging (350), and this has been done in
more than a dozen randomized trials.
Figure 18. Adjusted probability of death or cerebral bleeding in relation to fibrinolytic therapy in patients with ST-elevation myocar-
dial infarction (STEMI) who were 75 years or older (dotted line) versus that among patients with STEMI not receiving fibrinolysis (solid
line). At 30 days and 1 year this was 23% and 32% versus 26% and 36%, respectively. Modified with permission from Stenestrand
and Wallentin. Arch Intern Med 2003;163:965-71. Copyrighted © 2003, American Medical Association. All rights reserved (342).
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as strongly indicative of PH/intraventricular hemorrhage/
subarachnoid hemorrhage/subdural hematoma/epidural
hematoma until proven otherwise. Fibrinolytic, anticoagu-
lant, antiplatelet, and combined therapies should be discon-
tinued as soon as symptoms and signs are recognized. An
emergency CT scan should be performed as soon as possible
to identify the specific type of hemorrhagic complication and
to measure the volume of hematoma (372,373). It is useful to
document the severity of the coagulopathy, although emer-
gency patient management should not await the results of
laboratory testing. Immediate measures to reduce intracra-
nial pressure are reasonable and include mannitol infusion,
elevation of the head of the bed to 30 degrees, endotracheal
intubation, and hyperventilation to achieve a pCO2 of 25 to
30 mm Hg. Early involvement of neurologists, neurosur-
geons, and hematologists will optimize treatment decisions.
Once PH, intraventricular hemorrhage, subarachnoid hem-
orrhage, subdural hematoma, or epidural hematoma is docu-
mented, the patient should be given 10 U of cryoprecipitate,
which will increase the fibrinogen level by approximately
0.70 grams per liter and the factor VIII level by approxi-
mately 30% in a 70-kg adult. Fresh frozen plasma can be
used as a source of factors V and VIII and as a volume
Hemorrhagic complications of fibrinolytic therapy primari-
ly include ICH and other moderate or severe bleeding that
may or may not require transfusion. The slight but definite
excess risk of ICH occurs predominantly within the first day
of therapy (156). Summaries of the incidence of ICH with
various pharmacological reperfusion regimens are shown in
Table 14 (26-31,33,158,261,320,322,324,331,351-369). 
ICH may refer to parenchymal hemorrhage (PH), intraven-
tricular hemorrhage, subarachnoid hemorrhage, subdural
hematoma, and epidural hematoma. Between 65% and 77%
of ICHs occur within 24 hours of initiation of treatment, up
to 77% occur at lobar/subcortical lobar sites, 15% to 33% are
multiple PHs, and up to 15% are combined PH and subdural
hematoma. Typical presenting features include an acute
change in level of consciousness, unifocal or multifocal neu-
rological signs, coma, headache, nausea, vomiting, and
seizures, at times with acute hypertension. In many cases,
onset is catastrophic and rapidly fatal. 
Management of suspected ICH. An algorithm for the man-
agement of ICH in the STEMI setting is provided in Figure
19 (370,371). Any change in neurological function, particu-
larly in the first 24 hours after treatment, should be regarded
Figure 19. Algorithm for evaluation of intracranial hemorrhage complicating fibrinolytic therapy for ST-elevation myocardial infarction.
PT = prothrombin time; aPTT = activated partial thromboplastin time; LOE = level of evidence; H = hours; sOsm = serum osmolality;
mOsm = milliosmoles; UFH = unfractionated heparin; LMWH = low-molecular weight heparin. *As dictated by clinical circumstances
(see Section 6.3.1.6.3.5). Modified with permission from NINDS rt-PA Stroke Study Group. Stroke 1997;28:1530-40 (370).
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who did not (nondisabling stroke 20% versus 12%, p equals
0.15). Although not definitive, these data suggest that physi-
cians actively consider neurosurgical interventions in select-
ed patients. For patients with spinal epidural hematoma and
significant neurological deficits occurring after fibrinolysis,
early multilevel decompressive laminectomy should be per-
formed to minimize long-term disability (376). Survivors of
PH/subdural hematoma/epidural hematoma should receive
supportive care measures, including physical therapy, occu-
pational therapy, speech therapy, swallowing evaluation,
aspiration precautions, deep vein thrombosis (DVT) prophy-
laxis (pneumatic compression device), antibiotic therapy,
nutritional support, and rehabilitation, where appropriate.
The risk of 30-day mortality from ICH after coronary fibri-
nolysis may be predicted on the basis of prior trial experi-
ence. In GUSTO-I (322), the ICH mortality rate was 59.7%.
Glasgow Coma Scale score, age, time from fibrinolysis to
ICH onset, hydrocephalus, herniation, mass effect, intraven-
tricular hemorrhage, and volume and location of ICH were
significant univariable predictors, with a strong trend (p
equals 0.0546) for neurosurgical evacuation. The multivari-
able model showed that Glasgow Coma Scale score, time
from thrombolysis to ICH onset, ICH volume, and age were
significant predictors of mortality (377). A nomogram has
been developed to calculate the risk of dying of ICH (Figure
20) (377). Prospective studies are needed to confirm the util-
ity of this nomogram.
expander. In patients who are receiving UFH, 1 mg of prota-
mine for every 100 U of UFH given in the preceding 4 hours
may be administered. If the bleeding time is abnormal, infu-
sion of 6 to 8 U of platelets is indicated. In rare cases, antifib-
rinolytic agents, such as epsilon-aminocaproic acid, may be
necessary (374). These replacement/reversal therapies may
theoretically be accompanied by reocclusion of the infarct-
related artery. Control of blood pressure and blood glucose
levels may require a compromise between competing cardi-
ologic and neurological concerns. The decision to use vari-
ous measures to reduce increased intracranial pressure, such
as elevation of the head of the bed to 30 degrees, mannitol,
hyperventilation, and ventriculostomy, may be based on the
consensus of the management team. The use of mannitol and
hyperventilation are reserved for incipient brain herniation
syndromes. After the patient is stabilized, catheter-based
angiography may be necessary if a ruptured berry aneurysm
or arteriovenous malformation is suspected. 
In GUSTO-I (375), 46 (17.2%) of 268 PH/subdural
hematoma patients underwent neurosurgical evacuation by
open craniotomy or burr-hole craniectomy. Patients who
underwent neurosurgical evacuation had significantly higher
30-day survival rates than patients who did not (65.2% ver-
sus 35.1%, p less than 0.001), particularly in patients with
PH. Patients with both PH and subdural hematoma had a
very poor prognosis regardless of surgical treatment. There
was a trend for improved functional status in patients who
underwent neurosurgical evacuation compared with those
Figure 20. Nomogram for prediction of 30-day mortality following intracranial hemorrhage in patients receiving fibrinolysis.
Reproduced with permission from Sloan et al. Circulation 1998;98:1376-82 (377).
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6.3.1.6.3.6. Comparison of Fibrinolytic Agents
All of the fibrinolytic agents currently available and under
investigation are plasminogen activators (378). They work
enzymatically, directly or indirectly, to expose the active
enzymatic center of plasmin. Some comparative features of
the approved fibrinolytic agents for intravenous therapy are
presented in Table 15 (379-381). 
Data from GUSTO-I (25) and GUSTO-III (26) suggest that
accelerated alteplase and reteplase (administered as a double
bolus) with intravenous heparin are effective therapies for
achieving early coronary reperfusion and may provide an
advantage over streptokinase; however, both are substantial-
ly more expensive and confer a slightly greater risk of ICH.
Thus, the cost-benefit ratio is most favorable for alteplase or
reteplase in patients who present early after onset of chest
pain or symptoms and in those with a large area of injury
(e.g., anterior infarction) and at low risk of ICH. In ASSENT-
2, weight-adjusted TNK-tPA (tenecteplase) and alteplase
were compared in 16949 patients. Covariate-adjusted 30-day
mortality was virtually identical (i.e., 6.18% for tenecteplase
and 6.15% for alteplase), which met the predefined criteria
for equivalence. The rates of ICH were also similar (i.e.,
0.93% for tenecteplase and 0.94% for alteplase), but in
patients receiving tenecteplase, there were fewer systemic
mild-to-moderate bleeding complications (26.3% versus
28.95%, p equals 0.0003) and less requirement for blood
transfusion (4.25% versus 5.49%, p equals 0.0002) (28).
There is considerable ongoing investigation into the effec-
tiveness of fibrinolytic therapy with various ancillary thera-
pies (see Section 6.3.1.6.3.8). In 2 studies that evaluated the
combination of hirudin (desirudin) with alteplase and strep-
tokinase, there was no improvement in mortality rate, and the
therapeutic-to-severe bleeding window appeared to be very
narrow (382,383). See Section 6.3.1.6.8.1.3 for further dis-
cussion.
A number of proposals for selection of fibrinolytic regi-
mens after GUSTO-I have been suggested (384-387).
Additional considerations include avoiding the reuse of
streptokinase, preferably indefinitely because of a high
prevalence of potentially neutralizing antibody titers.
Alternatively, Simoons and Arnold (386) proposed consider-
ing primary PCI for those at highest risk (approximately 10%
of patients), alteplase for those at moderate to high risk
(40%), streptokinase for those at low to moderate risk (40%),
and no lytic therapy for those at lowest risk (10%). All of
these recommendations await prospective testing, and no
data are available to determine the best modes for routine
clinical practice.
Current use rates for fibrinolytic therapy. Because many
patients have contraindications or other exclusions for fibri-
nolytic agents, it has been difficult to ascertain the proportion
of patients with ST elevation who fail to receive fibrinolytic
therapy who actually should have received such therapy
(388). Critical to any such assessment of appropriateness of
care, however, is whether the diagnosis of STEMI was sus-
pected on entry into the healthcare system or whether a diag-
nosis made after 12 to 24 hours in the hospital or at some
later point before hospital discharge. Some increase in use
rates probably can be achieved, but contraindications prohib-
it a vast increase in the rate of use of fibrinolysis. 
6.3.1.6.3.7. Net Clinical Benefit
The decision to use reperfusion therapy is based on an esti-
mate of the patient’s underlying risk without treatment, the
expected benefit of the treatment, and the risk of the therapy.
In general, the higher the underlying risk, the more benefit
that can be gained and the fewer the number of patients who
need to be treated to save 1 life. 
Because decisions about reperfusion must be made rapidly
in order for the intervention to be maximally effective, it is
Table 15. Comparison of Approved Fibrinolytic Agents
Streptokinase Alteplase Reteplase Tenecteplase-tPA
Dose 1.5 MU over Up to 100 mg  10 U IV over 2 min 30-50 mg 
30-60 min in 90 min based on weight (379)†
(based on weight)*
Bolus administration No No Yes Yes
Antigenic Yes No No No
Allergic reactions Yes No No No
(hypotension 
most common)
Systemic fibrinogen Marked Mild Moderate Minimal
depletion
90-min patency rates, 50 75 75 (380)
approximate %
TIMI grade 3 flow, % 32 54 60 63
Cost per dose (US $)(381) $613 $2974 $2750 $2833 for 50 mg
MU = mega units.
* olus 15 mg, infusion 0.75 mg/kg times 30 minutes (maximum 50 mg), then 0.5 mg/kg not to exceed 35 mg over the next 60 
minutes
 
to
 
an
 
over-all maximum of 100 mg.
†Intravenous bolus over 5 sec 30 mg for weight less than 60 kg; 35 mg for 60-69 kg; 40 mg for 70-79 mg; 45 mg for 80-89 kg;
 50 mg for 90 kg or more.
(2nd dose 30 min
after the 1st)
Intravenous b
60–70
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rhage from 0.26% to 2.2% (for zero to 4 risk factors).
Although this score uses dichotomous cutpoints for the risk
factors, it is likely that the risk is a continuous function of the
factor (e.g., the higher the blood pressure or the older the
patient, the higher the risk) (322). Also, the studies of risk
were based on older regimens of fibrinolytic therapy and
higher dosages of UFH than are used currently. There is
some evidence that newer agents, with increased fibrin speci-
ficity and bolus administration, may not increase the risk of
ICH, but this issue deserves continued evaluation (156). In
addition, the use of ancillary therapies may influence the risk
of bleeding with fibrinolytic therapy.
6.3.1.6.3.8. Combination Therapy With 
GP IIb/IIIa Inhibitors
Class IIb
1. Combination pharmacological reperfusion with
abciximab and half-dose reteplase or tenecteplase
may be considered for prevention of reinfarction
(Level of Evidence: A) and other complications of
STEMI in selected patients: anterior location of MI,
age less than 75 years, and no risk factors for bleeding.
In two clinical trials of combination reperfusion, the
prevention of reinfarction did not translate into a sur-
vival benefit at either 30 days or 1 year (394a) (Level
of Evidence: B).
2. Combination pharmacological reperfusion with
abciximab and half-dose reteplase or tenecteplase
may be considered for prevention of reinfarction and
other complications of STEMI in selected patients:
anterior location of MI, age less than 75 years, and no
risk factors for bleeding in whom an early referral for
angiography and PCI (i.e., facilitated PCI) is planned.
(Level of Evidence: C)
Class III
Combination pharmacological reperfusion with
abciximab and half-dose reteplase or tenecteplase
should not be given to patients aged greater than 75
years because of an increased risk of ICH. (Level of
Evidence: B)
Studies evaluating the use of glycoprotein IIb/IIIa
inhibitors as the sole means of reperfusion (i.e., without a
fibrinolytic or in conjunction with PCI) do not suggest that
the isolated use of a GP IIb/IIIa inhibitor restores TIMI 3
flow in a sufficient proportion of patients to make it a viable
pharmacologic strategy (395a). To improve rates of achiev-
ing TIMI 3 flow by pharmacological reperfusion therapy,
GP IIb/IIIa antagonists have been combined with fibrinolyt-
ic agents to achieve both platelet disaggregation and fibrinol-
ysis (395). The phase 2 angiographic studies, TIMI-14,
SPEED (Strategies for Patency Enhancement in the
Emergency Department), and Intro AMI (Integrilin and low-
Dose Thrombolysis in Acute Myocardial Infarction)
(369,396,397), have demonstrated higher TIMI 3 flow rates
at 60 to 90 minutes. When combination therapy is used, the
not possible to take the time to confirm the diagnosis of
STEMI before administration of therapy. Data from the
Multicenter Chest Pain Study suggest that approximately
80% of patients with chest pain and ST-segment elevation
who present to the ED are having a STEMI (227). 
Several prediction models for short-term (30 days)
(240,242,298,389-393) and long-term (1 to 6 years)
(392,393) mortality after reperfusion therapy for STEMI
have been developed. These models have been derived from
clinical trials (240,242,389,394), administrative data sets
(298,390,392), and registries (391), and some have been val-
idated in other clinical trials (242) or registries (391,394).
Performance for some of these risk-prediction models, as
defined by the area under the receiver operating characteris-
tic curve, c-index, or standardized mortality ratio, is similar,
with c-indices ranging from 0.74 to 0.80 and correlation
coefficients for the standardized mortality ratios ranging
from 0.89 to 0.92 (298). The TIMI risk score developed in
the InTIME-II trial (242) performs well compared with data
from the TIMI-9 trial and NRMI-3 (394). In NRMI-3, prog-
nostic discriminatory capacity was similar between patients
who received fibrinolytics and primary PCI (c-index equals
0.80). Substantial differences in predicted mortality rates
(greater than 5%) between those patients who did or did not
receive reperfusion therapy were observed if the TIMI risk
score was greater than or equal to 7 (394). 
The expected benefit of fibrinolytic therapy can be estimat-
ed from the clinical trials (156,282). The fibrinolytic trials
showed “absolute mortality reductions of about 30 per 1000
for those presenting within 0-6 h and of about 20 per 1000
for those presenting 7 to 12 h from onset, and a statistically
uncertain benefit of about 10 per 1000 for those presenting at
13 to 18 h (with more randomized evidence needed in this
latter group to assess reliably the net effects of treatment)”
(156). The relative benefit, however, appeared to vary by age,
with a smaller relative reduction in risk for the oldest
patients. 
The major risk of pharmacological reperfusion therapy is
life-threatening hemorrhage (105). (See Section 6.3.1.6.3.2
for further information.) A study among Medicare patients
identified older age, female sex, black race, prior stroke, sys-
tolic blood pressure greater than or equal to 160 mm Hg,
lower weight (less than or equal to 65 kg for women, less
than or equal to 80 kg for men), excessive anticoagulation
(international normalized ratio [INR] greater than or equal to
4, prothrombin time greater than or equal to 24 sec), and
choice of fibrinolytic therapy (tPA associated with greater
risk than streptokinase) as risk factors for intracranial bleed-
ing (246). Patients with none or 1 of these factors had a risk
of 0.69% for intracranial bleeding, whereas those with 5 or
more factors had a risk of 4.1%. Simoons et al., using data
primarily from trials, identified older age, lower body weight
(less than 70 kg), systolic blood pressure greater than or
equal to 170 mm Hg or diastolic blood pressure greater than
or equal to 95 mm Hg, and the use of tPA (versus streptoki-
nase) as risk factors (329). Using these factors, a risk score
was developed that classified patients with a risk of hemor-
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dose of fibrinolytic agent is reduced by 50%. A large-scale
mortality study, GUSTO-V (30), tested half-dose reteplase (5
U and 5 U) and full-dose abciximab (abciximab 0.25 mg/kg
bolus and 0.125 mcg/kg/min [maximum of 10 mcg/min] for
12 hours) compared with full-dose reteplase (10 U and 10 U)
in 16 588 patients in the first 6 hours of STEMI. Thirty-day
mortality rates were similar in the 2 groups (5.9% versus
5.6%). However, nonfatal reinfarction rates were reduced in
the combination therapy group (2.3% versus 3.5%, p less
than 0.0001), as were other complications of MI, including
VF and tachycardia, high-grade AV block, and septal or free-
wall rupture. ICH rates were the same (0.6%), but moderate
to severe bleeding was significantly increased from 2.3% to
4.6% (p less than 0.001). Excess bleeding risks appear to be
limited to those over the age of 75 years, and the greatest
mortality benefit was seen for those with anterior MI. ICH
rates for those older than 75 years were 2.1% versus 1.1% (p
equals 0.069) for combination versus full-dose reteplase. In
contrast, the rates were similar for those younger than 75
years (0.5% versus 0.4%). However, there was an interaction
between age and risk of ICH with therapy. Younger patients
(age less than 70 years) appeared to have significantly lower
ICH rates with combination therapy (398). Despite the
reduction in reinfarction by combination therapy, the 1-year
mortality rates were the same (8.38%) in both groups (399).
Although early reinfarction was associated with a marked
increase in 1-year mortality, (22.6% versus 8.0% without
reinfarction), this did not result in an overall mortality differ-
ence owing to the low reinfarction rates. For those younger
than 75 years with anterior MI, 30-day mortality was 4.4%
for combination therapy versus 5.8% (p equals 0.029) for
full-dose rPA, and 1-year mortality was 7.1% versus 8.0% (p
equals 0.260), respectively. 
ASSENT-3 (31) randomized 6095 patients with STEMI to
full-dose tenecteplase with UFH versus full-dose tenecteplase
with enoxaparin or half-dose tenecteplase plus abciximab plus
weight-adjusted, reduced-dose UFH. Similar to the GUSTO-
V trial, combination of abciximab (abciximab 0.25 mg/kg
bolus and 0.125 mcg/kg/min [maximum of 10 mcg/min] for
12 hours) and half-dose tenecteplase did not reduce mortality
compared with full-dose tenecteplase but did result in signifi-
cantly reduced in-hospital infarction and refractory ischemia.
Notably, the major bleeding rate other than ICH, which was
the same in the 2 groups, was increased from 2.2% to 4.3% (p
less than 0.0005). Those over the age of 75 years were at
greatest risk for excess bleeding, with a 3-fold increase in
major bleeding complications. The tenecteplase plus enoxa-
parin arm showed superiority compared with UFH (see
Section 6.3.1.7.8.2.1). The need for urgent PCI was reduced
in the GP IIb/IIIa antagonist and fibrinolytic combination
therapy arms in both trials. The heparin regimen, when com-
bination therapy is used, is a weight-adjusted bolus of 40 U/kg
(ASSENT-3) or 60 U/kg (GUSTO-V) followed by a reduced
infusion dose of 7 U/kg/h. The lower bolus dose is preferable
for patients who have an increased risk for bleeding.
Given the observation that patients with TIMI 3 flow before
primary PCI have the best outcomes (346) and given the role
of GP IIb/IIIa antagonists in PCI, some have hypothesized
that administration of combination GP IIb/IIIa antagonists
and half-dose fibrinolytics will facilitate primary PCI, partic-
ularly when it cannot be accomplished very rapidly. This
remains to be tested prospectively in appropriately sized tri-
als. Combination pharmacological reperfusion regimens may
be associated with a slightly higher frequency of ICH and a
slightly lower frequency of cerebral infarction and stroke of
unknown cause than other reperfusion regimens (Table 14)
(26-30,31,33,158,261,320,322,324,331,351-369,400). 
6.3.1.6.4. PERCUTANEOUS CORONARY INTERVENTION.
Percutaneous coronary intervention is a very effective
method for re-establishing coronary perfusion and is suitable
for at least 90% of patients. Considerable data (40,282,401)
support the use of PCI for patients with STEMI. Reported
rates of achieving TIMI 3 flow range from 70% to 90%.
There is a 15% reocclusion rate after PTCA and a 5% reoc-
clusion rate after stenting (402). Although most evaluations
of PCI have been in patients who are eligible to receive fib-
rinolytic therapy, considerable experience supports the value
of PCI for patients who may not be suitable for fibrinolytic
therapy because of an increased risk of bleeding (403).
6.3.1.6.4.1. Coronary Angiography
Class I
Diagnostic coronary angiography should be per-
formed:
a. In candidates for primary or rescue PCI. (Level of
Evidence: A)
b. In patients with cardiogenic shock who are candi-
dates for revascularization. (Level of Evidence: A)
c. In candidates for surgical repair of ventricular sep-
tal rupture (VSR) or severe MR. (Level of
Evidence: B)
d. In patients with persistent hemodynamic and/or
electrical instability. (Level of Evidence: C)
Class III
Coronary angiography should not be performed in
patients with extensive comorbidities in whom the
risks of revascularization are likely to outweigh the
benefits. (Level of Evidence: C)
Acute cardiac catheterization has been proposed as an
anatomic risk stratification strategy. A subset of patients will
have severe 3-vessel or left main disease or anatomic features
unfavorable for PCI and may be candidates for urgent or
emergency CABG. Another subset of patients will have
spontaneously reperfused and will have minimal evidence of
atherosclerotic obstruction. They can be treated medically,
which avoids the risks of fibrinolytic therapy or PCI.
Additionally, identification of high-risk patients may facili-
tate additional strategies that will improve outcome, whereas
low-risk patients may be eligible for early hospital discharge.
Coronary angiography should not be performed in patients
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with extensive comorbidities or who will not consent to
coronary revascularization regardless of the findings.
6.3.1.6.4.2. Primary PCI
See Table 11 for additional consideration for selecting reper-
fusion therapy.
Class I
1. General considerations: If immediately available, pri-
mary PCI should be performed in patients with
STEMI (including true posterior MI) or MI with new
or presumably new LBBB who can undergo PCI of
the infarct artery within 12 hours of symptom onset, if
performed in a timely fashion (balloon inflation with-
in 90 minutes of presentation) by persons skilled in the
procedure (individuals who perform more than 75
PCI procedures per year). The procedure should be
supported by experienced personnel in an appropri-
ate laboratory environment (a laboratory that per-
forms more than 200 PCI procedures per year, of
which at least 36 are primary PCI for STEMI, and has
cardiac surgery capability). (Level of Evidence: A)
2. Specific considerations:
a. Primary PCI should be performed as quickly as
possible with a goal of a medical contact–to-balloon
or door-to-balloon interval of within 90 minutes.
(Level of Evidence: B)
b. If the symptom duration is within 3 hours and the
expected door-to-balloon time minus the expected
door-to-needle time is:
i) within 1 hour, primary PCI is generally pre-
ferred. (Level of Evidence: B)
ii) greater than 1 hour, fibrinolytic therapy (fibrin-
specific agents) is generally preferred. (Level of
Evidence: B)
c. If symptom duration is greater than 3 hours, pri-
mary PCI is generally preferred and should be per-
formed with a medical contact–to-balloon or door-
to-balloon interval as short as possible and a goal of
within 90 minutes. (Level of Evidence: B)
d. Primary PCI should be performed for patients less
than 75 years old with ST elevation or LBBB who
develop shock within 36 hours of MI and are suit-
able for revascularization that can be performed
within 18 hours of shock unless further support is
futile because of the patient’s wishes or contraindi-
cations/unsuitability for further invasive care.
(Level of Evidence: A)
e. Primary PCI should be performed in patients with
severe CHF and/or pulmonary edema (Killip class
3) and onset of symptoms within 12 hours. The
medical contact–to-balloon or door-to-balloon time
should be as short as possible (i.e., goal within 90
minutes). (Level of Evidence: B)
Class IIa
1. Primary PCI is reasonable for selected patients 75
years or older with ST elevation or LBBB or who
develop shock within 36 hours of MI and are suitable
for revascularization that can be performed within 18
hours of shock. Patients with good prior functional
status who are suitable for revascularization and
agree to invasive care may be selected for such an
invasive strategy. (Level of Evidence: B)
2. It is reasonable to perform primary PCI for patients
with onset of symptoms within the prior 12 to 24
hours and 1 or more of the following:
a. Severe CHF (Level of Evidence C)
b. Hemodynamic or electrical instability (Level of
Evidence: C)
c. Persistent ischemic symptoms. (Level of Evidence: C)
Class IIb
The benefit of primary PCI for STEMI patients eligi-
ble for fibrinolysis is not well established when per-
formed by an operator who performs fewer than 75
PCI procedures per year. (Level of Evidence: C)
Class III
1. PCI should not be performed in a noninfarct artery at
the time of primary PCI in patients without hemody-
namic compromise. (Level of Evidence: C)
2. Primary PCI should not be performed in asympto-
matic patients more than 12 hours after onset of
STEMI if they are hemodynamically and electrically
stable. (Level of Evidence: C)
Primary PCI has been compared with fibrinolytic therapy
in 22 randomized clinical trials (173,177,306,307,404-421).
An additional trial, SHOCK (301), which compared medical
stabilization with immediate revascularization for cardio-
genic shock, was included along with the above 22 trials in
an overview of primary PCI versus fibrinolysis (40). These
investigations demonstrate that PCI-treated patients experi-
ence lower short-term mortality rates (5.0% versus 7.0%, RR
0.70, 95% CI 0.58 to 0.85, p equals 0.0002), less nonfatal
reinfarction (3.0% versus 7.0%, RR 0.35, 95% CI 0.27 to
0.45, p equals 0.0003), and less hemorrhagic stroke (0.05%
versus 1.0%, RR 0.05, 95% CI 0.006 to 0.35, p equals
0.0001) than those treated by fibrinolysis but with an
increased risk for major bleeding (7.0% versus 5.0%, RR 1.3,
CI 1.02 to 1.65, p equals 0.032) (40). These results were
achieved in medical centers with experienced providers and
under circumstances in which PCI could be performed
promptly after patient presentation (Figure 14) (40).
Additional considerations that affect the magnitude of the
difference between PCI- and fibrinolysis-treated patients
include the fact that UFH was used as the antithrombin with
fibrinolytics as opposed to other antithrombins such as
enoxaparin (see Section 6.3.1.6.8.1.1) or bivalirudin (see
Section 6.3.1.6.8.1.2) that are associated with a reduction in
the rate of recurrent MI after fibrinolysis; a smaller but sta-
tistically significant advantage for PCI compared with a fib-
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between arrival and restoration of TIMI 3 flow (door-
to–TIMI 3 flow time), further underscoring the importance
of timely reperfusion in patients who undergo primary PCI
(429). Importantly, after adjustment for baseline characteris-
tics, time from symptom onset to balloon inflation is signifi-
cantly correlated with 1-year mortality in patients undergo-
ing primary PCI for STEMI (RR equals 1.08 for each 30-
minute delay from symptom onset to balloon inflation, p
equals 0.04) (Figure 21) (275). Given that the door-to-needle
time goal is 30 minutes, this Writing Committee joins the
Task Force on the Management of Acute Myocardial
Infarction of the European Society of Cardiology in lowering
the recommended medical contact–to-balloon or door-to-bal-
loon time goal from 120 to 90 minutes in an attempt to max-
imize the benefits for reperfusion by PCI (297) (Figure 22)
(294). 
If the expected door-to-balloon time exceeds the expected
door-to-needle time by more than 60 minutes, fibrinolytic
treatment with a fibrin-specific agent should be considered
unless it is contraindicated. This is particularly important
when symptom duration is less than 3 hours but is less
important with longer symptom duration, when less ischemic
myocardium can be salvaged. In both the CAPTIM trial
(173), which showed lower mortality with prehospital fibri-
nolysis than with primary PCI, and the PRAGUE-2 trial
(177), which showed lower mortality with primary PCI after
interhospital transfer than with on-site fibrinolysis, PCI was
superior to fibrinolysis when symptom duration was greater
than 2 to 3 hours but not when symptom duration was short-
er (see Section 6.3.1.6.2.1). In the early hours of STEMI,
prompt fibrinolytic therapy can decrease infarct size and the
risk of developing cardiogenic shock (176).
6.3.1.6.4.2.1. Complications of primary PCI.
Potential complications of an invasive strategy for treating
STEMI include problems with the arterial access site;
adverse reactions to volume loading, contrast medium, and
antithrombotic medications; technical complications; and
reperfusion events. Reocclusion occurs in 10% to 15% of
patients after PTCA but in fewer than 5% after stent implan-
tation. Likewise, angiographic restenosis occurs in 30% to
40% of patients after PTCA but in 15% to 20% after stent
implantation. The management of these complications is
beyond the scope of this guideline (430-432).
6.3.1.6.4.2.2. Primary PCI in 
fibrinolytic-ineligible patients.
Class I
Primary PCI should be performed in fibrinolytic-
ineligible patients who present with STEMI within 12
hours of symptom onset. (Level of Evidence: C)
Class IIa
It is reasonable to perform primary PCI for fibri-
nolytic-ineligible patients with onset of symptoms
within the prior 12 to 24 hours and 1 or more of the
following:
rin-specific fibrinolytic versus streptokinase; and variation
among the PCI arms as to whether a stent was implanted or
GP IIb/IIIa antagonists were administered. Figure 14 shows
the short-term and long-term outcomes of patients with
STEMI treated by fibrinolysis versus PCI and the number of
patients who need to be treated to prevent 1 event or cause 1
harmful complication when selecting PCI instead of fibrinol-
ysis as the reperfusion strategy (Figure 14) (40). When pri-
mary PCI is compared with tPA and the SHOCK trial is
excluded, the mortality rate is 5.5% versus 6.7% (OR 0.81%,
95% CI 0.64 to 1.03, p equals 0.081) (421a).
There is serious and legitimate concern that a routine poli-
cy of primary PCI for patients with STEMI will result in
unacceptable delays in achieving reperfusion in a substantial
number of cases and produce less than optimal outcomes if
performed by less-experienced operators. The mean time
delay for PCI instead of fibrinolysis in the randomized stud-
ies was approximately 40 minutes (40). Strict performance
criteria must be mandated for primary PCI programs so that
long door-to-balloon times and performance by low-volume
or poor-outcome operators/laboratories do not occur.
Interventional cardiologists and centers should strive for out-
comes to include 1) medical contact–to-balloon or door-to-
balloon times less than 90 minutes, 2) TIMI 2/3 flow rates
obtained in more than 90% of patients, 3) emergency CABG
rate less than 2% among all patients undergoing the proce-
dure, 4) actual performance of PCI in a high percentage of
patients (85%) brought to the laboratory, and 5) risk-adjust-
ed in-hospital mortality rate less than 7% in patients without
cardiogenic shock. This would result in a risk-adjusted mor-
tality rate with PCI comparable to that reported for fibri-
nolytic therapy in fibrinolytic-eligible patients (40) and
would be consistent with previously reported registry experi-
ence (422-425). Otherwise, the focus of treatment should be
the early use of fibrinolytic therapy (Figure 14) (40).
PCI appears to have its greatest mortality benefit in high-
risk patients. In patients with cardiogenic shock, an absolute
9% reduction in 30-day mortality with coronary revascular-
ization instead of immediate medical stabilization was
reported in the SHOCK trial (301). In NRMI-II, patients with
CHF had a 33% relative risk reduction with primary PCI
compared with a 9% relative risk reduction with fibrinolytic
therapy (302). Primary PCI in patients with anterior STEMI
reduces mortality compared with fibrinolytic therapy, but
there is no difference in patients with nonanterior STEMI
(426,427).
Time from symptom onset to reperfusion is an important
predictor of patient outcome. Two studies (294,295) have
reported increasing mortality rates with increasing door-to-
balloon times. Other studies have shown smaller infarct size,
better LV function, and fewer complications when reperfu-
sion occurs before PCI (345,346,428). An analysis of the ran-
domized controlled trials that compared fibrinolysis with a
fibrin-specific agent versus primary PCI suggests that the
mortality benefit with PCI exists when treatment is delayed
by no more than 60 minutes (Figure 15) (305). Mortality
increases significantly with each 15-minute delay in the time
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data are available to characterize the value of primary PCI for
this subset of patients with STEMI; however, the recommen-
dations in Section 4.2 are applicable to these patients.
Nevertheless, these patients are at increased risk for mortali-
ty (433), and there is a general consensus that PCI is an
appropriate means for achieving reperfusion in those who
cannot receive fibrinolytics because of increased risk of
bleeding (403,434-436).
a. Severe CHF (Level of Evidence: C)
b. Hemodynamic or electrical instability (Level of
Evidence: C)
c. Persistent ischemic symptoms. (Level of Evidence: C)
Randomized controlled trials evaluating the outcome of
PCI for patients who present with STEMI but who are ineli-
gible for fibrinolytic therapy have not been performed. Few
Figure 21. Symptom onset-balloon time and mortality in primary PCI for ST-elevation myocardial infarction. RCT = randomized con-
trolled trial; PCI = percutaneous coronary intervention. The relationship between time-to-treatment and 1-year mortality, as continuous
functions, was assessed using a quadratic regression model. The dotted lines represent 95% confidence intervals of the predicted
mortality. Modified with permission from De Luca. Circulation 2004;109:1223-25 (275).
Figure 22. Relationship between 30-day mortality and time from study enrollment to first balloon inflation. Patients assigned to angio-
plasty in whom angioplasty was not performed are also shown. PTCA = percutaneous transluminal coronary angioplasty. Reprinted
with permission from Berger et al. Circulation 1999;100:14-20 (294).
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6.3.1.6.4.2.3. Primary PCI without 
on-site cardiac surgery.
Class IIb
Primary PCI might be considered in hospitals without
on-site cardiac surgery, provided that a proven plan
for rapid transport to a cardiac surgery operating
room exists in a nearby hospital with appropriate
hemodynamic support capability for transfer. The
procedure should be limited to patients with STEMI
or MI with new, or presumably new, LBBB on ECG,
and should be done in a timely fashion (balloon infla-
tion within 90 minutes of presentation) by persons
skilled in the procedure (at least 75 PCIs per year) and
at hospitals performing a minimum of 36 primary
PCI procedures per year. (Level of Evidence: B)
Class III
Primary PCI should not be performed in hospitals
without on-site cardiac surgery capabilities and with-
out a proven plan for rapid transport to a cardiac sur-
gery operating room in a nearby hospital or without
appropriate hemodynamic support capability for
transfer. (Level of Evidence: C)
Reports on emergency primary PCI from hospitals without
established open heart surgery or elective PCI programs have
demonstrated generally favorable results (307,437-450). PCI
in the early phase of an acute STEMI can be difficult and
requires even more skill and experience than routine PCI in
the stable patient. The need for an experienced operator and
experienced laboratory technical support with availability of
the broad range of catheters, guidewires, stents, and other
devices (e.g., intra-aortic balloon pump [IABP]) required for
optimum results in an acutely ill patient is of major impor-
tance. Careful patient selection and continuous quality
improvement are critical components of a successful pro-
gram. If these complex patients are treated by interventional-
ists with limited experience at hospitals with low volume,
then the gains of early intervention may be lost because of
increased complications. In such circumstances, transfer to a
center that routinely performs complex PCI will often be a
more effective and efficient course of action. Fibrinolysis is
an acceptable form of therapy and is preferable to primary
PCI by an inexperienced team.
Criteria have been suggested for the performance of pri-
mary PCI at hospitals without on-site cardiac surgery
(432,445) (Tables 16 and 17). Large-scale registries have
shown an inverse relationship between the number of pri-
mary PCI procedures performed and in-hospital mortality
(295,303,304). The data suggest that both door-to-balloon
time and in-hospital mortality are significantly lower in insti-
tutions that perform a minimum of 36 primary PCI proce-
dures per year (295). Suboptimal results may relate to oper-
ator/staff inexperience and capabilities and to delays in per-
forming PCI for logistical reasons. From clinical data and
expert consensus, the Committee recommends that primary
PCI for acute STEMI performed at hospitals without estab-
lished elective PCI programs should be restricted to those
institutions capable of performing a requisite minimum num-
ber of primary PCI procedures (36 per year) with a proven
plan for rapid and effective PCI and rapid access to cardiac
surgery in a nearby hospital. The benefit of primary PCI is
not well established for operators who perform fewer than 75
PCIs per year or in a hospital that performs fewer than 36 pri-
mary PCI procedures per year. In addition, the benefit of
timely reperfusion of the infarct artery by primary PCI at
sites without on-site surgery must be weighed against the
small but finite risk of harm to the patient related to the time
required to transfer the patient to a site with CABG surgery
capabilities (452,453).
Table 16. Criteria for Performance of Primary PCI at Hospitals
Without Onsite Cardiac Surgery
The operators must be experienced interventionalists who regularly
perform elective PCI at a surgical center (at least 75 cases/year).
The catheterization laboratory must perform a minimum of 36 pri-
mary PCI procedures per year.
The nursing and technical catheterization laboratory staff must be
experienced in handling acutely ill patients and must be comfort-
able with interventional equipment. They must have acquired expe-
rience in dedicated interventional laboratories at a surgical center.
They participate in a 24-hour, 365-day call schedule.
The catheterization laboratory itself must be well equipped, with
optimal imaging systems, resuscitative equipment, and IABP sup-
port, and must be well stocked with a broad array of interventional
equipment.
The cardiac care unit nurses must be adept in hemodynamic monitor-
ing and IABP management.
The hospital administration must fully support the program and
enable the fulfillment of the above institutional requirements.
There must be formalized written protocols in place for immediate
and efficient transfer of patients to the nearest cardiac surgical
facility that are reviewed/tested on a regular (quarterly) basis.
Primary PCI must be performed routinely as the treatment of choice
around the clock for a large proportion of patients with STEMI, to
ensure streamlined care paths and increased case volumes.
Case selection for the performance of primary PCI must be rigorous.
Criteria for the types of lesions appropriate for primary PCI and for
the selection for transfer for emergent aortocoronary bypass sur-
gery are shown in Table 17.
There must be an ongoing program of outcomes analysis and formal-
ized periodic case review.
Institutions should participate in a 3- to 6-month-period of imple-
mentation, during which time development of a formalized primary
PCI program is instituted that includes establishment of standards,
training of staff, detailed logistic development, and creation of a
quality assessment and error management system.
PCI = percutaneous coronary intervention; IABP = intra-aortic balloon pump; STEMI =
ST-elevation myocardial infarction.
Modified from Wharton et al. J Am Coll Cardiol 1999;33:1257-65 (445).
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6.3.1.6.4.2.4. Interhospital transfer for primary PCI.
The enthusiasm for primary PCI has led to the concept of
emergency interhospital transfer for catheter-based reperfu-
sion rather than fibrinolytic therapy in the initial hospital
(454-456). Complication rates are low during transport, but
time to reperfusion is delayed, which results in larger infarct
size and lower LVEF (457). However, as noted in Section
6.3.1.6.2.1, selection bias of patients enrolled in randomized
trials likely resulted in an underestimation of the risk of inter-
hospital transfer expected in routine practice. Five random-
ized trials enrolled 2466 patients, with favorable results for
PCI versus fibrinolytic therapy (177,306,408,419,421).
Mortality was reduced with PCI (6.8% versus 9.6%, RR
0.69, 95% CI 0.51 to 0.0.92, p equals 0.01), as was the com-
bined end point of death, nonfatal reinfarction, and stroke
(8.5% versus 15.5%, RR 0.51, 95% CI 0.39 to 0.65, p less
than 0.0001). Importantly, mean time to treatment was
delayed only 44 minutes in these studies (Figure 23)
(177,306). In contrast, the time from presentation at the door
of the first hospital to balloon inflation in the second hospi-
tal, as recorded in 1346 patients in NRMI-4, was 185 minutes
in the United States in 2002 (Figure 24) (458). Emergency
transport in Europe is centrally organized and more efficient
than in the United States (Table 18)
(177,306,408,419,421,459) (Van de Werf; oral presentation,
American College of Cardiology 52nd Annual Scientific
Session, Chicago, IL, March 2003). Delays in door-to-bal-
loon time versus door-to-needle time of more than 60 min-
utes because of interhospital transfer might negate the poten-
tial mortality benefit of transfer for primary PCI over imme-
Table 17. Patient Selection for Primary PCI and Emergency Aorto-
Coronary Bypass at Hospitals Without Onsite Cardiac Surgery (445)
Avoid intervention in hemodynamically stable patients with:
Significant (greater than or equal to 60%) stenosis of an unpro-
tected left main coronary artery upstream from an acute occlu-
sion in the left coronary system that might be disrupted by the 
angioplasty catheter
Extremely long or angulated infarct-related lesions with TIMI 
grade 3 flow
Infarct-related lesions with TIMI grade 3 flow in stable patients 
with 3-vessel disease (432)
Infarct-related lesions of small or secondary vessels
Hemodynamically significant lesions in other than the infarct 
artery
Transfer for emergency aortocoronary bypass surgery patients:
After primary PCI of occluded vessels if high-grade residual left 
main or multivessel coronary disease with clinical or hemo-
dynamic instability present
Preferably with IABP support
PCI = percutaneous coronary intervention; TIMI = Thrombolysis in Myocardial Infarction;
IABP = intra-aortic balloon pump.
Figure 23. Comparison of elapsed time to fibrinolysis versus primary PCI. Time is presented as a continuous variable in minutes on
the horizontal axis. For DANAMI-2, times reflect components of delay from symptom onset to randomization (vertical bar) and are fur-
ther separated according to whether patients presented at community referral hospitals versus those equipped for primary PCI. For
those patients randomized to PCI at a referral hospital, the 3 components of delay after randomization are related to duration of stay
at referral hospital, time for transport to PCI hospital and delay from arrival at PCI hospital to balloon inflation. PCI = percutaneous
coronary intervention; Rand = Randomization; SK = streptokinase; Transp = Transportation. PRAGUE-2 data modified from Widimsky
et al. Eur Heart J 2003; 24:94-104.
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better immediate angiographic result with a larger arterial
lumen, less reocclusion and restenosis of the infarct-related
artery, and fewer subsequent ischemic events. 
Primary stenting has been compared with primary angio-
plasty in 9 studies (38,37,460-467). There were no differ-
ences in mortality (3.0% versus 2.8%) or reinfarction (1.8%
versus 2.1%) rates. However, major adverse cardiac events
were reduced, driven by the reduction in subsequent target-
vessel revascularization with stenting (Figure 25) (37).
Preliminary reports suggest that compared with conven-
tional bare metal stents, drug-eluting stents are not associat-
ed with increased risk when used for primary PCI in patients
with STEMI (468). Postprocedure vessel patency, biomarker
release, and the incidence of short-term adverse events were
similar in patients receiving sirolimus (n equals 186) or bare
metal (n equals 183) stents. Thirty-day event rates of death,
reinfarction, or revascularization were 7.5% versus 10.4%,
respectively (p equals 0.4) (468).
diate intravenous fibrinolysis with a fibrin-specific agent as
shown in these trials (305). To achieve optimal results, time
from the first hospital door to the balloon inflation in the sec-
ond hospital should be as short as possible, with a goal of
within 90 minutes. Significant reductions in door-to-balloon
times might be achieved by directly transporting patients to
PCI centers rather than transporting them to the nearest hos-
pital, if interhospital transfer will subsequently be required to
obtain primary PCI.
6.3.1.6.4.3. Primary Stenting
Of the 22 randomized trials that compared primary PCI with
fibrinolytic therapy, 12 involved a comparison of primary
PCI with stenting and fibrinolytic therapy
(40,173,177,306,307,408,409,414,417-421). These investi-
gations demonstrate that PCI-treated patients experience
lower mortality rates (5.9% versus 7.7%, OR 0.75, 95% CI
0.60 to 0.94, p equals 0.013), less reinfarction (1.6% versus
5.1%, OR 0.31, 95% CI 0.21 to 0.44, p equals 0.0001), and
less hemorrhagic stroke than those treated by fibrinolysis
(40). Compared with PTCA, intracoronary stents achieve a
Figure 24. Door-to-balloon times: patients transferred in NRMI 4. Data are expressed in minutes as median time (25th percentile-75th
percentile) Cath Lab = catheterization laboratory. Modified from NRMI-4 Investigators: The National Registry of Myocardial Infarction-
4 Quarterly Report. Genentech, South San Francisco, CA; March, 2003:2 (458).
Table 18. Transport of Patients With STEMI for Primary PCI
Time Between Randomization 
Study (Reference) No. Transported Distance, km and First Balloon Inflation, min
Vermeer et al. (419) 75 25-50 85*
PRAGUE-1 (408) 101 5-74 80*
AIR-PAMI (421) 71 51 plus or minus 58* 155†
PRAGUE-2 (177) 429 5-120 97*
DANAMI-2 (306) 559 3-150 90†
Total 1235 3-150
*Mean.
†Median.
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trials of facilitated PCI with a variety of pharmacological
regimens are in progress (473a).
6.3.1.6.4.5. Rescue PCI
Class I
1. Rescue PCI should be performed in patients less than
75 years old with ST elevation or LBBB who develop
shock within 36 hours of MI and are suitable for
revascularization that can be performed within 18
hours of shock unless further support is futile because
of the patient’s wishes or contraindications/unsuit-
ability for further invasive care. (Level of Evidence: B)
2. Rescue PCI should be performed in patients with
severe CHF and/or pulmonary edema (Killip class 3)
and onset of symptoms within 12 hours. (Level of
Evidence: B)
Class IIa
1. Rescue PCI is reasonable for selected patients 75 years
or older with ST elevation or LBBB or who develop
shock within 36 hours of MI and who are suitable for
revascularization that can be performed within 18
hours of shock. Patients with good prior functional
status who are suitable for revascularization and who
agree to invasive care may be selected for such an
invasive strategy. (Level of Evidence: B)
2. It is reasonable to perform rescue PCI for patients
with 1 or more of the following:
a. Hemodynamic or electrical instability (Level of
6.3.1.6.4.4. Facilitated PCI
Class IIb
Facilitated PCI might be performed as a reperfusion
strategy in higher-risk patients when PCI is not imme-
diately available and bleeding risk is low. (Level of
Evidence: B)
Facilitated PCI refers to a strategy of planned immediate
PCI after an initial pharmacological regimen such as full-
dose fibrinolysis, half-dose fibrinolysis, a GP IIb/IIIa
inhibitor, or a combination of reduced-dose fibrinolytic ther-
apy and a platelet GP IIb/IIIa inhibitor. Facilitated PCI
should be differentiated from primary PCI without fibrinoly-
sis or GP IIb/IIIa inhibitor therapy, from primary PCI with a
GP IIb/IIIa inhibitor started at the time of PCI, and from res-
cue PCI after unsuccessful fibrinolysis. Potential advantages
include earlier time to reperfusion, improved patient stabili-
ty, greater procedural success rates, higher TIMI flow rates,
and improved survival rates (36,346,428,469,470). However,
preliminary studies have not demonstrated any benefit in
reducing infarct size or improving outcomes (471-473). It is
unlikely that this strategy would be beneficial in low-risk
patients.
A strategy of facilitated PCI holds promise in higher-risk
patients when PCI is not immediately available. Potential
risks include increased bleeding complications, especially in
those 75 years of age or older (see Section 6.3.1.6.3.8), and
potential limitations include added cost. Several randomized
Figure 25. Primary stenting versus primary angioplasty. Odds Ratios and their 95% confidence intervals for primary stenting versus
primary angioplasty for the risk of death, reinfarction, target vessel revascularization (TVR), and major adverse cardiac events (MACE)
over a 6- to 12-month follow-up after ST-elevation myocardial infarction (STEMI). The meta-analysis was performed without (subtotal)
and with (total) the abciximab arms of the CADILLAC trial. Modified from Zhu M et al. Am J Cardiol 2001;88:299. Copyright 2001, with
permission from Excerpta Medica, Inc. (37).
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Rescue PCI fails to reestablish antegrade coronary flow in
approximately 10% of patients, and reocclusion of the infarct
artery occurs in as many as 20% of the remainder (481),
although use of GP IIb/IIIa inhibitors and stent implantation
may improve these results. Unsuccessful rescue PCI is asso-
ciated with a high mortality rate (482,483). Finally, coronary
reperfusion occurs over the subsequent hours after fibri-
nolytic therapy in many patients. Although infarct artery
patency is achieved in only 50% to 85% of patients 90 min-
utes after fibrinolytic therapy, it rises to 90% by 24 hours
(474). Such late reperfusion may improve survival without
the risk of invasive procedures coupled with fibrinolytic ther-
apy. Confounding the issue, both fibrinolytic therapy and
PCI may successfully restore flow in the epicardial artery but
fail to improve microvascular perfusion.
Hours to days after failed fibrinolysis. Patency of the infarct-
related artery is an important predictor of mortality in sur-
vivors of STEMI (475,476). Compared with those with a
patent infarct artery, survivors of STEMI with a persistently
occluded artery after fibrinolysis, PCI, or no reperfusion
therapy have 1) increased LV dilatation (484), 2) a greater
incidence of spontaneous and inducible ventricular arrhyth-
mias (485), and 3) a poorer prognosis (486). On the basis of
observational and experimental data, it has been hypothe-
sized that infarct artery patency may favorably influence LV
remodeling and electrical stability, even if accomplished at a
time when salvage of ischemic myocardium is unlikely (i.e.,
more than 12 hours to days after coronary artery occlusion).
Five small randomized trials, which enrolled a total of 562
patients, have directly tested the hypothesis that mechanical
opening of persistent total occlusions late after MI will
improve long-term LV remodeling and clinical outcomes
(the late open-artery hypothesis). Most studies enrolled a
combination of patients that included those who had failed
fibrinolysis and those who had not received reperfusion ther-
apy (487-489), with a range from almost no fibrinolytic ther-
apy (490) to fibrinolytic therapy in nearly all patients (491).
There was wide variation in the effect of routine PCI com-
pared with only medical therapy on LV size and function.
Most studies showed no significant differences between the
treatment groups (487,488). One single-center study of 83
patients with occlusions of the left anterior descending coro-
nary artery (LAD) reported improved LV volumes and clini-
cal outcomes (composite of CHF, MI, and death) at 6 months
in the PCI group (490). In contrast, a multicenter study of 66
patients with LAD occlusions reported significantly worse
LV remodeling, with progressive LV dilation at 1 year and
more clinical events in the PCI group than in those assigned
to optimal medical therapy alone (491). The latter included
very high rates of beta-blocker and ACE inhibitor use. The
largest multicenter study, DECOPI, enrolled 212 patients and
reported no difference in the primary end point, the compos-
ite of death, VT, and MI at 6 months (Steg PG; oral presen-
tation, European Society of Cardiology Congress 2003,
Vienna, Austria, September 2003). Stents were used in 80%
of patients in the PCI group, and GP IIb/IIIa antagonists were
Evidence: C)
b. Persistent ischemic symptoms. (Level of Evidence: C)
Immediately after failed fibrinolysis. Intravenous fibrinolytic
therapy successfully restores coronary TIMI 2/3 flow at 90
minutes in 50% to 85% of patients with STEMI (474). In
those in whom fibrinolysis is unsuccessful, antegrade coro-
nary flow can usually be restored with PCI. Several studies
have demonstrated the marked beneficial effect of infarct-
related artery patency (obtained via endogenous, pharmaco-
logical, or mechanical recanalization) on survival in patients
with STEMI (475,476). Survivors of STEMI with a patent
infarct-related artery demonstrated at 90 minutes after treat-
ment have an improved long-term outcome compared with
those with an occluded infarct-related artery, even when LV
systolic function is similar (476). Rescue (also known as sal-
vage) PCI is defined as PCI within 12 hours after failed fib-
rinolysis for patients with continuing or recurrent myocardial
ischemia. Rescue PCI has resulted in higher rates of early
infarct artery patency, improved regional infarct-zone wall
motion, and greater freedom from adverse in-hospital events
than with a deferred PCI strategy or medical therapy. The
Randomized Evaluation of Rescue PCI with Combined
Utilization End Points (RESCUE) trial demonstrated a
reduction in rates of in-hospital death and a combined end
point of death and CHF that was maintained up to 1 year
after study entry for patients presenting with anterior STEMI
who failed fibrinolytic therapy, when PCI was performed
within 8 hours after the onset of symptoms (477).
Improvement in TIMI grade flow from less than or equal to
2 to 3 may offer additional clinical benefit. Similar data are
not available for patients with nonanterior STEMI.
A major problem in adopting a strategy of rescue PCI lies
in the limitation of accurate identification of patients for
whom fibrinolytic therapy has not restored antegrade coro-
nary flow. Unless unsuccessful fibrinolysis is recognized and
corrected quickly (within 3 to 6 hours of onset of symptoms),
salvage of ischemic myocardium is unlikely. Unfortunately,
clinical markers of reperfusion, such as relief of ischemic-
type chest discomfort, partial resolution of ST-segment ele-
vation, and reperfusion arrhythmias, have limited predictive
value in identifying failure of fibrinolysis (478). In a prior era
in which the practice of PCI was less mature, immediate
catheterization of all patients after fibrinolytic therapy to
identify those with an occluded infarct artery was found to be
impractical, costly, and often associated with bleeding com-
plications (479,480). This strategy is being re-evaluated in
clinical trials testing facilitated PCI in the contemporary PCI
setting.
Even in the patient with documented failure of fibrinolysis,
rescue PCI has limitations. Because extensive myocardial
necrosis occurs when coronary occlusion has been present
for more than 3 hours (18), PCI may not salvage a substan-
tial amount of myocardium, considering the time delay asso-
ciated with presentation of the patient to the hospital after
onset of symptoms, infusion of the fibrinolytic agent, recog-
nition of failed fibrinolysis, and subsequent initiation of PCI.
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Three registries (496-498) have demonstrated a marked sur-
vival benefit for elderly patients who are clinically selected
for revascularization (approximately 1 of 5 patients), so age
alone should not disqualify a patient for early revasculariza-
tion. (See Section 7.6.5.)
Several additional discussions elsewhere in this guideline
are important to consider in these patients. Intra-aortic bal-
loon pump support or ventricular assist devices can stabilize
hemodynamics so that revascularization procedures can be
performed (see Section 7.6.7.6). Post hoc analyses (499-501)
have suggested that GP IIb/IIIa inhibitors reduce mortality,
but the studies are limited by lower than expected mortality
rates, larger than expected mortality reduction, and small
sample sizes (see Section 6.3.1.6.8.2.3). Although PCI in a
noninfarct artery is not recommended in stable patients, it
can be beneficial in hemodynamically compromised patients
if the stenotic artery perfuses a large area of myocardium and
the procedure can be done efficiently. In patients with signif-
icant left main disease or severe 3-vessel disease and without
RV infarction or major comorbidities such as renal insuffi-
ciency or severe pulmonary disease, CABG can be consid-
ered as the revascularization strategy (see Section 6.3.1.6.5)
(Figure 26) (502). 
6.3.1.6.4.7. Percutaneous Coronary Intervention 
After Fibrinolysis 
Class I
1. In patients whose anatomy is suitable, PCI should be
performed when there is objective evidence of recur-
rent MI. (Level of Evidence: C)
2. In patients whose anatomy is suitable, PCI should be
performed for moderate or severe spontaneous or
provocable myocardial ischemia during recovery
from STEMI. (Level of Evidence: B)
3. In patients whose anatomy is suitable, PCI should be
performed for cardiogenic shock or hemodynamic
instability. (See Section 6.3.1.6.4.6.) (Level of
Evidence: B)
Class IIa
1. It is reasonable to perform routine PCI in patients
with LVEF less than or equal to 0.40, CHF, or serious
ventricular arrhythmias. (Level of Evidence: C)
2. It is reasonable to perform PCI when there is docu-
mented clinical heart failure during the acute episode,
even though subsequent evaluation shows preserved
LV function (LVEF greater than 0.40). (Level of
Evidence: C)
Class IIb
Routine PCI might be considered as part of an inva-
sive strategy after fibrinolytic therapy. (Level of
Evidence: B)
Immediately after successful fibrinolysis. Randomized
prospective trials examined the efficacy and safety of imme-
diate PCI after fibrinolysis (479,480,503). These trials
used in 9%. The study reached fewer than one third of the
target sample size and was severely underpowered, as were
all the other studies, to assess clinical events.
There are no convincing data to support the routine use of
adjuvant PCI days after failed fibrinolysis or for patients who
do not receive reperfusion therapy. Nevertheless, this is being
done in some patients with STEMI as an extension of the
invasive strategy for patients with NSTEMI. The Occluded
Artery Trial (OAT) is currently randomizing patients to test
whether routine PCI days to weeks after MI improves long-
term clinical outcomes in asymptomatic high-risk patients
with an occluded infarct-related artery (493).
6.3.1.6.4.6. PCI for Cardiogenic Shock 
Class I
Primary PCI is recommended for patients less than 75
years old with ST elevation or LBBB who develop
shock within 36 hours of MI and are suitable for
revascularization that can be performed within 18
hours of shock unless further support is futile because
of the patient’s wishes or contraindications/unsuit-
ability for further invasive care. (Level of Evidence: A)
Class IIa
Primary PCI is reasonable for selected patients 75
years or older with ST elevation or LBBB who devel-
op shock within 36 hours of MI and are suitable for
revascularization that can be performed within 18
hours of shock. Patients with good prior functional
status who are suitable for revascularization and
agree to invasive care may be selected for such an
invasive strategy. (Level of Evidence: B)
Observational studies support the value of PCI for patients
who develop cardiogenic shock in the early hours of STEMI.
For patients who do not have mechanical causes of shock,
such as acute MR or septal or free wall rupture, mortality
among those having PCI is lower than for those treated med-
ically. However, undergoing cardiac catheterization alone,
with or without PCI, is associated with a lower mortality
owing to patient selection bias (494). 
Two small randomized clinical trials (301,495) have further
clarified the role of emergency revascularization in STEMI
complicated by cardiogenic shock. Both showed a statistical-
ly insignificant but clinically important absolute 9% reduc-
tion in 30-day mortality. In the SHOCK trial (301), the sur-
vival curves continued to progressively diverge such that at 6
months and 1 year, there was a significant mortality reduc-
tion with emergency revascularization (53% versus 66%, p
less than 0.03) (184). The prespecified subgroup analysis of
patients less than 75 years old showed an absolute 15%
reduction in 30-day mortality (p less than 0.02), whereas
there was no apparent benefit for the small cohort (n equals
56) of patients more than 75 years old. These data strongly
support the approach that patients younger than 75 years
with STEMI complicated by cardiogenic shock should
undergo emergency revascularization and support measures.
e65
Antman et al. 2004
ACC/AHA Practice Guidelines
ACC - www.acc.org
AHA - www.americanheart.org
complications if PCI is delayed for several days after fibri-
nolytic therapy and 2) routine PCI in the absence of sponta-
neous or provocable ischemia does not improve LV function
or survival (268,505-507). Thus, in unselected patients
receiving fibrinolytic therapy, PCI of the stenotic infarct-
related artery in the absence of evidence of recurrent
ischemia within 48 hours did not appear to be beneficial. 
Great improvements in equipment, operator experience,
and adjunctive pharmacotherapy have increased PCI success
rates and decreased complications. More recently, the inva-
sive strategy for patients with NSTEMI has been given a
Class I recommendation by the ACC/AHA 2002 Guideline
Update for the Management of Patients With Unstable
Angina/NSTEMI (4). Patients with STEMI are increasingly
being treated similarly as an extension of this approach.
Although 6 published reports (472,508-512) and 1 prelimi-
nary report (Lablanche JM; oral presentation, American
Heart Association 2002 Annual Scientific Sessions,
November 2002, Chicago, IL) support this strategy, random-
ized studies similar to those in NSTEMI need to be per-
formed.
One study supports the policy of performing catheteriza-
tion and subsequent revascularization for patients who do
showed no benefit of routine PCI of the stenotic infarct-relat-
ed artery immediately after fibrinolytic therapy. The strategy
did not appear to salvage myocardium, improve LVEF, or
prevent reinfarction or death. Those subjected to this
approach appeared to have an increased incidence of adverse
events, including bleeding, recurrent ischemia, emergency
CABG, and death. These studies have not been repeated in
the modern interventional era with improved equipment,
improved antiplatelet and anticoagulant strategies, and coro-
nary stents, thus leaving the question of routine PCI early
after successful fibrinolysis unresolved in contemporary
practice. Studies of facilitated PCI are presently enrolling
patients (36,396,471,504).
Hours to days after successful fibrinolysis. It was initially
suggested that elective PCI of the stenotic infarct-related
artery hours to days after fibrinolysis might allow sufficient
time for development of a more stable hemostatic milieu at
the site of previous thrombotic occlusion. In this setting, PCI
would be safer and more effective in reducing the incidence
of reocclusion and improving survival. Two large random-
ized, prospective trials from an earlier PCI era tested this
hypothesis, with both concluding that 1) there are fewer
Figure 26. Recommendations for initial reperfusion therapy when cardiogenic shock complicates STEMI. Early mechanical revascu-
larization with PCI/CABG is a class I recommendation for candidates less than 75 years of age with ST elevation or LBBB who devel-
op shock less than 36 hours from STEMI and in whom revascularization can be performed within 18 hours of shock, and a class IIa
recommendation for patients 75 years of age or older with the same criteria. Eighty-five percent of shock cases are diagnosed after
initial therapy for STEMI, but most patients develop shock within 24 hours. An IABP is recommended when shock is not quickly
reversed with pharmacological therapy, as a stabilizing measure for patients who are candidates for further invasive care. Dashed lines
indicate that the procedure should be performed in patients with specific indications only. Recommendations for staged CABG and PCI
are discussed in the text, as are definitions of moderate and severe 3-vessel CAD. PCI = percutaneous coronary intervention; STEMI
= ST-elevation myocardial infarction; IABP = intra-aortic balloon pump; CAD, coronary artery disease; IRA = infarct-related artery;
CABG = coronary artery bypass graft surgery; LBBB = left bundle-branch block. Modified with permission from Hochman. Circulation
2003;107:2998-3002 (502).
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who are in the early hours (6 to 12 hours) of an evolv-
ing STEMI, especially if severe multivessel or left
main disease is present. (Level of Evidence: B)
2. Emergency CABG can be effective in selected patients
75 years or older with ST elevation, LBBB, or posterior
MI who develop shock within 36 hours of STEMI, have
severe triple-vessel or left main disease, and are suitable
for revascularization that can be performed within 18
hours of shock. Patients with good prior functional sta-
tus who are suitable for revascularization and agree to
invasive care may be selected for such an invasive strat-
egy. (Level of Evidence: B)
Class III
1. Emergency CABG should not be performed in
patients with persistent angina and a small area of
risk who are hemodynamically stable. (Level of
Evidence: C)
2. Emergency CABG should not be performed in
patients with successful epicardial reperfusion but
unsuccessful microvascular reperfusion. (Level of
Evidence: C)
These recommendations are supplementary to those pub-
lished recently in a more complete set of general guidelines
and indications for CABG (518) and are restricted to patients
with STEMI and associated complications. The basis for rec-
ommending surgery in emergency circumstances is the doc-
umented benefit of CABG for severe multivessel disease or
left main coronary artery stenosis, particularly with reduced
LV function (518-521), with the recognition that risk of
emergency CABG is greater than that for elective operation. 
The widespread use of fibrinolysis and primary PCI has
largely superseded CABG for acute reperfusion of patients
with STEMI. However, CABG still plays an integral role in
the early reperfusion strategy for some patients. In the PAMI
(Primary Angioplasty in Myocardial Infarction)-2 trial (522),
of 1100 patients with MI and without cardiogenic shock, 5%
underwent CABG as the primary reperfusion strategy with
STEMI. Mortality was 6.4% if surgery was undertaken on an
urgent or emergency basis versus 2.0% if elective. Major risk
factors for death included poor LV function and advanced
age. In the setting of cardiogenic shock complicating
STEMI, emergency CABG has been used where other inter-
ventions have failed or have not been indicated. In the
SHOCK registry (523), of 136 patients undergoing emer-
gency CABG for cardiogenic shock due to LV failure, mor-
tality was 27.9% compared to 45.5% in 268 patients under-
going PTCA. For patients undergoing CABG within 18
hours of the onset of shock, mortality was 39.6%. In a review
of 25 papers reporting the outcome of CABG in 391 patients
with cardiogenic shock, mortality was 35% (524). In
GUSTO-I, mortality in a similar group of patients was 29%
(98 of 340) after CABG and 29% (165 of 567) (422,525,526)
after PTCA. On the basis of these studies, emergency CABG
should only be considered for patients with STEMI with
severe coronary artery disease. In the SHOCK trial, emer-
gency CABG was performed at a median of 14 hours after
have spontaneous or inducible angina after STEMI. The
DANAMI trial (515) randomly assigned 1008 survivors of a
first acute MI treated with fibrinolytic therapy within 12
hours of onset of symptoms to catheterization and subse-
quent revascularization or standard medical therapy if they
showed evidence of spontaneous or inducible angina. Those
who underwent revascularization had less unstable angina
and fewer nonfatal MIs during a 2.5-year period of follow-up
compared with those patients randomly assigned to medical
treatment only (18% and 5.6% versus 30% and 10.5%,
respectively). 
Days to weeks after successful fibrinolysis. Continued throm-
bus lysis and remodeling of the infarct artery stenosis occur
over the days to weeks after successful fibrinolysis, which
makes the underlying residual coronary stenosis more stable
and less prone to rethrombosis and reocclusion. Thus, delay-
ing PCI for days to weeks after fibrinolysis might improve
survival, even though earlier routine PCI does not. To date,
there have not been adequately sized trials to evaluate this
treatment strategy. Two older, small, randomized trials
(516,517) demonstrated similar LV function, rates of rein-
farction, and mortality in patients randomized to PCI or con-
servative therapy. 
6.3.1.6.5. ACUTE SURGICAL REPERFUSION.
Class I
Emergency or urgent CABG in patients with STEMI
should be undertaken in the following circumstances:
a. Failed PCI with persistent pain or hemodynamic
instability in patients with coronary anatomy suit-
able for surgery. (Level of Evidence: B)
b. Persistent or recurrent ischemia refractory to med-
ical therapy in patients who have coronary anato-
my suitable for surgery, have a significant area of
myocardium at risk, and are not candidates for
PCI or fibrinolytic therapy. (Level of Evidence: B)
c. At the time of surgical repair of postinfarction VSR
or mitral valve insufficiency. (Level of Evidence: B)
d. Cardiogenic shock in patients less than 75 years old
with ST elevation or LBBB or posterior MI who
develop shock within 36 hours of STEMI, have
severe multivessel or left main disease, and are suit-
able for revascularization that can be performed
within 18 hours of shock, unless further support is
futile because of the patient’s wishes or contraindi-
cations/unsuitability for further invasive care
(Level of Evidence: A)
e. Life-threatening ventricular arrhythmias in the
presence of greater than or equal to 50% left main
stenosis and/or triple-vessel disease. (Level of
Evidence: B)
Class IIa
1. Emergency CABG can be useful as the primary reper-
fusion strategy in patients who have suitable anatomy
and who are not candidates for fibrinolysis or PCI and
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recognized as useful techniques for assessing myocardial
perfusion. The relatively simple and readily available evalu-
ation of the ECG ST-segment resolution that exceeds 50% at
60 to 90 minutes after reperfusion is a good indicator of
enhanced myocardial perfusion (527). This finding is also
associated with enhanced recovery of LV function, reduced
infarct size, and improved prognosis (277,349,395,529-531).
In the TIMI-14 study of 888 patients, those with TIMI 3 per-
fusion and greater than 70% ST-segment resolution had sub-
stantial enhancement of survival compared with those with-
out ST-segment resolution and angiographically patent
infarct arteries (531).
Santoro and colleagues (532) evaluated 158 consecutive
patients with STEMI referred for direct angioplasty within 6
hours of symptom onset. In their observational study of
patients with TIMI grade 3 flow and less than 30% residual
stenosis, 42 patients had less than 50% reduction in maximal
ST elevation in a single lead versus 75 patients with at least
50% reduction in ST elevation. Those with ST-segment res-
olution had enhanced infarct-zone functional recovery and
improved ejection fraction. The reduction of ST-segment ele-
vation was the only independent predictor of functional
recovery. 
Persistence of unrelenting ischemic chest pain, absence of
resolution of the qualifying ST-segment elevation, and hemo-
dynamic or electrical instability are generally indicators of
failed pharmacological reperfusion and the need to consider
rescue PCI. Aggressive medical support may be necessary in
the interim. (See Section 6.3.1.6.4.5.)
6.3.1.6.8. ANCILLARY THERAPY. Ancillary therapy plays a
key role in the overall management of patients with STEMI
and can be usefully categorized as conjunctive, in which case
it facilitates and maintains coronary reperfusion, or adjunc-
tive, which aims to limit the consequences of myocardial
ischemia, enhance myocardial healing, and reduce the likeli-
hood of recurrent events.
6.3.1.6.8.1. Antithrombins as Ancillary Therapy to
Reperfusion Therapy
After rupture of a vulnerable or high-risk plaque, its contents
are exposed to the passing bloodstream. Vulnerable plaques
are laden with both lipid and collagen and are rich in tissue
factor, thereby resulting in activation of the coagulation cas-
cade, which ultimately results in the deposition of fibrin
strands. In addition, platelets are activated and aggregate.
Thrombin that is generated as a consequence of activation of
the coagulation cascade is a pivotal molecule not only for the
formation of fibrin strands but also for activation of platelets.
Therefore, there is considerable rationale for ancillary thera-
py to inhibit the coagulation cascade in patients with STEMI,
including both those who do and do not receive reperfusion
therapy. The general term used to include agents that alter the
function of 1 or more proteins in the coagulation cascade is
antithrombins (533). However, such a broad term does not do
justice to the biochemical complexities of agents that may
the onset of STEMI in 40% of those who underwent early
revascularization; most of the patients undergoing CABG
had significant left main or 3-vessel coronary artery disease.
The 30-day mortality rate was similar to those with less
severe coronary artery disease who underwent PTCA (42%
versus 45%).
6.3.1.6.6. PATIENTS WITH STEMI NOT RECEIVING
REPERFUSION. Many patients with suspected STEMI do not
receive reperfusion therapy. For some of these patients, the
lack of treatment represents a missed opportunity. For others,
patient preference led to a decision that the clinical benefit
was not worth the risk of the therapy. Other patients may
have contraindications to treatment owing to comorbid dis-
ease. Few studies have examined the care and outcomes of
patients with suspected STEMI who do not receive reperfu-
sion therapy. Many of the studies (e.g., beta-blocker trials)
that established therapies for MI patients preceded the reper-
fusion era, and so their efficacy in patients with STEMI who
did not receive reperfusion is clear. The acute use of aspirin
was shown to be effective in patients who did and did not
receive fibrinolytic therapy. Guideline-based recommenda-
tions for nonreperfusion treatments should not vary whether
or not patients received reperfusion therapy. The major dif-
ference is that patients not receiving reperfusion therapy are
considered to have a higher risk for future adverse events
(261). (See Section 6.3.1.6.8.1.2 for discussion of the TETA-
MI trial.) 
6.3.1.6.7. ASSESSMENT OF REPERFUSION.
Class IIa
It is reasonable to monitor the pattern of ST elevation,
cardiac rhythm, and clinical symptoms over the 60 to
180 minutes after initiation of fibrinolytic therapy.
Noninvasive findings suggestive of reperfusion include
relief of symptoms, maintenance or restoration of
hemodynamic and or electrical stability, and a reduc-
tion of at least 50% of the initial ST-segment elevation
injury pattern on a follow-up ECG 60 to 90 minutes
after initiation of therapy. (Level of Evidence: B)
A high priority exists for the development of simple, accu-
rate, readily available noninvasive techniques to assess the
success of pharmacological reperfusion early, i.e., 60 to 90
minutes after administration of therapy. Prior studies evalu-
ating clinical and ECG outcome measures of reperfusion
used angiographic TIMI 2 or 3 flow as the “gold standard”;
angiographic assessment of epicardial flow is now consid-
ered inadequate to completely assess myocardial perfusion.
Indeed, it is now clear that microvascular perfusion may be
impaired despite achievement of TIMI 3 flow and less than
50% coronary narrowing; moreover, abnormal microperfu-
sion has negative prognostic implications (395,527,528).
Myocardial contrast echocardiography, myocardial angio-
graphic perfusion with assessment of angiographic blush in
the myocardium, and ECG assessment of ST resolution are
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Over 60 000 patients were enrolled in the randomized 
ISIS-3 (357) and GISSI-2 (Gruppo Italiano per lo Studio della
Streptochinasi nell’Infarto Miocardico)/International
(353,354) trials comparing subcutaneous UFH with no rou-
tine heparin in conjunction with streptokinase, anistreplase,
and alteplase. During the period in which UFH was given, a
small reduction in mortality (4 to 5 lives per 1000 treated)
was observed in ISIS-3; however, by 30 days, the 2 to 3 lives
saved per 1000 treated was no longer statistically significant.
A small excess rate of hemorrhagic stroke (1 to 2 per 1000
treated patients) was observed together with a larger excess in
systemic bleeding (3 to 5 per 1000 patients), although total
stroke rate was not significantly increased. A meta-analysis of
these and several smaller studies enrolling a total of 68 000
patients showed that 5 lives were saved per 1000 patients
treated with UFH in addition to streptokinase (537). In the
GUSTO-I trial (25), more than 20 000 patients treated with
streptokinase were randomly assigned to routine intravenous
versus routine subcutaneous UFH. No significant differences
were observed in death, reinfarction, or nonhemorrhagic
stroke rates, whereas excess rates of systemic bleeding and
hemorrhagic strokes (trend) were observed in the intravenous
UFH group. There was a 36% crossover rate from subcuta-
neous to intravenous UFH in this trial.
Several angiographic studies have evaluated coronary per-
fusion as a function of UFH therapy (538-540). More rapid
resolution of ST-segment elevation has been reported in
patients treated with intravenous UFH immediately at the
time of streptokinase infusion than in those treated with
intravenous heparin started at a later time, but the OSIRIS
study (Optimization Study of Infarct Reperfusion
Investigated by ST Monitoring) showed no difference in per-
fusion at 24 hours (539). In the GUSTO-I angiographic sub-
study, patients treated with intravenous UFH had an 88%
patency rate at 5 to 7 days compared with a 72% rate in
patients treated with subcutaneous UFH (p less than 0.05),
although less reinfarction occurred in the subcutaneous UFH
group (3.4% versus 4.0%, p less than 0.05) (538). When
these angiographic studies are viewed as a whole, intra-
venous UFH appears to have no clinical advantage over sub-
cutaneous administration when used with a nonspecific fibri-
nolytic agent, and the evidence for use of subcutaneous UFH
is equivocal (541). There are few data comparing intravenous
UFH to placebo.
The clinical importance of the procoagulant increase in
thrombin activity after streptokinase administration is sup-
ported by the beneficial effect of newer antithrombins used in
conjunction with streptokinase (see Section 6.3.1.6.8.1.3).
The HERO (Hirulog and Early Reperfusion or Occlusion)-2
trial demonstrated reduced reinfarction with intravenous
bivalirudin compared with intravenous UFH (33). The 
AMI-SK study demonstrated in patients treated with strep-
tokinase improved ST-segment resolution at 180 minutes and
higher rates of infarct-related artery patency at 8 days for
enoxaparin compared with placebo. The composite of death,
MI, and recurrent angina was reduced, but severe bleeding
was increased (1.6% versus 0.8%), with no difference in ICH
inhibit the coagulation cascade at multiple positions (e.g.,
UFH and LMWH) or in a single position (e.g., direct
antithrombins). In addition to establishing and maintaining
patency of the infarct-related artery, the rationale for pre-
scribing antithrombins in selected patients with STEMI
includes prevention of DVT, pulmonary embolism, LV mural
thrombus formation, and cerebral embolization.
6.3.1.6.8.1.1. Unfractionated heparin as 
ancillary therapy to reperfusion therapy.
Class I
1. Patients undergoing percutaneous or surgical revascu-
larization should receive UFH. (Level of Evidence: C)
2. Unfractionated heparin should be given intravenously
to patients undergoing reperfusion therapy with
alteplase, reteplase, or tenecteplase with dosing as fol-
lows: bolus of 60 U/kg (maximum 4000 U) followed by
an infusion of 12 U/kg/hr (maximum 1000 U) initially
adjusted to maintain activated partial thromboplastin
time (aPTT) at 1.5 to 2.0 times control (approximate-
ly 50 to 70 seconds). (Level of Evidence: C)
3. Unfractionated heparin should be given intravenously
to patients treated with nonselective fibrinolytic
agents (streptokinase, anistreplase, urokinase) who
are at high risk for systemic emboli (large or anterior
MI, atrial fibrillation (AF), previous embolus, or
known LV thrombus). (Level of Evidence: B)
4. Platelet counts should be monitored daily in patients
taking UFH. (Level of Evidence: C)
Class IIb
It may be reasonable to administer UFH intravenous-
ly to patients undergoing reperfusion therapy with
streptokinase. (Level of Evidence: B)
Despite the use of UFH (533) in STEMI for over 40 years,
there is continued controversy regarding its role. In patients
who are treated with fibrinolytic therapy, recommendations
for UFH therapy depend on the fibrinolytic agent chosen.
The nonspecific fibrinolytic agents (streptokinase, anistre-
plase, and urokinase) that produce a systemic coagulopathy,
including depletion of factors V and VIII and massive pro-
duction of fibrin(ogen) degradation products, are themselves
anticoagulants. From this perspective, the need for conjunc-
tive systemic anticoagulation with these agents conceptually
is less compelling. However, the procoagulant potential of
streptokinase, which induces extensive plasmin-mediated
thrombin activity, has been noted as the rationale for
antithrombotics (534). The rationale for UFH is clear for the
more fibrin-specific agents, such as alteplase, reteplase, and
tenecteplase. They induce less effect on the systemic coagu-
lation system, and in many patients, very little breakdown of
fibrinogen or depletion of coagulation factors is evident
(535,536). Furthermore, the same procoagulant increase in
thrombin activity is seen (534).
e69
Antman et al. 2004
ACC/AHA Practice Guidelines
ACC - www.acc.org
AHA - www.americanheart.org
followed by a maintenance infusion of 12 U/kg/h (with a
maximum of 4000 U bolus and 1000 U/h initial infusion for
patients weighing more than 70 kg) is recommended. The
recommended weight-adjusted dose of UFH, when it is
administered without fibrinolytics, is a 60 to 70 U/kg IV
bolus and a 12 to 15 U/kg/h infusion (4). Higher UFH doses
are required for DVT and pulmonary embolism (80 U/kg and
18 U/kg/h) (550,551). Other factors that prolong aPTT
include age, sex, and creatinine level. Elderly women may
require lower bolus doses. Diabetics, smokers, and very
heavy patients (weight more than 100 kg) may require high-
er UFH doses (550,552). When used with fibrinolytic thera-
py, an aPTT goal of 60 to 90 seconds is associated with an
unacceptably high rate of ICH (359,553). The recommenda-
tion of an aPTT of 50 to 70 seconds was based on the
GUSTO trials and supported by an overview of several fibri-
nolytic trials (325,380). ASSENT-3 was the first large-scale
trial that used the recommended reduced-dose weight-adjust-
ed UFH regimen (31). This regimen resulted in similar ICH
rates but less bleeding than the higher dose used in ASSENT-
2, without an increase in ischemic events. An aPTT meas-
urement and dose adjustment are required beginning at 3
hours for those who receive UFH with fibrinolytics (28). The
aPTT should be remeasured 6 hours after each dose adjust-
ment until it is in the target range and daily thereafter. There
is wide variability in aPTT measurement between laborato-
ries, and it is not known what UFH level, as measured by
anti-Xa activity, corresponds with an aPTT of 50 to 70 sec-
onds. However, for most thromboplastin reagents, this corre-
sponds to 0.2 to 0.5 U/mL heparin by anti-Xa activity.
Once UFH has been started, the appropriate duration of
therapy is uncertain. The only randomized trial to address
this issue found that discontinuation of UFH after 24 hours
after fibrinolytic therapy with alteplase resulted in no meas-
urable increase in ischemic events (554), although this study
did not have adequate power to detect modest differences. A
reasonable approach is to use intravenous UFH for 48 hours
and then to use UFH according to the clinical characteristics
of the patient. UFH may be discontinued in low-risk patients,
given subcutaneously in patients at high risk of systemic
embolization, and given intravenously in patients at high risk
for coronary reocclusion. 
There is concern that when UFH is discontinued abruptly,
the patient undergoes a high-risk period for recurrent throm-
bosis (heparin rebound) because of increased thrombin activ-
ity (555,556). Despite this concern, no specific policy has
been tested to attempt to reduce this clinical rebound effect.
Several ongoing studies, however, are reducing UFH infu-
sions in a gradual fashion (e.g., by half within 6 hours, then
discontinuing over the subsequent 12 hours). 
Platelet counts should be monitored daily in patients being
treated with UFH. Evidence suggests the incidence of
heparin-induced thrombocytopenia is 3% and that this is
associated with a substantial risk of prothrombotic events
(557). If the platelet count drops below 100 000, a test for
heparin-induced thrombocytopenia should be obtained, and
the clinician should be vigilant for thrombotic complications,
(0% to 0.4%) (542). Additionally, a preliminary report of 5-
year GUSTO-I follow-up data demonstrated similar survival
rates for streptokinase with UFH versus alteplase-assigned
patients. In the context of these new data and the event reduc-
tion (5 fewer deaths per 1000 patients) demonstrated in the
meta-analysis (537), the recommendation for intravenous
UFH administration with non–fibrin-specific fibrinolytic
agents was changed from Class III to Class IIb. 
When alteplase is the fibrinolytic agent, the empirical
information to confirm the pathophysiological reasoning dis-
cussed above is primarily inferential. In a series of angio-
graphic trials (543-545), intravenous UFH led to higher rates
of infarct-related artery perfusion in conjunction with
alteplase. A direct relation between duration of aPTT and the
likelihood of infarct-related artery perfusion was observed
(544,545). An overview (546) points out, however, that the
effects of intravenous UFH on clinical outcomes from these
studies are not so convincing; a significant increase in the
rate of bleeding and nonsignificant increases in rates of rein-
farction and hemorrhagic and nonhemorrhagic stroke are evi-
dent (546). These negative findings are tempered by a point
estimate of an 18% reduction in mortality with broad confi-
dence limits. Until the uncertainty is resolved, it appears
judicious to use UFH for at least 48 hours with alteplase and
to target the aPTT to 1.5 to 2.0 times control (approximately
50 to 70 seconds). 
When primary PCI is chosen as the route of reperfusion,
weight-adjusted boluses of heparin of 70 to 100 U/kg are rec-
ommended. This recommendation does not come specifical-
ly from empirical data in the setting of STEMI but from gen-
eral observations in the setting of angioplasty that an activat-
ed clotting time of at least 250 to 350 seconds with the
HemoTec device and 300 to 350 seconds with the
Hemochron device is associated with a lower rate of compli-
cations than lower activated clotting times (432,547,548). 
When GP IIb/IIIa antagonists are used (see Section
6.3.1.6.8.2.3), the UFH bolus should be reduced to 50 to 70
U/kg to achieve a target activated clotting time of 200 sec-
onds with either the HemoTec or Hemochron device (432).
UFH doses used during PCI for failed fibrinolysis should be
similarly reduced and further lowered if used with GP
IIb/IIIa antagonists as well. 
The dose of UFH in the fibrinolytic-treated patient remains
somewhat controversial. Given the infarct-related artery per-
fusion results just described, it would be reasonable to rec-
ommend an aPTT value more than 3-fold higher than the
median control value. However, observational data strongly
support a lower aPTT, because death, stroke, reinfarction,
and bleeding were found to be lowest in the aPTT range of
50 to 70 seconds, or approximately 1.5 to 2.0 times the con-
trol value (549). Because of the evidence that the measured
effect of UFH on the aPTT is important for patient outcome
and that the predominant variable mediating the effect of a
given dose of heparin is weight (549), it is important to
administer the initial doses of UFH as a weight-adjusted
bolus (541). For fibrin-specific (alteplase, reteplase, and
tenecteplase) fibrinolytic-treated patients, a 60 U/kg bolus
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because the prognosis in patients with thrombocytopenia is
substantially worse (558). 
6.3.1.6.8.1.2. Low-molecular-weight heparin as
ancillary therapy to reperfusion therapy.
Class IIb
Low-molecular-weight heparin might be considered
an acceptable alternative to UFH as ancillary therapy
for patients aged less than 75 years who are receiving
fibrinolytic therapy, provided that significant renal
dysfunction (serum creatinine greater than 2.5 mg/dL
in men or 2.0 mg/dL in women) is not present.
Enoxaparin (30-mg IV bolus followed by 1.0 mg/kg
SC every 12 hours until hospital discharge) used in
combination with full-dose tenecteplase is the most
comprehensively studied regimen in patients aged less
than 75 years of age. (Level of Evidence: B)
Class III
1. Low-molecular-weight heparin should not be used as
an alternative to UFH as ancillary therapy in patients
aged more than 75 years who are receiving fibrinolyt-
ic therapy. (Level of Evidence: B)
2. Low-molecular-weight heparin should not be used as
an alternative to UFH as ancillary therapy in patients
less than 75 years who are receiving fibrinolytic ther-
apy but have significant renal dysfunction (serum cre-
atinine greater than 2.5 mg/dL in men or 2.0 mg/dL in
women). (Level of Evidence: B)
There have been no definitive phase III randomized trials of
LMWH in patients with STEMI to provide a firm basis for
recommendations. However, a number of phase II clinical
trials provide encouraging information that suggests that
LMWH may be an attractive alternative to UFH. These clin-
ical trials include those with LMWH as ancillary therapy to
fibrinolysis and those in patients not receiving fibrinolysis
(31,158,542,559-567). These 2 broad categories of trials with
LMWH involve either enoxaparin or dalteparin, the 2
LMWHs studied most extensively in patients with STEMI.
Clinical evaluation of LMWH as ancillary therapy to most of
the commonly prescribed fibrinolytics has been reported
with the exception of reteplase (Table 19) (31,158,542,559-
567).
The available data suggest that the rate of early (60 to 90
minutes) reperfusion of the infarct artery either assessed
angiographically or by noninvasive means is not enhanced by
administration of a LMWH. However, a generally consistent
theme of a lower rate of reocclusion of the infarct artery,
reinfarction, or recurrent ischemic events emerges in patients
receiving LMWH regardless of whether the control group
was given placebo or UFH.
The most comprehensive data available are from the
ASSENT-3 trial, in which patients received tenecteplase and
either UFH (bolus 60 U/kg; initial infusion 12 U/kg/h; dura-
tion of treatment equals 48 hours) or enoxaparin (bolus 30
mg; subcutaneous injections 1.0 mg/kg every 12 hours; dura-
tion of treatment equals duration of hospital stay) (31). Each
of the elements of the composite end point of 30-day mortal-
ity, in-hospital reinfarction, or in-hospital recurrent ischemia
were reduced with enoxaparin treatment. This was associat-
ed with a slight, nonsignificant increase in noncerebral
bleeding complications. In patients aged more than 75 years,
the rate of noncerebral major bleeds was 4.1% with UFH and
7.2% with enoxaparin. Patients with significant renal dys-
function (serum creatinine greater than 2.5 mg/dL for men
and greater than 2 mg/dL for women) were excluded from
ASSENT-3, and therefore enoxaparin cannot be recommend-
ed for use in combination with tenecteplase in patients with
severe renal dysfunction until more data are available. At 1
year, no difference was noted in the composite end point
noted above between the UFH and enoxaparin groups in
ASSENT-3 (31).
However, results from the third Assessment of the Safety
and Efficacy of a New Thrombolytic PLUS (ASSENT-3
PLUS) trial underscore the need for continued evaluation of
the safety of LMWH as an adjunct to fibrinolysis (158).
Among 1639 patients with STEMI receiving tenecteplase
and either enoxaparin or UFH in a prehospital setting, high-
er rates of both major bleeding (4.0% versus 2.8%; p equals
0.18) and ICH (2.2% versus 1.0%; p equals 0.05) were seen
in the enoxaparin group than in the UFH group. There was a
significant interaction between patient age and risk of bleed-
ing because almost all cases of excess ICH were confined to
patients older than 75 years (158,568). The Enoxaparin and
Thrombolysis Reperfusion for Acute Myocardial Infarction
Treatment-Thrombolysis In Myocardial Infarction - Study 25
(EXTRACT-TIMI-25) trial is evaluating enoxaparin versus
UFH in patients receiving fibrinolytic therapy and will pro-
vide information on the efficacy and safety of reduced doses
of enoxaparin in the elderly.
The combination of tirofiban and enoxaparin was studied
in 1224 patients presenting with STEMI in the Treatment of
Enoxaparin and Tirofiban in Acute Myocardial Infarction
(TETAMI) trial (566). Patients ineligible for fibrinolysis
were randomized in a 2×2 fashion to receive either enoxa-
parin (intravenous 30 mg bolus and subcutaneous injection
of 1 mg/kg twice daily) or UFH (intravenous 70 U/kg bolus
and 15 U/kg/h infusion) with or without tirofiban (intra-
venous 10 mcg/kg bolus and 0.1 mcg/kg/min infusion) for 2
to 8 days. There were no differences noted in the primary
efficacy end point (30-day combined incidence of death,
reinfarction, or recurrent angina) between either enoxaparin
and UFH monotherapy groups (15.4% versus 17.3%) or
between enoxaparin and UFH combination groups (16.1%
versus 17.2%). Major bleeding was rare and not statistically
different among all 4 groups.
6.3.1.6.8.1.3. Direct antithrombins as 
ancillary therapy to reperfusion therapy.
Class IIa
In patients with known heparin-induced thrombocy-
topenia, it is reasonable to consider bivalirudin as a
useful alternative to heparin to be used in conjunction
with streptokinase. Dosing according to the HERO 2
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regimen (a bolus of 0.25 mg/kg followed by an intra-
venous infusion of 0.5 mg/kg/h for the first 12 hours
and 0.25 mg/kg/h for the subsequent 36 hours) (33) is
recommended, but with a reduction in the infusion
rate if the partial thromboplastin time is above 75 sec-
onds within the first 12 hours. (Level of Evidence: B)
A number of direct thrombin inhibitors are now available
for use in heparin-induced thrombocytopenia and DVT but
have not yet been approved for the treatment of acute coro-
nary syndrome (Table 20) (39,359,368,382,383,553,569-
573). One, (bivalirudin) has been approved for use in patients
with unstable angina undergoing PCI. A meta-analysis eval-
uated 11 trials that collectively enrolled more than 35 000
patients, comparing direct thrombin inhibitors with UFH
(39). There was an approximately 25% reduction in the inci-
dence of MI in patients with STEMI treated with either
hirudin or bivalirudin, but there was less evident efficacy for
univalent thrombin inhibitors (argatroban, efegatran, and ino-
gatran). Major bleeding was reduced with bivalirudin com-
pared with heparin (4.2% versus 9.0%; OR 0.44 [0.34 to
0.56]). There was an excess of bleeding after the use of
hirudin and no difference with univalent inhibitors; statistical
heterogeneity among these 3 groups of trials existed (39).
Subsequent to the meta-analysis, a large phase 3 study
(HERO-2) of 17 073 patients with STEMI who presented
within 6 hours of onset of chest pain was performed to eval-
uate the efficacy of bivalirudin versus UFH administered in
conjunction with streptokinase (33). In the HERO-2 trial,
bivalirudin did not reduce mortality compared with UFH
(10.8% versus 10.9%) but was associated with a lower rate of
adjudicated myocardial reinfarction within 96 hours (1.6%
versus 2.3%, p equals 0.005). Although it was anticipated
there would be fewer hemorrhagic complications with
bivalirudin, severe bleeding occurred in 0.7% of the
bivalirudin group versus 0.5% for heparin (p equals 0.07),
and intracerebral bleeding occurred in 0.6% versus 0.4% (p
equals 0.09), respectively, possibly related to higher aPTT
levels in the bivalirudin group. The frequency of moderate
and mild bleeding was also greater with bivalirudin (33,323).
Bivalirudin is currently indicated only for anticoagulation
in patients with unstable angina who are undergoing percuta-
neous coronary angioplasty (574). On the basis of the data in
the HERO-2 trial, the Writing Committee believes that
bivalirudin could be considered an acceptable alternative to
UFH in those patients with STEMI who receive fibrinolysis
with streptokinase, have heparin-induced thrombocytopenia,
and who, in the opinion of the treating physician, would ben-
efit from anticoagulation.
6.3.1.6.8.1.4. Other.
A phase 2 angiographic trial Pentasaccharide as an Adjunct
in ST-Segment Myocardial Infarction (PENTALYSE) evalu-
ated fondaparinux, a synthetic pentasaccharide that is a high-
ly selective inhibitor of factor Xa. Fondaparinux selectively
binds antithrombin III, inducing a conformational change
that increases the anti-Xa activity of antithrombin III more
than 300 times, which results in dose-dependent inhibition of
factor Xa (575). A total of 333 patients with evolving STEMI
were treated with aspirin and alteplase and randomized to
UFH given intravenously for 48 to 72 hours or to a low,
medium, or high dose of fondaparinux. The percentage of
patients achieving TIMI grade 3 flow at 90 minutes was 68%
in the UFH control group and ranged between 60% and 69%
with fondaparinux. Thus, selective factor Xa inhibition
appears to be an attractive therapeutic concept in patients
presenting with STEMI; however, further study is required
before it can be recommended for routine administration.
6.3.1.6.8.2. Antiplatelets 
6.3.1.6.8.2.1. Aspirin.
Class I
A daily dose of aspirin (initial dose of 162 to 325 mg
orally; maintenance dose of 75 to 162 mg) should be
given indefinitely after STEMI to all patients without
a true aspirin allergy. (Level of Evidence: A)
As discussed in Section 7.4.4 and Section 6.3.1.4, aspirin
should be given to the patient with suspected STEMI as early
as possible and continued indefinitely, regardless of the strat-
egy for reperfusion and regardless of whether additional
antiplatelet agents are administered. True aspirin allergy is
the only exception to this recommendation.
6.3.1.6.8.2.2. Thienopyridines.
Class I
1. In patients who have undergone diagnostic cardiac
catheterization and for whom PCI is planned, clopi-
dogrel should be started and continued for at least 1
month after bare metal stent implantation, for several
months after drug-eluting stent implantation (3
months for sirolimus, 6 months for paclitaxel), and up
to 12 months in patients who are not at high risk for
bleeding. (Level of Evidence: B)
2. In patients taking clopidogrel in whom CABG is
planned, the drug should be withheld for at least 5
days, and preferably for 7 days, unless the urgency for
revascularization outweighs the risks of excess bleed-
ing. (Level of Evidence: B)
Class IIa
Clopidogrel is probably indicated in patients receiving
fibrinolytic therapy who are unable to take aspirin
because of hypersensitivity or major gastrointestinal
intolerance. (Level of Evidence: C)
Ticlopidine and clopidogrel are ADP-receptor antagonists
and are quite similar chemically. Ticlopidine can cause neu-
tropenia and thrombotic thrombocytopenia. Clopidogrel is
preferred because of fewer side effects, lack of need for lab-
oratory monitoring, and once-daily dosing. Clopidogrel com-
bined with aspirin is recommended for patients with STEMI
who undergo coronary stent implantation (576-580). There
are no safety data available regarding the combination of fib-
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(88% with STEMI) undergoing primary PTCA or stenting;
half received placebo, and half were treated with abciximab
in the catheterization laboratory. At 30 days, the incidence of
the primary composite end point of death, reinfarction, revas-
cularization, or disabling stroke was highest in the group
assigned to receive PTCA alone (8.3%), and the lower rates
in the other 3 groups were not significantly different from
one another (4.8% PTCA plus abciximab, 5.7% stenting
alone, 4.4% stenting plus abciximab). The Anticoagulation
for Cardioversion using Enoxaparin (ACE) study (582) ran-
domized 400 patients to stenting alone or stenting plus abcix-
imab (administered immediately before the procedure). At 30
days, the incidence of the primary composite end point of
death, reinfarction, target-vessel revascularization, or stroke
was reduced in the stent-plus-abciximab group (4.5%) versus
the stent-alone group (10.5%; p equals 0.023); the majority
of the benefit of abciximab on the primary end point in the
ACE study was driven by a reduction in the rate of reinfarc-
tion. It is unclear whether the different 30-day results in the
studies described above are related to patient selection and
risk, timing of abciximab administration, or patency rates
before revascularization (583). Assessment of the benefit of
abciximab at 6 months varies depending on the composite
end point, with evidence in favor of its use derived from
composite end points of death/reinfarction or death/reinfarc-
tion/urgent target-vessel revascularization, whereas evidence
of long-term benefit of abciximab is lost if elective revascu-
larization is added to the end point (34,36,583). 
The Writing Committee believes that it is reasonable to
start treatment with abciximab as early as possible in patients
undergoing primary PCI (with or without stenting), but given
the size and limitations of the available data set, assigned a
Class IIa recommendation. The data on tirofiban and eptifi-
batide in primary PCI are far more limited than for abcix-
imab. However, given the common mode of action of the
agents, a modest amount of angiographic data (584), and
general clinical experience to date, tirofiban or eptifibatide
may be useful as antiplatelet therapy to support primary PCI
for STEMI, with or without stenting (Class IIb recommenda-
tion).
6.3.1.6.9. OTHER PHARMACOLOGICAL MEASURES.
6.3.1.6.9.1. Inhibition of Renin-Angiotensin-
Aldosterone System
Class I
1. An ACE inhibitor should be administered orally within
the first 24 hours of STEMI to patients with anterior
infarction, pulmonary congestion, or LVEF less than
0.40, in the absence of hypotension (systolic blood pres-
sure less than 100 mm Hg or less than 30 mm Hg below
baseline) or known contraindications to that class of
medications. (Level of Evidence: A)
2. An angiotensin receptor blocker (ARB) should be
administered to STEMI patients who are intolerant of
ACE inhibitors and who have either clinical or radio-
logical signs of heart failure or LVEF less than 0.40.
rinolytic agents and clopidogrel, but ongoing trials will pro-
vide this information in the future. However, in patients in
whom aspirin is contraindicated because of aspirin sensitivi-
ty, clopidogrel is probably useful as a substitute for aspirin to
reduce the risk of occlusion (581). There are no safety data
comparing 300 and 600 mg as loading doses for clopidogrel.
We do not recommend routine administration of clopidogrel
as pretreatment in patients who have not yet undergone diag-
nostic cardiac catheterization and in whom CABG surgery
would be performed within 5 to 7 days if warranted (431).
6.3.1.6.8.2.3. Glycoprotein IIb/IIIa inhibitors.
Class IIa
It is reasonable to start treatment with abciximab as
early as possible before primary PCI (with or without
stenting) in patients with STEMI. (Level of Evidence: B)
Class IIb
Treatment with tirofiban or eptifibatide may be con-
sidered before primary PCI (with or without stenting)
in patients with STEMI. (Level of Evidence: C)
The use of intravenous GP IIb/IIIa receptor inhibitors in
combination with fibrinolytic agents is discussed in Section
6.3.1.6.3.8. Intravenous GP IIb/IIIa receptor inhibitors have
also been studied as supportive antiplatelet therapy in
patients undergoing PCI. Five randomized trials compared
abciximab to placebo control in a collective total of 3666
patients undergoing primary PCI for STEMI (34-36,38,582).
A total of 1843 patients received abciximab, a relatively
small data set on which to base recommendations for treat-
ment. In addition, in the setting of primary PCI, periproce-
dural recurrent MI is not easily measured, so the benefit of
antiplatelet therapy with GP IIb/IIIa inhibitors is harder to
determine. Finally, only 1 of the trials, CADILLAC
(Controlled Abciximab and Device Investigation to Lower
Late Angioplasty Complications), provided data on the effect
of abciximab on patients who underwent PTCA without
stenting and on patients who had a stent implanted at the time
of PCI (38). 
The ADMIRAL study (Abciximab Before Direct
Angioplasty and Stenting in Myocardial Infarction
Regarding Acute and Long-Term Follow-Up) (36) enrolled
300 patients with STEMI undergoing primary stenting; half
received placebo and half received abciximab in the mobile
intensive care unit or the ED before arrival at the catheteri-
zation laboratory. Abciximab-treated patients had higher
infarct-artery patency (TIMI 2/3 flow) rates (25.9% versus
10.8%) before revascularization and a better LVEF (0.61 ver-
sus 0.57) 6 months after revascularization. Abciximab-treat-
ed patients had a lower rate of death, reinfarction, or need for
subsequent target-vessel revascularization at 30 days (6.0%
versus 14.6%, p equals 0.01) and at 6 months (7.4% versus
15.9%, p equals 0.02); the majority of the benefit of abcix-
imab on the composite primary end point in ADMIRAL was
driven by a reduction in urgent target-vessel revasculariza-
tion. The CADILLAC study (38) enrolled 2082 patients
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support a role for ACE inhibitors in the early and convales-
cent phases of STEMI. 
All trials with oral ACE inhibitors have shown benefit from
its early use, including those in which early entry criteria
included clinical suspicion of acute infarctions. Data from
these trials indicate that ACE inhibitors should generally be
started within the first 24 hours, ideally after fibrinolytic
therapy has been completed and blood pressure has stabi-
lized. ACE inhibitors should not be used if systolic blood
pressure is less than 100 mm Hg or less than 30 mm Hg
below baseline, if clinically relevant renal failure is present,
if there is a history of bilateral stenosis of the renal arteries,
or if there is known allergy to ACE inhibitors.
The meta-analyses of the large ACE inhibitor trials have
been useful in defining those patient subgroups most likely
to demonstrate the greatest benefit from early post-MI ACE
inhibitor therapy. According to a meta-analysis of nearly
100000 randomized patients, the benefits of early oral ACE
inhibitors are greatest among those aged 55 to 74 years,
with an anterior infarct, and with a heart rate of 80 bpm or
higher (589).
ACE inhibitor therapy after STEMI should start with low-
dose oral administration and increase steadily to achieve a
full dose within 24 to 48 hours. For example, in ISIS-4, an
initial 6.25-mg dose of captopril was given and, if tolerated,
was followed by 12.5 mg 2 hours later, 25 mg 10 to 12 hours
later, and then 50 mg twice per day. GISSI-3 patients
received 5 mg or oral lisinopril at the time of randomization,
5 mg after 24 hours, 10 mg after 48 hours, and then 10 mg
daily for 6 weeks or open control. Similar graded-dose
schedules should be used with other ACE inhibitors such as
ramipril, zofenopril, enalapril, and quinapril. Regarding the
potential for aspirin to blunt the effect of ACE inhibitors, the
Writing Committee thought that any adverse drug interaction
between aspirin and ACE inhibitors was of a small magni-
tude and was far outweighed by the benefit of the combined
administration of both drugs to patients recovering from
STEMI (430,590,591). Lower doses of aspirin are likely to
minimize any potential interaction.
Finally, the only trial that did not show a benefit with ACE
inhibitors was the Cooperative New Scandinavian Enalapril
Survival Study (CONSENSUS) II, in which patients were
randomly assigned within the first day to receive either intra-
venous enalaprilat or placebo followed by increasing oral
dosages of either enalapril or placebo (592). This trial was
terminated early by its Safety Committee because of the high
probability that a significant benefit of enalapril over place-
bo was unlikely to be demonstrated with continuation of the
trial, as well as concern over an adverse effect among elder-
ly patients who experienced an early hypotensive reaction.
The 95% confidence limits ranged from showing a 7% ben-
efit to 29% harm. Thus, intravenous enalaprilat should be
avoided.
The use of ARBs has not been explored as thoroughly as
ACE inhibitors in patients with STEMI. However, clinical
experience in the management of patients with heart failure
and data from clinical trials in patients with STEMI (see
Valsartan and candesartan have established efficacy
for this recommendation. (Level of Evidence: C)
Class IIa
An ACE inhibitor administered orally within the first
24 hours of STEMI can be useful in patients without
anterior infarction, pulmonary congestion, or LVEF
less than 0.40 in the absence of hypotension (systolic
blood pressure less than 100 mm Hg or less than 30
mmHg below baseline) or known contraindications to
that class of medications. The expected treatment ben-
efit in such patients is less (5 lives saved per 1000
patients treated) than for patients with LV dysfunc-
tion. (Level of Evidence: B)
Class III
An intravenous ACE inhibitor should not be given to
patients within the first 24 hours of STEMI because of
the risk of hypotension. (A possible exception may be
patients with refractory hypertension.) (Level of
Evidence: B)
A number of large, randomized clinical trials have assessed
the role of ACE inhibitors early in the course of acute MI. All
trials in which ACE inhibitors were administered orally
demonstrated a benefit in mortality. In the ISIS-4 trial, 58000
patients with suspected acute MI were randomly assigned
within the first 24 hours (median 8 hours) to receive either
oral captopril or placebo; a significant 7% relative reduction
was observed in 5-week mortality among those randomly
assigned to captopril (absolute difference of 4.9 fewer deaths
per 1000 patients treated for 1 month) (152). The largest ben-
efit was among those with an anterior infarction. Among the
143 fewer deaths in the group allocated captopril, 44
occurred in days 0 through 1 and 37 in days 2 through 7
(585), which demonstrates that early therapy is important. In
the GISSI-3 trial, more than 19 000 patients with either ST-
segment elevation or depression were randomly assigned to
lisinopril or open control (586). There was a significant
reduction in 6-week mortality (OR 0.88; 95% CI 0.79 to
0.99); 60% of the lives were saved during the first 5 days of
treatment. The SMILE (Survival of Myocardial Infarction:
Long-Term Evaluation) study involved 1556 patients ran-
domly assigned within 24 hours to receive either placebo or
zofenopril (587). The patient population was restricted to
those with anterior MI who had not received fibrinolytic ther-
apy. Use of an early ACE inhibitor in this trial suggested a
trend of more lives saved in the first 6 weeks (RRR 25%, p
equals 0.19). A Chinese captopril study involving more than
13 600 patients with suspected acute MI also revealed an
approximate 0.5% absolute mortality benefit among those
who were randomly assigned to the ACE inhibitor compared
with the control population (588). A meta-analysis of these
major trials along with 11 smaller trials that collectively
enrolled more than 100 000 patients revealed a 6.5% overall
odds reduction (p equals 0.006) with an absolute benefit of
4.6 fewer deaths per 1000 patients treated among those who
received the ACE inhibitor (585). These data conclusively
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The acute phase of STEMI is associated with a dramatic
increase in catecholamine levels in the blood and ischemic
myocardium. The insulin level remains low while cortisol
and glucagon levels increase, which leads to decreased
insulin sensitivity that contributes to impaired glucose uti-
lization. Free fatty acid levels and the concentration of their
metabolites increase, potentiating ischemic injury through
several mechanisms: direct myocardial toxicity, increased
oxygen demand, and direct inhibition of glucose oxidation. It
has been suggested that agents that support glucose oxidation
could reduce postischemic contractile dysfunction. Insulin
promotes glucose oxidation, increases adenosine triphos-
phate levels, and may improve the fibrinolytic profile of
patients with STEMI (599,600). Insulin reduces free fatty
acids by reducing lipolysis and enhances glycolysis. Insulin
specifically enhances glucose, lactate, and pyruvate uptake
and switches the reliance of the myocardium from fat to car-
bohydrate without a change in oxygen consumption. The
oxygen requirement of the heart is stimulated by free fatty
acids without an improvement in mechanical activity (601).
Intensive insulin management of endogenous elevation of
glucose in diabetics, supplemented by potassium as needed,
has potential metabolic benefits similar to GIK for nondia-
betics. The DIGAMI study randomized 620 diabetic patients
to intensive insulin therapy with an insulin-glucose infusion
for 24 hours followed by 3 months of subcutaneous injec-
tions of insulin 4 times daily or usual care (602). With con-
tinuous insulin infusion, blood glucose decreased in the first
24 hours from 15.4 to 9.6 mmol/L in the infusion group ver-
sus 15.7 to 11.7 mmol/L in the control group (p less than
0.0001). There was a trend toward lower 30-day mortality
and significantly lower 1-year mortality (18.6% versus
26.1%, p equals 0.027). 
Compelling evidence for tight glucose control in intensive
care unit patients (a large proportion of whom were there
after cardiac surgery) supports the importance of intensive
insulin therapy to achieve a normal blood glucose (80 to 110
mg/dL) in critically ill patients (603,603a). Van den Berghe
et al. reported that 12-month mortality rates were reduced
from 8.0% to 4.6% (p less than 0.04; n equals 1548) for crit-
ically ill patients assigned to intensive insulin therapy (604).
Goldberg et al. reported successful implementation of a nurs-
ing protocol with an insulin infusion to achieve a target blood
glucose of 100 to 139 mg/dL in an intensive care setting
(605). The studies by Van den Berghe et al. and Goldberg et
al. underscore the importance and feasibility of intensive
infusion therapy in the intensive care setting. The precise tar-
get blood glucose range requires further study.
Management of diabetic patients with STEMI should also
involve consideration of long-term hypoglycemic therapy. A
review of the oral hypoglycemic therapy of type 2 diabetes
mellitus indicated that with few exceptions, the available oral
antidiabetic agents are equally effective in lowering glucose
levels. Their mechanisms of action are different. As a result,
they appear to have distinct metabolic effects that may influ-
ence their profile and affect cardiovascular risk (606). As
suggested by Inuzzuchi, in terms of hypoglycemic effect
alone, there is no compelling reason to favor one of the major
Sections 7.4.3 and 7.6.4) suggest that ARBs may be useful in
patients with depressed LV function or clinical heart failure
who are intolerant of an ACE inhibitor. Use of aldosterone
antagonists in patients with STEMI is discussed in Sections
7.4.3 and 7.6.4.
6.3.1.6.9.2. Metabolic Modulation of the Glucose-
Insulin Axis
Metabolic modulation of patients with STEMI was original-
ly proposed by Sodi-Pallares et al. (593) in 1962. A meta-
analysis of 1932 patients in trials conducted between 1965
and 1987 demonstrated a 28% relative mortality reduction,
with an absolute benefit of 49 lives saved per 1000 patients
treated (Table 21) (594-597). Subsequent trials in the reper-
fusion era show promising but variable results. High-dose
infusions of glucose-insulin-potassium (GIK) (25% glucose,
50 IU/L soluble insulin, and 80 mmol/L KCl at a rate of 1.5
mL/kg/h for 24 hours) or a low-dose infusion (10% glucose,
20 IU/L soluble insulin, and 40 mmol/L KCl at a rate of 1
mL/kg/h for 24 hours) were compared to usual care. The
ECLA (Estudios Cardiológicos Latinoamérica) pilot sug-
gested a relationship between the time from symptom onset
and impact of GIK infusion; a significant reduction in mor-
tality rate was observed in patients treated 12 hours or less
after symptom onset (595). The high-dose GIK regimen is
being tested in large, ongoing international trials. The poten-
tial beneficial effect of GIK in high-risk patients with acute
ischemic syndromes who have been revascularized is sup-
ported by a study of 322 post–cardiac surgery patients with
postoperative cardiogenic shock (598). Those assigned to
GIK had a 34% (p less than 0.02) reduction in in-hospital
mortality. GIK was not superior to placebo in a study of 940
patients who underwent primary PCI (597). There appeared
to be an interaction between treatment and Killip class, with
possible mortality reduction at 30 days in Killip class I
patients and excess mortality for those in Killip class II or
higher. No definitive recommendations regarding GIK can be
formulated until ongoing trials are completed.
6.3.1.6.9.2.1. Strict glucose control during STEMI. 
Class I
An insulin infusion to normalize blood glucose is rec-
ommended for patients with STEMI and complicated
courses. (Level of Evidence: B)
Class IIa
1. During the acute phase (first 24 to 48 hours) of the
management of STEMI in patients with hyper-
glycemia, it is reasonable to administer an insulin
infusion to normalize blood glucose even in patients
with an uncomplicated course. (Level of Evidence: B)
2. After the acute phase of STEMI, it is reasonable to
individualize treatment of diabetics, selecting from a
combination of insulin, insulin analogs, and oral
hypoglycemic agents that achieve the best glycemic
control and are well tolerated. (Level of Evidence: C)
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The MAGIC (Magnesium in Coronaries) trial investigated
the benefits of early administration of intravenous magne-
sium to high-risk patients with STEMI (stratum I: age 65
years or older and eligible for reperfusion therapy; stratum II:
patients of any age who were not eligible for reperfusion
therapy) (614). At 30 days, 475 (15.3%) patients in the mag-
nesium group and 472 (15.2%) in the placebo group had died
(OR 1.0, 95% CI 0.9 to 1.2, p equals 0.96). Potential expla-
nations for the null effect of magnesium in MAGIC include
the possibility that publication bias and an inadequate sam-
ple size in several earlier trials could have led to an overesti-
mation of the benefit of magnesium through a large type I
error and that the combination of mechanisms proposed for
the benefits of magnesium overlapped with and were super-
seded by aspirin, beta-blockers, and ACE inhibitors (pre-
scribed infrequently in earlier trials but commonly in ISIS-4
and MAGIC).
Between 1980 and 2002, a total of 68 684 patients were
studied in a series of 15 randomized trials (Table 22) (614-
628). On the basis of the totality of available evidence, in
current coronary care practice, there is no indication for the
routine administration of intravenous magnesium to patients
with STEMI at any level of risk. Magnesium can continue to
be administered for repletion of documented electrolyte
deficits and life-threatening ventricular arrhythmias such as
torsade de pointes (629).
6.3.1.6.9.4. Calcium Channel Blockers
Class IIa
It is reasonable to give verapamil or diltiazem to
patients in whom beta-blockers are ineffective or con-
traindicated (e.g., bronchospastic disease) for relief of
ongoing ischemia or control of a rapid ventricular
response with AF or atrial flutter after STEMI in the
absence of CHF, LV dysfunction, or AV block. (Level
of Evidence: C)
Class III
1. Diltiazem and verapamil are contraindicated in
patients with STEMI and associated systolic LV dys-
function and CHF. (Level of Evidence: A)
2. Nifedipine (immediate-release form) is contraindicat-
ed in the treatment of STEMI because of the reflex
sympathetic activation, tachycardia, and hypotension
associated with its use. (Level of Evidence: B)
Nifedipine. In patients with STEMI, immediate-release
nifedipine does not reduce the incidence of reinfarction or
mortality when given early (less than 24 hours) or late.
Immediate-release nifedipine may be particularly detrimen-
tal in patients with hypotension or tachycardia; in these
patients, it may induce a reduction in coronary perfusion
pressure, disproportionate dilatation of the coronary arteries
adjacent to the ischemic area (so-called “steal”), and/or
reflex activation of the sympathetic nervous system, with an
increase in myocardial oxygen demands (630-637).
classes of oral antidiabetic agents (606). The overarching
principle is that diabetic patients with STEMI should ulti-
mately receive a regimen that achieves the best glycemic
control, is well tolerated, and is likely to be maintained by
the patient over the long term.
Although it is well appreciated that type I diabetic patients
require insulin, most type 2 diabetics will also eventually
need insulin to achieve the target of a HbA1C level less than
7%, a value that has been shown to be associated with
reduced cardiovascular complications. It is reasonable that
the prescription for care of diabetics with STEMI be individ-
ualized, selected from an armamentarium of insulin, insulin
analogs, and oral hypoglycemic agents alone or in combina-
tion (607). A popular combination is metformin with insulin
because it results in similar metabolic control, less weight
gain, lower insulin doses, and fewer hyperglycemic episodes
than insulin alone or insulin plus sulfonylurea therapy (607).
The use of metformin must be tempered with the knowledge
that metformin is contraindicated in the presence of CHF and
renal failure. It should be withheld for 48 hours after intra-
venous contrast injection (608). 
6.3.1.6.9.3. Magnesium
Class IIa
1. It is reasonable that documented magnesium deficits
be corrected, especially in patients receiving diuretics
before the onset of STEMI. (Level of Evidence: C)
2. It is reasonable that episodes of torsade de pointes-
type VT associated with a prolonged QT interval be
treated with 1 to 2 grams of magnesium administered
as an IV bolus over 5 minutes. (Level of Evidence: C)
Class III
In the absence of documented electrolyte deficits or
torsade de pointes-type VT, routine intravenous mag-
nesium should not be administered to STEMI patients
at any level of risk. (Level of Evidence: A)
Meta-analyses of 7 randomized trials published between
1984 and 1991 suggested a significant mortality benefit of
magnesium (4.4% absolute risk difference [ARD]; OR 0.44,
CI 0.27 to 0.71) (609,610). The Second Leicester
Intravenous Magnesium Intervention Trial (LIMIT-2) subse-
quently reported a significant reduction in mortality with
magnesium treatment (2.5% ARD; 24% RRR; p equals 0.03)
(611). 
The ISIS-4 investigators enrolled 58 050 patients, of whom
29 011 were allocated to magnesium and 29 039 to control
(152). There were 2216 deaths (7.64%) by 35 days in the
magnesium group and 2103 deaths (7.24%) in the control
group (OR 1.06; CI 0.99 to 1.13), which suggests no mortal-
ity benefit of magnesium administration and even the possi-
bility of slight harm. Critiques of ISIS-4 raised the possibili-
ty that the null effect of magnesium resulted from late admin-
istration of treatment to patients who were predominantly at
low risk (612,613).
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control of angina, hypertension, or heart failure.
(Level of Evidence: A)
3. The ongoing need for supplemental oxygen should be
assessed by monitoring arterial oxygen saturation.
When stable for 6 hours, the patient should be
reassessed for oxygen need (i.e., O2 saturation of less
than 90%), and discontinuation of supplemental oxy-
gen should be considered. (Level of Evidence: C)
4. Nursing care should be provided by individuals certi-
fied in critical care, with staffing based on the specific
needs of patients and provider competencies, as well
as organizational priorities. (Level of Evidence: C)
5. Care of STEMI patients in the coronary care unit
(CCU) should be structured around protocols derived
from practice guidelines. (Level of Evidence: C)
6. Electrocardiographic monitoring leads should be
based on the location and rhythm to optimize detec-
tion of ST deviation, axis shift, conduction defects,
and dysrhythmias. (Level of Evidence: B)
Class III
It is not an effective use of the CCU environment to
admit terminally ill, “do not resuscitate” patients with
STEMI, because clinical and comfort needs can be
provided outside of a critical care environment. (Level
of Evidence: C)
Treatment of the patient with STEMI begins in the EMS
system/ED/catheterization laboratory and is consolidated in
the CCU. On arrival at the CCU, initial patient evaluation
includes assessment of vital signs, pulse oximetry, cardiac
rhythm and ST segments, and symptoms of acute cardiac
ischemia. Research has also shown the importance of assess-
ing anxiety and depression, because outcomes are worse in
patients with even moderate elevations in dysphoria.
Outstanding (and abnormal) laboratory results should be fol-
lowed up, and standard orders to CCU should be implement-
ed. All CCUs should have the equipment and personnel nec-
essary to monitor intra-arterial pressure and pulmonary
artery catheter pressures (Swan-Ganz catheter). Such moni-
toring is useful for severely hypotensive patients. An IABP
should be available in tertiary care CCUs for treatment of
cardiogenic shock. The patient’s medication orders should be
reviewed to confirm the administration of aspirin and beta-
blockers in an adequate dose to control heart rate and to
assess the need for intravenous nitroglycerin for control of
angina, hypertension, or acute heart failure. 
Ideally, all CCU nursing staff should have certification in
critical care nursing (CCRN, Critical Care Registered Nurse)
as endorsed by the American Association of Critical-Care
Nurses (647). Advanced cardiac life support certification
(ACLS) is highly recommended. The need for ACLS certifi-
cation is usually determined by institutional policy. 
There has been documentation of the positive correlation
between nurse staffing levels and patient outcome in inten-
sive care units (648-650). The nurse-to-patient ratio has var-
ied depending on nurse availability and the needs of the
Verapamil. Although the overall results of trials with 
verapamil showed no mortality benefits, subgroup analysis
showed that immediate-release verapamil initiated several
days after STEMI in patients who were not candidates for a
beta-blocking agent may have been useful in reducing the
incidence of the composite end point of reinfarction and death,
provided LV function was well preserved with no clinical evi-
dence of heart failure. Verapamil is detrimental to patients
with heart failure or bradyarrhythmias during the first 24 to 48
hours after STEMI (638-641). One randomized study of 1700
patients less than 75 years of age using verapamil within 2
weeks of STEMI showed a significant reduction in major
events (death or reinfarction) over 18 months (3.6% ARD;
17% RRR; p equals 0.03) (642).
Diltiazem. Data from the Multicenter Diltiazem
Postinfarction Trial (MDPIT; Q-wave and non–Q-wave
infarction) (643) and the Diltiazem Reinfarction Study
(DRS; non–Q-wave infarction) (639,640,644,645) suggest
that patients with non–Q-wave MI or those with Q-wave
infarction, preserved LV function, and no evidence of heart
failure may benefit from immediate-release diltiazem.
Diltiazem was begun in MDPIT 3 to 15 days after STEMI
and in DRS 24 to 72 hours afterward. The results of MDPIT
may be confounded by the fact that 53% and 55% of place-
bo- and diltiazem-treated patients, respectively, received con-
comitant beta-blocker therapy (643). Also, both the MDPIT
and DRS projects were conducted in an era when the use of
aspirin was not as prevalent as it is today, which raises fur-
ther uncertainty about the relevance of their findings for con-
temporary management of STEMI. Of particular clinical
importance is the detrimental mortality effect of diltiazem in
patients with LV dysfunction. 
Diltiazem was tested in patients with STEMI but without
CHF who were undergoing fibrinolytic therapy in the
INTERCEPT trial (Incomplete Infarction Trial of European
Research Collaborators Evaluating Prognosis post-
Thrombolysis) (646). No effect on the cumulative occurrence
of fatal and nonfatal end points was demonstrated during a 6-
month follow-up, but there was a modest decrease in nonfa-
tal cardiac events, in large part due to reductions in recurrent
ischemia. 
7. HOSPITAL MANAGEMENT 
7.1. Location
7.1.1. Coronary Care Unit
Class I
1. STEMI patients should be admitted to a quiet and
comfortable environment that provides for continuous
monitoring of the ECG and pulse oximetry and has
ready access to facilities for hemodynamic monitoring
and defibrillation. (Level of Evidence: C)
2. The patient’s medication regimen should be reviewed
to confirm the administration of aspirin and beta-
blockers in an adequate dose to control heart rate and
to assess the need for intravenous nitroglycerin for
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Because changes in the ST segment can shift among vari-
ous ECG leads in the same person over time owing to differ-
ent ischemic mechanisms, a consensus statement on ST mon-
itoring has recommended that 12-lead monitoring be done
(662). Patients with acute coronary syndromes, including
STEMI, are the highest priority for ST-segment monitoring.
It is recommended they be monitored for a minimum of 24
hours and until they remain event-free for 12 to 24 hours.
Potential benefits in patients with STEMI include the ability
to assess patency of the culprit artery after fibrinolytic thera-
py (664-668); detect abrupt reocclusion after PCI (669);
detect ongoing ischemia (i.e., failed reperfusion therapy),
recurrent ischemia, and infarct extension; and detect tran-
sient myocardial ischemia. 
Blood pressure should be measured repeatedly; actual fre-
quency will depend on the severity of the illness. Although
invasive arterial monitoring is preferred in the hypotensive
patient, noninvasive monitoring is adequate for most
patients. Monitoring with an automatic device that inflates
and deflates at programmed intervals is useful, but it must be
recognized that measurements may be inaccurate because of
inappropriate cuff size or muscle contractions; marked
peripheral vasoconstriction can result in falsely low readings.
Furthermore, many patients report that the device is irritating
and disrupts rest. 
7.1.2. Stepdown Unit
Class I
1. It is a useful triage strategy to admit low-risk STEMI
patients who have undergone successful PCI directly
to the stepdown unit for post-PCI care rather than to
the CCU. (Level of Evidence: C)
2. STEMI patients originally admitted to the CCU who
demonstrate 12 to 24 hours of clinical stability
(absence of recurrent ischemia, heart failure, or
hemodynamically compromising dysrhythmias)
should be transferred to the stepdown unit. (Level of
Evidence: C)
Class IIa
1. It is reasonable for patients recovering from STEMI
who have clinically symptomatic heart failure to be
managed on the stepdown unit, provided that facilities
for continuous monitoring of pulse oximetry and
appropriately skilled nurses are available. (Level of
Evidence: C)
2. It is reasonable for patients recovering from STEMI
who have arrhythmias that are hemodynamically well
tolerated (e.g., AF with a controlled ventricular
response; paroxysms of nonsustained VT lasting less
than 30 seconds) to be managed on the stepdown unit,
provided that facilities for continuous monitoring of
the ECG, defibrillators, and appropriately skilled
nurses are available. (Level of Evidence: C)
Class IIb
Patients recovering from STEMI who have clinically
significant pulmonary disease requiring high-flow
patient, e.g., 1 nurse per patient for an intubated patient, to
1:2 (651). In 1999, the state of California mandated a ratio of
1:2 in the intensive care unit/CCU, 1:4 in the stepdown unit,
and 1:5 in the telemetry unit (652). A study of the effect of
the California state law showed a continued wide variation of
staffing ratios among hospitals (653). The American
Association of Critical Care Nurses has issued a policy state-
ment that staffing decisions in the critical care setting should
optimally be based on the specific needs of patients and
provider competencies, as well as organizational priorities.
Within this framework, staffing should reflect the number
and type of staff that meet a group of patients’ needs instead
of a mandated single staffing ratio or mix (654). 
Patients with STEMI may experience heart failure, serious
arrhythmias, or recurrent ischemia (655). Accordingly, nurs-
ing-related care is commonly prescribed as part of a standing
order (i.e., measurement of height and weight on admission
and thereafter daily weight, especially if heart failure is pres-
ent; routine post-STEMI vital signs, including oxygen satu-
ration; ECG monitoring; and activity level such as bathroom
privileges and progressive cardiac rehabilitation).
Medications such as stool softeners or antianxiety agents
should be given based on nursing judgment. 
The current medical-legal-economic climate demands that
CCUs be operated at peak efficiency, optimizing quality of
care and minimizing complications. Practical and ethical
dilemmas present the CCU director with issues of futile care,
triage, and the administration of appropriate care (656). It is
generally accepted that terminal patients (no-code) or
patients whose comorbidities make survival unlikely should
not be admitted to a CCU. Similarly, patients with improving
CHF or stable dysrhythmia should be transferred to a non-
CCU, monitored bed.
7.1.1.1. Monitoring and Treatment for 
Adverse Events
Early general measures focus on monitoring for adverse
events, preventing such events through protective measures,
and treating these adverse events when they do occur.
Electrocardiographic monitoring is an essential role of CCU
staff, who must be adept at rhythm interpretation, lead selec-
tion based on infarct location and rhythm, and lead place-
ment for detection of RV involvement (657-660). Computer
algorithms have proved superior to medical personnel for
detection of arrhythmias (661). Accurate and consistent lead
placement and careful electrode and skin preparation are
important to improve the clinical usefulness of ST monitor-
ing (662). 
Nurses should monitor the ST segment for ischemia, par-
ticularly during routine morning care, because patients have
been reported to have a greater likelihood of ischemic events
between 6 AM and noon than at other times (663). Currently,
ECG monitors operate with computerized arrhythmia analy-
sis alone or with both arrhythmia and ischemia analysis. ST-
segment monitoring is generally underutilized in American
hospitals.
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The current literature suggests that the deconditioning
effects of bedrest are independent of the patient’s clinical
condition but rather are associated with the absence of regu-
lar exposure to “orthostatic stress” (produced by assumption
of an upright posture). The absence of habitual exposure to
the upright posture occurs naturally with prolonged periods
of bedrest and deprives the cardiovascular system of stimula-
tion needed to maintain adequate blood pressure regulation.
As a result, these patients commonly develop orthostatic
hypotension or frank syncope during their initial ambulation
attempt in the in-patient setting. Studies have found that
intermittent but regular exposure to sitting or standing during
convalescence can counteract these deconditioning effects
(672). 
The 1996 ACC/AHA Guidelines for the Management of
Patients with Acute MI cited evidence of the continued prac-
tice of “coronary precautions” that were advocated in the
1960s (2), and specific directions were given about what
were or were no longer considered to be coronary precau-
tions. It is assumed that current practice has advanced suffi-
ciently such that patients with STEMI are no longer kept on
bedrest or fed by nurses. Avoidance of the Valsalva maneu-
ver remains an important consideration (673,674), especially
in younger patients (e.g., under the age of 45 years) (673-
676). Otherwise, current practice routinely entails a short
period of bedrest (except for patients who have recurrent
ischemic discomfort, symptoms of heart failure, or serious
rhythm disturbances). Low-level activities such as toileting,
assisted bathing, and light ambulation can prevent physio-
logical deconditioning (673-676). Sample admitting orders
reflecting the standard of care are presented in Table 23 (3).
7.2.2. Diet
Class I
1. Patients with STEMI should be prescribed the NCEP
Adult Treatment Panel III (ATP III) Therapeutic
Lifestyle Changes (TLC) diet, which focuses on
reduced intake of fats and cholesterol, less than 7% of
total calories as saturated fats, less than 200 mg of
cholesterol per day, increased consumption of omega-
3 fatty acids, and appropriate caloric intake for ener-
gy needs. (Level of Evidence: C)
2. Diabetic patients with STEMI should have an appro-
priate food group balance and caloric intake. (Level of
Evidence: B)
3. Sodium intake should be restricted in STEMI patients
with hypertension or heart failure. (Level of Evidence: B)
The NCEP ATP III has recommended that a complete
blood lipid profile be taken in all patients with established
CHD (50). In the STEMI patient, this should be done at the
time of admission or within 24 hours of the onset of symp-
toms, because low-density lipoprotein cholesterol (LDL-C)
levels begin to decrease soon after an event and are signifi-
cantly reduced by 48 hours and remain so for many weeks.
Thus, LDL-C measurements several days after STEMI may
supplemental oxygen or noninvasive mask ventila-
tion/bilevel positive airway pressure/continuous posi-
tive airway pressure may be considered for care on a
stepdown unit provided that facilities for continuous
monitoring of pulse oximetry and appropriately
skilled nurses with a sufficient nurse:patient ratio are
available. (Level of Evidence: C)
Although the CCU was traditionally the hospital location to
which patients with STEMI were first admitted, increasing
use of catheter-based reperfusion and increasing sophistica-
tion of monitoring equipment and staff experience has result-
ed in a shift toward admitting patients with low-risk STEMI
who have undergone successful reperfusion with PCI direct-
ly to a stepdown unit. In addition, patients originally admit-
ted to the CCU who demonstrate 12 to 24 hours of clinical
stability are typically transferred to the stepdown unit. The
same nurse staffing and certification considerations apply to
the stepdown unit (coronary observation unit, telemetry unit)
as described for the CCU to ensure optimal evaluation and
response to any deterioration of the patient with STEMI.
Pulse oximetry and ECG monitoring and defibrillation
equipment should be available. Optimally, the nursing staff
should have a skill set similar to CCU nurses so that they
may evaluate and respond to any deterioration of a patient
with STEMI. The initial evaluation of patients with STEMI
who are admitted directly to the stepdown unit is similar to
that described in Section 7.1.1 for the CCU.
7.2. Early, General Measures
7.2.1. Level of Activity
Class IIa
After 12 to 24 hours, it is reasonable to allow patients
with hemodynamic instability or continued ischemia
to have bedside commode privileges. (Level of
Evidence: C)
Class III
Patients with STEMI who are free of recurrent
ischemic discomfort, symptoms of heart failure, or
serious disturbances of heart rhythm should not be on
bed rest for more than 12 to 24 hours. (Level of
Evidence: C)
Limiting early physical exertion and minimizing sympa-
thetic stimulation (e.g., acute ischemic-type chest discomfort
and anxiety) are methods of minimizing myocardial oxygen
demand (670). In an earlier era, the duration of bed rest was
extended to several weeks, until it was ascertained that pro-
longed immobility is harmful because of the physiological
deconditioning that occurs after even 6 hours in the supine
position (671). Preload decreases because of plasma volume
losses that occur early in the bedrest period. Shifts in ven-
tricular filling activate the body’s compensatory mechanisms
to buffer pressure and volume alterations. 
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(450 mg) of caffeine did not increase ventricular arrhythmias
in a small group of patients with ischemic heart disease
(681). People who drink caffeinated beverages regularly
develop a tolerance after 1 to 4 days (682,683), regardless of
dose. Withdrawal of caffeine is associated with headache
(684,685) and increases in heart rate (686). The available evi-
dence suggests that patients with STEMI who are routine
caffeine drinkers be allowed to consume up to 4 to 5 cups of
caffeinated coffee a day while in the CCU or progressive care
unit, under the surveillance of nursing staff (680,687). As a
practical matter in the acute care setting, 1 to 2 cups of cof-
fee, enough to avert caffeine withdrawal, seems appropriate.
7.2.3. Patient Education in the Hospital Setting
Class I
1. Patient counseling to maximize adherence to evi-
dence-based post-STEMI treatments (e.g., compliance
with taking medication, exercise prescription, and
not be representative of the patient’s average LDL-C. In the
context of possible early cardiac catheterization, it would be
helpful for patients to have been on a clear liquid diet that
extended to a period of “nothing by mouth” (NPO) before the
procedure. Patients with STEMI should receive a reduced
saturated fat and cholesterol diet per the ATP III TLC
approach (677). (See Section 7.12.2.) Diabetes experts no
longer recommend a single meal plan for all people with dia-
betes. Instead, they recommend meal plans that are flexible
and take into account a person’s lifestyle and particular
health needs, ideally with consultation from a registered die-
titian to design a meal plan. Sodium intake should be restrict-
ed in patients with STEMI with hypertension or heart failure
to a maximum of 2000 mg/d (Table 23) (3).
Blood pressure increases after caffeine intake (678), but the
increase is not clinically significant until 400 mg of caffeine
(i.e., 2 to 4 cups of coffee, depending on strength and brew-
ing method) is ingested (679,680). Moderately high doses
Table 23. Sample Admitting Orders for the Patient With STEMI
1. Condition: Serious
2. IV: NS on D5W to keep vein open. Start a second IV if IV medication is being given. This may be a saline lock.
3. Vital signs: every 1.5 h until stable, then every 4 h and as needed. Notify physician if HR is less than 60 bpm or greater than 100 bpm,
BP is less than 100 mm Hg systolic or greater than 150 mm Hg diastolic, respiratory rate is less than 8 or greater than 22 bpm.
4. Monitor: Continuous ECG monitoring for arrhythmia and ST-segment deviation.
5. Diet: NPO except for sips of water until stable. Then start 2 grams sodium/day, low saturated fat (less than 7% of total calories/day), low choles-
terol (less than 200 mg/d) diet, such as Total Lifestyle Change (TLC) diet.
6. Activity: Bedside commode and light activity when stable.
7. Oxygen: Continuous oximetry monitoring. Nasal cannula at 2 L/min when stable for 6 h, reassess for oxygen need (i.e., O2 saturation 
less than 90%), and consider discontinuing oxygen.
8. Medications:
a. Nitroglycerin (See Section 6.3.1.2 for further discussion.)
1. Use sublingual NTG 0.4 mg every 5 min as needed for chest discomfort.
2. Intravenous NTG for CHF, hypertension, or persistent ischemia.
b. Aspirin (See Section 6.3.1.4.)
1. If aspirin not given in the ED, chew non–enteric-coated aspirin† 162 to 325 mg.
2. If aspirin has been given, start daily maintenance of 75 to 162 mg. May use enteric-coated for gastrointestinal protection.
c. Beta-Blocker (See Section 6.3.1.5.)
1. If not given in the ED, assess for contraindications, i.e., bradycardia and hypotension. Continue daily assessment to ascertain eligibility 
for beta-blocker.
2. If given in the ED, continue daily dose and optimize as dictated by HR and BP.
d. ACE Inhibitor (See Section 6.3.1.6.9.1.)
1. Start ACE inhibitor orally in patients with anterior infarction, pulmonary congestion, or LVEF less than 0.40 if the following are absent:
hypotension (SBP less than 100 mm Hg or less than 30 mm Hg below baseline) or known contraindications to this class of medications.
e. Angiotensin Receptor Blocker (See Section 6.3.1.6.9.1.)
1. Start ARB orally in patients who are intolerant of ACE inhibitors and who have either clinical or radiological signs of heart failure or
LVEF less than 0.40. 
f.  Pain Medications (See Section 6.3.1.3.)
2. IV morphine sulfate 2 to 4 mg with increments of 2 to 8 mg IV at 5- to 15-minute intervals as needed to control pain.
g.  Anxiolytics (based on a nursing assessment) (See Section 7.2.4.)
h.  Daily Stool Softener
9. Laboratory Tests: Serum biomarkers for cardiac damage,*CBC with platelet count, INR, aPTT, electrolytes, magnesium, BUN, creatinine, glu-
cose, serum lipids (see Table 9).
STEMI = ST-elevation myocardial infarction; IV = intravenous; NS = normal saline; h = hours; bpm = beats per minute; ECG = electrocardiogram; NPO = nothing by mouth; min = min-
utes; NTG = nitroglycerin; CHF = congestive heart failure; ED = emergency department; HR = heart rate; BP = blood pressure; ACE = angiotensin converting enzyme; LVEF = left ven-
tricular ejection fraction; SBP = systolic blood pressure; ARB = angiotensin receptor blocker; CBC = complete blood count; INR = international normalized ratio; aPTT = activated partial
thromboplastin time; BUN = blood urea nitrogen. 
*Do not wait for results before implementing reperfusion strategy.
†Although some trials have used enteric-coated aspirin for initial dosing, more rapid buccal absorption occurs with non–enteric-coated formulations.
Modified with permission from Ryan et al. J Am Coll Cardiol 1999;34:890-911 (3).
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educating the patient and simply handing out written infor-
mation or other media without discussion. One-to-one teach-
ing is effectively enhanced and reinforced with the use of
appropriate media (688,695). 
Challenges to patient education in the inpatient setting are
shorter lengths of hospital stay (696); older, sicker patients
with more psychosocial issues; cultural and literacy barriers
(697); and patient anxiety (698). Inpatient education has
been shown to reduce anxiety (699,700), improve knowledge
(688), and decrease length of hospital stay (700,701).
In standardizing care for these patients, the use of guideline-
based tools has been reported to facilitate improvement in the
quality of care for patients with STEMI among a variety of
institutions, patients, and caregivers (5). Programs such as the
AHA’s “Get With the Guidelines” (see the “Get With the
Guidelines’ Hospital Tool Kit” at: http://www.american-
heart.org/downloadable/heart/1107_HospTool.pdf) and the
ACC’s “Guidelines Applied in Practice” (see sample forms at:
http://www.acc.org/gap/mi/ami_permissionprocess.htm) offer
tools such as educational plans for patients explaining what
they can expect over the course of their hospitalization (e.g.,
procedures and the treatment plan), care paths, standing orders
for providers, discharge protocols that incorporate evidence-
based recommendations (for providers and patients), and a
data-based patient management tool (702).
Support groups provided by some hospitals and cardiac
rehabilitation programs may help patients adjust to their
diagnosis and newly prescribed lifestyle and medication reg-
imens. For example, Mended Hearts is a national nonprofit
organization affiliated with the AHA that offers visiting pro-
grams, support group meetings, and educational forums
through partnerships with hospitals and rehabilitation clinics.
The organization is particularly interested in helping patients
deal with the emotional recovery from heart disease through
facilitating a positive patient-care experience for heart dis-
ease patients, their families, caregivers, and others impacted
by heart disease (703). Table 24 shows suggested topics for
educating the patient with STEMI.
7.2.4. Analgesia/Anxiolytics
Class IIa
1. It is reasonable to use anxiolytic medications in
STEMI patients to alleviate short-term anxiety or
altered behavior related to hospitalization for STEMI.
(Level of Evidence: C)
2. It is reasonable to routinely assess the patient's anxi-
ety level and manage it with behavioral interventions
and referral for counseling. (Level of Evidence: C)
It is useful to monitor patients for increased anxiety or
altered behavior of the patient in the CCU. Anxiolytics can
play an important role in patient management in this setting.
Treatment with benzodiazepines should be limited to the
minimal dose for a limited period of time (261). 
Hospitalized smokers may experience symptoms of nico-
tine withdrawal, including anxiety, insomnia, depression,
smoking cessation) should begin during the early
phase of hospitalization, occur intensively at dis-
charge, and continue at follow-up visits with providers
and through cardiac rehabilitation programs and
community support groups, as appropriate. (Level of
Evidence: C)
2. Critical pathways and protocols and other quality-
improvement tools (e.g., the ACC’s “Guidelines
Applied in Practice” and the AHA’s “Get with the
Guidelines”) should be used to improve the applica-
tion of evidence-based treatments by patients with
STEMI, caregivers, and institutions. (Level of
Evidence: C)
Patient education should be viewed as a continuous process
that should be part of every patient encounter (i.e., on hospi-
tal arrival, at inpatient admission, at discharge, and at follow-
up visits). On admission to the coronary care unit, patients
should receive an orientation to their surroundings (e.g.,
location of the call light), an explanation of the equipment
used for their care (e.g., electrodes and cardiac monitor, IV
line/heparin lock, central line, nasal cannula, and pulse
oximetry), nursing care routines and their “round-the-clock”
nature, level of activity permitted, an explanation of the pain
assessment scale that will be used, and the importance of
reporting any symptoms. 
In general, effective education involves the use of a combi-
nation of good communication skills, patient assessment of
prior knowledge and readiness to learn, and effective teach-
ing strategies. One-to-one teaching is the most common
patient education method in the inpatient setting and is pre-
ferred by patients as well (688). Ideally, family members
should be present to hear what patients are being told so they
can reinforce the information later (689). 
For more complex topics, the most effective educational
intervention involves being responsive to the patient’s
attempts to communicate (e.g., not changing the topic
abruptly or engaging in tasks unrelated to the conversation);
using good eye contact; not denying the patient’s feelings
(e.g., “You should not worry about that!”); and being aware
of one’s own nonverbal cues that encourage or discourage
communication (e.g., failure to sit down), as well as those of
the patient’s.
Inpatient education has been reported to stimulate some
lifestyle change after discharge, most frequently in the areas
of activity and smoking cessation (690). However, post-MI
knowledge alone does not ensure behavioral change
(691,692). Providers should be aware that many patients who
have had a STEMI may be in the early stages of behavioral
change, such as “precontemplation,” where they do not yet
see a need to change behavior. Others may be in the “con-
templation” stage, where, for example, the experience of
STEMI may cause them to acknowledge that they need and
want to make a change, but that thought is not yet translated
into action (691-694).
With 1-to-1 teaching in the hospital, the provider should
strike a balance between not using any teaching aids when
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difficulty concentrating, irritability, anger, restlessness, and
slowed heart rate (704). Patients experiencing nicotine with-
drawal can benefit from anxiolytics. Use of bupropion and
nicotine replacement therapy in the acute setting should also
be considered as options, depending on the severity of the
patient's withdrawal syndrome. Agitation and delirium are
not uncommon in the CCU, particularly in patients with
complicated STEMI and protracted stays in the intensive
care setting. In addition, a number of medications used in the
CCU, such as lidocaine, mexiletine, procainamide, atropine,
cimetidine, and meperidine, can induce delirium.
Intravenous haloperidol is a rapidly acting neuroleptic that
can be given safely and effectively to cardiac patients with
agitation. It rarely produces hypotension or need for assisted
ventilation. If patients exhibit altered sensorium and have
received fibrinolytics, consideration should be given to
ordering a computed axial tomography/magnetic resonance
imaging scan to rule out ICH before sedating the patient. 
Anxiety and depression are prevalent in patients hospital-
ized for STEMI because patients are confronted with a diag-
nosis that is major, both psychologically and physically
(705,706). In addition, the experience of a cardiac event is a
significant source of stress for family members trying to
adjust to the initial diagnosis and confront the uncertainties
associated with hospitalization and the initial recovery phase.
Anxiety has been demonstrated to predict inhospital recur-
rent ischemia and arrhythmias (707) and cardiac events dur-
ing the first year after an MI (708). Physicians’ and nurses’
subjective judgments of patient anxiety are not accurate
when compared with measurements of anxiety on validated
scales (709,710). 
The provision of information, discussed later in this guide-
line, and liberal visiting policies can also help patients with
STEMI feel more in control (711,712). In addition, psycho-
logical support and counseling during hospitalization can
decrease anxiety and depression immediately and for up to 6
months after STEMI (713,714). At least 1 randomized con-
trolled trial demonstrated that in-hospital anxiety and depres-
sion could be reduced by a structured nursing support inter-
vention (714).
Liberalized visiting rules for patients in critical care can be
helpful; several studies have demonstrated no harmful phys-
Table 24. Milestones and Recommended Information for Educating the Patient With ST-Elevation Myocardial Infarction
Following is the range of information providers should address with patients with STEMI and their family members:
Before the event—(ongoing by primary care provider, especially with high-risk patients)
Assess and manage cardiac risk factors
Review recommendations for recognizing and responding to heart attack symptoms (See: http://www.nhlbi.nih.gov/health/prof/heart/
mi/provider.htm)
At hospital/ED admission—(day of admission)
Explain diagnosis
Review plan for inpatient treatment and projected length of stay
Inpatient testing/procedures—(day of admission until discharge)
Explain the purpose of tests and procedures that are ordered
Describe what to expect with tests and procedures: duration; level of discomfort and invasiveness; sensory information
Cardiac care unit/stepdown unit—(day of admission)
Orient to surroundings/routine of unit
Explain nursing care plan
Describe the importance of reporting symptoms, needs
At discharge—(day of discharge or before)
Review risk factor goals and management plan
Review prescribed medications and lifestyle changes/recommendations
Review information on recognizing and responding to heart attack symptoms
Recommend that family member(s) attend a CPR training program and cardiac support group
Refer patient to cardiac rehabilitation program
Schedule a follow-up appointment with primary care provider 
Discuss plans for obtaining prescribed medication that day (immediately after discharge)
At follow-up visits with primary care provider—(first follow-up appointment and ongoing)
Review diagnosis with patient and hospital course/outcome
Review medical and lifestyle regimens prescribed
Ensure aggressive risk factor modification and follow-up
Discuss recognition and response to acute symptoms; review action plan, including taking nitroglycerin in response to acute symptoms if pre-
scribed, and calling 9-1-1
Assess for depression, other psychosocial responses
Suggested milestones for educating patients over the spectrum of cardiac care, both before and after the STEMI event. Risk factor assessment and management and counseling about recogni-
tion and response to heart attack symptoms should be done by the primary care provider. Once admitted for STEMI, the provider should review with the patient and family members the diag-
nosis, treatment plan, and projected length of stay; purpose and what to expect of tests and procedures that are ordered; the coronary care unit (or equivalent) environment and nursing care
plan; and at discharge, the prescribed medications and lifestyle changes, follow-up testing, and referral. 
STEMI = ST-elevation myocardial infarction; ED = emergency department; CPR = cardiopulmonary resuscitation.
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iological effects attributable to unrestricted visiting policies
(711,712). Patients whose anxiety is very severe or persistent
in spite of medications should be referred for consultation for
formal anxiety assessment and treatment. Consultation could
be obtained from a nurse specialist, psychiatric social work-
er, or a psychiatrist.
7.3. Risk Stratification During Early 
Hospital Course
Several groups have proposed risk stratification scores for
patients with suspected STEMI based on their admission
characteristics (241,242,394). Risk stratification is a contin-
uous process and requires the updating of initial assessments
with data obtained during the hospital stay. Indicators of
failed reperfusion (e.g., recurrence of chest pain, persistence
of ECG findings indicating infarction) identify a patient who
should undergo coronary angiography. Similarly, findings
consistent with mechanical complications (e.g., sudden onset
of heart failure, presence of a new murmur) herald increased
risk and suggest the need for rapid intervention. For patients
who did not undergo primary reperfusion, changes in clinical
status (e.g., development of shock) may herald a worsening
clinical status and are an indication for coronary angiogra-
phy.
Patients with a low risk of complications may be candidates
for early discharge. The lowest-risk patients are those who
did not have STEMI, despite the initial suspicions. Clinicians
should strive to identify such patients within 8 to 12 hours of
onset of symptoms. Serial sampling of serum cardiac bio-
markers and use of 12-lead ECGs and their interpretation in
the context of the number of hours that have elapsed since
onset of the patient's symptoms can determine the presence
of STEMI better than adherence to a rigid protocol that
requires that a specified number of samples be drawn in the
hospital. Among those with STEMI treated with reperfusion,
it has been suggested that an uncomplicated course after 72
hours of hospitalization identifies a group with a low enough
risk for discharge (715). Newby and colleagues calculated
that extending the hospital stay of these patients by another
day would cost $105 629 per year of life saved (715).
Concerns have been raised that shortening the length of stay
to 72 hours may adversely affect patient education regarding
STEMI and the identification of the optimum dose of critical
medications such as beta-blockers and ACE inhibitors (696).
Work on transitional care has shown the effectiveness of an
advanced practice nurse intervention in helping patients,
many with ischemic heart disease, during the transition from
hospital to home and in reducing costs in the process (716).
7.4. Medication Assessment
7.4.1. Beta-Blockers
Class I
1. Patients receiving beta-blockers within the first 24
hours of STEMI without adverse effects should con-
tinue to receive them during the early convalescent
phase of STEMI. (Level of Evidence: A)
2. Patients without contraindications to beta-blockers
who did not receive them within the first 24 hours
after STEMI should have them started in the early
convalescent phase. (Level of Evidence: A)
3. Patients with early contraindications within the first
24 hours of STEMI should be re-evaluated for candi-
dacy for beta-blocker therapy. (Level of Evidence: C)
There is overwhelming evidence for the benefits of early
beta-blockade in patients with STEMI and without con-
traindications to their use (see Section 6.3.1.5). Benefits have
been demonstrated for patients with and without concomitant
fibrinolytic therapy, both early and late after STEMI. Meta-
analysis of trials from the prefibrinolytic era involving more
Figure 27. Summary of data from meta-analysis of trials of beta-blocker therapy from the prefibrinolytic era in patients with myocar-
dial infarction. No. = number; RR = relative risk; CI = confidence interval. Reprinted with permission from Antman and Braunwald. Acute
Myocardial Infarction. In: Braunwald, Zipes, Libby, eds. Heart Disease: A Textbook of Cardiovascular Medicine, 6th ed., Philadelphia,
PA: W.B. Saunders; 2001:1168 (718).
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The use of nitrates in the patient with STEMI on presenta-
tion and in the early phase of infarction is reviewed in
Section 6.3.1.2. Clinical trials have suggested only a modest
benefit of nitroglycerin used acutely in STEMI and contin-
ued subsequently (152,586). Nitrates are most clearly indi-
cated for persistent or recurrent ischemia and in patients with
CHF. Because protocols in large clinical trials included acute
followed by sustained therapy, there is little evidence to
establish the duration of nitrate therapy after STEMI.
Common clinical practice is to continue nitrate therapy for
24 to 48 hours. In view of their marginal treatment benefits,
nitrates should not be used if hypotension limits the admin-
istration of beta-blockers or ACE inhibitors, which have
more powerful benefits for both early use and secondary pre-
vention after STEMI.
Nitrate tolerance develops with prolonged continuous
exposure to nitrates, presumably through the mechanism of
depletion of sulfhydryl groups in the vessel wall. If sustained
therapy with nitrates is planned, intravenous nitrate therapy
is usually changed to oral or topical preparations with a
nitrate-free interval.
7.4.3. Inhibition of the Renin-Angiotensin-
Aldosterone System
Class I
1. An ACE inhibitor should be administered orally dur-
ing convalescence from STEMI in patients who toler-
ate this class of medication, and it should be continued
over the long term. (Level of Evidence: A)
2. An ARB should be administered to STEMI patients
who are intolerant of ACE inhibitors and have either
clinical or radiological signs of heart failure or LVEF
less than 0.40. Valsartan and candesartan have
demonstrated efficacy for this recommendation.
(Level of Evidence: B)
3. Long-term aldosterone blockade should be prescribed
for post-STEMI patients without significant renal
dysfunction (creatinine should be less than or equal to
2.5 mg/dL in men and less than or equal to 2.0 mg/dL
in women) or hyperkalemia (potassium should be less
than or equal to 5.0 mEq/L) who are already receiving
therapeutic doses of an ACE inhibitor, have an LVEF
of less than or equal to 0.40, and have either sympto-
matic heart failure or diabetes. (Level of Evidence: A)
Class IIa
In STEMI patients who tolerate ACE inhibitors, an
ARB can be useful as an alternative provided there
are either clinical or radiological signs of heart failure
or LVEF is less than 0.40. Valsartan and candesartan
have established efficacy for this recommendation.
(Level of Evidence: B)
The use of ACE inhibitors in the initial management of the
patient with STEMI is reviewed in Section 6.3.1.6.9.1.
The proportional benefit of ACE inhibitor therapy is largest
in higher-risk subgroups, including those with previous
than 24 000 patients receiving beta-blockers in the convales-
cent phase showed a 14% RRR in mortality through 7 days
and a 23% RRR in long-term mortality (717). These data are
summarized in Figure 27 (718). 
Beta-blockers should be initiated early in the course of
STEMI and continued unless adverse effects have been
observed. In appropriately selected patients, these benefits
occur at a risk of approximately a 3% incidence of provoca-
tion of CHF or complete heart block and a 2% incidence of
the development of cardiogenic shock. Beta-blockers are
especially beneficial in patients in whom STEMI is compli-
cated by persistent or recurrent ischemia, evidence for infarct
extension, or tachyarrhythmias. 
Some clinicians do not start beta-blockers in the emergency
phase of STEMI management because of error, late presen-
tation, concern about relative or absolute contraindications,
or concern about the benefits of beta-blockade in the face of
other contemporary treatments. Benefits of beta-blockers ini-
tiated in the convalescent phase for secondary prevention of
ischemic events are established (717). The Beta-blocker
Heart Attack Trial (BHAT) (719) and the more contemporary
CAPRICORN trial (273) confirm the substantial benefit of
beta-blockers in addition to ACE inhibitor therapy in patients
with transient or sustained postinfarction LV dysfunction. A
reasonable general rule is to initiate beta-blockade after 24 to
48 hours of freedom from a relative contraindication, such as
bradycardia, mild-to-moderate heart failure, or first-degree
heart block. 
7.4.2. Nitroglycerin
Class I
1. Intravenous nitroglycerin is indicated in the first 48
hours after STEMI for treatment of persistent
ischemia, CHF, or hypertension. The decision to
administer intravenous nitroglycerin and the dose
used should take into account that it should not pre-
clude therapy with other proven mortality-reducing
interventions such as beta-blockers or ACE inhibitors.
(Level of Evidence: B)
2. Intravenous, oral, or topical nitrates are useful
beyond the first 48 hours after STEMI for treatment
of recurrent angina or persistent CHF if their use does
not preclude therapy with beta-blockers or ACE
inhibitors. (Level of Evidence: B)
Class IIb
The continued use of nitrate therapy beyond the first
24 to 48 hours in the absence of continued or recur-
rent angina or CHF may be helpful, although the ben-
efit is likely to be small and is not well established in
contemporary practice. (Level of Evidence: B)
Class III
Nitrates should not be administered to patients with
systolic blood pressure less than 90 mm Hg or greater
than or equal to 30 mm Hg below baseline, severe
bradycardia (less than 50 bpm), tachycardia (more
than 100 bpm), or RV infarction. (Level of Evidence: C)
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The use of ARBs after STEMI has not been explored as
thoroughly as ACE inhibitors in patients with STEMI. The 
OPTIMAAL trial (Optimal Trial in Myocardial Infarction
with Angiotensin II Antagonist Losartan) found no signifi-
cant differences between losartan (target dose 50 mg once
daily) and captopril (target dose 50 mg 3 times daily) in all-
cause mortality (724), but there was a trend toward better
outcome with captopril. The VALIANT trial (Valsartan in
Acute Myocardial Infarction Trial) compared the effects of
captopril (target dose 50 mg 3 times daily), valsartan (target
dose 160 mg twice daily), and their combination (captopril
target dose 50 mg 3 times daily; valsartan target dose 80 mg
twice daily) on mortality in post-MI patients with LV dys-
function (725). During a median follow-up of 24.7 months,
death occurred in 19.9% of the valsartan group, 19.5% of the
captopril group, and 19.3% of the combined-treatment
group. The hazard ratio for death in the valsartan group com-
pared with the captopril group was 1.00 (97.5% CI, 0.90 to
1.11; p equals 0.98), and the hazard ratio for death in the val-
sartan and captopril combined versus the captopril group was
0.98 (97.5% CI, 0.8 to 1.09; p equals 0.73) (725). The com-
bination captopril and valsartan group had the most drug-
related adverse events. In the monotherapy groups, hypoten-
sion and renal dysfunction were more common in the valsar-
tan group, and cough, rash, and taste disturbance were more
common in the captopril group.
Given the extensive randomized trial and routine clinical
experience with ACE inhibitors, they remain the logical first
agent for inhibition of the renin-angiotensin-aldosterone sys-
tem in patients convalescing from STEMI (726). Valsartan
monotherapy (target dose 160 mg twice daily) should be
administered to patients with STEMI who are intolerant of
ACE inhibitors and who have evidence of LV dysfunction.
Valsartan monotherapy can be a useful alternative to ACE
inhibitors; the decision in individual patients may be influ-
enced by physician and patient preference, cost, and antici-
pated side-effect profile.
7.4.4. Antiplatelets
Class I
1. Aspirin 162 to 325 mg should be given on day 1 of
STEMI and in the absence of contraindications
should be continued indefinitely on a daily basis there-
after at a dose of 75 to 162 mg. (Level of Evidence: A)
2. A thienopyridine (preferably clopidogrel) should be
administered to patients who are unable to take
aspirin because of hypersensitivity or major gastroin-
testinal intolerance. (Level of Evidence: C)
3. For patients taking clopidogrel for whom CABG is
planned, the drug should be withheld for at least 5
days if possible, and preferably for 7, unless the
urgency for revascularization outweighs the risks of
bleeding. (Level of Evidence: B)
4. For patients who have undergone diagnostic cardiac
catheterization and for whom PCI is planned, clopi-
dogrel should be started and continued for at least 1
month after bare metal stent implantation and for sev-
infarction, heart failure, depressed LVEF, and tachycardia
(585,589,720). Survival benefit for patients more than 75
years old and for a low-risk subgroup without the features
noted above is equivocal (589,720).
The duration of ACE inhibitor therapy after STEMI
requires detailed analysis of trial results. In general, the trials
that administered ACE inhibitors to an unselected population
of patients early after MI had a short follow-up of 5 to 7
weeks. In contrast, trials that selected patients with post-MI
LV dysfunction or clinical heart failure followed patients up
to 5 years. Thus, when there is no evidence of symptomatic
or asymptomatic LV dysfunction by 4 to 6 weeks, the indi-
cations for long-term ACE inhibitor use should be re-evalu-
ated. The Heart Outcomes Prevention Evaluation (HOPE)
trial enrolled patients whose entry characteristics were age
55 years or older, evidence of vascular disease, or diabetes
plus 1 other cardiovascular risk factor (721). In the HOPE
population, the use of ramipril at doses up to 10 mg daily
demonstrated a significant reduction in the primary outcome,
a composite of MI, stroke, or death of cardiovascular causes
(3.8% absolute risk reduction; RRR 0.78, 95% CI, 0.70 to
0.86; p less than 0.001).
Aldosterone blockade is another means of inhibiting the
renin-angiotensin-aldosterone system that has been applied
to patients in the post-STEMI setting. Again, additional
information can be inferred from heart failure studies that
enrolled a large proportion of patients with a history of MI.
The RALES study (Randomized Aldactone Evaluation
Study) randomized patients with New York Heart
Association class III to IV heart failure to either spironolac-
tone (initial dose 25 mg daily with the option to increase to
50 mg daily) or placebo (722). Ischemic heart disease was
the cause of heart failure in 55% of patients, and 95% were
treated concurrently with an ACE inhibitor. Over 24 months
of follow-up, spironolactone treatment was associated with
an 11% ARD (24% RRR) in all-cause mortality. The 
EPHESUS study (Eplerenone Post-Acute Myocardial
Infarction Heart Failure Efficacy and Survival Study) ran-
domized 6632 post-MI patients with an ejection fraction of
0.40 or less and heart failure or diabetes to receive the aldos-
terone blocker eplerenone (target dose 50 mg daily) or place-
bo in conjunction with routine indicated cardiac medications.
There was a significant reduction in overall mortality, car-
diovascular mortality, and cardiac hospitalizations (723). The
benefit was seen in patients managed with optimal therapy,
including reperfusion, aspirin, ACE inhibitors, beta-blockers,
and statins. Thus, the RALES and EPHESUS studies support
the long-term use of an aldosterone blocker in patients with
STEMI with heart failure and/or an ejection fraction of 0.40
or less, provided the serum creatinine is less than or equal to
2.5 mg/dL in men and less than or equal to 2.0 mg/dL in
women and serum potassium concentration is less than or
equal to 5.0 mEq/L. The risk of hyperkalemia was greatest in
patients with creatinine clearance estimated to be less than
50 mL/min. Close monitoring of potassium levels is indicat-
ed for those patients, and the risk-to-benefit ratio should be
weighed for those with moderate to severe reductions despite
a serum creatinine of less than 2.5 mg/dL.
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Use of the thienopyridines ticlopidine and clopidogrel in
the early management of STEMI is discussed above (Section
6.3.1.6.8.2.2). Clopidogrel 75 mg daily is generally preferred
to ticlopidine 250 mg twice daily because of fewer side
effects and once-daily dosing (740,741). 
In the Clopidogrel vs. Aspirin in Patients at Risk of
Ischemic Events (CAPRIE) trial of patients with UA/NSTE-
MI, there was a statistically significant risk reduction in vas-
cular death, MI, or stroke in favor of clopidogrel (0.51%
ARD; RRR 8.7%) (742). Clopidogrel has also demonstrated
efficacy in addition to aspirin versus aspirin alone in patients
with acute coronary syndrome (728). Therefore, a thienopy-
ridine (preferably clopidogrel) should be substituted for
aspirin in patients with STEMI for whom aspirin is con-
traindicated because of hypersensitivity or major gastroin-
testinal intolerance. On the basis of several randomized trials
of combination antiplatelet therapy (577,741,743), clopido-
grel, in combination with low-dose aspirin (75 to 162 mg, to
minimize the risk of bleeding), is recommended for all
patients after stent implantation (432).
7.4.5. Antithrombotics
Class I
Intravenous UFH (bolus of 60 U/kg, maximum 4000-U
IV bolus; initial infusion of 12 U/kg/h, maximum 1000
U/h) or LMWH should be used in patients after
STEMI who are at high risk for systemic emboli (large
or anterior MI, AF, previous embolus, known LV
thrombus, or cardiogenic shock). (Level of Evidence: C)
Class IIa
It is reasonable that STEMI patients not undergoing
reperfusion therapy who do not have a contraindica-
tion to anticoagulation be treated with intravenous or
subcutaneous UFH or with subcutaneous LMWH for
at least 48 hours. In patients whose clinical condition
necessitates prolonged bedrest and/or minimized
activities, it is reasonable that treatment be continued
until the patient is ambulatory. (Level of Evidence: C)
Class IIb
Prophylaxis for DVT with subcutaneous LMWH
(dosed appropriately for specific agent) or with sub-
cutaneous UFH, 7500 to 12 500 U twice per day until
completely ambulatory, may be useful, but the effec-
tiveness of such a strategy is not well established in the
contemporary era of routine aspirin use and early
mobilization. (Level of Evidence: C)
In patients treated with fibrinolytic therapy, there is little
evidence of the benefit of UFH in the modern era, during
which aspirin, beta-blockers, nitrates, and ACE inhibitors are
routinely available. Nevertheless, the best available data
emanate from a series of randomized clinical trials per-
formed before the reperfusion era. A systematic overview of
these studies demonstrated a reduction in mortality (3.5%
ARD; 23% RRR) and a reduction in risk of reinfarction
(1.5% ARD; 18% RRR) with UFH (537). The control groups
eral months after drug-eluting stent implantation (3
months for sirolimus, 6 months for paclitaxel) and for
up to 12 months in patients who are not at high risk
for bleeding. (Level of Evidence: B)
Aspirin. The use of aspirin in patients with STEMI on ini-
tial presentation and in early management is discussed above
(Sections 6.3.1.4 and 6.3.1.6.8.2.1). Aspirin should be given
to the patient with suspected STEMI as early as possible and
continued indefinitely, regardless of the strategy for reperfu-
sion and regardless of whether additional antiplatelet agents
are administered. True aspirin allergy is the only exception to
this recommendation. Maintenance aspirin doses for second-
ary prevention of cardiovascular events in large trials have
varied from 75 to 325 mg per day, but no trial has directly
compared the efficacy of different doses after STEMI. An
overview of trials with different doses of aspirin in the long-
term treatment of patients with coronary disease suggests
similar efficacy for daily doses ranging from 75 to 325 mg
(727). An analysis from the CURE trial (Clopidogrel in
Unstable angina to prevent Recurrent Events) suggests a
dose-dependent increase in bleeding in patients receiving
aspirin plus placebo: The major bleeding event rate was 2.0%
in patients taking less than 100 mg of aspirin, 2.3% with 100
to 200 mg, and 4.0% with greater than 200 mg per day
(728,729). Therefore, lower aspirin doses of 75 to 162 mg
per day are preferred for long-term treatment.
The side effects of aspirin are mainly gastrointestinal and
dose related (730). Gastric side effects may also be reduced
by administration of diluted solutions of aspirin (731), treat-
ment with H2 antagonists (732), antacids (731,733), or use of
enteric-coated or buffered aspirin (734,735). 
Aspirin should be avoided in those with a known hyper-
sensitivity and used cautiously in those with blood dyscrasias
or severe hepatic disease (see additional discussion in
Sections 7.12.5 and 7.12.11). If the patient has a history of
bleeding peptic ulcers, the use of rectal aspirin suppositories
may be safer because it eliminates the local effect of aspirin
on the gastric mucosa. However, antiplatelet effects may still
pose a risk. Another potentially deleterious effect of aspirin
is risk of bleeding from surgical sites. Patients who received
aspirin in the Veterans Administration Cooperative Study
(736) were noted to have significantly increased postopera-
tive chest drainage and reoperation for bleeding (6.5% for
aspirin groups compared with 1.7% for nonaspirin groups; p
less than 0.01). Others have noted that preoperative aspirin
use has been associated with increased postoperative chest
drainage but not an increased rate of reoperation for bleeding
(737,738). In another Veterans Administration Cooperative
Study (739), starting aspirin 6 hours after surgery conferred
the benefits of improved saphenous vein bypass graft paten-
cy without the increased postoperative bleeding seen with
preoperative administration of aspirin. Aspirin (81 to 365
mg) should be administered as soon as possible (within 24
hours) after CABG unless contraindicated (see Section
7.10.7).
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emia may require continuous positive pressure breathing or
endotracheal intubation and mechanical ventilation. 
7.5. Estimation of Infarct Size
Measurement of infarct size is an important element in the
overall care of patients with STEMI. The extent of infarction
bears a direct relationship to prognosis, assists in establish-
ing the efficacy of reperfusion therapy, guides both short-
and long-term therapeutic decision making, and provides a
useful surrogate for the investigation of novel experimental
therapies. 
There are 5 major modalities that can be applied to sizing
MI. A discussion of each follows.
7.5.1. ECG Techniques
Class I
All patients with STEMI should have follow-up ECGs
at 24 hours and at hospital discharge to assess the suc-
cess of reperfusion and/or the extent of infarction,
defined in part by the presence or absence of new Q
waves. (Level of Evidence: B)
The extent of ST-segment deviation on the baseline ECG
provides a semiquantitative measure of the amount of jeop-
ardized myocardium and an estimate of the subsequent
infarct size likely to ensue in a nonreperfused population.
With a QRS scoring system based on the duration and ampli-
tude of individual waveforms within the QRS complex, the
size of the infarction can be estimated from a point score
derived and weighted from the 12-lead ECG (748). Each
point so derived represents approximately 3% of the LV, and
the utility of this approach has been validated in postmortem
studies of patients with confirmed MI (749). This method,
however, is time consuming and is limited in patients with
concomitant LV hypertrophy or fascicular or bundle-branch
block and when major ST-segment shift distorts the appear-
ance of the QRS complex.
In the fibrinolytic era, simple characterization of the pres-
ence or absence of the Q wave has also been used. In the
early convalescent period after fibrinolytic therapy, the 20%
of patients in the GUSTO angiographic study who did not
develop Q waves had better global and regional LV function
and improved 2-year survival (6.3% versus 10.1% for
patients with developed Q waves; p equals 0.02) (750). 
7.5.2. Cardiac Biomarker Methods
The most widely accepted method for quantifying infarction
has been the use of serial CK and the CK-MB isoenzyme.
With a mathematical formulation based on rates of degrada-
tion in specific compartments, the rate of myocardial bio-
marker release, its volume of distribution, and its clearance
rate, it is possible to estimate the quantity of myocardium
infarcted (751). Reasonable correlations have been estab-
lished with anatomic estimates derived from postmortem
human studies (752). Whereas other biomarkers of myocar-
in these trials were not treated with other therapies, particu-
larly aspirin, that are now considered routine. Not-
withstanding this, it is primarily these randomized data from
an earlier era that support the recommendation to use UFH in
patients not treated with fibrinolytic therapy.
The occurrence of a large anterior infarction, documenta-
tion of thrombus in the LV by echocardiography, history of a
previous embolic event, and AF have been associated with a
high risk of embolic stroke. Although no randomized trial
evidence exists to demonstrate a definite benefit specific to
this group, some empirical evidence exists that the risk of
systemic emboli in the general population of MI patients can
be reduced by early initiation of UFH (744). In the SCATI
trial (Studio sulla Calciparina nell’Angina e nella Trombosi
Ventricolare nell’Infarto), patients were randomly assigned
to a 2000-IU bolus of UFH followed by 12 500 U subcuta-
neously twice per day or to placebo. In the subgroup also
treated with streptokinase, aspirin was withheld. In-hospital
mortality was 4.6% in the UFH group and 8.8% in the con-
trol group, and a reduction in stroke was observed.
Therefore, UFH is recommended for these patients at high
risk for systemic arterial emboli, regardless of the fibrinolyt-
ic agent given. A LMWH may be used in place of UFH.
Initial anticoagulation with UFH or a LMWH should be fol-
lowed by warfarin in patients at high risk for systemic emboli
(see Section 7.12.11 for additional discussion).
The previous ACC/AHA guidelines on acute MI (744) and
the American College of Chest Physicians’ guidelines (746)
recommended 7500 U of subcutaneous UFH twice per day.
The empirical basis for this recommendation was the demon-
stration that DVT was reduced from 12% to 4% in an
overview of 3 randomized controlled trials (747). Continued
adherence to this practice may be useful, although routine
earlier mobilization and use of aspirin may make this treat-
ment unnecessary.
7.4.6. Oxygen
Class I
Supplemental oxygen therapy should be continued
beyond the first 6 hours in STEMI patients with arte-
rial oxygen desaturation (SaO2 less than 90%) or
overt pulmonary congestion. (Level of Evidence: C)
The use of oxygen in patients presenting with STEMI is
discussed in Section 6.3.1.1. In view of its expense (approx-
imately $70 per day), there is little justification for continu-
ing its routine use beyond 6 hours in uncomplicated cases.
Pulse oximetry is now routine for continuous monitoring of
oxygen saturation and is helpful for providing early warning
of hypoxemia. In patients with oxygen saturation less than
90%, supplemental oxygen by nasal prongs is usually admin-
istered, especially if the patient is experiencing ongoing or
intermittent ischemia. This therapy is based on experimental
data that suggest that normal levels of oxygen reduce infarct
size. In patients with severe heart failure, pulmonary edema,
or mechanical complications of STEMI, significant hypox-
e93
Antman et al. 2004
ACC/AHA Practice Guidelines
ACC - www.acc.org
AHA - www.americanheart.org
diogram has not been performed. (Level of
Evidence: C)
2. Intra-arterial pressure monitoring should be per-
formed for the following:
a. Patients with severe hypotension (systolic arterial
pressure less than 80 mmHg). (Level of Evidence: C)
b. Patients receiving vasopressor/inotropic agents.
(Level of Evidence: C)
c. Cardiogenic shock. (Level of Evidence: C)
Class IIa
1. Pulmonary artery catheter monitoring can be useful
for the following:
a. Hypotension in a patient without pulmonary con-
gestion who has not responded to an initial trial of
fluid administration. (Level of Evidence: C)
b. Cardiogenic shock. (Level of Evidence: C)
c. Severe or progressive CHF or pulmonary edema
that does not respond rapidly to therapy. (Level of
Evidence: C)
d. Persistent signs of hypoperfusion without hypoten-
sion or pulmonary congestion. (Level of Evidence: C)
e. Patients receiving vasopressor/inotropic agents.
(Level of Evidence: C)
2. Intra-arterial pressure monitoring can be useful for
patients receiving intravenous sodium nitroprusside
or other potent vasodilators. (Level of Evidence: C)
Class IIb
Intra-arterial pressure monitoring might be consid-
ered in patients receiving intravenous inotropic
agents. (Level of Evidence: C)
Class III
1. Pulmonary artery catheter monitoring is not recom-
mended in patients with STEMI without evidence of
hemodynamic instability or respiratory compromise.
(Level of Evidence: C)
2. Intra-arterial pressure monitoring is not recommend-
ed for patients with STEMI who have no pulmonary
congestion and have adequate tissue perfusion with-
out use of circulatory support measures. (Level of
Evidence: C)
Measurements made via pulmonary artery catheter read-
ings may be helpful in the management of STEMI and con-
comitant hemodynamic instability, including low cardiac
output, hypotension, persistent tachycardia, pulmonary
edema, and apparent cardiogenic shock. In the patient with
hypotension and tachycardia, the pulmonary artery catheter
can assist in the differentiation of 1) inadequate intravascular
volume, with a resultant low left-sided filling pressure; 2)
adequate intravascular volume and a high left-sided filling
pressure due to extensive LV dysfunction; and 3) low left-
sided filling pressure with elevated right atrial pressure con-
sistent with RV infarction (758). Treatment of the former is
prompt expansion of intravascular volume (with normal
saline), whereas management of the latter often includes
diuresis, inotropic support, afterload reduction, or other sup-
dial necrosis exist, such as myoglobin and lactate dehydro-
genase, the highly sensitive cardiac troponins (I or T) have
greater myocardial tissue specificity and higher sensitivity
than conventional biomarkers. Measurement of cardiac tro-
ponin T at 72 hours provides an estimate of infarct size in
patients with STEMI who do and do not receive reperfusion
therapy (753,754). In a consensus document of the Joint
European Society of Cardiology and the ACC, the use of car-
diac troponins was supported for the assessment of MI. The
Joint Committee has emphasized that high-sensitivity car-
diac biomarkers, such as troponins, can identify patients with
small areas of myocardial necrosis weighing less than 1.0 g
(755). 
7.5.3. Radionuclide Imaging
The most comprehensive assessment of STEMI with
radionuclide imaging was developed with the Technetium
sestamibi SPECT approach (756). This technique has been
validated extensively and offers the opportunity for both
early and late imaging to initially assess the area of ischemic
risk as opposed to the ultimate infarct size. This approach is
well delineated in the ACC/AHA/ASNC Guidelines on Car-
diac Radionuclide Imaging (239). Radionuclide angiography
with a variety of radiolabeled isotopes can also provide an
estimate of regional and global LV function. 
7.5.4. Echocardiography
Global and regional LV function provides an assessment of
the functional consequences of STEMI and ischemia. Such
measures may be enhanced by an assessment of the extent of
regional systolic wall thickening. Readers are referred
Section 7.11.1.2 and to the ACC/AHA/ASE 2003 Guideline
Update for the Clinical Application of Echocardiography
(226).
7.5.5. Magnetic Resonance Imaging
Measurement of infarct size with magnetic resonance imag-
ing is a promising new technique that affords enhanced spa-
tial resolution, thereby permitting more accurate assessment
of both the transmural and circumferential extent of infarc-
tion (757). However, additional experience and comparison
with other methods of assessing infarct size are required
before any clinical recommendations can be provided.
7.6. Hemodynamic Disturbances
7.6.1. Hemodynamic Assessment
Class I
1. Pulmonary artery catheter monitoring should be per-
formed for the following:
a. Progressive hypotension, when unresponsive to
fluid administration or when fluid administration
may be contraindicated. (Level of Evidence: C)
b. Suspected mechanical complications of STEMI,
(i.e., VSR, papillary muscle rupture, or free wall
rupture with pericardial tamponade) if an echocar-
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ance, veno-vasodilation, intrathoracic pressure, position, vol-
ume). Dynamic changes in ventricular compliance and the
use of vasodilating medications result in rapid changes in
PCWP that do not reflect intravascular volume. For example,
pulmonary artery catheter placement after intravenous nitro-
glycerin administration for pulmonary edema may reflect
PCWP less than 15 mm Hg despite marked elevation 1 hour
earlier. An acute ischemic episode may raise PCWP substan-
tially without a concomitant change in volume. 
All CCUs should have sufficient equipment and skilled
personnel to monitor intra-arterial pressure. Such monitoring
is useful in all hypotensive patients, particularly those with
cardiogenic shock. Long-term monitoring is best accom-
plished through the radial artery, although the brachial or
femoral arteries may be used as alternatives. Perfusion of the
limb or hand distal to the catheter site must be examined
carefully and periodically for evidence of ischemia. Intra-
arterial and central catheters can be left in place with a ster-
ile occlusive dressing. Before insertion, the site should be
adequately prepared under sterile conditions. Antibacterial
ointments are no longer recommended. Because of the risk of
arterial thrombosis and infection, intra-arterial catheters gen-
erally should not remain in the same arterial site for longer
than 4 to 5 days (763).
7.6.2. Hypotension
Class I
1. Rapid volume loading with an intravenous infusion
should be administered to patients without clinical
evidence for volume overload. (Level of Evidence: C)
2. Rhythm disturbances or conduction abnormalities
causing hypotension should be corrected. (Level of
Evidence: C)
3. Intra-aortic balloon counterpulsation should be per-
formed in patients who do not respond to other inter-
ventions, unless further support is futile because of
the patient’s wishes or contraindications/unsuitability
for further invasive care. (Level of Evidence: B)
4. Vasopressor support should be administered for
hypotension that does not resolve after volume load-
ing. (Level of Evidence: C)
5. Echocardiography should be used to evaluate
mechanical complications unless these are assessed by
invasive measures. (Level of Evidence: C)
Hypotension (systolic pressure less than 90 mm Hg or 30
points below previous systolic arterial pressure) can result
from hypovolemia, arrhythmias, RV or LV failure, mechani-
cal complications of MI, or superimposed complications,
such as sepsis or pulmonary embolism. Hypovolemia is a
common occurrence and may be due to inadequate intake,
diaphoresis and vomiting, overdiuresis, excessive use of
vasodilators, or inappropriate reflex peripheral vasodilation.
Hemorrhage is an increasingly common problem associated
with the use of invasive procedures, fibrinolytics, antiplatelet
agents, and anticoagulant agents. Therefore, rapid volume
portive measures. In those with extensive LV dysfunction, a
pulmonary artery catheter can be used to monitor therapeutic
efforts to adjust the left-sided filling pressure so as to maxi-
mize cardiac output at the lowest possible filling pressure
(758). In some patients, these sophisticated manipulations of
intracardiac pressures and cardiac output are facilitated by
information provided by a pulmonary artery catheter. 
Although the pulmonary artery catheter is quite safe when
used by experienced operators, its use has a recognized asso-
ciation with adverse events, including ventricular tach-
yarrhythmias (during its manipulation) and pulmonary hem-
orrhage or infarction. Transient right bundle-branch block
may develop, which can lead to heart block in those with pre-
existing LBBB. In addition, it causes some patient discomfort
and requires that the patient be relatively immobile. Because
the pressure waveform recorded from the catheter tip may be
distorted, the clinician should routinely examine the actual
waveform rather than rely on the digital display of pressure.
Because of the risk of infection, pulmonary artery catheters
generally should not remain in the same site for more than 4
to 5 days. The catheter should not be inserted if the patient
quickly responds to other interventions or if treatment is
expected to be futile. The catheter should be removed expe-
ditiously when it is no longer needed to monitor therapy.
The diagnosis of acute mechanical complications (MR,
ventricular septal defect, myocardial rupture) usually can be
diagnosed quickly and safely in the ED by transthoracic
echocardiography. However, the ordering and performing of
an echocardiogram should not delay transfer of a hemody-
namically unstable patient to the interventional cardiology
laboratory, where hemodynamic stabilization, diagnosis, and
treatment can usually best be initiated. Similarly, insertion of
a pulmonary artery catheter in the CCU should not delay
transfer of the patient to the interventional cardiology labo-
ratory if indicated. 
Insertion of a pulmonary artery catheter to measure hemo-
dynamics in patients developing progressive CHF or
hypotension may permit the early diagnosis of a preshock
state in which appropriate support can prevent the onset of
cardiogenic shock (759). Before PCI is performed for car-
diogenic shock, the interventional cardiologist should insert
a pulmonary artery catheter to maximize the hemodynamic
status of the patient and to diagnose unrecognized mechani-
cal complications. After reperfusion therapy, if shock does
not rapidly reverse, the pulmonary artery catheter may be
used to guide diuretic, inotropic, and vasopressor agents in
hemodynamically unstable patients while stunned myocardi-
um is recovering. Unfortunately, there are no data from ran-
domized controlled trials testing whether or not hemody-
namic monitoring alters clinical outcome in STEMI.
It is possible that therapeutic interventions in response to
erroneous data or inappropriate maneuvers in response to
accurate data contribute to the excess mortality rates previ-
ously associated with pulmonary artery catheter use (760-
762). Clinicians should understand the multiple determinants
of pulmonary capillary wedge pressure (PCWP) to avoid
equating filling pressure with intravascular volume (compli-
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monary congestion. Coronary artery revascularization of
ischemic myocardium with either PCI or CABG has been
shown to decrease mortality in patients with cardiogenic
shock and is strongly recommended in suitable candidates
(184,301). Likewise, patients with VSR, papillary muscle
rupture, or free wall rupture with pericardial tamponade may
benefit from emergency surgical repair.
7.6.4. Pulmonary Congestion
Class I
1. Oxygen supplementation to arterial saturation
greater than 90% is recommended for patients with
pulmonary congestion. (Level of Evidence: C)
2. Morphine sulfate should be given to patients with pul-
monary congestion. (Level of Evidence: C)
3. ACE inhibitors, beginning with titration of a short-
acting ACE inhibitor with a low initial dose (e.g., 1 to
6.25 mg of captopril) should be given to patients with
pulmonary edema unless the systolic blood pressure is
less than 100 mm Hg or more than 30 mm Hg below
baseline. Patients with pulmonary congestion and
marginal or low blood pressure often need circulatory
support with inotropic and vasopressor agents and/or
intra-aortic balloon counterpulsation to relieve pul-
monary congestion and maintain adequate perfusion.
(Level of Evidence: A)
4. Nitrates should be administered for patients with pul-
monary congestion unless the systolic blood pressure
is less than 100 mm Hg or more than 30 mm Hg below
baseline. Patients with pulmonary congestion and
marginal or low blood pressure often need circulatory
support with inotropic and vasopressor agents and/or
intra-aortic balloon counterpulsation to relieve pul-
monary congestion and maintain adequate perfusion.
(Level of Evidence: C)
5. A diuretic (low- to intermediate-dose furosemide, or
torsemide or bumetanide) should be administered to
patients with pulmonary congestion if there is associ-
ated volume overload. Caution is advised for patients
who have not received volume expansion. (Level of
Evidence: C)
6. Beta-blockade should be initiated before discharge for
secondary prevention. For those who remain in heart
failure throughout the hospitalization, low doses
should be initiated, with gradual titration on an out-
patient basis. (Level of Evidence: B)
7. Long-term aldosterone blockade should be prescribed
for post-STEMI patients without significant renal
dysfunction (creatinine should be less than or equal to
2.5 mg/dL in men and less than or equal to 2.0 mg/dL
in women) or hyperkalemia (potassium should be less
than or equal to 5.0 mEq/L) who are already receiving
therapeutic doses of an ACE inhibitor, have an LVEF
of less than or equal to 0.40, and have either sympto-
matic heart failure or diabetes. (Level of Evidence: A)
loading is recommended as an initial therapeutic strategy in
all patients without clinical evidence for volume overload.
Persistent hypotension should be evaluated with an echocar-
diogram to define the cardiac anatomy and with a hemoglo-
bin measurement. Correction or control of rhythm distur-
bances or conduction abnormalities often reverses hypoten-
sion. In patients with inotropic failure, vasopressors and
inotropic agents are required. Vasopressor agents, including
high-dose dopamine and norepinephrine, have alpha-vaso-
constricting properties, whereas inotropic agents such as
dobutamine have beta-receptor–stimulating properties.
Norepinephrine and dopamine have both vasopressor and
inotropic properties. When blood pressure is low, dopamine
is the agent of first choice. If the patient is markedly hypoten-
sive, intravenous norepinephrine, which is a more potent
vasoconstrictor with less potential for tachycardia, should be
administered until systolic arterial pressure rises to at least
80 mm Hg, at which time a change to dopamine may be
attempted, initiated at 2.5 to 5 mcg/kg/min and titrated as
needed to 5 to 15 mcg/kg/min. Once arterial pressure is
brought to at least 90 mm Hg, intravenous dobutamine may
be given simultaneously in an attempt to reduce the rate of
the dopamine infusion. In addition, consideration should be
given to initiating intra-aortic balloon counterpulsation. (See
Section 7.6.1.)
7.6.3. Low-Output State
Class I
1. Left ventricular function and potential presence of a
mechanical complication should be assessed by
echocardiography if these have not been evaluated by
invasive measures. (Level of Evidence: C)
2. Recommended treatments for low output states
include:
a. Inotropic support. (Level of Evidence: B)
b. Intra-aortic counterpulsation. (Level of Evidence: B)
c. Mechanical reperfusion with PCI or CABG. (Level
of Evidence: B)
d. Surgical correction of mechanical complications.
(Level of Evidence: B)
Class III
Beta-blockers or calcium channel antagonists should
not be administered to patients in a low-output state
due to pump failure. (Level of Evidence: B)
A preshock state of hypoperfusion with normal blood pres-
sure may develop before circulatory collapse and is mani-
fested by cold extremities, cyanosis, oliguria, or decreased
mentation (759). Hospital mortality is high, so these patients
should be aggressively diagnosed and treated as though they
had cardiogenic shock. The initial pharmacological interven-
tion for low cardiac output is often a dobutamine infusion.
Intra-aortic counterpulsation therapy may be required to
improve coronary artery perfusion pressure if hypotension is
present. If the blood pressure permits, afterload-reducing
agents should be added to decrease cardiac work and pul-
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depletion in the early phase. Acute diuresis and agents that
induce hypotension can precipitate cardiogenic shock. 
The cause of pulmonary edema (i.e., systolic, diastolic, or
a mechanical complication [MR or VSR]) should be assessed
rapidly with a 2-dimensional echocardiograph with color
flow Doppler. Indications for right heart catheterization are
reviewed in Section 7.6.1. On the basis of data that high-risk
patients derive greater benefit from PCI than from fibrinolyt-
ic therapy, primary PCI is preferred when available for those
who present with pulmonary edema complicating STEMI.
There are no randomized trials that assess this comparison.
However, analysis of the GUSTO-IIB trial shows similar rel-
ative and greater absolute benefit from PCI for Killip class 2
to 3 patients (765). The NRMI registry showed a marked
benefit of PCI compared with fibrinolysis for patients with
CHF (447). Coronary angiography and revascularization,
based on the anatomy, should be performed when late CHF
complicates the hospital course. Mechanical ventilation may
be required during angiography and PCI, especially for pri-
mary PCI during STEMI. 
Management includes the use of agents that acutely reduce
preload (i.e., nitrates, morphine sulfate, and diuretics)
(Figure 28) (766), and avoidance of acute administration of
negative inotropic agents (i.e., beta-blockers and calcium
channel antagonists). Nitrates are initially administered by
sublingual tablets or spray nitroglycerin followed by intra-
venous nitroglycerin. Intravenous nitroglycerin is a venodila-
tor that acutely reduces ventricular filling pressures. At high
doses, it dilates arterioles. It is effective at relieving pul-
monary congestion and ischemia and may be used in patients
who have normal or elevated systemic arterial pressure. A
10- to 20-mcg bolus should be administered, followed by 10
mcg per minute, increased by 5 to 10 mcg per minute every
5 to 10 minutes until dyspnea is relieved, the mean arterial
pressure is lowered by 10% in normotensive patients or 30%
in hypertensive patients, or until the heart rate increases by
more than 10 bpm. Loop diuretics (furosemide, torsemide, or
bumetanide) should be initiated in low to intermediate doses
only in patients with associated hypervolemia (see above).
Low doses should be used unless there is renal insufficiency,
chronic diuretic use, or the presence of chronic CHF and
hypervolemia as described above. Typical furosemide doses
range from 20 to 80 mg IV (0.5 to 1.0 mg/kg).
Angiotensin converting enzyme inhibitors are indicated for
patients with pulmonary congestion. Oral ACE inhibitors,
preferably a short-acting agent such as captopril, beginning
with 1 to 6.25 mg, should be instituted early in normotensive
or hypertensive patients. The dosage may be doubled with
each subsequent dose as tolerated up to 25 to 50 mg every 8
hours, then changed to a long-acting agent. Although the risk
of hypotension and shock after vasodilator or diuretic admin-
istration during the acute phase of MI is substantial for those
without a hypertensive response to pulmonary edema, the
risk is lower in the late phase after MI. Hence, most patients
can tolerate ACE inhibitors before discharge. For patients
who presented with CHF complicating MI, ramipril adminis-
tration between days 3 and 10 significantly reduced 30-day
8. Echocardiography should be performed urgently to
estimate LV and RV function and to exclude a
mechanical complication. (Level of Evidence: C)
Class IIb
It may be reasonable to insert an IABP for the man-
agement of patients with refractory pulmonary con-
gestion. (Level of Evidence: C)
Class III
Beta-blockers or calcium channel blockers should not
be administered acutely to STEMI patients with frank
cardiac failure evidenced by pulmonary congestion or
signs of a low-output state. (Level of Evidence: B)
Left ventricular filling pressures, and hence PCWP, may
rise rapidly after acute coronary occlusion. This rise is due to
acute systolic or diastolic dysfunction that may be associated
with superimposed MR. The rise in PCWP leads to rapid
redistribution of fluid from the intravascular space into the
extravascular space (lung interstitium and alveoli). The pres-
ence of any pulmonary congestion on examination or X-ray
increases the risk of dying, and pulmonary edema is associ-
ated with a 20% to 40% 30-day mortality rate even in the fib-
rinolytic era (28,240,242,764). 
Immediate management goals include adequate oxygena-
tion and preload reduction to relieve pulmonary congestion.
Because of sympathetic stimulation, the blood pressure
should be elevated in the presence of pulmonary edema.
Patients with this appropriate response can typically tolerate
the required medications, all of which lower blood pressure.
However, iatrogenic cardiogenic shock may result from
aggressive simultaneous use of agents that cause hypoten-
sion, initiating a cycle of hypoperfusion-ischemia. If acute
pulmonary edema is not associated with elevation of the sys-
temic blood pressure, impending cardiogenic shock must be
suspected. If pulmonary edema is associated with hypoten-
sion, cardiogenic shock is diagnosed. Those patients often
need circulatory support with inotropic and vasopressor
agents and/or intra-aortic balloon counterpulsation to relieve
pulmonary congestion and maintain adequate perfusion (see
Section 7.6.5 and Figure 26).
Pulmonary edema may occur as an acute event with the
onset of STEMI or reinfarction or as the culmination of slow-
ly progressive CHF over the first several days after infarc-
tion. Acute pulmonary edema on presentation with STEMI
may occur in a patient with prior myocardial damage and
systolic dysfunction, with or without a prior diagnosis of
CHF. Alternatively, it may develop in patients with a first
STEMI, especially those with preceding diastolic dysfunc-
tion due to hypertension or diabetes. Pulmonary edema days
after STEMI or on presentation in patients who have prior
CHF or LV dysfunction is often associated with hyper-
volemia. In contrast, patients who present with pulmonary
edema without prior LV dysfunction (and who have not
received fluid administration) usually have a normal total
body sodium and fluid status. The acute redistribution of
fluid into the lungs results in relative intravascular volume
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sis in patients with volume overload and decompensated
chronic CHF (class 3 to 4) (770). It has not been investigat-
ed in STEMI and is not indicated for treatment of pulmonary
edema in these patients. Nesiritide is a potent vasodilator and
may result in hypotension, particularly in patients with
STEMI, in whom CHF usually is not due to volume over-
load.
An aldosterone antagonist, eplerenone, was found to be
effective for secondary prevention of death and recurrent
hospitalization in patients 3 to 14 days after MI with CHF
and LVEF less than 0.40. Spironolactone has been demon-
strated to improve survival in a population of patients with
chronic CHF, which includes those with remote MI (722)
(see Section 7.12.6). In contrast to the recommendation to
avoid initiation of beta-blockade during pulmonary edema,
beta-blockers are strongly recommended before hospital dis-
charge for secondary prevention of cardiac events (273). The
initial dose and titration should be based on clinical heart
failure status and LVEF. For patients who remain in heart
failure during the hospitalization, a low dose should be initi-
ated and gradually titrated as an outpatient, per CHF guide-
mortality (relative hazard 0.73; 95% CI 0.602 to 0.89; p
greater than 0.002) in 2006 patients in the Acute Infarction
Ramipril Efficacy Study (767). Given the good tolerability of
ACE inhibition within 24 hours of MI in the ISIS-4 and
GISSI-3 (lisinopril) studies and the beneficial effects on
early infarct expansion, it is recommended that ACE
inhibitors be initiated early for those who have pulmonary
congestion. However, hypotension should be avoided, partic-
ularly during and immediately after reperfusion therapy
(767,768). Routine intravenous enalapril is not recommend-
ed (769) unless severe hypertension is present. ACE
inhibitors are the only adjunctive medication (beyond aspirin
and reperfusion therapy) demonstrated to reduce 30-day
mortality when CHF complicates STEMI. Therefore, if
blood pressure limits use of vasodilators, ACE inhibitors are
preferred. Intravenous sodium nitroprusside substantially
reduces afterload and preload; however, its use has been
associated with coronary steal. Digitalis has no role in the
management of pulmonary edema complicating STEMI
unless rapid AF is present. Nesiritide (synthetic natriuretic
brain peptide) is a new vasodilator agent that promotes diure-
Figure 28. Emergency management of complicated ST-elevation myocardial infarction (STEMI). The emergency management of
patients with cardiogenic shock, acute pulmonary edema or both is outlined. IV = intravenous; SL - sublingual; SBP = systolic BP; BP
= blood pressure; ACE = angiotensin converting enzyme; MI = myocardial infarction. *Furosemide less than 0.5 mg/kg for new onset
acute pulmonary edema without hypovolemia. 1 mg/kg for acute or chronic volume overload, renal insufficiency. Nesiritide has not
been studied adequately in patients with STEMI. Combinations of medications (e.g., dobutamine and dopamine) may be used.
Modified with permission from Guidelines 2000 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Part 7: The
Era of Reperfusion. Section 1: Acute Coronary Syndromes (Acute Myocardial Infarction). Circulation 2000;102: I-172 - I-216 (766).
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shock. In large clinical trials, such patients have an in-hospital
survival rate that ranges from 20% to 50% when treated with
intravenous fibrinolytic therapy (482,483,772,773). In other
case series, mechanical reperfusion with PCI has been report-
ed to result in hospital survival rates as high as 70%, but
selection bias influenced these findings. However, a multi-
center, prospective, randomized study confirmed this gener-
al approach (184). The SHOCK trial tested the hypothesis
that emergency revascularization for cardiogenic shock due
to an ST-elevation/Q-wave or new LBBB MI would result in
reduction in all-cause 30-day mortality compared with initial
medical stabilization and delayed revascularization as clini-
cally determined. In the SHOCK trial, cardiogenic shock was
defined as clinical evidence of systemic hypoperfusion with
systolic blood pressure less than 90 mm Hg for at least 30
minutes (or the need for supportive measures to maintain
systolic blood pressure greater than 90 mm Hg), cardiac
index of no more than 2.2 L/min/m2 and PCWP of at least 15
mm Hg.
In the SHOCK trial, 152 patients were randomly assigned
to the emergency revascularization strategy, and 150 patients
were assigned to a strategy of initial medical stabilization.
The 30-day mortality rate for emergency revascularization
patients was 46.7% versus 56.0% for initial medical stabi-
lization patients (95% CI minus 20.5 to plus 1.9%, p equals
0.11). However, the mortality rate at 6 and 12 months (sec-
ondary end points) was significantly lower in the emergency
revascularization group (53.3% versus 66.4%, p less than
0.03, 12 months) (184,494). The prespecified subgroup
analysis of patients less than 75 years old showed a 15.4%
absolute reduction in the primary end point at 30 days (initial
medical stabilization group 56.8% versus emergency revas-
cularization group 41.4%, p less than 0.01), whereas no treat-
ment benefit was apparent for the 56 patients greater than 75
years old. Intra-aortic balloon pump support was used in
86% of both groups; 63% of the initial medical stabilization
group received thrombolytic agents, and 25% underwent
delayed revascularization (Figure 29) (184). The (S)MASH
study [(Swiss) Multicenter Trial of Angioplasty for Shock]
randomly assigned 55 refractory shock patients to either PCI
or conventional care. The mortality rate in the PCI group was
9 absolute percentage points lower at 30 days (69% versus
78%) than in the conventional therapy group but did not
reach statistical significance (495). The group difference was
similar to that observed at 30 days in the SHOCK trial (494).
Given the large overall treatment benefit of 13 lives saved
per 100 patients treated, emergency revascularization is rec-
ommended for those less than 75 years who are suitable for
revascularization. Patients with life-shortening illnesses, no
vascular access, previously defined coronary anatomy that
was unsuitable for revascularization, anoxic brain damage,
and prior cardiomyopathy were excluded from the trial. For
those enrolled, the treatment benefit was similar for all other
subgroups examined: diabetics, women, prior MI or hyper-
tension, and early or late developing shock. The elderly pose
a special problem. There were only 56 patients 75 years of
age or older in the SHOCK trial, and firm conclusions can-
lines (771). This is supported by the beneficial effects of
beta-blockade in patients with LV dysfunction after STEMI
(771).
See also Sections 7.4.3 (hospital phase) and 7.12.6 (sec-
ondary prevention) for recommendations on ARBs. 
7.6.5. Cardiogenic Shock
Class I
1. Intra-aortic balloon counterpulsation is recommend-
ed for STEMI patients when cardiogenic shock is not
quickly reversed with pharmacological therapy. The
IABP is a stabilizing measure for angiography and
prompt revascularization. (Level of Evidence: B)
2. Intra-arterial monitoring is recommended for the
management of STEMI patients with cardiogenic
shock. (Level of Evidence: C)
3. Early revascularization, either PCI or CABG, is rec-
ommended for patients less than 75 years old with ST
elevation or LBBB who develop shock within 36 hours
of MI and who are suitable for revascularization that
can be performed within 18 hours of shock unless fur-
ther support is futile because of the patient’s wishes or
contraindications/unsuitability for further invasive
care. (Level of Evidence: A)
4. Fibrinolytic therapy should be administered to STEMI
patients with cardiogenic shock who are unsuitable for
further invasive care and do not have contraindica-
tions to fibrinolysis. (Level of Evidence: B)
5. Echocardiography should be used to evaluate
mechanical complications unless these are assessed by
invasive measures. (Level of Evidence: C)
Class IIa
1. Pulmonary artery catheter monitoring can be useful
for the management of STEMI patients with cardio-
genic shock. (Level of Evidence: C)
2. Early revascularization, either PCI or CABG, is rea-
sonable for selected patients 75 years or older with ST
elevation or LBBB who develop shock within 36 hours
of MI and who are suitable for revascularization that
can be performed within 18 hours of shock. Patients
with good prior functional status who agree to inva-
sive care may be selected for such an invasive strategy.
(Level of Evidence: B)
Cardiogenic shock in patients with STEMI is most com-
monly (75% of cases) caused by extensive LV dysfunction,
but important other causes include mechanical complications
(acute severe MR, VSR, and subacute free-wall rupture with
tamponade). Important conditions that may mimic cardio-
genic shock include aortic dissection and hemorrhagic shock.
Echocardiography with color flow Doppler is extremely use-
ful to assess the cause of shock. (See Section 7.6.1 for dis-
cussion on hemodynamic assessment.)
Nonrandomized studies have suggested that mechanical
reperfusion of occluded coronary arteries by PCI or CABG
may improve survival in patients with MI and cardiogenic
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Coronary artery bypass graft surgery is the preferred mode of
revascularization for many of these patients on the basis of
unsuitability for PCI and to achieve complete revasculariza-
tion, unload the heart, and administer cardioprotective agents
(775,776). The SHOCK trial recommended emergency
CABG within 6 hours of randomization for those with severe
3-vessel or left main coronary artery disease. Among the
group of patients who underwent emergency early revascu-
larization, 60% received PCI, and 40% had CABG; the 30-
day mortality rate was 45% and 42%, respectively. Thirty-
day outcome was similar despite more severe coronary artery
disease and twice the frequency of diabetes in those who
underwent CABG. This is in contrast to the 69% in-hospital
mortality rate reported for those with 3-vessel disease who
underwent PCI for shock (777). Perhaps distal embolization
in the non–infarct-related artery is not tolerated by patients in
shock. For moderate 3-vessel disease, the SHOCK trial rec-
ommended proceeding with PCI of the infarct-related artery,
followed by delayed CABG for those who stabilized (Figure
26) (494,502).
It is recommended that patients who arrive at the hospital
in cardiogenic shock (15% of cases) or who develop cardio-
genic shock after arrival at the hospital (85%) be transferred
to a regional tertiary care center with revascularization facil-
ities and experience with these patients. (The SHOCK trial
included both transferred [55%] and directly admitted
patients and demonstrated the same relative treatment bene-
fit). If skilled personnel are available, IABP placement
before transport will help stabilize the patient. If the patient
presents in shock within 3 to 6 hours of MI onset and delays
in transport and intervention are anticipated, fibrinolytic
therapy and IABP may be initiated. Nonrandomized studies
suggest that this combination is beneficial (778), and a small
randomized trial observed a trend toward benefit for those in
not be drawn. The mortality rate for the elderly patients
assigned to initial medical stabilization was similar to
younger patients assigned to initial medical stabilization and
was therefore unexpectedly low (53.1%). Imbalances in
baseline characteristics of the 56 elderly patients assigned to
the emergency revascularization versus initial medical stabi-
lization groups may also have played a role in the apparent
lack of treatment effect (301). Those elderly patients (n
equals 277) who were clinically selected for early revascu-
larization (17% of the cohort) in the larger, nonrandomized
SHOCK registry had a marked survival benefit compared
with those with late or no revascularization, even after
covariate adjustment and exclusion of early deaths (496).
Two other large registries reported a substantial survival ben-
efit for the elderly who were clinically selected on the basis
of physician judgment. In these 2 registries, 16% to 33% of
the elderly were selected for an invasive strategy (497,498).
Although not reported, selection is typically based on prior
functional status, comorbidity, suitability for revasculariza-
tion, and patient and family preferences. An analysis of
Medicare patients admitted to hospitals with or without
revascularization capability reported no significant reduction
in mortality by institution type for patients who presented in
shock (0.6%) (774). They did not examine the much larger
cohort (approximately 7%) who develop shock. The elderly
require individualized judgments, and it is reasonable to con-
sider those with a good functional status and who agree to an
aggressive strategy for early revascularization. 
Interventions should be performed as soon as possible.
However, the time window for early revascularization, as
defined in the SHOCK trial, extends to shock that develops
up to 36 hours after MI and revascularization within 18 hours
of shock. Triple-vessel disease (60%) and left main disease
(20%) are often present when shock complicates STEMI.
Figure 29. Kaplan-Meier survival of cardiogenic shock after early revascularization curve 1-year postrandomization. Survival estimates
for early revascularization (n=152) and initial medical stabilization (n=149) groups. Log-rank test P = 0.04. Reprinted with permission
from Hochman et al. JAMA 2001;285:190-2. Copyrighted © 2001, American Medical Association. All rights reserved (184).
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nificantly higher mortality (25% to 30%) and thus identifies
a high-risk subgroup of patients with inferior STEMIs (6%)
who should be considered high-priority candidates for reper-
fusion (780). One group of investigators reported a 31% in-
hospital mortality rate in patients with inferior STEMIs com-
plicated by RV infarction compared with 6% in patients who
had an inferior STEMI without RV involvement (780). An
analysis of patients with predominant RV infarction and car-
diogenic shock from the SHOCK trial registry demonstrated
an unexpectedly high mortality rate similar to that for
patients with LV shock (53.1% versus 60.8%) (782). The
treatment of patients with RV ischemic dysfunction is differ-
ent and, in several ways, diametrically opposed to manage-
ment of LV dysfunction. 
Anatomic and Pathophysiological Considerations. The right
coronary artery usually supplies most of the RV myocardi-
um; thus, occlusion of this artery proximal to the RV branch-
es will lead to RV ischemia (783). Hemodynamically signif-
icant RV infarctions occur almost exclusively in the setting
of inferior STEMIs (784). Because the RV has a much small-
er muscle mass than the LV, owing to the lower vascular
resistance of the pulmonary circuit, myocardial oxygen
demand is significantly less than that of the LV (785).
Coronary perfusion of the RV occurs in both systole and
diastole (785). The RV also has a more favorable oxygen
supply-demand ratio than the LV because of the more exten-
sive collateral flow from left to right (786,787). These factors
likely explain the absence of hemodynamically significant
RV ischemia in most patients with proximal right coronary
artery occlusions, as well as improvement in RV function
observed in the majority of patients after RV ischemia (788). 
The severity of the hemodynamic derangements associated
with RV ischemia is related to 1) the extent of ischemia and
subsequent RV dysfunction, 2) the restraining effect of the
surrounding pericardium, and 3) interventricular dependence
related to the shared interventricular septum. When the RV
becomes ischemic, it dilates acutely, which results in
increased intrapericardial pressure caused by the restraining
forces of the pericardium. As a consequence, there is a reduc-
tion in RV systolic pressure and output, decreased LV pre-
load, a reduction in LV end-diastolic dimension and stroke
volume, and a shifting of the interventricular septum toward
the LV (789). Because of this RV systolic and diastolic dys-
function, the pressure gradient between the right and left
atria becomes an important driving force for pulmonary per-
fusion. Factors that reduce preload (volume depletion, diuret-
ics, nitrates) or diminish augmented right atrial contraction
(concomitant atrial infarction, loss of AV synchrony) and fac-
tors that increase RV afterload (concomitant LV dysfunction)
are likely to have profoundly adverse hemodynamic effects
(790-794). Goldstein and coworkers (791,794) demonstrated
the importance of a paradoxical interventricular septal
motion that bulges in piston-like fashion into the RV, gener-
ating systolic force, which allows pulmonary perfusion. The
loss of this compensatory mechanism, with concomitant sep-
tal infarction, may result in further deterioration in patients
with RV ischemia. 
classic shock, with acceptable complication rates.
Fibrinolytic therapy should be administered to those patients
who are not candidates for early revascularization and who
do not have a contraindication to fibrinolysis. 
When shock has resolved, ACE inhibitors and beta-block-
ers, initiated in low doses with progressive increases as rec-
ommended in the ACC/AHA Guidelines for the Evaluation
and Management of Heart Failure, should be administered
before discharge (771). (See Section 7.6.7.6 for discussion of
mechanical support for the failing heart.)
7.6.6. Right Ventricular Infarction
Class I
1. Patients with inferior STEMI and hemodynamic com-
promise should be assessed with a right precordial
V4R lead to detect ST-segment elevation and an
echocardiogram to screen for RV infarction. (See the
ACC/AHA/ASE 2003 Guideline Update for the
Clinical Application of Echocardiography (226)).
(Level of Evidence: B)
2. The following principles apply to therapy for patients
with STEMI and RV infarction and ischemic dysfunc-
tion:
a. Early reperfusion should be achieved if possible.
(Level of Evidence: C)
b. Atrioventricular synchrony should be achieved,
and bradycardia should be corrected. (Level of
Evidence: C)
c. Right ventricular preload should be optimized,
which usually requires initial volume challenge in
patients with hemodynamic instability provided
the jugular venous pressure is normal or low.
(Level of Evidence: C)
d. Right ventricular afterload should be optimized,
which usually requires therapy for concomitant LV
dysfunction. (Level of Evidence: C)
e. Inotropic support should be used for hemodynam-
ic instability not responsive to volume challenge.
(Level of Evidence: C)
Class IIa
After infarction that leads to clinically significant RV
dysfunction, it is reasonable to delay CABG surgery
for 4 weeks to allow recovery of contractile perform-
ance. (Level of Evidence: C)
Right Ventricular Infarction and Dysfunction. Right ventric-
ular infarction encompasses a spectrum of disease states
ranging from asymptomatic mild RV dysfunction through
cardiogenic shock. Most patients demonstrate a return of
normal RV function over a period of weeks to months, which
suggests that RV stunning, rather than irreversible necrosis,
has occurred. In this sense, RV ischemia can be demonstrat-
ed in up to half of all inferior STEMIs, although only 10% to
15% of patients show classic hemodynamic abnormalities of
clinically significant RV infarction (780,781). 
Right ventricular infarction with hemodynamic abnormali-
ties accompanying inferior STEMI is associated with a sig-
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physicians to ensure that hospital personnel (house officer,
nurse, technician) recording the ECG in this setting know
how to properly record lead V4R, especially in view of the
variety of multilead recording systems available. All patients
with inferior STEMI should be screened initially for this
finding at the time of admission. Echocardiography can be
helpful in patients with suspicious but nondiagnostic findings
(226). It can show RV dilation and asynergy, abnormal inter-
ventricular and interatrial septal motion, and even right to left
shunting through a patent foramen ovale (800-802). Right to
left shunting should be suspected when persistent hypoxia is
not responsive to supplemental oxygen (802).
Management of RV Ischemia/Infarction. Treatment of RV
ischemia/infarction includes early maintenance of RV pre-
load, reduction of RV afterload, inotropic support of the dys-
functional RV, and early reperfusion (Figure 30) (257,803).
Because of their influence on preload, drugs routinely used
in management of LV infarctions, such as nitrates and diuret-
ics, may reduce cardiac output and produce severe hypoten-
sion when the RV is ischemic. Indeed, a common clinical
presentation is profound hypotension after administration of
sublingual nitroglycerin, with the degree of hypotension
often out of proportion to the ECG severity of the infarct.
Volume loading with normal saline alone often resolves
Clinical Diagnosis. Evidence of RV ischemia/infarction
should be sought in all patients with inferior STEMI. The
clinical triad of hypotension, clear lung fields, and elevated
jugular venous pressure in the setting of a STEMI is charac-
teristic of RV ischemia/infarction. Although specific, this
triad has a sensitivity of less than 25% (795). Distended neck
veins alone or the presence of Kussmaul’s sign (distention of
the jugular vein on inspiration) are both sensitive and specif-
ic for RV ischemia/infarction in patients with a STEMI
(796). These findings may be masked in the setting of vol-
ume depletion and may only become evident after adequate
volume loading. Right heart catheterization may be helpful
in diagnosing RV ischemia/infarction. A right atrial pressure
of 10 mm Hg or greater and greater than 80% of pulmonary
wedge pressure is a relatively sensitive and specific finding
in patients with RV ischemia/infarction (797). 
Patients with RV hypertrophy, commonly due to the pul-
monary hypertension associated with chronic obstructive
pulmonary disease, have increased myocardial demand and
may be more likely to suffer RV MI. Demonstration of 1-mm
ST-segment elevation in lead V1 and in the right precordial
lead V4R is the single most predictive ECG finding in
patients with RV ischemia (798). The finding may be tran-
sient; half of patients show resolution of ST elevation within
10 hours of onset of symptoms (799). It is important for
Figure 30. Right ventricular infarction. JVP = jugular venous pressure; RA = right atrial; RV = right ventricular; PA = pulmonary artery;
PCW = pulmonary capillary wedge. AV = atrioventricular. Modified with permission from Wellens. N Engl J Med 1999;340:381. Copyright
© 1999 Massachusetts Medical Society. All rights reserved (803).
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ated with the need for high levels of support, inability to
close the chest owing to cardiac dilation, need for ventricular
assist devices, prolonged convalescence, transplantation, or
death (792). 
The best defense is an index of suspicion and recognition
of the RV dysfunction by physical examination (795,810)
ECG (right precordial leads), echocardiography, or radionu-
clide-gated blood pool study (793,810,823,824). If early PCI
of the right coronary artery is indicated on the basis of
angiography, this should be performed promptly. It is rea-
sonable to delay coronary bypass surgery for 4 weeks to
allow recovery of RV function.
Prognosis. The mere presence of RV ischemia/infarction that
is evident by noninvasive criteria is associated with signifi-
cantly increased short-term morbidity and mortality and may
also influence long-term outcome (780,812,825). However,
clinical and hemodynamic recovery often occur even in
patients with RV dysfunction that persists for weeks or
months (796,826-828). This return to normal may be due to
improvement of concomitant LV dysfunction, which results
in a reduction in RV afterload, or to a gradual stretching of
the pericardium with amelioration of its restraining effect
(826).
7.6.7. Mechanical Causes of Heart Failure/
Low-Output Syndrome
7.6.7.1. Diagnosis
Mechanical defects, when they occur, usually present within
the first week after STEMI. On physical examination, the
presence of a new cardiac murmur indicates the possibility of
either a VSR or MR. Detailed characteristics of these
mechanical defects are listed in Table 25 (829) (Figure 31).
A precise diagnosis can usually be established with transtho-
racic or transesophageal echocardiography. A pulmonary
artery monitoring catheter may also be useful in establishing
the diagnosis of a mechanical defect and in its subsequent
management. In VSR, oxygen saturation will be higher
(“step-up”) in the pulmonary artery than in the right atrium.
With acute MR, a large C-V wave may be evident on the pul-
monary artery wedge pressure tracing. However, a prominent
V wave does not necessarily indicate the presence of MR and
may also be present in patients with severe LV dysfunction
associated with decreased left atrial compliance (830). A V
wave may also be seen with VSR. In patients with free-wall
ventricular rupture and subsequent pericardial tamponade,
equalization of diastolic pressures may be seen.
Surgical consultation should be obtained when a mechani-
cal defect is suspected so that an early decision regarding
surgical management can be made. In general, prompt surgi-
cal repair is indicated in most cases, because medical treat-
ment alone is associated with an extremely high mortality.
Insertion of an IABP, particularly in patients with papillary
muscle rupture or VSR, can help stabilize the patient.
Although there is a need to minimize invasive procedures
before early surgical correction of mechanical complications,
accompanying hypotension and improves cardiac output
(804). The Trendelenburg position may effectively raise pre-
load in patients who develop hypotension after vasodilator
administration. Although volume loading is a critical first
step in the management of hypotension associated with RV
ischemia/infarction, inotropic support (in particular, dobuta-
mine hydrochloride) should be initiated promptly if cardiac
output fails to improve after 0.5 to 1 L of fluid have been
given. Excessive volume loading may further alleviate the
right-sided filling pressure and RV dilatation, resulting in
decreased LV output (805-807) through shift of the interven-
tricular septum for RV toward the LV.
Another important factor for sustaining adequate RV pre-
load is maintenance of AV synchrony. High-degree heart
block is common, occurring in as many as half of these
patients (808). Atrioventricular sequential pacing leads to a
significant increase in cardiac output and reversal of shock,
even when ventricular pacing alone has not been of benefit
(806). Atrial fibrillation may occur in up to one third of
patients with RV ischemia/infarction (807) and has profound
hemodynamic effects. Prompt cardioversion from AF should
be considered at the earliest sign of hemodynamic compro-
mise. When LV dysfunction accompanies RV ischemia/
infarction, the RV is further compromised because of
increased RV afterload and reduction in stroke volume (809).
In such circumstances, the use of afterload-reducing agents
or an intra-aortic counterpulsation device is often necessary
to unload the LV and subsequently the RV. Fibrinolytic ther-
apy and primary PCI with subsequent reperfusion have been
shown to improve RV ejection fraction (793,810) and reduce
the incidence of complete heart block (810-812). 
Right ventricular failure secondary to an ischemic RV
(either infarction or stunning) presents a particularly haz-
ardous situation (813). The prototypical patient has an
occluded right coronary artery proximal to the major RV
branches and presents with an inferior MI with or without
recognized RV failure (784,795,814-821). Angiography may
demonstrate that the coronary anatomy is best treated surgi-
cally, but the opportunity for maximal benefit of an emer-
gency operation (initial 4 to 6 hours) has often passed. There
is substantial risk in operating after this small window of
opportunity but before the recovery of RV function, which
usually occurs at 4 weeks after injury (793). During this
postinfarct month, the RV is at great risk for severe postop-
erative dysfunction, which often requires extraordinary lev-
els of perioperative pharmacological and mechanical support
and is associated with a very high mortality rate. The non-
surgical postinfarction patient can most often be supported
with pacing, volume loading, and judicious inotropic admin-
istration (792). In the surgical setting, the RV takes on dif-
ferent characteristics. There is loss of the pericardial con-
straint immediately on exposing the heart, which results in
acute dilation of the dysfunctional RV. The RV often fails to
recover in this setting, even when state-of-the-art myocardial
protection schemes and revascularization are used (822). The
parallel effects of RV dilatation and dysfunction on LV dias-
tolic and systolic function are magnified and may be associ-
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echocardiography. All patients with papillary muscle rupture
should be considered for urgent surgery. The patient should
be stabilized with an IABP, inotropic support, and afterload
reduction (to reduce regurgitant volume and pulmonary con-
gestion) while emergency surgery is arranged. Coronary
angiography should also be undertaken before surgery.
Although emergency mitral valve replacement is associated
with a relatively high mortality rate (20%), overall mortality
and ventricular function are improved compared with med-
ical therapy alone. Delay in operation appears to increase the
risk of further myocardial injury, other organ injury, and sub-
sequent death (834). Most patients will require mitral valve
replacement, although mitral valve repair has also been
reported in selected circumstances. Five-year survival after
surgery has been reported to be 60% to 70% (835-839).
Severe MR, in the absence of papillary muscle rupture,
often indicates extensive infarction and severe LV dysfunc-
tion. These patients may present a much more difficult man-
agement problem, particularly if surgery is required. Initial
management should include afterload reduction and possible
IABP. In many cases, the MR will improve over the next sev-
eral days with aggressive medical management. If surgery is
required because of critical coronary anatomy or ongoing
ischemia, an intraoperative transesophageal echo should be
undertaken to assess the mitral valve. Mitral valve surgery,
usually annuloplasty, should be undertaken at the same time
as CABG for patients with ischemic MR greater than 2+
(840,841). Clearly, operative mortality is increased in such
patients, particularly in the elderly, with a marked decrease in
LV function. 
7.6.7.3. Ventricular Septal Rupture After STEMI
Class I
1. Patients with STEMI complicated by the development
of a VSR should be considered for urgent cardiac sur-
gical repair, unless further support is considered futile
because of the patient’s wishes or contraindi-
cations/unsuitability for further invasive care. (Level
of Evidence: B)
initial coronary angiography to assess coronary anatomy
appears warranted in most cases of VSR and papillary mus-
cle rupture. However, the evidence for the benefit of con-
comitant CABG associated with surgical repair of acute VSR
is inconclusive (831). In the majority of patients, right and
left heart catheterization are unnecessary unless other studies
(e.g., echocardiography) are not clear in demonstrating a
mechanical defect.
7.6.7.2. Mitral Valve Regurgitation
Class I
1. Patients with acute papillary muscle rupture should
be considered for urgent cardiac surgical repair,
unless further support is considered futile because of
the patient’s wishes or contraindications/unsuitability
for further invasive care. (Level of Evidence: B)
2. Coronary artery bypass graft surgery should be
undertaken at the same time as mitral valve surgery.
(Level of Evidence: B)
Severe MR after STEMI, accompanied by cardiogenic
shock, has a poor prognosis. In the SHOCK trial registry,
approximately 10% of patients with shock presented with
severe MR and had an overall hospital mortality of 55%
(832). Mortality with medical treatment only was 71% com-
pared with 40% with surgery (832). In the Survival and
Ventricular Enlargement (SAVE) trial, in which patients
were treated with an ACE inhibitor after MI, even patients
with mild MR experienced a worse prognosis than those
without MR (833).
Severe MR may be due to infarction of the posterior papil-
lary muscle, and in such instances, the area of infarction
tends to be less extensive than in those patients in whom the
MR is due to severe LV dysfunction. Consequently, LV func-
tion may also be better preserved in these patients. The pres-
ence of pulmonary edema or cardiogenic shock in a patient
with inferior STEMI should alert the physician to the possi-
bility of acute MR and papillary muscle rupture (Figure 31).
Diagnosis is made by transthoracic or transesophageal
Figure 31. Mechanical complications of ST-elevation myocardial infarction (STEMI). See Table 25 for additional information. Images
courtesy of William D. Edwards, M.D. (Mayo Clinic).
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854) (Figure 31). Left ventricular free-wall rupture is typi-
cally heralded by chest pain and ECG ST-T-wave changes,
with rapid progression to hemodynamic collapse and electro-
mechanical dissociation. The frequency of cardiac rupture
has 2 peaks: an early peak within 24 hours and a late one
from 3 to 5 days after STEMI. Early rupture is related to the
initial evolution of infarction before significant collagen dep-
osition, and late rupture is related to expansion of the infarct-
related ventricular wall (852,855). Cardiac rupture is
observed most frequently in patients with their first MI, those
with anterior infarction, the elderly, and women. Other risk
factors include hypertension during the acute phase of
STEMI, lack of previous angina and MI, lack of collateral
blood flow, Q waves on the ECG, use of corticosteroids or
nonsteroidal anti-inflammatory drugs (NSAIDs), and use of
fibrinolytic therapy more than 14 hours after onset (854,855).
Fibrinolytic therapy decreases risk of cardiac rupture
(853,856). Although there is an increase in the risk of early
rupture after late administration of fibrinolytic therapy (i.e.,
more than 14 hours), the overall incidence of rupture is
reduced. The most important determinants in preventing rup-
ture are successful early reperfusion and the presence of col-
lateral circulation (852,853). Pseudoaneurysm is a serious
complication after rupture of the free wall. Clot forms in the
pericardial space, and an aneurysmal wall containing clot
and pericardium prevents exsanguination. Prompt surgical
correction is always indicated for pseudoaneurysm to prevent
rupture. 
Pericardiocentesis for relief of tamponade and emergency
surgical repair may be lifesaving (857,858). Ideally, the peri-
cardium in this case should be opened surgically or tapped in
the operating room. Echocardiography is valuable in the
diagnosis of free-wall rupture and pseudoaneurysm, but for
relief of tamponade in this setting, rapid fluid replacement is
essential. Ideally, the patient should be in the operating room
as soon as possible and fully prepared for cardiopulmonary
bypass to prevent hemodynamic collapse. In these circum-
stances, delay to perform coronary angiography is inadvis-
able (859). 
Surgery includes repair of the ventricle with a direct suture
technique or patch to cover the ventricular perforation (857),
in addition to CABG as needed. Alternatively, the use of
cyanoacrylate glue has been described to hold the patch in
place over necrotic myocardium (860). Most series of
patients reaching the operating room for management of this
complication are small, with the surgical mortality rate in
these patients being up to 60% (859,861).
7.6.7.5. Left Ventricular Aneurysm
Class IIa
It is reasonable that patients with STEMI who 
develop a ventricular aneurysm associated with
intractable ventricular tachyarrhythmias and/or
pump failure unresponsive to medical and catheter-
2. Coronary artery bypass grafting should be undertak-
en at the same time as repair of the VSR. (Level of
Evidence: B)
The frequency of acute rupture of the intraventricular sep-
tum (VSR) (Figure 31) appears to have declined in the reper-
fusion era. It is estimated to occur in fewer than 1% of
patients with STEMI (GUSTO-I) (829,842). Whereas previ-
ous pathological and clinical studies indicated the mean time
from MI to rupture as 3 to 5 days, data from the GUSTO-I
trial and SHOCK registry indicate that the highest risk for
development of a postinfarct VSR occurred within the first
24 hours after infarction in patients receiving fibrinolytic
therapy (842,843). Although emergency surgical repair was
formerly thought to be necessary only in patients with pul-
monary edema or cardiogenic shock, it is now recognized as
equally important in hemodynamically stable patients (844-
846). Because all septal perforations are exposed to shear
forces and necrotic tissue removal processes by
macrophages, the rupture site can abruptly expand, resulting
in sudden hemodynamic collapse even in patients who
appear to be clinically stable with normal LV function (846).
Insertion of an IABP and prompt surgical referral are recom-
mended for almost every patient with an acute VSR. Invasive
monitoring is recommended in all patients, together with
judicious use of inotropes and a vasodilator to maintain opti-
mal hemodynamics. Nitroprusside is often used because it
provides afterload reduction and can be titrated intravenous-
ly. Surgical repair usually involves excision of all necrotic
tissue and patch repair of the VSR, together with coronary
artery grafting. Surgical mortality remains high and has been
reported to be between 20% and 50% (842-845,847,848).
Mortality is particularly high in patients with cardiogenic
shock (844,849) and was reported to be 87% in the SHOCK
registry. However, surgical mortality is significantly less than
for medically treated patients. In GUSTO-I (842), the mor-
tality rates for surgical or medically treated patients were
47% and 94%, respectively.
A limited number of patients with postinfarction VSR have
been treated by transcatheter closure with a septal occluding
device. Most of these cases have been managed several
weeks after infarction or have had prior surgical intervention
with a residual defect. At this time, surgical closure remains
the procedure of choice, although percutaneous closure does
offer some hope for the future (850).
7.6.7.4. Left Ventricular Free-Wall Rupture
Class I
1. Patients with free-wall rupture should be considered
for urgent cardiac surgical repair, unless further sup-
port is considered futile because of the patient’s wish-
es or contraindications/unsuitability for further inva-
sive care. (Level of Evidence: B)
2. CABG should be undertaken at the same time as
repair of free wall rupture. (Level of Evidence: C)
Cardiac rupture may account for recurrent pain and occurs
in 1% to 6% of all patients admitted with STEMI (829,851-
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Class IIa
It is reasonable to manage STEMI patients with
refractory polymorphic VT with intra-aortic balloon
counterpulsation to reduce myocardial ischemia. See
Section 7.7.1.2. (Level of Evidence: B)
Class IIb
It may be reasonable to use intra-aortic balloon coun-
terpulsation in the management of STEMI patients
with refractory pulmonary congestion. See Section
7.6.4. (Level of Evidence: C)
The IABP improves diastolic coronary blood flow and
reduces myocardial work. These physiological effects of the
IABP are especially helpful in patients with STEMI with
ongoing or recurrent ischemic discomfort, hypotension from
ischemia-mediated LV dysfunction, and cardiogenic shock
(see section 7.6.5). The IABP is a useful stabilizing measure
for patients in whom cardiac catheterization and revascular-
ization are being considered.
Selected patients with cardiogenic shock after STEMI,
especially if not candidates for revascularization, may be
considered for either a short- or long-term mechanical sup-
port device to serve as a bridge to recovery or to subsequent
cardiac transplantation. Of the many devices available to
support these patients (868), short-term devices include cen-
trifugal pumps and LV assist devices (LVADs) (869).
Extracorporeal membrane oxygenation (ECMO), a car-
diopulmonary bypass system placed through either the
femoral or intrathoracic vessels, serves patients with heart
failure and concomitant respiratory failure. These systems
are limited by their short-term usefulness of less than 1 week
and by problems with bleeding and thrombosis. Some con-
sider ECMO a poor method of support because it does not
decompress the LV (869). Patients who are subsequently
determined to be transplant candidates may also be convert-
ed to a bridge-to-transplant device, thus creating a bridge to
a bridge. About 10% of all patients treated with LVADs have
them inserted for hemodynamic support after STEMI. This
application has not been widely used because of the many
comorbidities encountered in such patients, many of whom
die before surgery. Experience with LVADs implanted in
selected patients within 14 days after infarction has shown a
survival rate of 74% to transplantation or explantation (870).
This experience suggests that ventricular assist device
implantation for cardiogenic shock after STEMI may reduce
the mortality currently associated with medical management.
The use of assist devices has been extensively reviewed in a
separate ACC consensus conference report (868).
7.6.7.7. Cardiac Transplantation After STEMI
Cardiac transplantation has been reported for patients who
have sustained irreversible acute myocardial injury associat-
ed with cardiogenic shock (871-873). Most patients so trans-
planted have been initially treated with an LVAD as a bridge
to recovery or transplantation. Many such patients, however,
do not meet criteria for transplantation because of advanced
based therapy be considered for LV aneurysmectomy
and CABG surgery. (Level of Evidence: B)
Ventricular aneurysm after STEMI usually occurs on the
anterior aspect of the LV in association with total LAD
occlusion and a wide area of infarction. Clinical conse-
quences include angina pectoris, CHF, thromboembolism,
and ventricular arrhythmias. Patients with STEMI who
receive fibrinolytic therapy and exhibit a patent infarct-relat-
ed artery have a significantly reduced incidence of LV
aneurysm formation compared with those who do not (7.2%
versus 18.8%) (862). The need for surgery for ventricular
aneurysm early after STEMI is rare, but it may be necessary
for control of heart failure or intractable ventricular arrhyth-
mias unresponsive to conventional therapy (863). Surgical
techniques include plication, excision with linear repair, and
ventricular reconstruction with endoventricular patches to
maintain better physiological function (863-865). The ade-
quacy of the residual LV in terms of size and function is a
critical determinant on prognosis. Current mortality rates are
reported to be 3.3% to 7.2% (863,864). Patients with severe
LV dysfunction have an increase in mortality that has been
reported to be as high as 19% for an ejection fraction less
than 0.20 (866). Operative survivors have clear improvement
in New York Heart Association class and a 60% 5-year sur-
vival rate (867). 
7.6.7.6. Mechanical Support of the Failing Heart
7.6.7.6.1. INTRA-AORTIC BALLOON
COUNTERPULSATION.
Class I
1. Intra-aortic balloon counterpulsation should be used
in STEMI patients with hypotension (systolic blood
pressure less than 90 mmHg or 30 mmHg below base-
line mean arterial pressure) who do not respond to
other interventions, unless further support is futile
because of the patient’s wishes or contraindications/
unsuitability for further invasive care. See Section
7.6.2. (Level of Evidence: B)
2. Intra-aortic balloon counterpulsation is recommend-
ed for STEMI patients with low-output state. See
Section 7.6.3. (Level of Evidence: B)
3. Intra-aortic balloon counterpulsation is recommend-
ed for STEMI patients when cardiogenic shock is not
quickly reversed with pharmacological therapy. IABP
is a stabilizing measure for angiography and prompt
revascularization. See Section 7.6.5. (Level of
Evidence: B)
4. Intra-aortic balloon counterpulsation should be used
in addition to medical therapy for STEMI patients
with recurrent ischemic-type chest discomfort and
signs of hemodynamic instability, poor LV function,
or a large area of myocardium at risk. Such patients
should be referred urgently for cardiac catheteriza-
tion and should undergo revascularization as needed.
See Section 7.8.2. (Level of Evidence: C)
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Class III
Prophylactic administration of antiarrhythmic 
therapy is not recommended when using fibrinolytic
agents. (Level of Evidence: B)
Disturbances of cardiac rhythm are common during
STEMI. Early-phase arrhythmias are probably largely a
result of microreentry. Although other electrophysiological
mechanisms such as enhanced automaticity and triggered
activity have been proposed in experimental models of
STEMI, convincing evidence for their role in human STEMI
is not yet established (876). Important contributory factors
include heightened adrenergic nervous system tone,
hypokalemia, hypomagnesemia, intracellular hypercalcemia,
acidosis, free fatty acid production from lipolysis, and free
radical production from reperfusion of ischemic myocardium
(876-878). The relative importance of each of these factors in
the pathogenesis of arrhythmias during STEMI has not been
established, nor has it been clearly shown that aggressive
measures specifically targeted at 1 or more of these mecha-
nisms can be relied on clinically to reduce arrhythmia fre-
quency in STEMI. 
Primary VF should be distinguished from secondary VF,
the latter occurring in the presence of severe CHF or cardio-
genic shock (879). Late VF develops more than 48 hours
after onset of STEMI. Ventricular fibrillation is more com-
mon in the elderly (greater than 75 years of age) (880). The
incidence of primary VF is highest (around 3% to 5%) in the
first 4 hours after STEMI and declines markedly thereafter
(881). Some epidemiological data suggest that the incidence
of primary VF in STEMI may be decreasing in the current
era, possibly owing to aggressive attempts at infarct-size
reduction, correction of electrolyte deficits, and a greater use
of beta-adrenoceptor–blocking agents (882). Additional epi-
demiological data from the Worcester Heart Attack Study
more convincingly demonstrate that the case-fatality rate of
primary VF has declined over time (883). Contrary to prior
belief, primary VF appears to be associated with significant-
ly higher in-hospital mortality, but those persons who survive
to hospital discharge, particularly if primary VF occurred
within the first 4 hours after STEMI, have the same long-
term prognosis as patients who do not experience primary VF
(884). 
Primary VF remains an important contributor to risk of
mortality during the first 24 hours after STEMI. Therefore, a
reliable method for its prediction and prevention remains
desirable but has not been established despite extensive clin-
ical investigation. Classification of ventricular arrhythmias in
ascending order of risk of primary VF (warning arrhythmias)
was proposed, but this approach lacks appropriate specificity
and sensitivity (885-887). 
Accelerated idioventricular rhythm occurs frequently dur-
ing the first 12 hours of infarction. Data from the prereperfu-
sion era do not support development of accelerated idioven-
tricular rhythm as a risk factor for development of VF
(886,888). In patients receiving fibrinolysis or undergoing
primary PCI, accelerated idioventricular rhythm may be a
age and extensive comorbidity. With appropriate case selec-
tion, satisfactory results can be obtained. Of 25 patients with
post-STEMI cardiogenic shock and a mean age of 48 years,
3 died while on devices and 18 (72%) survived transplanta-
tion (873). 
7.7. Arrhythmias After STEMI
Cardiac arrhythmias are common in patients with STEMI
and occur most frequently early after development of symp-
toms. The mechanisms for ventricular tachyarrhythmias
include loss of transmembrane resting potential, reentrant
mechanisms due to dispersion of refractoriness in the border
zones between infarcted and nonischemic tissues (874), and
the development of foci of enhanced automaticity.
Reperfusion arrhythmias, more commonly seen in the post-
fibrinolytic era, appear to involve washout of toxic metabo-
lites and of various ions such as lactate and potassium (875).
Atrial arrhythmias have as additional causes excessive sym-
pathetic stimulation, increased atrial stretch due to ventricu-
lar failure or AV valvular insufficiency, proarrhythmic effects
of pericarditis, and atrial infarction. Bradyarrhythmias may
be due to overstimulation of vagal afferent receptors and
resulting cholinergic stimulation, as well as to ischemic
injury of conducting tissues. The treatment of cardiac
arrhythmias is based on the presumptive mechanism, the
ongoing hemodynamic consequences, and, whenever possi-
ble, the results of clinical studies.
7.7.1. Ventricular Arrhythmias
7.7.1.1. Ventricular Fibrillation
Class I
Ventricular fibrillation or pulseless VT should be
treated with an unsynchronized electric shock with an
initial monophasic shock energy of 200 J; if unsuc-
cessful, a second shock of 200 to 300 J should be given,
and then, if necessary, a third shock of 360 J. (Level of
Evidence: B)
Class IIa
1. It is reasonable that VF or pulseless VT that is refrac-
tory to electric shock be treated with amiodarone (300
mg or 5 mg/kg, IV bolus) followed by a repeat unsyn-
chronized electric shock. (Level of Evidence: B)
2. It is reasonable to correct electrolyte and acid-base
disturbances (potassium greater than 4.0 mEq/L and
magnesium greater than 2.0 mg/dL) to prevent recur-
rent episodes of VF once an initial episode of VF has
been treated. (Level of Evidence: C)
Class IIb
It may be reasonable to treat VT or shock-refractory
VF with boluses of intravenous procainamide.
However, this has limited value owing to the length of
time required for administration. (Level of Evidence: C)
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different from the CCU population with primary VF, many
patients with out-of-hospital VF have STEMI as the precipi-
tating cause (894). These randomized trials have shown that
the use of intravenous amiodarone is superior to placebo
(895) and to lidocaine (896) in survival to hospital admission
for patients with shock-resistant VF or VT. Neither trial,
however, demonstrated improved survival to hospital dis-
charge. In contrast, small studies comparing lidocaine to
bretylium failed to show significant differences in the pro-
portion of patients surviving to hospital admission (897,898);
the use of procainamide in cardiac arrest is based on a small,
20-patient study (899). The use of lidocaine to treat VF
refractory to electric shock or pulseless VT followed by
unsynchronized electric shock has not been demonstrated to
be beneficial in this setting and has been labeled “class inde-
terminate” by the Guidelines 2000 for Cardiopulmonary
Resuscitation and Emergency Cardiovascular Care (900).
There are no firm data to help define an optimal manage-
ment strategy for prevention of recurrent VF in patients who
have sustained an initial episode of VF in the setting of
STEMI. It seems prudent to correct any electrolyte and acid-
base disturbances and to administer beta-adrenoceptor–
blocking agents to inhibit increased sympathetic nervous
system tone and prevent ischemia (876). The clinical trials of
amiodarone cited above studied bolus administration of
amiodarone only during the arrest setting. Thus, in the
absence of arrhythmia recurrence, antiarrhythmic drugs
should not be maintained beyond a 6- to 24-hour period.
They should then be discontinued so that the patient’s ongo-
ing need for antiarrhythmic treatment can be reassessed. 
7.7.1.2. Ventricular Tachycardia
Class I
1. Sustained (more than 30 seconds or causing hemody-
namic collapse) polymorphic VT should be treated
with an unsynchronized electric shock with an initial
monophasic shock energy of 200 J; if unsuccessful, a
second shock of 200 to 300 J should be given, and, if
necessary, a third shock of 360 J. (Level of Evidence: B)
2. Episodes of sustained monomorphic VT associated
with angina, pulmonary edema, or hypotension (blood
pressure less than 90 mmHg) should be treated with a
synchronized electric shock of 100 J of initial
monophasic shock energy. Increasing energies may be
used if not initially successful. Brief anesthesia is
desirable if hemodynamically tolerable. (Level of
Evidence: B)
3. Sustained monomorphic VT not associated with angi-
na, pulmonary edema, or hypotension (blood pressure
less than 90 mm Hg) should be treated with:
a. Amiodarone: 150 mg infused over 10 minutes
(alternative dose 5 mg/kg); repeat 150 mg every 10
to 15 minutes as needed. Alternative infusion: 360
mg over 6 hours (1 mg/min), then 540 mg over the
next 18 hours (0.5 mg/min). The total cumulative
dose, including additional doses given during car-
reperfusion arrhythmia and does not indicate an increased
risk of VF (889). Thus, it is best managed by observation and
should not trigger initiation of antiarrhythmic prophylaxis
against VF. 
A meta-analysis of randomized trials of prophylaxis with
lidocaine has shown a relative reduction in the incidence of
primary VF by about 33%, but this was offset by a trend
toward increased mortality, probably from fatal episodes of
bradycardia and asystole (890). The use of prophylactic lido-
caine was assessed in patients with STEMI in the GUSTO-I
and GUSTO-IIb trials (891). After adjustment for baseline
imbalances, the odds of death were not significantly different
with or without lidocaine. Thus, even though it is less clear
that lidocaine causes harm, there is no convincing evidence
that its prophylactic use reduces mortality, and the prior prac-
tice of routine (prophylactic) administration of lidocaine to
all patients with known or suspected STEMI has been large-
ly abandoned. 
Routine administration of intravenous beta-adrenoceptor
blockers to patients without hemodynamic or electrical (AV
block) contraindications is associated with a reduction in
incidence of early VF (892). In the absence of contraindica-
tions (see Section 6.3.1.5), it is reasonable to initiate beta-
blockade intravenously, followed by an oral regimen.
Suitable regimens include intravenous metoprolol at 5 mg
every 2 minutes for 3 doses, if tolerated, followed by 50 mg
orally twice per day for at least 24 hours and then increased
to 100 mg twice per day. An alternative regimen is atenolol 5
to 10 mg IV followed by 100 mg orally on a daily basis. 
Clinical experience and observational data from CCU pop-
ulations have identified hypokalemia as an arrhythmogenic
risk factor for VF (877,878). Low serum levels of magnesium
have not been clearly shown to be associated with an
increased risk of VF (878), although tissue depletion of mag-
nesium remains a potential risk factor. Although randomized
clinical trial data do not exist to confirm the benefits of reple-
tion of potassium and magnesium deficits in preventing VF,
it is sound clinical practice to maintain serum potassium lev-
els at greater than 4.0 mEq/L and magnesium levels at
greater than 2.0 mEq/L in patients with acute MI. 
Ventricular fibrillation should be treated with an unsyn-
chronized electric shock using an initial monophasic shock
energy of 200 J. If this is unsuccessful, a second shock using
200 to 300 J and, if necessary, a third shock using 360 J is
indicated (893). The appearance of biphasic waveform defib-
rillators has led to some confusion regarding the comparabil-
ity of biphasic to monophasic defibrillating energies.
Overall, the energy requirement for equivalent biphasic ther-
apeutic effect is about one half of the energy requirement for
a monophasic discharge. Given the rapid evolution of resus-
citation methodology, clinicians should follow the most cur-
rent ACLS protocol (629). For example, for patients with VF
not easily converted by defibrillation, vasopressin 40 U IV
push may be substituted for epinephrine 1 mg. Randomized
trials have addressed the use of intravenous amiodarone ver-
sus placebo and versus lidocaine for patients with out-of-hos-
pital cardiac arrest. Although this population is somewhat
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arrhythmic substrate deserving of further evaluation by an
EP study.
MANAGEMENT STRATEGIES FOR VT. Cardioversion is always
indicated for episodes of sustained, hemodynamically com-
promising VT (876). In the absence of clinical evidence of
effective perfusion, urgent electrical conversion of VT is
indicated. Rapid, polymorphic-appearing VT should be con-
sidered similar to VF and managed with an unsynchronized
discharge of 200 J, whereas monomorphic VT with rates
greater than 150 bpm can usually be treated with a 100-J syn-
chronized discharge (893). Immediate cardioversion is gen-
erally not needed for rates below 150 bpm unless hemody-
namic compromise is present. 
Episodes of sustained VT that are somewhat better tolerat-
ed hemodynamically may initially be treated with drug regi-
mens including amiodarone or procainamide. Unfortunately,
the data supporting the use of any specific antiarrhythmic
therapy in this setting are scant. Although the Guidelines
2000 for Cardiopulmonary Resuscitation and Emergency
Cardiac Care differentiate between patients with normal and
impaired LV function, impairment of LV function is likely in
the STEMI setting. Thus, recommendations for patients with
STEMI parallel the Guidelines 2000 for Cardiopulmonary
Resuscitation and Emergency Cardiac Care for patients with
impaired LV function and place the use of amiodarone above
that of other antiarrhythmics (900). Indeed, amiodarone has
produced favorable data in cardiac arrest, and in long-term
randomized trials, it is associated with a reduction in arrhyth-
mic death and a small reduction in overall mortality (904).
Knowledge of the pharmacokinetics of antiarrhythmic agents
in patients with STEMI is important because dosing varies
considerably, depending on age, weight, and hepatic and
renal function. 
Rare episodes of drug-refractory sustained polymorphic
VT (electrical storm) have been reported in cases of STEMI.
Anecdotal evidence suggests that these episodes may be
related to uncontrolled ischemia and increased sympathetic
tone and are best treated by intravenous beta-adrenoceptor
blockade (905), intravenous amiodarone (906), left stellate
ganglion blockade (907), IABP, or emergency revasculariza-
tion. Intravenous amiodarone and/or intravenous magnesium
may also be used.
Nonsustained VT is not a common cause of hemodynamic
compromise and consequently does not require acute thera-
py (Figure 10) (223). Nonetheless, it is an important arrhyth-
mia that may denote a high-risk arrhythmic substrate.
Indeed, when it occurs more than 4 days after STEMI in
patients with a depressed ejection fraction, it may be a har-
binger of future risk of sudden death (908). In unusual cases,
although the VT is nonsustained, the rate may be so rapid as
to reduce cerebral perfusion sufficiently to cause symptoms
(i.e., nonsustained VT at a rate of 200 bpm for 10 seconds).
In those cases, pharmacotherapy similar to that recommend-
ed for sustained VT may be instituted. 
diac arrest, must not exceed 2.2 g over 24 hours.
(Level of Evidence: B)
b. Synchronized electrical cardioversion starting at
monophasic energies of 50 J (brief anesthesia is
necessary). (Level of Evidence: B)
Class IIa
It is reasonable to manage refractory polymorphic VT
by:
a. Aggressive attempts to reduce myocardial
ischemia, and adrenergic stimulation, including
therapies such as beta-adrenoceptor blockade,
IABP use, and consideration of emergency
PCI/CABG surgery. (Level of Evidence: B)
b. Aggressive normalization of serum potassium to
greater than 4.0 mEq/L and of magnesium to
greater than 2.0 mg/dL. (Level of Evidence: C)
c. If the patient has bradycardia to a rate less than 60
bpm or long QTc, temporary pacing at a higher
rate may be instituted. (Level of Evidence: C)
Class IIb
It may be useful to treat sustained monomorphic VT
not associated with angina, pulmonary edema, or
hypotension (blood pressure less than 90 mmHg) with
a procainamide bolus and infusion (Level of Evidence:
C)
Class III
1. The routine use of prophylactic antiarrhythmic drugs
(i.e., lidocaine) is not indicated for suppression of iso-
lated ventricular premature beats, couplets, runs of
accelerated idioventricular rhythm, and nonsustained
VT. (Level of Evidence: B)
2. The routine use of prophylactic antiarrhythmic 
therapy is not indicated when fibrinolytic agents are
administered. (Level of Evidence: B)
Several definitions have been used for VT in the setting of
STEMI. Nonsustained VT lasts less than 30 seconds, where-
as sustained VT lasts more than 30 seconds and/or causes
earlier hemodynamic compromise that requires immediate
intervention. On the basis of ECG appearance, VT has also
been categorized as monomorphic or polymorphic. Although
short bursts (fewer than 5 beats) of nonsustained VT of either
monomorphic or polymorphic configuration may be seen
frequently, contemporary epidemiological data do not sug-
gest that they are associated with a sufficiently increased risk
of sustained VT or VF to warrant prophylactic therapy. 
The vast majority of episodes of VT and VF after STEMI
occur within the first 48 hours (881). Traditionally, sustained
VT or VF that occurs outside of this time frame is thought to
deserve especially careful evaluation, including considera-
tion of electrophysiology (EP) studies. In addition,
monomorphic VT at rates less than 170 bpm is unusual as an
arrhythmia early after STEMI and suggests a more chronic
(mature) arrhythmogenic substrate (515,901-903). VT that
occurs more than 48 hours after STEMI may denote an
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7.7.1.3. Ventricular Premature Beats
Class III
Treatment of isolated ventricular premature beats,
couplets, and nonsustained VT is not recommended
unless they lead to hemodynamic compromise. (Level
of Evidence: A)
Before the present era of care of the STEMI patient with
antiplatelet therapy, beta-blockade, ACE inhibitors, and,
above all, reperfusion strategies, it was thought that ventric-
ular warning arrhythmias preceded VF. Careful monitoring
has refuted this concept, and treatment of these rhythm dis-
turbances is not recommended unless they lead to hemody-
namic compromise. All post-STEMI patients with ventricu-
lar arrhythmias should undergo assessment of electrolyte lev-
els (especially potassium and magnesium) and have other
metabolic parameters (i.e., arterial pH) assessed.
The effect on survival of the pharmacological suppression
of ventricular premature beats after MI was assessed in the
Cardiac Arrhythmia Suppression Trial (909). Patients receiv-
ing class I antiarrhythmic drugs for suppression of ventricu-
lar premature beats did more poorly than the placebo-treated
patients. Therefore, suppression of ventricular premature
beats with class I antiarrhythmic drugs is not a goal of post-
STEMI therapy.
7.7.1.4. Accelerated Idioventricular Rhythms and
Accelerated Junctional Rhythms
Class III
1. Antiarrhythmic therapy is not indicated for accelerat-
ed idioventricular rhythm. (Level of Evidence: C)
2. Antiarrhythmic therapy is not indicated for accelerat-
ed junctional rhythm. (Level of Evidence: C)
Accelerated idioventricular rhythms are characterized by a
wide QRS complex, with a regular rate higher than the atrial
rate and lower than 100 bpm. The appearance of an idioven-
tricular rhythm is an inexact indicator of reperfusion.
Treatment of idioventricular rhythm is not indicated, and
suppression of the rhythm may lead to hemodynamic com-
promise.
Accelerated junctional rhythms are characterized by a reg-
ular narrow QRS not preceded by atrial activity, with rates
above 60 bpm. This rhythm may indicate digitalis intoxica-
tion and is more often seen in inferior STEMI than in anteri-
or STEMI. In general, treatment of accelerated junctional
rhythm is not indicated.
7.7.1.5. Implantable Cardioverter Defibrillator
Implantation in Patients After STEMI
Class I
1. An implantable cardioverter defibrillator (ICD) is
indicated for patients with VF or hemodynamically
significant sustained VT more than 2 days after
STEMI, provided the arrhythmia is not judged to be
due to transient or reversible ischemia or reinfarction.
(Level of Evidence: A)
2. An ICD is indicated for patients without spontaneous
VF or sustained VT more than 48 hours after STEMI
whose STEMI occurred at least 1 month previously,
who have an LVEF between 0.31 and 0.40, demon-
strate additional evidence of electrical instability (e.g.,
nonsustained VT), and have inducible VF or sustained
VT on EP testing. (Level of Evidence: B)
Class IIa
If there is reduced LVEF (0.30 or less) at least 1 month
post-STEMI and 3 months after coronary artery
revascularization, it is reasonable to implant an ICD
in post-STEMI patients without spontaneous VF or
sustained VT more than 48 hours after STEMI. (Level
of Evidence: B)
Class IIb
1. The usefulness of an ICD is not well established in
STEMI patients without spontaneous VF or sustained
VT more than 48 hours after STEMI who have a
reduced LVEF (0.31 to 0.40) at least 1 month after
STEMI but who have no additional evidence of elec-
trical instability (e.g., nonsustained VT). (Level of
Evidence: B)
2. The usefulness of an ICD is not well established in
STEMI patients without spontaneous VF or sustained
VT more than 48 hours after STEMI who have a
reduced LVEF (0.31 to 0.40) at least 1 month after
STEMI and additional evidence of electrical instabili-
ty (e.g., nonsustained VT) but who do not have
inducible VF or sustained VT on EP testing. (Level of
Evidence: B)
Class III
An ICD is not indicated in STEMI patients who do not
experience spontaneous VF or sustained VT more
than 48 hours after STEMI and in whom the LVEF is
greater than 0.40 at least 1 month after STEMI. (Level
of Evidence: C)
In general, VF or hemodynamically significant sustained
VT taking place more than 2 days after STEMI in the
absence of recurrent MI or potentially reversible ischemia
indicates electrical instability and portends a poor prognosis
(910,911). There are only 3 randomized trials (AVID
[Antiarrhythmics Versus Implantable Defibrillators], CASH
(Cardiac Arrest Study Hamburg), and CIDS [Canadian
Implantable Defibrillator Study]) that compare the ICD with
antiarrhythmic therapy in this patient population (912-914).
Although the focus of these studies was not specifically the
patient with prior or recent STEMI, the populations, as
expected, all had a high prevalence of coronary disease and
prior MI (Table 26) (912-914). 
Only the AVID study showed a benefit of ICD therapy on
mortality. However, the meta-analysis by Connolly et al.
(914) clearly demonstrated the similarity of the trials and the
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STEMI, ICD therapy was not implemented until at least 1
month after MI and 3 months after coronary artery revascu-
larization (Figure 32). 
Thus, evidence from the randomized trials conclusively
supports the concept that for patients with coronary disease,
LV dysfunction, and high risk of life-threatening ventricular
arrhythmias, ICD therapy is more effective than antiarrhyth-
mic therapy. Indeed, an important contribution of the ran-
domized clinical trials has been to refine the estimated con-
tribution of risk factors for arrhythmic death or cardiac arrest
in patients with coronary disease and LV dysfunction. For
example, in the MUSTT database, each 5% decrease in
LVEF from 0.40 to 0.20 conferred a 19% incremental rela-
tive risk of arrhythmic death or cardiac arrest. Inducibility at
EP study increased risk by 63%. These simple risk factors,
therefore, allow the clinician to select those patients most
likely to benefit from ICD therapy in the late post-STEMI
phase (922). The published studies, however, do not system-
atically address management considerations within the first
month after STEMI. MADIT enrolled patients at least 3
weeks after MI, MUSTT at least 4 days, and MADIT 2 at
least 1 month. Nonetheless, there is conceptual uniformity of
the results of all 3 trials to support ICD therapy for patients
at high risk of sudden cardiac death after STEMI. 
Although the ejection fraction criteria used to define a
degree of LV dysfunction severe enough to confer high risk
are not uniform from study to study, a reduced ejection frac-
tion remains the critical measurement to determine whether
a post-STEMI patient is at high risk for late ventricular
arrhythmia. Furthermore, ejection fraction is not always sta-
ble after STEMI. In a cohort of 252 patients who had sus-
tained an anterior wall STEMI, 53% had at least a 5-point
increase in ejection fraction at 90 days, whereas only 16%
had a drop of at least 5 points (923). Thus, ejection fraction
should be measured at least 1 month after STEMI before a
decision regarding ICD placement is made. Finally, the vari-
ability of ejection fraction measured by different techniques
(924) should also be taken into account by the clinician car-
ing for the patient. 
If there is reduced EF (0.30 or less) at least 1 month after
STEMI and 3 months after coronary artery revascularization,
it is reasonable to implant an ICD without a preceding diag-
nostic EP study. If the patient has an EF between 0.31 and
0.40, additional evidence of electrical instability should be
sought to help with management decisions. If markers of
electrical instability are detected on noninvasive testing (non-
sustained on monitoring), an EP study is the next diagnostic
consistency of overall results for patients with prior MI. The
summary hazard ratio was 0.72 (95% CI 0.60 to 0.87; p
equals 0.0006) for total mortality and 0.50 (95% CI 0.37 to
0.67; p less than 0.0001) for arrhythmic death. Thus, patients
with VF or hemodynamically significant sustained VT that
takes place more than 2 to 3 days after STEMI in the absence
of recurrent MI or other readily reversible cause should
receive an ICD (Table 27) (915-918).
The management of nonsustained VT in patients with prior
MI has proven more challenging. In the presence of LV dys-
function, this arrhythmia is associated with a 2-year mortali-
ty estimated at 30% (919,920), of which approximately 50%
is believed to be arrhythmic in origin. Subsequent studies
suggest that this degree of risk occurs principally in patients
with inducible sustained VT not treated with an ICD (921).
Three large randomized trials have been performed to study
primary prevention of sudden death in these patients.
However, because these trials were purposely not designed as
post-STEMI trials, a conservative interpretation requires
knowledge of when patients were randomized in relationship
to their last previous known MI.
In the first prospective randomized trial completed in such
a patient population, improved survival was documented
after implantation of ICDs in patients with nonsustained VT
and EP study–inducible and nonsuppressible ventricular
tachyarrhythmias compared with conventional drug therapy,
including amiodarone (915). Patients could not be random-
ized until at least 3 weeks after MI. Results of another
prospective randomized trial, the Multicenter Unsustained
Tachycardia Trial (MUSTT), showed reduced mortality with
aggressive therapy for patients with low ejection fraction
(0.40 or less), nonsustained VT on Holter monitoring, and
inducible sustained ventricular tachyarrhythmias at EP study
(916). Most of this benefit appeared to be due to ICD place-
ment (918). In MUSTT, patients could be randomized as
early as 4 days after MI; however, only 16% of patients were
enrolled within 1 month of MI, which limits conclusions
regarding benefit in patients early after STEMI. The MADIT
2 (Multicenter Automatic Defibrillator Implantation Trial 2)
study enrolled 1232 post-MI patients with an LVEF of 0.30
or less. Patients were randomized to ICD therapy or not with-
out the requirement for EP screening for inducible ventricu-
lar tachyarrhythmia (917). At a mean follow-up of 20
months, mortality was 14.2% in individuals who had ICDs
and 19.8% in the conventionally treated group, a 5.6%
absolute and 31% relative risk reduction for death. Of poten-
tial importance for management of patients recovering from
Table 26. Clinical Trials of Secondary Prevention of Sudden Death in ICDs: Applicability to
the Post-MI Population
Study AVID (912) CASH (913) CIDS (914)
Patients 1016 191 659
Prior MI, % 61 51 77
LVEF 0.32 ± 0.13 0.45 ± 0.18 0.34 ± 0.14
Presenting arrhythmia: 100 100 86
VF or VT, %
ICD = implantable cardioverter defibrillator; MI = myocardial infarction; LVEF = left ventricular ejection fraction; VF =
ventricular fibrillation; VT = ventricular tachycardia.
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step. If inducible VF or sustained VT is found at EP study, an
ICD is indicated. The Writing Committee endorses addition-
al research on noninvasive markers of electrical instability
and the results of EP testing to help clarify management of
decisions in such patients (see Section 7.11). The usefulness
of an ICD is less well established for patients in whom no
inducible VF or sustained VT is detected at EP study. As
shown in Figure 32, such patients do not receive an ICD but
should receive medical therapy (post-STEMI) as discussed in
this guideline. An ICD is not indicated in patients with
STEMI who do not experience spontaneous VF or sustained
VT more than 48 hours after STEMI and in whom the ejec-
tion fraction is greater than 0.40 at least 1 month after
STEMI.
Unfortunately, published clinical trials have not addressed
the patient with a low ejection fraction within the first month
after STEMI, which is thought to be a particularly high-risk
period. Preliminary findings from DINAMIT (Defibrillator
in Acute Myocardial Infarction Trial), a clinical trial of ICD
versus conventional therapy in patients 6 to 40 days after MI
with ejection fraction less than 0.35 and evidence of
impaired autonomic tone, showed a reduction in arrhythmic
mortality at the cost of an increase in nonarrhythmic mortal-
ity, yielding no net benefit of an ICD implanted in the first
month after STEMI (Connelly S; oral presentation, American
College of Cardiology 53rd Annual Scientific Session,
March 2004, New Orleans, LA). Given this gap in knowl-
edge, the ongoing Home Automatic External Defibrillator
Trial is testing the hypothesis that provision of an AED to
patients with anterior STEMI for home use will improve sur-
vival beyond that achieved from the typical lay response to
sudden cardiac arrest (135). Additionally, wearable external
defibrillators have been developed that may be applicable for
high-risk patients after STEMI (926).
7.7.2. Supraventricular Arrhythmia/AF
Class I
1. Sustained AF and atrial flutter in patients with hemo-
dynamic compromise should be treated with one or
more of the following:
a. Synchronized cardioversion with an initial
monophasic shock of 200 J for AF and 50 J for flut-
ter, preceded by brief general anesthesia or con-
scious sedation whenever possible. (Level of
Evidence: C)
b. For episodes of AF that do not respond to electrical
cardioversion or recur after a brief period of sinus
rhythm, the use of antiarrhythmic therapy aimed
at slowing the ventricular response is indicated.
One or more of these pharmacological agents may
be used:
i. Intravenous amiodarone (927). (Level of
Evidence: C)
ii. Intravenous digoxin for rate control, principally
for patients with severe LV dysfunction and
heart failure. (Level of Evidence: C)
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2. Sustained AF and atrial flutter in patients with ongoing
ischemia but without hemodynamic compromise
should be treated with one or more of the following:
a. Beta-adrenergic blockade is preferred, unless con-
traindicated. (Level of Evidence: C)
b. Intravenous diltiazem or verapamil. (Level of
Evidence: C)
c. Synchronized cardioversion with an initial
monophasic shock of 200 J for AF and 50 J for flut-
ter, preceded by brief general anesthesia or con-
scious sedation whenever possible. (Level of
Evidence: C)
3. For episodes of sustained AF or flutter without hemo-
dynamic compromise or ischemia, rate control is indi-
cated. In addition, patients with sustained AF or flut-
ter should be given therapy with anticoagulants.
Consideration should be given to conversion of sinus
rhythm in patients without a history of atrial fibrilla-
tion or flutter prior to STEMI. (Level of Evidence: C)
4. Re-entrant paroxysmal supraventricular tachycardia,
because of its rapid rate, should be treated with the
following in the sequence shown:
a. Carotid sinus massage. (Level of Evidence: C)
b. Intravenous adenosine (6 mg × 1 over 1 to 2 sec-
onds; if no response, 12 mg IV after 1 to 2 minutes
may be given; repeat 12 mg dose if needed. (Level
of Evidence: C)
c. Intravenous beta-adrenergic blockade with meto-
prolol (2.5 to 5.0 mg every 2 to 5 minutes to a total
of 15 mg over 10 to 15 minutes) or atenolol (2.5 to
5.0 mg over 2 minutes to a total of 10 mg in 10 to 15
minutes. (Level of Evidence: C)
d. Intravenous diltiazem (20 mg [0.25 mg/kg]) over 2
minutes followed by an infusion of 10 mg/h. (Level
of Evidence: C)
e. Intravenous digoxin, recognizing that there may be
a delay of at least 1 hour before pharmacological
effects appear (8 to 15 mcg/kg [0.6 to 1.0 mg in a
person weighing 70 kg]). (Level of Evidence: C)
Class III
Treatment of atrial premature beats is not indicated.
(Level of Evidence: C)
Atrial fibrillation occurs more frequently than atrial flutter
or paroxysmal supraventricular tachycardia in patients with
STEMI. The consequences and acute treatment of all 3
Figure 32. An evidence-based algorithm for primary prevention of sudden death in post-STEMI patients without spontaneous VF or
sustained VT at least 1 month post-STEMI to aid in selection of implantable cardioverter/defibrillator (ICD) in patients with STEMI and
diminished ejection fraction (EF). The appropriate management path is selected based upon left ventricular ejection fraction (LVEF)
measured at least one month after STEMI. These criteria, that are based on the published data, form the basis for the full-text guide-
lines in section 7.7.1.5. All patients, whether an ICD is implanted or not, should receive medical therapy as outlined in the full-text
guidelines. VF = ventricular fibrillation; VT = ventricular tachycardia; STEMI = ST-elevation myocardial infarction; NSVT = nonsustained
VT; LOE = level of evidence; EPS = electrophysiological study; LVEF = left ventricular EF.
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arrhythmias may be considered together, recognizing that in
atrial flutter and supraventricular tachycardia, atrial pacing
may be effective in terminating the tachycardia (928-933).
Estimates of the incidence of AF in patients with STEMI
vary depending on the population sampled. In the CCP, 22%
of Medicare patients aged 65 years or older who were hospi-
talized for STEMI had AF (934). In the Trandolapril Cardiac
Evaluation (TRACE) study of patients with LV dysfunction
associated with STEMI, 21% had AF (935). Among the caus-
es of AF in the immediate post-STEMI setting are excessive
sympathetic stimulation, atrial stretch due to LV or RV dys-
function, atrial infarction due to circumflex or right coronary
lesions, pericarditis, hypokalemia, underlying chronic lung
disease, and hypoxia (807,929,936-940). Thus, AF occurs
more often in patients with larger infarcts or anterior location
of reinfarction and in those whose hospital course is compli-
cated by CHF, complex ventricular arrhythmias, advanced
AV block, atrial infarction, or pericarditis. Atrial fibrillation
may also occur in patients with inferior STEMI secondary to
proximal right coronary artery occlusion with compromise of
flow in the sinoatrial nodal artery, the major blood supply to
the atria. In some studies, the incidence of AF after STEMI
is decreased in patients receiving fibrinolytic therapy
(929,941), whereas in other studies, the incidence is similar
(942). In the GUSTO trial, patients treated with accelerated
alteplase and intravenous UFH had a significantly lower inci-
dence of AF and atrial flutter than patients treated with other
fibrinolytic therapies (25). Systemic embolization is more
frequent in patients with paroxysmal AF (1.7%) than in those
without (0.6%), with half of the embolic events occurring on
the first day of hospitalization and more than 90% occurring
by the fourth day (943). Because AF can be associated with
pericarditis, the development of PR-segment displacement
on serial ECGs may predict risk of developing AF during
hospitalization (941). 
The development of AF is associated with a worse in-hos-
pital and long-term prognosis. In a study of 106 780 elderly
(Medicare) patients with AF during MI, about half presented
with AF and half developed AF during hospitalization (934).
The presence of AF during hospitalization increased short-
and long-term relative mortality by 20% and 34%, respec-
tively (Table 28) (935,944-946). Patients who developed AF
during hospitalization had a worse prognosis than those with
AF on admission (934). Stroke rates are also increased in
patients with MI and AF compared with those without AF
(944). Outcomes appear to have improved in the fibrinolytic
era for patients with AF and STEMI compared with experi-
ence between 1981 and 1983 (942), but a stroke rate of 3.1%
in the setting of AF and STEMI (944) emphasizes the impor-
tance of this association even in the era of fibrinolysis. 
When AF occurs, the clinician must consider and correct, if
possible, the underlying causes. The initial clinical decision
is whether to proceed immediately to electrical cardioversion
if the patient is unstable with a rapid heart rate and hypoten-
sion, intractable heart failure, or ischemic pain. Cardio-
version should be performed when the patient is under ade-
quate general anesthesia or has received medication to pro-
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Intravenous amiodarone is effective and well tolerated in
critically ill patients who develop rapid atrial tachyarrhyth-
mias refractory to conventional treatment, but its effective-
ness has not been evaluated sufficiently in patients with
STEMI. In a small observational study of critically ill
patients, there was a reduction in ventricular rate of 37 bpm
after a 1-hour infusion of 242 mg of amiodarone (951).
Amiodarone is considered a first-line agent for heart rate
control in critically ill patients (951) and a second-line agent
for those patients who are less hemodynamically unstable
and can tolerate intravenous diltiazem. Amiodarone is the
preferred agent to control repeat AF in patients with CHF or
a low-output state.
Although intravenous digoxin may effectively slow the
ventricular rate at rest, there is a delay of at least 60 minutes
before onset of a therapeutic effect in most patients, and a
peak effect does not develop for up to 6 hours. Digoxin is no
more effective than placebo in converting AF to sinus rhythm
(790,792,795) and may prolong the duration of AF
(790,952). The efficacy of digoxin is reduced in states of
high sympathetic tone, a common precipitant of paroxysmal
AF. In a review of 139 episodes of paroxysmal AF recorded
on Holter monitoring, there was no difference in the ventric-
ular rates of patients taking digoxin and those not taking this
medication (952). Other investigators, however, have found
that digoxin reduces the frequency and severity of AF recur-
rence (953). Furthermore, the combination of digoxin and
atenolol has been shown to be effective for ventricular rate
control (954). Given the availability of more effective agents,
digoxin is no longer first-line therapy for management of
acute AF, but it plays a continuing role in patients with heart
failure or LV dysfunction (955). Rapid administration of
digoxin to achieve rate slowing may be accomplished by giv-
ing intravenous digoxin (8 to 15 mcg/kg [0.6 to 1.0 mg in a
person weighing 70 kg]), with half the dose administered ini-
tially and the additional increment in 4 hours (956). This
method provides a slower response than intravenous beta-
adrenoceptor blockade or amiodarone; however, some effect
on rate slowing may be detectable in 30 minutes to 2 hours. 
Given that the databases reporting a marked increase in the
risk of stroke in post-STEMI patients with AF do not report
the time duration of AF at which stroke risk increases, it is
unclear whether all post-STEMI patients with AF, even if
transient, should receive anticoagulation or whether this
aggressive posture should be reserved only for those with
sustained AF of at least a few hours’ duration. Indeed, the
clinical circumstances, in particular whether there are other
risk factors for post-STEMI stroke, should modulate the
threshold for anticoagulation in the patient with transient AF.
When it has been determined that anticoagulation is
required, either UFH or LMWH may be used. When UFH is
selected, an intravenous bolus of 60 U/kg followed by a con-
tinuous intravenous infusion at 12 U/kg/h to maintain an
aPTT of 50 to 70 seconds (approximately 1.5 to 2 times con-
trol) should be given. Alternatively, one of the LMWHs may
be used at doses recommended by the manufacturer for full
anticoagulation.
duce conscious sedation to avoid pain related to delivery of
the electric shock. Short-acting anesthetic drugs or agents
that produce conscious sedation are preferred because car-
dioversion patients should recover rapidly after the proce-
dure (947). 
Proper synchronization of the electric shock with the QRS
complex calls for triggering by monitoring the R wave with
an appropriately selected lead. In addition to R-wave ampli-
tude, it is important that the monitored lead give a good view
of P waves, thus facilitating assessment of the outcome of the
procedure. The initial energy delivered with a monophasic
waveform may be low (50 J) for cardioversion of atrial flut-
ter. Higher monophasic shock energy is required for AF car-
dioversion, starting with at least 200 J. The monophasic
shock energy output is increased successively in increments
of 100 J until a maximum of 400 J is reached. Some physi-
cians begin with higher energies to reduce the number of
shocks (and thus the total energy) delivered (948). Energy
settings should be reduced by about 50% of those noted
above for monophasic shocks if a device that delivers a
biphasic waveform is used. To avoid myocardial damage, the
interval between 2 consecutive shocks should not be less than
1 minute (949). The optimal paddle position remains contro-
versial; however, the electrodes should be in direct contact
with the chest wall and not, for example, positioned over
breast tissue. There is little experience with novel methods
such as transvenous electrical cardioversion in patients with
STEMI. 
When medical therapy is selected, and in the absence of
CHF or severe pulmonary disease, one of the most effective
means of slowing the ventricular rate in AF is the use of
intravenous beta-adrenoceptor–blocking agents such as
metoprolol (2.5 to 5.0 mg every 2 to 5 minutes to a total of
15 mg over 10 to 15 minutes) or atenolol (2.5 to 5.0 mg over
2 minutes to a total of 10 mg in 10 to 15 minutes). Heart rate,
blood pressure, and the ECG should be monitored, and treat-
ment should be halted when therapeutic efficacy is achieved
or if systolic blood pressure falls below 100 mm Hg or there
is excessive bradycardia (e.g., a heart rate below 50 bpm dur-
ing treatment). 
When there are absolute contraindications to beta-adrener-
gic blockade (bronchospastic lung disease or allergy), rate
slowing may also be achieved by intravenous diltiazem (20
mg [0.25 mg/kg]) over 2 minutes followed by an infusion of
10 mg/h) or verapamil (2.5 to 10 mg IV over 2 minutes; may
repeat a 5- to 10-mg dose after 15 to 30 minutes). There are
concerns regarding the negative inotropic effects of these
drugs and reports of increased post-STEMI mortality in
patients with LV dysfunction taking long-term, short-acting
oral diltiazem (950). Calcium antagonists, therefore, are not
recommended for long-term rate control in post-STEMI
patients; however, they may be useful for short-term rate
control in hospitalized patients when beta-blockers are
absolutely contraindicated.
Amiodarone has both sympatholytic and calcium antago-
nistic properties, depresses AV conduction, and is effective in
controlling the ventricular rate in patients with AF.
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extent of the ischemic/infarcted segment. As such, AV block
predicts an increased risk of in-hospital mortality but is less
predictive of long-term mortality in those who survive to
hospital discharge (962-964). Nonetheless, in fibrinolysis tri-
als, bundle-branch block was present on admission in only
4% but was predictive of a substantially increased in-hospi-
tal mortality rate (156). Indeed, the development of sudden
AV block in the setting of anterior STEMI, once a feared
complication, is quite unusual in the present CCU population
in the postreperfusion era. Thus, the use of transvenous pac-
ing has diminished, and the reliance on transcutaneous pac-
ing has increased (Table 30) (965).
7.7.3.1. Acute Treatment of Conduction
Disturbances and Bradyarrhythmias
Treatment of the conduction disturbances and resulting brad-
yarrhythmias can have either a prophylactic or therapeutic
focus. The purpose of prophylactic pacing is to prevent
symptomatic or catastrophic bradycardia by selecting and
placing a transcutaneous or transvenous temporary pacemak-
er. Prophylactic pacing requires the clinician to predict which
patients will develop sudden complete heart block with an
inadequate ventricular escape mechanism. Fortunately, con-
duction disturbances generally occur in a stepwise fashion,
so that knowledge of the specific ECG pattern can be used to
estimate the risk of developing complete heart block and thus
to guide the need for prophylactic temporary pacing. These
estimates of risk, however, must be interpreted in the context
of the risk of performing a procedure, particularly transve-
nous temporary pacing, on an unstable patient in the acute
phase after STEMI, with all the attendant modern antithrom-
botic therapies increasing the risk of bleeding complications.
Additionally, most of the clinically based algorithms to esti-
mate risk of developing complete heart block were developed
in the prefibrinolytic era, so they must be interpreted cau-
tiously when applied to a modern post-STEMI population. In
some cases, after the development of advanced AV block
after STEMI, temporary transcutaneous or transvenous pac-
ing must be used to maintain a stable cardiac rhythm and
adequate hemodynamics. When the patient becomes pace-
maker-dependent owing to a persistent conduction defect,
however, temporary transvenous pacing is preferred com-
pared with long-term transcutaneous pacing.
The pharmacological treatment of bradycardia and AV con-
duction disturbances during STEMI is a therapeutic, not pro-
phylactic, measure. Pharmacotherapy centers on the use of
atropine at doses of 0.6 to 1.0 mg IV repeated every 5 min-
utes until there is the desired effect or a total dose of 0.04
mg/kg (2 mg for a 50-kg person) has been reached. When
there is infranodal block, however, atropine may increase the
sinus rate without affecting infranodal conduction, and so the
effective ratio of conduction may decrease, and the ventricu-
lar rate may decrease. 
Other pharmacotherapies to treat bradyarrhythmias, such
as isoproterenol and aminophylline, are not recommended
because they are arrhythmogenic and increase myocardial
oxygen demand. Glucagon has been used to treat bradycar-
Once rate control has been accomplished, clinicians may
opt to convert the patient to sinus rhythm to attain optimal
hemodynamics and ultimately permit discontinuation of anti-
coagulants. Guidelines for electrical and chemical cardiover-
sion for the stable patient with AF have been formulated
(955). In patients with STEMI, special attention must be
given to considerations of proarrhythmia with many com-
monly used antiarrhythmic agents. The preferred agent for
intermediate or long-term use in the STEMI patient, based on
the best safety record in post-MI trials, is amiodarone.
Indeed, in a meta-analysis of 6553 randomized patients, 78%
of whom were in post-MI trials, amiodarone resulted in a rel-
ative reduction in risk of death of 13%, which was wholly
due to a greater reduction in arrhythmic death (914). The
excess risk of pulmonary toxicity was only 1% per year. A
post hoc analysis of GUSTO-III patients with AF also
addressed the relative safety of other antiarrhythmic agents,
including sotalol, in the post-STEMI setting. In a total of 317
patients with AF who received antiarrhythmic agents, no
agent or class of agents was associated with increased mor-
tality (957). However, the totality of evidence is much less
compelling than for amiodarone after STEMI. Transient AF
does not obligate the patient to receive long-term anticoagu-
lation or antiarrhythmic agents, but if such treatment is elect-
ed, it is appropriate to limit their use to 6 weeks if sinus
rhythm has been restored. In outpatients with paroxysmal
AF, a controversy regarding the relative merits of rate control
versus maintenance of sinus rhythm has been addressed by a
large randomized clinical trial (958). AFFIRM (Atrial
Fibrillation Follow-up Investigation of Rhythm Manage-
ment) demonstrated no clear survival benefit for either strat-
egy. However, patients with STEMI were not enrolled, and
only 38.2% of the population had a prior diagnosis of coro-
nary artery disease. Thus, the conclusions of AFFIRM should
not be applied to the STEMI population, and the decision to
continue chronic adjustable-dose oral anticoagulation indefi-
nitely should be based on an overall assessment of the risk of
thromboembolism in the individual patient.
7.7.3. Bradyarrhythmias
See Table 29 for recommendations. Sinus bradycardia
occurs frequently, constituting 30% to 40% of AMI-associat-
ed cardiac arrhythmias. It is especially frequent within the
first hour of inferior STEMI and with reperfusion of the right
coronary artery (Bezold-Jarisch reflex) as a result of
increased parasympathetic activity (vagal tone) (959). There
are several other potential mechanisms, operating in isolation
or in parallel, that account for the high incidence of sinus
bradycardia. These include local increases in adenosine,
local hyperkalemia, systemic metabolic derangements, and
concomitant use of bradycardia-promoting medications
(960). 
Heart block may develop in approximately 6% to 14% of
patients with STEMI. Intraventricular conduction delay has
been reported in about 10% to 20% of patients with STEMI
in past reviews (961). The development of AV and intraven-
tricular blocks during STEMI is generally related to the
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Ventricular asystole may be caused either by failure of the
sinus node to generate a cardiac impulse or by the develop-
ment of complete heart block. In either case, there is concur-
rent failure of the usual underlying escape mechanisms,
whether atrial, junctional, or ventricular. Treatment of the
acute event requires prompt institution of transcutaneous
pacing, vasopressin, epinephrine, and atropine. It is impor-
tant to address the underlying cause and discontinue medica-
tions that either suppress sinus node function, decrease AV
nodal conduction, or suppress a potential escape mechanism.
Cardiopulmonary resuscitation according to guidelines must
be instituted (900). Transvenous pacing should be instituted
unless the asystole is brief and a precipitating cause is found
dia caused by beta-blockers and calcium antagonists,
although principally only when these agents have been used
in toxic doses, particularly in combination (966). 
The recommendations for prophylactic treatment of AV
and intraventricular conduction blocks and the possible com-
binations are contained in Table 29. 
7.7.3.1.1. VENTRICULAR ASYSTOLE.
Class I
Prompt resuscitative measures, including chest com-
pressions, atropine, vasopressin, epinephrine, and
temporary pacing, should be administered to treat
ventricular asystole. (Level of Evidence: B)
Table 29. Continued
This table is designed to summarize the atrioventricular (column headings) and intraventricular (row headings) conduction dis-
turbances that may occur during acute anterior or nonanterior STEMI, the possible treatment options, and the indications for each
possible therapeutic option.
AV = atrioventricular; MI = myocardial infarction; A = atropine; TC = transcutaneous pacing; TV = temporary transvenous pac-
ing; LAFB = left anterior fascicular block; LPFB = left posterior fascicular block; RBBB = right bundle-branch block.
Action
There are 4 possible actions, or therapeutic options, listed and classified for each bradyarrhythmia or conduction problem:
1. Observe: continued ECG monitoring, no further action planned.
2. A, and A*: atropine administered at 0.6 to 1.0 mg IV every 5 minutes to up to 0.04 mg/kg. In general, because the increase in 
sinus rate with atropine is unpredictable, this is to be avoided unless there is symptomatic bradycardia that will likely respond
to a vagolytic agent, such as sinus bradycardia or Mobitz I, as denoted by the asterisk, above.
3. TC: application of transcutaneous pads and standby transcutaneous pacing with no further progression to transvenous pacing
imminently planned.
4. TV: temporary transvenous pacing. It is assumed, but not specified in the table, that at the discretion of the clinician, transcu-
taneous pads will be applied and standby transcutaneous pacing will be in effect as the patient is transferred to the fluoroscopy
unit for temporary transvenous pacing.
Class
Each possible therapeutic option is further classified according to ACC/AHA criteria as I, IIa, IIb, and III. The level of evidence
for all cells and all treatments is B or C. There are no randomized trials available that address or compare specific treatment
options. Moreover, the data for this table and recommendations are largely derived from observational data of pre–thrombolytic
era databases. Thus, the recommendations above must be taken as recommendations and tempered by the clinical circumstances.
Level of Evidence
This table was developed from (1) published observational case reports and case series, (2) published summaries, not meta-analy-
ses, of these data; and (3) expert opinion, largely from the prereperfusion era. There are no published randomized trials compar-
ing different strategies of managing conduction disturbances after STEMI. Thus, the level of evidence for the recommendations
in the table is C.
How to use the table
Example: 54-year-old man is admitted with an anterior STEMI and a narrow QRS on admission. On day 1, he develops a right
bundle-branch block (RBBB), with a PR interval of 0.28 seconds. 
1. RBBB is an intraventricular conduction disturbance, so look at row “New bundle-branch block.”
2. Find the column for “First-Degree AV Block.”
3. Find the “Action” and “Class” cells at the convergence.
4. Note that “Observe” and “Atropine” are class III, not indicated; transcutaneous pacing (TC) is class I. Temporary transvenous 
pacing (TV) is class IIb.
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Table 30. Features of AV Conduction Disturbances in Acute Myocardial Infarction
Location of AV Conduction Disturbance
Feature Proximal Distal
Site of block Intranodal Infranodal
Site of infarction Inferoposterior Anteroseptal
Compromised arterial RCA (90%), LCx (10%) Septal perforators of LAD
supply
Pathogenesis Ischemia, necrosis, Ischemia, necrosis, hydropic
hydropic cell swelling, cell swelling
excess parasympathetic activity
Predominant type of First degree (pulse rate greater Mobitz type II second degree
AV nodal block than 200 msec) Third degree
Mobitz type I second degree
Common promontory (a) First-second-degree AV block
features of third-degree (b) Mobitz type I pattern
AV block
Features of escape after (a) Proximal conduction (a) Distal conduction
third-degree block system (His bundle) system (bundle branches)
(a) Location (b) Less than 0.12 sec* (b) Greater than 0.12 sec*
(b) QRS width (c) 45-60 per min but may (c) Often less than 30 per min
(c) Rate be as low as 30 per min (d) Rate often unstable with
(d) Stability of escape rhythm (d) Rate usually stable; moderate to high risk of 
asystole uncommon ventricular asystole
Duration of high-grade Usually transient (2-3 days) Usually transient, but some
AV block form of AV conduction
disturbances and/or intra-
ventricular defect may persist
Associated mortality rate Low unless associated with High because of extensive
hypotension and/or CHF infarction associated with power 
failure or ventricular arrhythmias
Pacemaker therapy
(a) Temporary (a) Rarely required; may be (a) Indicated in patients with
considered for bradycardia anteroseptal infarction and 
associated with LV power acute bifascicular block  
failure, syncope, or angina
(b) Permanent (b) Almost never indicated (b) Indicated for patients with
because conduction defect high-grade AV block with
is usually transient block in His-Purkinje systems and
those with transient advanced AV 
block and associated bundle-branch
block
AV = atrioventricular; RCA = right coronary artery; LCx = left circumflex artery; LAD = left anterior descending artery; sec = seconds; min = minutes; CHF =
congestive heart failure; LV = left ventricular.
*Some studies suggest that a wide QRS escape rhythm (greater than 0.12 sec) after high-grade AV block in inferior infarction is associated with a worse prog-
nosis.
Modified with permission from Antman EM. Cardiovascular Therapeutics: A Companion Guide to Braunwald’s Heart Disease. 2nd ed. Philadelphia, PA: WB 
Saunders Co Ltd; 2001:273 (965).
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Indications for permanent pacing after STEMI in patients
experiencing AV block are related in large measure to the
presence of intraventricular conduction defects (Table 29).
Unlike some other indications for permanent pacing, the cri-
teria for patients with STEMI and AV block do not necessar-
ily depend on the presence of symptoms. Furthermore, the
requirement for temporary pacing in STEMI does not by
itself constitute an indication for permanent pacing (3). 
The long-term prognosis for survivors of STEMI who have
had AV block is related primarily to the extent of myocardial
injury and the character of intraventricular conduction dis-
turbances rather than the AV block itself (970-974). Patients
with STEMI who have intraventricular conduction defects,
with the exception of isolated left anterior fascicular block,
have an unfavorable short- and long-term prognosis and an
increased risk of sudden death (970,971,973,975). This unfa-
vorable prognosis is not necessarily due to development of
high-grade AV block, although the incidence of such block is
higher in postinfarction patients with abnormal intraventric-
ular conduction (971,976,977).
When AV or intraventricular conduction block complicates
STEMI, the type of conduction disturbance, location of
infarction, and relation of electrical disturbance to infarction
must be considered if permanent pacing is contemplated.
Even with data available, the decision is not always straight-
forward because the reported incidence and significance of
various conduction disturbances vary widely (978). Despite
the use of fibrinolytic therapy and primary PCI, which have
decreased the incidence of AV block in STEMI, mortality
remains high if AV block occurs (962,979-981). 
Although more severe disturbances in conduction are gen-
erally associated with greater arrhythmic and nonarrhythmic
mortality (971-974,976,978), the impact of pre-existing bun-
dle-branch block on mortality after STEMI is controversial
(978,982). A particularly ominous prognosis is associated
with LBBB combined with advanced second- or third-degree
AV block and with right bundle-branch block combined with
left anterior or left posterior fascicular block
(964,972,974,982) (Figure 33). Irrespective of whether the
infarction is anterior or inferior, the development of an intra-
ventricular conduction delay reflects extensive myocardial
damage rather than an electrical problem in isolation (974).
Although AV block that occurs during inferior STEMI can be
associated with a favorable long-term clinical outcome, in-
hospital survival is impaired, regardless of the use of tempo-
rary or permanent pacing in this situation (964,979,980,983).
Furthermore, pacemakers should not be implanted if the peri-
infarctional AV block is expected to resolve or to not have a
negative effect on long-term prognosis, as in the case of infe-
rior STEMI (981) with Mobitz I second-degree AV block.
With regard to sinus node dysfunction precipitated or
unmasked by STEMI or associated necessary medical thera-
py, the indications for permanent pacing do not differ from
the indications.
(893,967,968). Vasopressin is an effective vasopressor and is
as useful as epinephrine for the treatment of adult shock-
refractory VF and pulseless electrical activity (969). In a
study of patients with asystole out of the hospital, vaso-
pressin use was associated with significantly higher rates of
hospital admission (29.0% versus 20.3% in the epinephrine
group; p equals 0.02) and hospital discharge (4.7% versus
1.5%, p equals 0.04). Among patients in whom spontaneous
circulation was not restored with 2 injections of either vaso-
pressin or epinephrine, additional treatment with epinephrine
resulted in significant improvement in the rates of survival to
hospital admission and hospital discharge in the vasopressin
group but not in the epinephrine group (hospital admission
rate 25.7% versus 16.4%; p equals 0.002; hospital discharge
rate 6.2% versus 1.7%; p equals 0.002). Cerebral perform-
ance was similar in the 2 groups (969). Thus, in patients with
STEMI with ventricular asystole, vasopressin (40 IU) would
appear to be the preferable vasoconstrictor to administer first.
7.7.3.2. Use of Permanent Pacemakers
7.7.3.2.1. PERMANENT PACING FOR BRADYCARDIA OR
CONDUCTION BLOCKS ASSOCIATED WITH STEMI.
Class I
1. Permanent ventricular pacing is indicated for persist-
ent second-degree AV block in the His-Purkinje sys-
tem with bilateral bundle-branch block or third-
degree AV block within or below the His-Purkinje sys-
tem after STEMI. (Level of Evidence: B)
2. Permanent ventricular pacing is indicated for tran-
sient advanced second- or third-degree infranodal AV
block and associated bundle-branch block. If the site
of block is uncertain, an EP study may be necessary.
(Level of Evidence: B)
3. Permanent ventricular pacing is indicated for persist-
ent and symptomatic second- or third-degree AV
block. (Level of Evidence: C)
Class IIb
Permanent ventricular pacing may be considered for
persistent second- or third-degree AV block at the AV
node level. (Level of Evidence: B)
Class III
1. Permanent ventricular pacing is not recommended for
transient AV block in the absence of intraventricular
conduction defects. (Level of Evidence: B)
2. Permanent ventricular pacing is not recommended for
transient AV block in the presence of isolated left ante-
rior fascicular block. (Level of Evidence: B)
3. Permanent ventricular pacing is not recommended for
acquired left anterior fascicular block in the absence
of AV block. (Level of Evidence: B)
4. Permanent ventricular pacing is not recommended for
persistent first-degree AV block in the presence of
bundle-branch block that is old or of indeterminate
age. (Level of Evidence: B)
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7.7.3.2.3. PACING MODE SELECTION IN STEMI
PATIENTS
Class I
All patients who have an indication for permanent
pacing after STEMI should be evaluated for ICD indi-
cations. (Level of Evidence: C)
Class IIa
1. It is reasonable to implant a permanent dual-chamber
pacing system in STEMI patients who need perma-
nent pacing and are in sinus rhythm. It is reasonable
that patients in permanent AF or atrial flutter receive
a single-chamber ventricular device. (Level of
Evidence: C)
2. It is reasonable to evaluate all patients who have an
indication for permanent pacing after STEMI for
biventricular pacing (cardiac resynchronization ther-
apy). (Level of Evidence: C)
With regard to permanent pacing mode, there are no ran-
domized trials that specifically address pacing mode selec-
tion (dual-chamber versus single-chamber ventricular pac-
ing, with or without rate modulation) in patients with
STEMI. In general, patients who need permanent pacing sys-
tems and are in sinus rhythm should receive a permanent
dual-chamber pacemaker. In contrast, patients who have per-
manent AF or atrial flutter should receive a ventricular-pac-
ing system. In post-STEMI patients with frequent episodes
of paroxysmal AF or a persistent episode for which eventual
7.7.3.2.2. SINUS NODE DYSFUNCTION AFTER STEMI
Class I
Symptomatic sinus bradycardia, sinus pauses greater
than 3 seconds, or sinus bradycardia with a heart rate
less than 40 bpm and associated hypotension or signs
of systemic hemodynamic compromise should be
treated with an intravenous bolus of atropine 0.6 to
1.0 mg. If bradycardia is persistent and maximal (2
mg) doses of atropine have been used, transcutaneous
or transvenous (preferably atrial) temporary pacing
should be instituted. (Level of Evidence: C)
Sinus node dysfunction may be unmasked or caused by MI
owing to disruption in the blood supply to the sinoatrial
node, or owing to the use of medications such as beta-adren-
ergic blocking agents or calcium antagonists. The overall
recommendations, indications, and levels of evidence are not
different in non-MI and patients with STEMI, except that
transient sinus bradycardia often occurs in the setting of infe-
rior wall infarction, and treatment should avoid permanent
pacing whenever possible. Thus, the published ACC/
AHA/NASPE 2002 Guideline Update for Implantation of
Cardiac Pacemakers and Antiarrhythmia Devices (984)
should be used to guide therapy in patients with  STEMI with
persistent sinus node dysfunction. These guidelines should
be applied with the proviso that new sinus node dysfunction
that has first appeared during STEMI may be reversible, and
when clinically possible, the decision to implant a permanent
pacemaker should be delayed several days.
Figure 33. Twelve-lead ECG in a patient with anterior STEMI complicated by right bundle-branch block (RBBB) and left anterior fas-
cicular block. Note the convex upward ST-elevation in V2-V3 consistent with anterior STEMI RBBB; the anticipated r-wave of the con-
ventional rsR' pattern of RBBB has been replaced by a Q wave in V1-V2 as a result of anterior STEMI. The initial 80-ms forces of the
QRS in the frontal plane are deviated to the left as a result of left anterior fascicular block. ECG = electrocardiogram; STEMI = ST-ele-
vation myocardial infarction.
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7.8.1. Pericarditis
Class I
1. Aspirin is recommended for treatment of pericarditis
after STEMI. Doses as high as 650 mg orally (enteric-
coated) every 4 to 6 hours may be needed. (Level of
Evidence: B)
2. Anticoagulation should be immediately discontinued
if pericardial effusion develops or increases. (Level of
Evidence: C)
Class IIa
For episodes of pericarditis after STEMI that are not
adequately controlled with aspirin, it is reasonable to
administer 1 or more of the following:
a. Colchicine 0.6 mg orally every 12 hours (Level of
Evidence: B)
b. Acetaminophen 500 mg orally every 6 hours. (Level
of Evidence: C)
Class IIb
1. Corticosteroids might be considered only as a last
resort in patients with pericarditis refractory to
aspirin or NSAIDs. Although corticosteroids are effec-
tive for pain relief, their use is associated with an
increased risk of scar thinning and myocardial rup-
ture. (Level of Evidence: C)
2. Nonsteroidal anti-inflammatory drugs may be consid-
ered for pain relief; however, they should not be used
for extended periods because of their effect on platelet
function, an increased risk of myocardial scar thin-
ning, and infarct expansion. (Level of Evidence: B)
Class III
Ibuprofen should not be used for pain relief because it
blocks the antiplatelet effect of aspirin and it can
cause myocardial scar thinning and infarct expansion.
(Level of Evidence: B)
Pericarditis in STEMI occurs with extension of necrosis
across the full thickness of the myocardial wall to the epi-
cardium. Patients with pericarditis have larger infarcts, a
lower ejection fraction, and a higher incidence of CHF
(988,989). Pericarditis may appear up to several weeks after
STEMI. Anterior chest discomfort mimicking ischemia can
occur with pericarditis. However, pericardial pain usually has
distinguishing characteristics, such as pleuritic and/or posi-
tional discomfort; radiation to the left shoulder, scapula, or
trapezius muscle; and a pericardial rub, ECG J-point eleva-
tion with concave upward ST-segment elevation and PR
depression. Detection of a 3-component rub is diagnostic of
pericarditis. Pericardial effusion is evident echocardiograph-
ically in more than 40% of cases (990) but is rarely of hemo-
dynamic consequence. A small effusion is not diagnostic of
pericarditis because it can be demonstrated in the majority of
patients with STEMI (991). On occasion, pericarditis may be
a clinical clue to the presence of subacute myocardial rupture
(see Section 7.6.7.4). 
cardioversion is planned, the clinician must judge the likeli-
hood of the patient being in sinus rhythm chronically before
selecting a permanent dual-chamber or ventricular device.
The data from randomized trials of pacing mode selection,
although admittedly not obtained in a post-STEMI popula-
tion, suggest specific programming features and goals to
improve, or at least not further impair, LV function due to
forced ventricular desynchronization by RV pacing. The
DAVID (Dual Chamber and VVI Implantable Defibrillator )
trial in ICD patients without bradycardia but with LV dys-
function demonstrated that patients programmed to DDD at
70 bpm developed more heart failure than did patients pro-
grammed to VVI backup at a low rate (985). A post hoc
analysis of the Mode Selection Trial (MOST) reported that in
dual-chamber–paced patients with sinus node dysfunction
and a median ejection fraction of 0.55, cumulative percent
ventricular pacing above 40% was associated with an
increase in heart failure hospitalizations. These emerging
data suggest that when bradycardia pacing is instituted, the
clinician might consider minimizing ventricular dyssyn-
chrony through selection of devices and programming strate-
gies to maintain low cumulative percent ventricular pacing
(986). Whether the clinical application of these concepts will
improve post-STEMI outcomes is unknown because these
studies did not address the specific population on which
these guidelines focus. Thus, the Committee has chosen not
to incorporate these programming recommendations into the
guidelines, pending the design and execution of more appli-
cable prospective trials. 
Nonetheless, when a permanent pacemaker is being con-
sidered for a post-STEMI patient, the clinician should
address 2 additional questions regarding the patient: is there
an indication for biventricular pacing, and is there an indica-
tion for ICD use? (986) Biventricular pacing has found a
place in the treatment of advanced heart failure for patients
with a low ejection fraction and a QRS duration greater than
130 ms (984). Patients with severe LV dysfunction may be
eligible for implantation of an ICD for primary prevention of
life-threatening ventricular arrhythmia, as well as bradycar-
dia support. The algorithm to define whether an ICD is indi-
cated is contained in Figure 32. See Section 7.7.1.5 for fur-
ther discussion.
7.8. Recurrent Chest Pain After STEMI
The 2 most common cardiac causes of recurrent chest pain
after STEMI are pericarditis and ischemia, the latter being
the more common and potentially more serious. An ECG
taken during the recurrent pain should be compared with
ECGs from the index STEMI event (987). Usually, recurrent
pain within the first 12 hours after onset of STEMI is con-
sidered to be related to the original infarction itself.
Pericarditis is probably not responsible for significant chest
discomfort in the first 24 hours.
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7.8.2. Recurrent Ischemia/Infarction
Class I
1. Patients with recurrent ischemic-type chest discom-
fort after initial reperfusion therapy for STEMI
should undergo escalation of medical therapy with
nitrates and beta-blockers to decrease myocardial
oxygen demand and reduce ischemia. Intravenous
anticoagulation should be initiated if not already
accomplished. (Level of Evidence: B)
2. In addition to escalation of medical therapy, patients
with recurrent ischemic-type chest discomfort and
signs of hemodynamic instability, poor LV function,
or a large area of myocardium at risk should be
referred urgently for cardiac catheterization and
undergo revascularization as needed. Insertion of an
IABP should also be considered. (Level of Evidence: C)
3. Patients with recurrent ischemic-type chest discom-
fort who are considered candidates for revasculariza-
tion should undergo coronary arteriography and PCI
or CABG as dictated by coronary anatomy. (Level of
Evidence: B)
Class IIa
It is reasonable to (re)administer fibrinolytic therapy
to patients with recurrent ST elevation and ischemic-
type chest discomfort who are not considered candi-
dates for revascularization or for whom coronary
angiography and PCI cannot be rapidly (ideally less
than 60 minutes from the onset of recurrent discom-
fort) implemented. (Level of Evidence: C)
Class III
Streptokinase should not be readministered to treat
recurrent ischemia/infarction in patients who received
a non–fibrin-specific fibrinolytic agent more than 5
days previously to treat the acute STEMI event. (Level
of Evidence: C)
It is important to differentiate pain due to pericarditis from
pain due to ischemia. The latter is more likely when the chest
pain is similar to the initial ischemic-type chest discomfort,
occurring at rest or with limited activity during hospitaliza-
tion. This may or may not be associated with re-elevation of
the CK-MB, ST-segment depression or elevation, or pseudo-
normalization of inverted T waves (T-wave inversion on
baseline ECG becoming upright during ischemia) (990). 
Reinfarction occurs in 4% to 5% of patients who have
received fibrinolytic therapy and aspirin
(25,43,851,1009,1010). Reinfarction is associated with re-
elevation of biomarkers after the initial peak of the index
infarction. Diagnosis of reinfarction within 18 hours after
initiation of fibrinolytic therapy should be based on recur-
rence of severe ischemic-type chest discomfort that lasts at
least 30 minutes, usually but not always accompanied by
recurrent ST-segment elevation of at least 0.1 mV in at least
2 contiguous ECG leads and re-elevation of CK-MB to more
than the upper limit of normal or increased by at least 50%
over the previous value (37). Pathological findings of rein-
Focal pericarditis can be diagnosed electrocardiographical-
ly by either persistently positive T waves or reversal of ini-
tially inverted T waves during the first week after STEMI.
However, similar T-wave alterations have also been observed
when postinfarction pericardial effusion exists in the absence
of clinically recognized pericarditis (992). Pericarditis is not
associated with re-elevation of CK-MB. There are data to
suggest its incidence has decreased in the reperfusion era
(993-995). Interestingly, the Dressler syndrome (post-MI
syndrome), an autoimmune-type carditis, has essentially dis-
appeared (996) in the reperfusion era. 
Neither the configuration of the ECG nor the absence or
presence of the cardiac markers can absolutely establish a
diagnosis of, or rule out, pericarditis. Jain described anterior
ST-segment elevation secondary to acute pericarditis (997).
Bonnefoy et al. studied 69 consecutive patients with idio-
pathic acute pericarditis (998). Cardiac troponin I was detect-
ed in 34 patients (49%), and the level of troponin was beyond
the 1.5 ng/ml threshold in 15 (22%). Seven of these 15
patients underwent coronary angiography. All 7 patients had
normal coronary angiograms. ST-segment elevation was
found in 93% of the patients with troponin I greater than 1.5
ng/ml compared with 57% without troponin elevation (p less
than 0.01). Patients with cardiac troponin I higher than 1.5
versus 31%; p equals 0.01) and were younger (age 37 plus or
minus 14 years versus 52 plus or minus 16 years; p equals
0.002).
Aspirin (162 to 325 mg/d) is the treatment of choice, but
higher doses (650 mg every 4 to 6 hours) may be required
(956,999). Nonsteroidal anti-inflammatory drugs may be
considered for pain relief; however, they should not be used
for extended periods because of their effect on platelet func-
tion, an increased risk of myocardial scar thinning, and
infarct expansion. Corticosteroids, which are also efficacious
for pain relief, are associated with scar thinning in the infarct
zone and myocardial rupture (1000,1001). Therefore, corti-
costeroids should not be used except as a last resort. The risk-
benefit ratio of continuing antithrombotic therapy in the pres-
ence of acute pericarditis always presents a clinical chal-
lenge. Usually such therapy can be continued safely but
requires added vigilance for the detection of enlarging peri-
cardial effusion or signs of hemodynamic instability. Any
evidence of impending cardiac tamponade is an indication
for prompt termination of antithrombotic therapy. 
If NSAIDs are used, misoprostol, 200 mcg every 6 hours,
should be used for gastric and renal protection (1002-1004).
On the basis of the proven efficacy of colchicine therapy for
familial Mediterranean fever, several small studies showed
that colchicine could successfully treat or prevent the recur-
rence of acute pericarditis after conventional therapy, includ-
ing corticosteroid therapy, had failed (1005). Colchicine may
be administered at 0.6 mg every 12 hours, with or without a
loading dose (1006-1008). 
ng/ml were more likely to have had a recent infection (66%
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obstruction. For patients who are considered candidates for
revascularization, prompt reperfusion with PCI or CABG is
indicated as dictated by the coronary anatomy (Figure 34)
(509,515,1012). For patients who are not considered candi-
dates for revascularization or for whom coronary angiogra-
phy and PCI cannot be implemented rapidly (ideally in less
than 60 minutes), readministration of fibrinolytic therapy is
reasonable. 
Another cause of chest discomfort to consider in patients
recovering from STEMI is infarct expansion. This is charac-
terized by nonspecific repolarization of abnormalities on the
ECG, worsening hemodynamics, but no re-elevation of car-
diac biomarkers (43). Management of infarct expansion
should focus on diuresis and inhibition of the renin-
angiotensin-aldosterone system (see Section 7.4.3).
7.9. Other Complications
7.9.1. Ischemic Stroke
Class I
1. Neurological consultation should be obtained in
STEMI patients who have an acute ischemic stroke.
(Level of Evidence: C)
farction show areas of healing myocardium along with the
more recent necrosis, usually in the same vascular risk region
of myocardial tissue perfused by the original infarct-related
artery. Death, severe CHF, and arrhythmias are early compli-
cations of reinfarction, and there is an increased incidence of
cardiogenic shock or cardiac arrest (25,43,1011). An algo-
rithm for diagnosing reinfarction both early and late after fib-
rinolytic therapy is shown in Figure 12. In patients with
recurrent MI after fibrinolysis, the mortality rate is increased
up to 2 years; however, most of the deaths occur early (in the
hospital), with little additional risk of death between the
index hospitalization and 2 years later (512). 
Patients with recurrent ischemic-type chest discomfort
should undergo escalation of medical therapy, including
beta-blockers (intravenously and then orally) and nitrates
(sublingually and then intravenously); consideration should
be given to initiation of intravenous anticoagulation if the
patient is not already therapeutically anticoagulated.
Secondary causes of recurrent ischemia, such as poorly con-
trolled heart failure, anemia, and arrhythmias, should be cor-
rected (Figure 34) (1012).
With recurrent suspected ischemic-type chest discomfort,
coronary arteriography often clarifies the cause of chest dis-
comfort with demonstration of a high-grade coronary
Figure 34. Algorithm for management of recurrent ischemia/infarction after ST-elevation myocardial infarction (STEMI). IABP = intra-
aortic balloon pump; ECG = electrocardiogram; PCI = percutaneous coronary intervention; CABG = coronary artery bypass graft sur-
gery. *Ideally within 60 minutes from the onset of recurrent discomfort. Modified with permission from Braunwald et al. Heart Disease:
A Textbook of Cardiovascular Medicine. 6th ed. Philadelphia, PA: WB Saunders; 2001:1196 (718).
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2. It is reasonable that STEMI patients with nonfatal
acute ischemic stroke receive supportive care to mini-
mize complications and maximize functional outcome.
(Level of Evidence: C)
Class IIb
Carotid angioplasty/stenting, 4 to 6 weeks after
ischemic stroke, might be considered in STEMI
patients who have an acute ischemic stroke attributa-
ble to an internal carotid artery–origin stenosis of at
least 50% and who have a high surgical risk of 
morbidity/mortality early after STEMI. (Level of
Evidence: C)
Acute stroke complicates 0.75% to 1.2% of MIs and is one
of the most dreaded outcomes of STEMI (326,1013,1014).
Although survival from STEMI has been increasing, mortal-
ity from post-STEMI stroke remains over 40% (1013). Prior
stroke, hypertension, old age, decreased ejection fraction or
multiple ulcerated plaques, and AF are the major risk factors
for embolic stroke after STEMI (326,944,1015-1017).
Anterior STEMI is often cited as a risk factor, but other
infarct locations appear to have similar risk (1015,1018). AF
2. STEMI patients who have an acute ischemic stroke
should be evaluated with echocardiography, neu-
roimaging, and vascular imaging studies to determine
the cause of the stroke. (Level of Evidence: C)
3. STEMI patients with acute ischemic stroke and per-
sistent AF should receive lifelong moderate-intensity
(INR 2 to 3) warfarin therapy. (Level of Evidence: A)
4. STEMI patients with or without acute ischemic stroke
who have a cardiac source of embolism (AF, mural
thrombus, or akinetic segment) should receive moder-
ate-intensity (INR 2 to 3) warfarin therapy in addition
to aspirin (see Figure 35). The duration of warfarin
therapy should be dictated by clinical circumstances
(e.g., at least 3 months for patients with an LV mural
thrombus or akinetic segment and indefinitely in
patients with persistent AF). The patient should
receive LMWH or UFH until adequately anticoagu-
lated with warfarin. (Level of Evidence: B)
Class IIa
1. It is reasonable to assess the risk of ischemic stroke in
patients with STEMI. (Level of Evidence: A)
Figure 35. Algorithm for postreperfusion ischemic stroke treatment. Daily doses of antithrombotic therapy are shown in the algorithm.
ASA = aspirin; INR = international normalized ratio; PTA = percutaneous transluminal angioplasty (carotid); CEA = carotid endarterec-
tomy. *An INR of 2.0-3.0 is acceptable with tight control, but the lower end of the range is preferable. The combination of antiplatelet
therapy and warfarin may be considered in patients aged less than 75 years, with low bleeding risk, and who can be monitored reli-
ably.
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appropriate. However, for patients with ischemic cerebral
infarction who undergo PCI and have no cardioembolic risk
factors, the use of clopidogrel 75 mg/d (for at least 12
months) plus aspirin 75 to 162 mg/d (indefinitely) after
STEMI is reasonable (578,728,1032). Patients with STEMI
who have ischemic stroke but do not undergo PCI and do not
have a cardiac source of embolism or surgically important
carotid stenosis may be treated with aspirin/extended-release
dipyridamole 25/200 mg plus aspirin 81 mg/d (1033).
A subgroup analysis from the CAPRIE trial (1032) in
patients with a prior history of ischemic events suggested a
benefit of clopidogrel (mean duration of treatment 1.6 years)
over aspirin for the composite end point of ischemic stroke,
MI, or vascular death (3.4% ARD, 95% CI 0.2 to 7.0; 14.9%
RRR; p equals 0.045). Thus, for the STEMI patient who has
an ischemic stroke without a documented cardiac source of
embolism while on aspirin therapy, clopidogrel may be
added for a period of 18 months.
Patients with cardiogenic sources of embolism, such as AF,
LV mural thrombi, or akinetic segment of the LV myocardi-
um, should receive moderate-intensity (INR 2 to 3) warfarin
anticoagulation in combination with aspirin. The duration of
moderate-intensity warfarin anticoagulation will vary
according to the underlying strong source of cardiogenic
embolism. Ischemic stroke patients with pre-existing or per-
sistent AF require lifelong warfarin therapy (958), irrespec-
tive of 2-dimensional echocardiography findings. In general,
patients with STEMI with LV mural thrombus should receive
3 months of warfarin therapy, a time believed to be suffi-
ciently long for clot adherence and re-endothelialization to
occur, leading to reduced embolic risk. However, if follow-
up 2-dimensional echocardiography at 3 months in the
STEMI patient with acute ischemic stroke shows findings
that suggest an ongoing risk of cardiogenic embolism (e.g.,
new or enlarging mural thrombi or thrombi that are pedun-
culated or mobile), then long-term moderate-intensity war-
farin anticoagulation is recommended.
If a surgically important internal carotid artery stenosis that
explains the clinical findings is found, either carotid
endarterectomy (1029,1034,1035) or carotid angioplasty
with stenting and a distal protection device (1036,1037)
(Yadav J; oral presentation, 2002 American Heart
Association Annual Scientific Session, November 2002,
Chicago, IL) could be performed. If surgical morbidity and
mortality are acceptable, carotid endarterectomy may be per-
formed 4 to 6 weeks after cerebral infarction. Preliminary
data from 307 randomized patients in the Stenting and
Angioplasty with Protection in Patients at High Risk for
Endarterectomy (SAPPHIRE) trial (Yadav J; oral presenta-
tion, 2002 American Heart Association Annual Scientific
Session, November 2002, Chicago, IL) showed a significant
reduction in the composite end point of 30-day death,
STEMI/NSTEMI, or stroke in the stent arm compared with
the endarterectomy arm (5.8% versus 12.6%, p equals
0.047). There was no difference in the occurrence of TIAs or
major bleeding between the 2 groups, although the occur-
rence of cranial nerve injury was significantly higher in the
is by far the most important of these risk factors (1019). In
the SAVE trial (1017), decreased ejection fraction (18%
increased risk per every 5% decrease in ejection fraction)
was independently associated with long-term stroke risk in
patients with STEMI. Thrombus formation is promoted by
extensive wall-motion abnormality, such as anteroapical aki-
nesia or dyskinesia, and Killip class III or IV (1020).
Embolic stroke after STEMI originates from LV thrombus or
from the left atrium in the setting of AF and occurs even in
patients treated with fibrinolysis (1015). It does not appear to
be useful to test patients with STEMI, even with mural
thrombus formation, for prothrombotic syndromes such as
factor V Leiden mutation (1021). Several studies in patients
with STEMI suggest that aggressive short- and long-term
anticoagulation may reduce but not totally prevent mural
thrombus formation (744,1022,1023) and occurrence of
stroke (1024-1028). Most ischemic cerebral infarctions after
fibrinolytic therapy for STEMI occur more than 48 hours
after treatment (218,320,322,586). The highest-risk period is
the first 28 days after STEMI (1014), but risk is elevated at
least to 1 year. In GUSTO-I (1015), Mahaffey et al. found
that the risk of ischemic stroke after coronary fibrinolysis
may be predicted (1015). Prospective studies are needed to
verify this observation. Compared with ICH, patients with
ischemic cerebral infarction present more commonly with
focal neurological deficits and less commonly with
depressed level of consciousness; headache, vomiting, and
coma are uncommon (360). 
An algorithm for evaluation and antithrombotic therapy for
ischemic stroke is shown in Figure 35. If the STEMI patient
has sudden onset of a focal neurological deficit and the ini-
tial CT scan is negative for blood or mass effect, then
ischemic cerebral dysfunction may be presumed in the
absence of a severe metabolic disorder, seizures, autoim-
mune disease, or cancer. Neurological consultation is recom-
mended to assist with planning the neurovascular evaluation
and management issues. The location and nature of the
ischemic brain lesion should be defined with repeat CT scan
or magnetic resonance imaging scan. Vascular lesions should
be evaluated with noninvasive techniques, such as carotid
duplex sonography, transcranial Doppler, magnetic reso-
nance angiography, CT angiography, or transesophageal
echocardiography. For carotid territory symptoms and signs,
evidence for a surgically important stenosis (greater than
50% linear diameter reduction on a catheter-based cerebral
angiogram using the North American Symptomatic Carotid
Endarterectomy Trial [NASCET] method) (1029) should
clearly be sought. 
The subacute to chronic pathophysiology of STEMI pro-
vides a rationale for clinicians to consider when choosing
antithrombotic therapies for stroke prevention and treatment
in this setting. A hypercoagulable state may exist for up to 6
months after STEMI (1030). This state may be accentuated
by withdrawal of heparin and warfarin therapy (555).
In ISIS-2 (1031), use of aspirin was shown to reduce the
occurrence of ischemic stroke. Thus, aspirin administration
after STEMI, with or without ischemic cerebral infarction, is
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should consult an evidence-based guideline on venous
thromboembolic disease (1041,1043).
7.10. Coronary Artery Bypass Graft Surgery 
After STEMI
7.10.1. Timing of Surgery
Class IIa
In patients who have had a STEMI, CABG mortality
is elevated for the first 3 to 7 days after infarction, and
the benefit of revascularization must be balanced
against this increased risk. Patients who have been
stabilized (no ongoing ischemia, hemodynamic com-
promise, or life-threatening arrhythmia) after STEMI
and who have incurred a significant fall in LV func-
tion should have their surgery delayed to allow
myocardial recovery to occur. If critical anatomy
exists, revascularization should be undertaken during
the index hospitalization. (Level of Evidence: B)
There are no clear data regarding optimal timing of bypass
surgery after STEMI (518,1045-1047). Most published stud-
ies are retrospective and observational in nature, with het-
erogenous patient cohorts and differences in inclusion crite-
ria. Moreover, many patients undergoing emergency surgery
tend to have comorbidities and risk factors, including
decreased LV function, which are normally associated with
an increase in operative mortality.
Coronary artery bypass grafting early after STEMI may
carry substantial risk, particularly in unstable patients with
Q-wave infarction and decreased LV function. Prior CABG,
female gender, and advanced age compound this risk consid-
erably (1045). Lee et al. (1048) reviewed 44 365 patients
from New York State undergoing CABG. Mortality for those
with or without a history of MI was 3.1% and 1.6%, respec-
tively. Mortality was higher for patients with transmural
infarction who underwent surgery within the first 24 hours
(12.1% at less than 6 hours, 13.6% at 6 to 23 hours). At 2
weeks, mortality was 2.6%. Mortality for patients with non-
transmural MIs was also elevated (11.5% at less than 6 hours,
6.2% at 6 to 23 hours) (Table 31) (1048). In another large
series of 2296 patients undergoing CABG after MI, Creswell
et al. reported mortality from surgery to be 9.1% at less than
6 hours after MI, 8.3% at 6 to 48 hours, 5.2% at 2 to 14 days,
6.5% at 2 to 6 weeks, and 2.9% at greater than 6 weeks.
Urgency of surgery was the most important predictor of oper-
ative mortality (1049). When adjustments were made for the
independent risk factors of urgency of operation, increased
patient age, renal insufficiency, number of previous MIs, and
hypertension, the timing between MI and CABG was not a
significant predictor for death. 
In reviewing 11 retrospective and prospective observation-
al studies regarding CABG and MI, Crossman et al. (1046)
concluded that timing of surgery after infarction was not
necessarily an independent predictor of outcome. However,
these studies did “appear to support an approach of medical
stabilization for unstable patients post MI wherever possible
endarterectomy arm (0% versus 5.3%, p less than 0.01). One-
year follow-up data are pending.
7.9.2. Deep Venous Thrombosis and 
Pulmonary Embolism
Class I
1. Deep venous thrombosis or pulmonary embolism
after STEMI should be treated with full-dose LMWH
for a minimum of 5 days and until the patient is 
adequately anticoagulated with warfarin. Start war-
farin concurrently with LMWH and titrate to INR of
2-3. (Level of Evidence: A)
2. Patients with CHF after STEMI who are hospitalized
for prolonged periods, unable to ambulate, or consid-
ered at high risk for DVT and are not otherwise anti-
coagulated should receive low-dose heparin prophy-
laxis, preferably with LMWH. (Level of Evidence: A)
Prevention. Deep venous thrombosis and pulmonary
embolism historically were relatively frequent complications
of STEMI, but in the current era in which patients with
STEMI almost universally receive anticoagulants, specific
prophylaxis is seldom needed (1039). For patients with CHF
after STEMI who are hospitalized for prolonged periods or
unable to ambulate and who are not otherwise anticoagulat-
ed, the best evidence of safety and efficacy supports the use
of low-dose LMWH (1040). Dosing depends on the specific
LMWH chosen, and product-specific information should be
consulted at the time of treatment.
Treatment. A high index of suspicion for DVT and pul-
monary embolism is necessary, and patients suspected of
having either condition should be evaluated immediately
with an appropriate evidence-based diagnostic strategy
(1041). Most patients with DVT or pulmonary embolism
should be anticoagulated with LMWH. It is at least as effec-
tive as UFH in clinical trials, and a meta-analysis suggests it
offers a lower total mortality (1042). Outside of carefully
supervised clinical trials, LMWH is generally superior,
because overshooting and undershooting the therapeutic
range is commonplace with UFH in routine clinical practice.
Low-molecular-weight heparin is less costly overall because
it avoids intravenous administration and frequent laboratory
testing. Dosing of LMWH depends on the specific product,
and product-specific information should be consulted at the
time of treatment. Warfarin should be initiated concurrently
with LMWH, and LMWH should be continued until the INR
reaches the therapeutic range of 2 to 3 (1041,1043). Warfarin
should be continued for a duration specific to the individual
patient’s risk profile (1044). Patients with contraindications
to anticoagulation with heparins will require alternative ther-
apies, and some will require placement of an inferior vena
cava filter. Detailed discussion of warfarin therapy duration,
alternative anticoagulants, and vena cava filter placement cri-
teria are beyond the scope of this guideline, and the reader
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used arterial conduits in 96% of 47 patients undergoing
emergency CABG within a mean of 27 hours from infarc-
tion, and operative mortality was 6.4%. In a further study,
Hirotani et al. (1052) performed CABG on 68 patients with-
in 30 days of infarction, with a mortality rate of 7.4%. CABG
without arterial grafts was the sole predictor of an adverse
survival. Although surgeons may be reluctant to use the IMA
in patients after STEMI because of limited flow through the
arterial graft and the time necessary to harvest it, the data
suggest that IMA grafts can be used safely soon after STEMI
with no increase in mortality; their use is associated with bet-
ter long-term survival. 
7.10.3. Coronary Artery Bypass Graft Surgery
After Fibrinolytic Therapy
In the 3339 patients enrolled in the TIMI-II trial, CABG was
performed as an emergency procedure (1.6%) or electively
(10% during initial hospitalization), primarily for left main
coronary stenosis or coronary anatomy not amenable to PCI
and continuing, recurrent, or exercise-induced ischemia
(1053). Of the 41021 patients enrolled in the GUSTO-I trial,
CABG was used in 8.6% at a mean of 8.5 days after fibri-
nolytic therapy (1054). Unstable patients undergoing CABG
shortly after fibrinolytic therapy, primarily for continuing
myocardial ischemia, have a higher operative mortality rate
(13% to 17%) and increased use of blood products
(1053,1055,1056) than hemodynamically stable patients
operated on within 8 hours of fibrinolytic therapy, who have
a relatively low (2.8%) mortality rate (1057). The only inde-
pendent predictor of perioperative mortality in TIMI-II was
performance of CABG within 24 hours of entry or PCI. The
low 1-year mortality rate (2.2%) noted for operative sur-
vivors in this group may support the use of emergency oper-
ation for selected patients, however (1053). In the SHOCK
trial (301), CABG was as successful as PCI in reducing mor-
tality in patients with cardiogenic shock, although they had
more complex coronary artery anatomy. The intraoperative
use of aprotinin may reduce hemorrhage related to use of
thrombolytic agents (1058).
to convert high risk emergency operations to lower risk more
elective procedures” (1046). The Writing Committee
believes that if stable patients with STEMI with preserved
LV function require surgical revascularization, then CABG
can be undertaken within several days of the infarction with-
out an increased risk. In addition, surgery for patients who
have mechanical complications of MI, such as VSR or papil-
lary muscle rupture, or who have ongoing ischemia that has
been unresponsive to other medical therapy and have vessels
suitable for bypass, cannot usually be delayed. However,
patients who have had a significant decrease in LV function
as a result of STEMI and who are hemodynamically stable
may benefit from a longer period of medical treatment to
allow myocardial recovery to occur before surgical revascu-
larization is undertaken. If a patient has critical coronary
anatomy, such as greater than 75% left main coronary artery
stenosis, then CABG should be undertaken during the same
hospitalization. (See Section 3.2.2 of the ACC/AHA
Guidelines for Coronary Artery Bypass Graft Surgery (518).)
7.10.2. Arterial Grafting
Class I
An internal mammary artery graft to a significantly
stenosed LAD should be used whenever possible in
patients undergoing CABG after STEMI. (Level of
Evidence: B)
The routine use of the left internal mammary artery (IMA)
for LAD grafting, with supplemental saphenous vein grafts
to other coronary lesions, is generally accepted as the stan-
dard grafting method. A large, long-term follow-up study
comparing patients receiving the left IMA-to-LAD and sup-
plemental vein grafts to patients receiving saphenous vein
grafts only demonstrated a significantly lower rate of recur-
rent angina and MI, a lower incidence of reoperation or PCI,
and a higher actuarial 10-year survival among patients with
IMA grafts (1050). Despite the clear advantage of the IMA
graft, not all patients receive arterial grafts. In the PAMI-2
trial (522) of 120 patients undergoing surgery, only 31%
received an IMA graft; no patients had cardiogenic shock at
the time of surgery. On the other hand, Hirose et al. (1051)
Table 31. Comparison of Hospital Mortality for CABG With Respect to Time of Operation:
Transmural Versus Nontransmural MI 
Transmural MI Nontransmural MI
Time Since Operation n* Mortality, % Mortality, %
Less than 6 hours 885 12.1 11.5
6-23 hours 556 13.6 6.2
1-7 days 7554 4.3 3.5
8-14 days 6712 2.4 2.7
Greater than or equal 28 658 2.6 2.7
to 15 days
CABG = coronary artery bypass graft surgery; MI = myocardial infarction.
*Number of the 44 365 patients in the NY State Cardiac Surgery Registry who underwent CABG as the sole procedure from 
1993-1996 and whose data were used in the analysis.
Modified from Lee et al. Ann Thorac Surg 2001;71:1197-202, Copyright © 2001, with permission from the Society of Thoracic
Surgeons (1048).
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2. Coronary artery bypass graft surgery is recommend-
ed for patients with stable angina who have left main
equivalent disease: significant (at least 70%) stenosis
of the proximal LAD and proximal left circumflex
artery. (Level of Evidence: A)
3. Coronary artery bypass graft surgery is recommend-
ed for patients with stable angina who have 3-vessel
disease. (Survival benefit is greater when LVEF is less
than 0.50.) (Level of Evidence: A)
4. Coronary artery bypass graft surgery is beneficial for
patients with stable angina who have 1- or 2-vessel
coronary disease without significant proximal LAD
stenosis but with a large area of viable myocardium
and high-risk criteria on noninvasive testing. (Level of
Evidence: B)
5. Coronary artery bypass graft surgery is recommend-
ed in patients with stable angina who have 2-vessel
disease with significant proximal LAD stenosis and
either ejection fraction less than 0.50 or demonstrable
ischemia on noninvasive testing. (Level of Evidence: A)
The role of surgical revascularization has been reviewed
extensively in the ACC/AHA Guideline Update on Coronary
Artery Bypass Graft Surgery (518). Consideration for revas-
cularization after STEMI includes PCI and CABG. Providers
should individualize patient management on the basis of clin-
ical circumstances, available revascularization options, and
patient preference. Elective CABG should improve survival
relative to medical therapy in patients with MI who have 1)
left main coronary artery stenosis; 2) left main equivalent
(significant [at least 70%] stenosis of the proximal LAD and
proximal left circumflex artery); 3) 3-vessel disease, particu-
larly with decreased LV function; 4) 2-vessel disease with
significant proximal LAD stenosis not amenable to PCI and
either ejection fraction less than 0.50 or demonstrable
ischemia on noninvasive testing; and 5) 1- or 2-vessel disease
not amenable to PCI without proximal LAD stenosis but with
a large area of viable myocardium at risk and high-risk crite-
ria on noninvasive testing. The optimal timing of surgery has
not been established. The risk is greatest within the first 48
hours of infarction and decreases over the next 2 weeks. Risk
of operation is greatest for patients with decreased LV func-
tion, advanced age, female sex, renal failure, peripheral vas-
cular disease, diabetes, chronic obstructive pulmonary dis-
ease, and previous CABG (1048,1061,1065).
7.10.7. Coronary Artery Bypass Surgery 
After STEMI and Antiplatelet Agents
Class I
1. Aspirin should not be withheld before elective or non-
elective CABG after STEMI. (Level of Evidence: C)
2. Aspirin (75 to 325 mg/d) should be prescribed as soon
as possible (within 24 hours) after CABG unless con-
traindicated. (Level of Evidence: B)
3. In patients taking clopidogrel in whom elective CABG
is planned, the drug should be withheld for 5 to 7
days. (Level of Evidence: B)
7.10.4. Coronary Artery Bypass Graft Surgery
for Recurrent Ischemia After STEMI
Class I
Urgent CABG is indicated if the coronary angiogram
reveals anatomy that is unsuitable for PCI. (Level of
Evidence: B)
Coronary artery bypass graft surgery should be considered
when recurrent ischemia occurs in patients with STEMI
whose coronary artery anatomy is not suitable for PCI.
Operative mortality in such patients is correlated closely with
ejection fraction, and for patients with normal ejection frac-
tion, it is nearly the same as that of elective CABG (1059-
1061). The survival benefit for patients with reduced LV
function supports the use of CABG in this situation.
7.10.5. Case Selection Concerns in CABG 
After STEMI
As cardiac surgical programs and individual surgeons come
under scrutiny with regard to operative mortality rates, con-
cern has been raised about the possibility that salvageable but
high-risk patients may not be offered surgery. Omoigui et al.
(1062) suggested that the reduction in mortality noted in
New York State was caused by an outmigration of high-risk
patients due to the increased scrutiny provoked by public
release of mortality data. In a survey of New York State car-
diac surgeons, Burack et al. (1063) reported that many sur-
geons refused to operate on at least 1 high-risk patient over
the prior year, primarily because of public reporting. The
Writing Committee believes strongly that patients should be
offered surgical treatment if the treating team believes that
the benefits outweigh the risks and that meaningful survival
of the patient could result. Furthermore, appropriately vali-
dated risk-adjusted outcome measures should be used when
evaluating the performance of an individual surgeon or sur-
gical program. The ACC/AHA Guideline Update on Coro-
nary Artery Bypass Graft Surgery has addressed the issue of
institutional and individual surgical caseloads (518). Studies
suggest that survival after CABG has improved over the last
decade but is negatively affected when the surgery is per-
formed in institutions that do fewer than a threshold of 200
cases per year. However, some institutions and practitioners
maintain excellent outcomes despite relatively low volumes.
In reviewing the outcome of 13 644 CABG procedures at 56
US hospitals, mortality was significantly lower at high-vol-
ume hospitals only for those patients considered as being at
high or moderate risk (1064). Therefore, targeted transfer of
high- to moderate-risk post-STEMI patients to high-volume
institutions may be appropriate.
7.10.6. Elective CABG After STEMI in 
Patients With Angina
Class I
1. Coronary artery bypass graft surgery is recommended
for patients with stable angina who have significant left
main coronary artery stenosis. (Level of Evidence: A)
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acid (1072). Because clopidogrel, when added to aspirin,
increases the risk of bleeding during major surgery, clopido-
grel should be withheld for at least 5 days (728) and prefer-
ably for 7 days before surgery in patients who are scheduled
for elective CABG (1073). 
7.11. Convalescence, Discharge, and Post-MI Care
7.11.1. Risk Stratification at Hospital Discharge
Informal risk estimates are updated continually as the
patient's clinical condition evolves and other information
becomes available. For example, tests such as an echocardio-
gram may be obtained early during hospitalization to define
an abnormal physical finding and thus provide data for risk
stratification, even though they were not ordered for that
purpose. Because patient preference is a critical determinant
for any management pathway, it is difficult to produce a rigid
algorithm for risk stratification.
There is, nevertheless, value in outlining general strategies
for performing risk stratification testing, with an emphasis on
avoiding redundancy. The most important immediate man-
agement decision is whether to refer a patient for cardiac
catheterization. Patients who have not had catheterization as
part of their initial treatment strategy should be evaluated for
their risk of future cardiac events. Another major decision is
referral for EP testing and possible placement of an ICD.
The risk stratification approach for decision making about
catheterization is described in Figure 36. For patients who
did not have an early catheterization and in whom revascu-
larization therapy would be considered, the approach
includes an early quantitative assessment of LVEF. Patients
with an LVEF less than 0.40 should be considered for
catheterization. For those with a higher LVEF, further strati-
fication with stress testing is recommended. Various
approaches are considered acceptable, including a submaxi-
mal stress test, a symptom-limited stress imaging test, or a
pharmacological stress imaging test. Ambulatory ECG mon-
itoring for ischemia after STEMI has significant limitations
(e.g., resting ECG abnormal after infarction) and has not
been incorporated into the algorithm in Figure 36 (71,1074).
A symptom-limited stress test was not formerly recommend-
ed but is supported by data from DANAMI (515). The deci-
sion for referral to cardiac catheterization should then be
based on the stress test results, with an indication related to
the amount of ischemia quantified by test results. Patients
with little or no ischemia may be better treated with medical
therapy, a strategy supported by DANAMI.
The suggested algorithm for EP testing and ICD placement
is shown in Figure 32. Electrophysiology testing is not indi-
cated for patients with an LVEF less than 0.30 because they
are presumed to benefit from an ICD, and an EP test is not
necessary. Patients with VF after 48 hours, sustained VT, or
hemodynamically significant VT are recommended for ICD
placement without an EP test. For patients with an ejection
fraction less than 0.40, an EP test is reserved those whose
telemetry or Holter monitor show nonsustained VT. 
Aspirin therapy, particularly within the first 48 hours after
CABG, appears to have significant benefits (1066,1067).
Mangano et al. (1066) studied 5022 patients in a global reg-
istry who survived CABG. Aspirin therapy begun within 48
hours after surgery resulted in a 60% lower death rate at 30
days, as well as decreased rates of MI, stroke, renal failure,
and bowel infarction. It is likely that these effects are medi-
ated by both the anti-inflammatory and antithrombotic
actions of aspirin (1067). Bleeding complications were also
lower in the aspirin-treated group. 
Patients with STEMI undergoing revascularization fre-
quently receive 1 or more antiplatelet agents in addition to
heparin, all of which may increase risk of serious bleeding
during and after cardiac surgery. Because the mechanism and
duration of action of the antiplatelet effects of aspirin, the
ADP antagonists (ticlopidine and clopidogrel), and GP
IIb/IIIa receptor antagonists (abciximab and eptifibatide) dif-
fer, the potential exists for an additive effect with a combina-
tion of these agents. In the CURE trial (728), in which 12562
patients with unstable angina or NSTEMI were randomized
to placebo plus aspirin or clopidogrel plus aspirin, there was
an increased risk of major bleeding in the clopidogrel group
(3.7%) compared with the placebo group (2.7%). Also, risk
of bleeding was increased in patients undergoing CABG
within the first 5 days of stopping clopidogrel. In a prospec-
tive study of 224 patients having CABG, Hongo et al. (1068)
found reoperation for bleeding to be 10-fold higher in
patients who had received clopidogrel within 7 days of sur-
gery than in those who had received no clopidogrel. In the
EPIC trial (Evaluation Prevention of Ischemic
Complications; placebo or abciximab bolus or abciximab
infusion) (1069), transfusion of red blood cells and platelets
was significantly higher after treatment with abciximab. 
Singh et al. (1070) found transfusion requirements to be
higher for patients who underwent urgent CABG after hav-
ing received abciximab during PCIs. In an analysis of 85 sur-
gical patients in the EPILOG (Evaluation of PTCA to
Improve Long-Term Outcome by c7E3 GP IIb/IIIa Receptor
Blockade) and EPISTENT (Evaluation of Platelet IIb/IIIa
Inhibition in Stenting) trials, although platelet transfusions
were higher in the abciximab groups, rates of major blood
loss and transfusions of whole blood and packed red cells
were the same in the abciximab and placebo groups (1071).
Management strategies for patients who require surgery and
subsequent treatment with antiplatelet agents will differ
according to type of agent used and the urgency of surgery. 
In many circumstances, it may not be feasible to delay sur-
gery until platelet function has recovered. In patients treated
with the small-molecule GP IIb/IIIa receptor antagonists,
tirofiban and eptifibatide, platelet function returns toward
normal within 4 hours of stopping treatment. Platelet aggre-
gation does not return toward normal for more than 48 hours
in patients treated with abciximab. Management strategies
other than delaying surgery include platelet transfusions for
patients who were recently treated with abciximab, reduced
heparin dosing during cardiopulmonary bypass, and possible
use of antifibrinolytic agents such as aprotinin or tranexamic
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not selected for cardiac catheterization and without
high-risk features to assess the presence and extent of
inducible ischemia. (Level of Evidence: B)
2. In patients with baseline abnormalities that compro-
mise ECG interpretation, echocardiography or
myocardial perfusion imaging should be added to
standard exercise testing. (Level of Evidence: B)
Class IIb
Exercise testing might be considered before discharge
of patients recovering from STEMI to guide the post-
discharge exercise prescription or to evaluate the
functional significance of a coronary lesion previously
identified at angiography. (Level of Evidence: C)
Class III
1. Exercise testing should not be performed within 2 to 3
days of STEMI in patients who have not undergone
successful reperfusion. (Level of Evidence: C)
2. Exercise testing should not be performed to evaluate
patients with STEMI who have unstable postinfarc-
tion angina, decompensated CHF, life-threatening
cardiac arrhythmias, noncardiac conditions that
Physicians and their patients must make decisions about
risk-reduction lifestyle and pharmacological approaches. At
this point, however, all patients with STEMI are considered
to be at sufficiently high risk to merit use of these secondary
prevention interventions, including the use of cardiac reha-
bilitation, aspirin, appropriate lipid-lowering therapy, and
beta-blockers (Table 32) (68).
There is a clear need for tools that can integrate compre-
hensive risk-stratification information in explicit estimates of
absolute risks of cardiovascular outcomes with management
decisions. Current risk stratification tests generally provide
relative risk information, indicating average increases in risk,
but their utility in guiding clinical decisions remains to be
defined. The Writing Committee believes that further
research in this area is necessary before making recommen-
dations about the best use of these emerging risk stratifica-
tion tools.
7.11.1.1. Role of Exercise Testing
Class I
1. Exercise testing should be performed either in the
hospital or early after discharge in STEMI patients
Figure 36. Evidence-based approach to need for catheterization (cath) and revascularization after ST-elevation myocardial infarction
(STEMI). The algorithm shows treatment paths for patients who initially undergo a primary invasive strategy, receive fibrinolytic thera-
py, or do not undergo reperfusion therapy for STEMI. Patients who have not undergone a primary invasive strategy and have no high-
risk features should undergo functional evaluation with one of the noninvasive tests shown. When clinically significant ischemia is
detected, patients should undergo catheterization and revascularization as indicated; if no clinically significant ischemia is detected,
medical therapy is prescribed after STEMI. *Please see Table 23 of the ACC/AHA 2002 Guideline Update for the Management of
Patients With Chronic Stable Angina for further definition (71). †Please see Table 3, Section 6.3.1.6.2 and Section 7.3 in the STEMI
guideline for further discussion.
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Table 32. Secondary Prevention for Patients With STEMI
Goals Intervention Recommendations
Smoking: Assess tobacco use. Strongly encourage patient and family to stop smoking and to avoid secondhand smoke.
Goal Provide counseling, pharmacological therapy (including nicotine replacement and bupropion), and formal 
Complete cessation smoking cessation programs as appropriate. (See Section 7.12.4 in the full-text guidelines for further 
discussion.)
Blood pressure control: If blood pressure is 120/80 mm Hg or greater:
Goal • Initiate lifestyle modification (weight control, physical activity, alcohol moderation, moderate sodium 
Less than 140/90 mm Hg or restriction, and emphasis on fruits, vegetables, and low-fat dairy products) in all patients.
less than 130/80 mm Hg if 
chronic kidney disease or diabetes If blood pressure is 140/90 mm Hg or greater or 130/80 mm Hg or greater for individuals with chronic
kidney disease or diabetes:
• Add blood pressure–reducing medications, emphasizing the use of beta-blockers and inhibitors of the 
renin-angiotensin-aldosterone system. (See Sections 7.12.6, 7.12.7, and 7.12.8.)
Lipid management: Start dietary therapy in all patients (less than 7% of total calories as saturated fat and less than 200 mg/d
(TG less than 200 mg/dL) cholesterol). Promote physical activity and weight management. Encourage increased consumption of
omega-3 fatty acids. 
Primary goal: Assess fasting lipid profile in all patients, preferably within 24 hours of STEMI. Add drug therapy accord-
LDL-C substantially less ing to the following guide. (See Section 7.12.2.)
than 100 mg/dL
Lipid management: If TGs are greater than or equal to 150 mg/dL or HDL-C is less than 40 mg/dL:
(TG 200 mg/dL or greater)
Primary goal If TG is 200-499 mg/dL:
Non–HDL-C* substantially 
less than 130 mg/dL
If TG is greater than or equal to 500 mg/dL:
(See Section 7.12.2.)
Physical activity: Assess risk, preferably with exercise test, to guide prescription.
Minimum goal Encourage minimum of 30 to 60 minutes of activity, preferably daily but at least 3 or 4 times weekly
30 minutes 3 to 4 days per week (walking, jogging, cycling, or other aerobic activity) supplemented by an increase in daily lifestyle
Optimal daily activities (e.g., walking breaks at work, gardening, household work). Cardiac rehabilitation programs are 
recommended for patients with STEMI, particularly those with multiple modifiable risk factors and/or
those moderate- to high-risk patients in whom supervised exercise training is warranted. (See Sections
7.12.12 and 8.2.)
Continued on next page
LDL-C less than 100 mg/dL LDL-C greater than or equal to 
(baseline or on treatment): 100 mg/dL (baseline or on treatment):
• Statins should be used to • Intensify LDL-C–lowering therapy
lower LDL-C. with drug treatment, giving prefer-
ence to statins.
• Emphasize weight management and physical activity. Advise smoking cessation.
• After LDL-C–lowering therapy,† consider adding fibrate or niacin.‡
• Consider fibrate or niacin‡ before LDL-C–lowering therapy.†
• Consider omega-3 fatty acids as adjunct for high TG.
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severely limit their ability to exercise, or other
absolute contraindications to exercise testing (1075).
(Level of Evidence: C)
3. Exercise testing should not be used for risk stratifica-
tion in patients with STEMI who have already been
selected for cardiac catheterization. (Level of
Evidence: C)
Exercise testing after STEMI may be performed to 1)
assess functional capacity and the patient’s ability to perform
tasks at home and at work; 2) establish exercise parameters
for cardiac rehabilitation; 3) evaluate the efficacy of the
patient’s current medical regimen; 4) risk-stratify the post-
patient with STEMI according to the likelihood of a subse-
quent cardiac event (1076-1080); 5) evaluate chest pain
symptoms after STEMI; and 6) provide reassurance to
patients regarding their functional capacity after STEMI as a
guide to return to work. 
Patients who receive reperfusion therapy have a smaller
infarct size (1081). Coronary angiography is frequently per-
formed during hospitalization due to recurrent chest pain,
which identifies many patients with severe disease who sub-
sequently undergo revascularization (1082). The low cardiac
event rate after discharge in patients with STEMI who are
successfully reperfused substantially reduces the predictive
accuracy of early exercise testing. The ability to perform an
exercise test 1 month after STEMI provides a favorable prog-
nosis irrespective of the test results (1075).
Low-level exercise testing appears to be safe if patients
have undergone in-hospital cardiac rehabilitation, including
low-level exercise, have had no symptoms of angina or heart
failure, and have a stable baseline ECG 48 to 72 hours before
the exercise test. Two different protocols have been used to
determine the end points of these very early exercise tests
(1083-1085):
The traditional submaximal exercise test (done at 3 to 5
days in patients without complications) incorporates a series
of end points, including a peak heart rate of 120 to 130 bpm
or 70% of maximal predicted heart rate for age, a peak work
level of 5 metabolic equivalents (METs), or clinical or ECG
Table 32. Continued
Goals Intervention Recommendations
Weight management: Calculate BMI and measure waist circumference as part of evaluation. Monitor response of BMI and 
Goal waist circumference to therapy.
BMI 18.5-24.9 kg/m2 Start weight management and physical activity as appropriate. Desirable BMI range is 18.5-24.9 kg/m2.
Waist circumference: If waist circumference is greater than or equal to 35 inches in women or greater than or equal to 40 inches
Women: less than 35 in in men, initiate lifestyle changes and treatment strategies for metabolic syndrome.
Men: less than 40 in (See Section 7.12.3.)
Diabetes management:
Goal Appropriate hypoglycemic therapy to achieve near-normal fasting plasma glucose, as indicated by HbA1c.
HbA1C less than 7% Treatment of other risk factors (e.g., physical activity, weight management, blood pressure, and choles-
terol management). (See Section 7.12.9.)
Antiplatelet agents/ Start and continue indefinitely aspirin 75 to 162 mg/d if not contraindicated. Consider clopidogrel 75 
anticoagulants mg/d or warfarin if aspirin is contraindicated. Manage warfarin to INR 2.5 to 3.5 in post-STEMI patients
when clinically indicated or for those not able to take aspirin or clopidogrel. (See Sections 7.12.5 and 
7.12.11 and Figure 37 for further details of antiplatelet and anticoagulant therapy at hospital discharge.)
Renin-angiotensin- ACE inhibitors in all patients indefinitely; start early in stable high-risk patients (anterior MI, previous 
aldosterone MI, Killip class greater than or equal to II [S3 gallop, rales, radiographic CHF], LVEF less than 0.40). 
system blockers 
Angiotensin receptor blockers in patients who are intolerant of ACE inhibitors and with either clinical or 
radiological signs of heart failure or LVEF less than 0.40.
Aldosterone blockade in patients without significant renal dysfunction§ or hyperkalemia|| who are already
receiving therapeutic doses of an ACE inhibitor, have an LVEF less than or equal to 0.40, and have either 
diabetes or heart failure. (See Section 7.12.6.)
Beta-Blockers Start in all patients. Continue indefinitely. Observe usual contraindications. (See Section 7.12.7.)
STEMI = ST-elevation myocardial infarction; TG = triglycerides; LDL-C = low-density lipoprotein cholesterol; HDL-C = high-density lipoprotein cholesterol; BMI = body mass index;
INR = international normalized ratio; ACE = angiotensin converting enzyme; MI = myocardial infarction; CHF = congestive heart failure; LVEF = left ventricular ejection fraction.
*Non–HDL-C = total cholesterol minus HDL-C.
†Treat to a goal of non–HDL-C substantially less than 130 mg/dL.
‡Dietary-supplement niacin must not be used as a substitute for prescription niacin, and over-the-counter niacin should be used only if approved and monitored by a physician.
§Creatinine should be less than or equal to 2.5 mg/dL in men or less than or equal to 2.0 mg/dL in women.
||Potassium should be less than 5.0 mEq/L.Modified with permission from Smith et al. Circulation 2001;104:1577-9 (68).
Modified from Smith et al. Circulation 2001;104:1577-9 (68).
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intracardiac thrombus, and pericardial effusion.
(Level of Evidence: C)
4. Stress echocardiography (or myocardial perfusion
imaging) should be used in patients with STEMI for
in-hospital or early postdischarge assessment for
inducible ischemia when baseline abnormalities are
expected to compromise ECG interpretation. (Level of
Evidence: C)
Class IIa
1. Echocardiography is reasonable in patients with
STEMI to re-evaluate ventricular function during
recovery when results are used to guide therapy.
(Level of Evidence: C)
2. Dobutamine echocardiography (or myocardial perfu-
sion imaging) is reasonable in hemodynamically and
electrically stable patients 4 or more days after
STEMI to assess myocardial viability when required
to define the potential efficacy of revascularization.
(Level of Evidence: C)
3. In STEMI patients who have not undergone contrast
ventriculography, echocardiography is reasonable to
assess ventricular function after revascularization.
(Level of Evidence: C)
Class III
Echocardiography should not be used for early rou-
tine re-evaluation in patients with STEMI in the
absence of any change in clinical status or revascular-
ization procedure. Reassessment of LV function 30 to
90 days later may be reasonable. (Level of Evidence: C)
The widespread availability, portability, and relatively low
cost of echocardiography have resulted in its increased use as
a practical and reliable means of assessing both global ven-
tricular function and regional wall-motion abnormalities.
Transthoracic imaging and Doppler techniques are generally
sufficient for evaluating patients with suspected or docu-
mented ischemic heart disease. However, transesophageal
echocardiography may be needed in some patients, particu-
larly those with serious hemodynamic compromise but non-
diagnostic transthoracic echocardiography studies. The uses
of echocardiography in STEMI are discussed in detail in the
ACC/AHA/ASE 2003 Guideline Update for the Clinical
Application of Echocardiography (226). 
Assessment of Prognosis and Complication. Echo-
cardiography assesses global and regional ventricular func-
tion. The sum of segmental wall-motion abnormalities may
overestimate infarct size because it includes regions of prior
infarction and areas with ischemic stunning or hibernation of
myocardium. However, LVEF and echocardiographically
derived infarct size are predictive of early and late complica-
tions and mortality (1088-1091).
Echocardiography can be used to evaluate at the bedside,
when needed, virtually any complication of STEMI. These
complications include acute MR, cardiogenic shock, infarct
end points of mild angina or dyspnea, ST-segment depression
greater than 2 mm, exertional hypotension, or 3 or more con-
secutive premature ventricular contractions, whichever end
point is reached first. The second protocol is performance of
a symptom-limited exercise test (done at 5 days or later)
without stopping for target heart rates or MET levels.
Although this level will result in a higher frequency of abnor-
mal exercise tests, the prognostic value of ST depression that
occurs at higher work levels in deconditioned patients is
uncertain. The safety of early symptom-limited exercise test-
ing is based on relatively limited data; therefore, clinical
judgment must be used (1075). The results of this symptom-
limited test can also be used to establish intensity and target
heart rate during cardiac rehabilitation. 
The duration of exercise is also known to be an important
predictor of outcomes, and the ability to perform at least 5
METs without early exercise ST depression and show a nor-
mal rise in systolic blood pressure is important in constitut-
ing a negative predictive value (1086,1087). The optimum
time for performing the exercise test after STEMI remains
unresolved. It is argued that a predischarge exercise test pro-
vides psychological benefits to the patient and will permit
detection of profound ischemia that could be associated with
postdischarge cardiac events that might occur before a sched-
uled 3- to 6-week postdischarge, symptom-limited stress test.
It also provides parameters for cardiac rehabilitation exercise
programs. On the other hand, deferring exercise testing until
approximately 3 weeks after STEMI in clinically low-risk
patients appears safe and reasonable and enables more opti-
mal assessment of functional capacity. It is the consensus of
this Writing Committee that patients without complications
who have not undergone coronary arteriography before dis-
charge from the hospital and who might be potential candi-
dates for revascularization procedures should undergo exer-
cise electrocardiography before or just after discharge.
7.11.1.2. Role of Echocardiography
Noninvasive imaging in patients recovering from STEMI
includes echocardiography and radionuclide imaging. This
section discusses the role of echocardiography. (See Sections
7.11.1.3, 7.11.1.4, and 7.11.1.5 for additional discussion on
imaging considerations.)
Class I
1. Echocardiography should be used in patients with
STEMI not undergoing LV angiography to assess
baseline LV function, especially if the patient is hemo-
dynamically unstable. (Level of Evidence: C)
2. Echocardiography should be used to evaluate patients
with inferior STEMI, clinical instability, and clinical
suspicion of RV infarction. (See the ACC/AHA/ASE
2003 Guideline Update for Clinical Application of
Echocardiography (226).) (Level of Evidence: C)
3. Echocardiography should be used in patients with
STEMI to evaluate suspected complications, including
acute MR, cardiogenic shock, infarct expansion, VSR,
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patients judged to be unable to exercise. (Level of
Evidence: B)
Class IIa
Myocardial perfusion imaging or dobutamine
echocardiography is reasonable in hemodynamically
and electrically stable patients 4 to 10 days after
STEMI to assess myocardial viability when required
to define the potential efficacy of revascularization.
(Level of Evidence: C)
Before the use of reperfusion therapy, the prognostic value
of exercise myocardial perfusion imaging was found to be
superior to that of exercise ECG testing (1113-1116).
Pharmacological stress perfusion imaging was shown to have
predictive value for postinfarction cardiac events (1117-
1119). The key issues are whether these results apply to cur-
rent patient populations in the reperfusion era and whether
myocardial perfusion imaging is worth the additional cost for
risk stratification (1120). The same issues outlined previous-
ly with respect to exercise echocardiographic testing apply to
this methodology. In patients with STEMI who have received
fibrinolytic therapy, several studies using myocardial perfu-
sion imaging have found that it is less valuable than previ-
ously thought for risk stratification (1121-1123), primarily
because of the low rate of late cardiac events. 
In patients in the current era who have not received reper-
fusion therapy, particularly those who have not undergone
revascularization, the same considerations regarding subse-
quent patient outcome that were outlined above for exercise
ECG testing apply. There is evidence that myocardial perfu-
sion imaging is useful for risk stratification in such patients,
despite their better overall prognosis (1124). It appears like-
ly that the previously demonstrated superiority of stress
myocardial perfusion imaging probably continues to apply to
this population, although there is limited evidence on this
point. Prospective studies are difficult to conduct because cli-
nicians frequently intervene in patients with abnormal pre-
discharge stress perfusion imaging studies. 
Myocardial perfusion imaging with either Tl 201 (1125),
Tc 99m sestamibi (1126), or Tc 99m tetrofosmin can assess
infarct size. The measurement of infarct size by any one of
these techniques is significantly associated with subsequent
patient mortality after fibrinolytic therapy (1125-1127). Data
are also emerging to suggest that vasodilator stress nuclear
scintigraphy is safe and can be used for early (48 to 72 hours)
risk stratification (1128). The ACC/AHA/ASNC Guidelines
for the Clinical Use of Cardiac Radionuclide Imaging, a revi-
sion of the 1995 guidelines, stress the ability of pharmaco-
logical stress perfusion imaging to risk-stratify patients after
STEMI early and safely, thereby facilitating the development
of clinical strategies (239). 
Recommended strategies for exercise test evaluations after
STEMI are presented in Figure 36. These strategies and the
data on which they are based are reviewed in more detail in
the ACC/AHA 2002 Guideline Update for Exercise Testing
(1075). 
expansion, VSR, intracardiac thrombus, and pericardial effu-
sion.
Assessment of Therapy. Given the frequent use of reperfusion
therapy (fibrinolytic agents or primary angioplasty) in
patients with STEMI, assessment of myocardial salvage is an
important clinical issue. After successful reperfusion,
myocardial stunning may occur and may last for days to
months. Wall-motion segments that demonstrate hypokinesia
or akinesia at rest but improved function during low-dose
dobutamine infusion often recover contractility (1092-1101),
which suggests that these segments are stunned. Failure of
such segments to show improvement suggests functional
recovery is unlikely to occur (1092-1101). These issues are
discussed in more detail in the ACC/AHA/ASE 2003 Guide-
line Update for the Clinical Application of Echocardiogra-
phy (226).
Predischarge Evaluation With Stress Echocardiography. The
role of exercise testing in evaluation of patients with STEMI
before discharge is discussed in Section 7.11.1.1. As previ-
ously noted, the ability to perform an exercise test 1 month
after STEMI provides a favorable prognosis regardless of test
results (1075). The incremental value of exercise echocar-
diography over regular exercising testing after STEMI has
not been established. Prospective natural history studies are
difficult to accomplish because many clinicians now perform
angiography and recommend revascularization in patients
with significant coronary obstructions. Echocardiography or
perfusion imaging (see Section 7.11.1.3) should be added to
exercise testing whenever baseline abnormalities are expect-
ed to compromise ECG interpretation.
Although serious complications have been reported (1093),
general experience suggests that pharmacological stress
echocardiography with a graded protocol and with low doses
of dobutamine initially appears to be feasible and safe when
performed 4 to 10 days after STEMI (1092,1094-1102).
Pharmacological challenge can substitute for exercise in pre-
discharge functional testing for ischemia in patients with lim-
ited exercise capacity and can help in assessing myocardial
viability early after STEMI (1092,1094,1103-1112). Beta-
blockade may limit the sensitivity of dobutamine echocar-
diography in assessing ischemia.
7.11.1.3. Exercise Myocardial Perfusion Imaging
Noninvasive imaging in patients recovering from STEMI
includes echocardiography and radionuclide imaging. This
section discusses the role of exercise myocardial perfusion
imaging. (See Sections 7.11.1.2, 7.11.1.4, and 7.11.1.5 for
additional discussion on imaging considerations.)
Class I
Dipyridamole or adenosine stress perfusion nuclear
scintigraphy or dobutamine echocardiography before
or early after discharge should be used in patients
with STEMI who are not undergoing cardiac
catheterization to look for inducible ischemia in
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7.11.1.5. Myocardial Viability
Noninvasive imaging in patients recovering from STEMI
includes echocardiography and radionuclide imaging. This
section discusses techniques for assessing myocardial viabil-
ity. Either of the above imaging techniques can provide clin-
ically useful information.
As previously noted, LV function is a well established and
powerful predictor of outcome after STEMI. In some
patients, LV dysfunction results from necrosis and scar for-
mation. In others, viable but dysfunctional myocardium con-
tributes to LV dysfunction and may be significantly
reversible with revascularization. Myocardial hibernation
(chronic low-flow state associated with depressed myocar-
dial function) (1134) and stunning (depression of ventricular
function after acute ischemia despite adequate restoration of
blood flow) (1135) contribute to the potential reversibility of
ventricular function. Up to one third of patients with signifi-
cant ischemic LV dysfunction may improve with revascular-
ization (1136). Therefore, the distinction between ventricular
dysfunction caused by fibrosis and that arising from viable
but dysfunctional myocardium may have important prognos-
tic and therapeutic implications.
Several noninvasive imaging modalities have been estab-
lished as predictors of myocardial viability. Radionuclide
imaging and dobutamine echocardiography have acceptable
accuracy in predicting recovery of regional wall-motion
abnormalities (239). More recently, relatively small studies
have suggested the ability of viability studies to identify
patients most likely to benefit from revascularization in terms
of symptoms and natural history (1137-1140). These data are
reviewed in more detail in the ACC/AHA/ASNC Guidelines
for Cardiac Radionuclide Imaging (239) and the
ACC/AHA/ASE 2003 Guideline Update for the Clinical
Application of Echocardiography (226). Positron emission
tomography, although not currently as widely available as
other radionuclide techniques, may provide slightly better
overall accuracy in predicting recovery of regional function
(1141). More recently, contrast-enhanced magnetic reso-
nance imaging has demonstrated promising results in pre-
dicting improvement of regional myocardial function in
patients after STEMI (1142-1144).
The data noted above suggest that assessment of myocar-
dial viability after STEMI, particularly in patients with
severe LV dysfunction, may identify those with the highest
risk, in whom revascularization can be of clinical benefit.
However, myocardial viability remains incompletely under-
stood. Viability testing is not a standard until more conclu-
sive diagnostic efficacy studies are performed to demonstrate
patient benefit.
7.11.1.6. Invasive Evaluation
Class I
1. Coronary arteriography should be performed in
patients with spontaneous episodes of myocardial
ischemia or episodes of myocardial ischemia provoked
7.11.1.4. Left Ventricular Function
Noninvasive imaging in patients recovering from STEMI
includes echocardiography and radionuclide imaging. This
section discusses the importance of measurement of LV
function. Either of the above imaging techniques can provide
clinically useful information.
Class I
Left ventricular ejection fraction should be measured
in all STEMI patients. (Level of Evidence: B)
Assessment of LV function after STEMI has been shown to
be one of the most accurate predictors of future cardiac
events in both the prereperfusion (1129) and the reperfusion
(1130,1131) eras. Multiple techniques for assessing LV func-
tion of patients after STEMI have important prognostic
value. Because of the dynamic nature of LV function recov-
ery after STEMI, clinicians should consider the timing of the
imaging study relative to the index event when assessing LV
function. (See Table 6 of the ACC/AHA/ASE 2003 Guide-
line Update for the Clinical Application of Echocardiography
for further discussion of the impact of timing on assessment
of LV function and inducible ischemia) (226). The assess-
ment can include such basic factors as clinical estimates
based on patients’ symptoms (e.g., exertional dyspnea, func-
tional status), physical findings (e.g., rales, murmurs, elevat-
ed jugular venous pressure, cardiomegaly, S3 gallop), and
measurement of ejection fraction by contrast ventriculogra-
phy, radionuclide ventriculography, and 2-dimensional
echocardiography. Zaret and colleagues (1130) found that an
LVEF less than 0.30 as assessed by radionuclide ventricu-
lography was still predictive of mortality in patients surviv-
ing infarction treated with fibrinolytic therapy, despite the
significantly reduced mortality of these patients compared
with those in the prereperfusion era. White and colleagues
(1132) performed contrast left ventriculography in 605
patients 1 to 2 months after MI. They found that postinfarc-
tion LV dilation, demonstrated by increased end-systolic vol-
ume greater than 130 ml, was an even better predictor of
mortality after MI than an LVEF less than 0.40 or increased
end-diastolic volume. In patients with normal ejection frac-
tions, however, end-systolic volume did not provide any fur-
ther stratification according to risk.
Assessment of LV function by different techniques may
produce different results. The SOLVD (Studies Of Left
Ventricular Dysfunction) investigators compared LVEF
determined by echocardiography or radionuclide angiogra-
phy and noted higher mortality for patients with LVEF less
than 0.35 by echocardiography than for patients with the
same value determined by the radionuclide technique (1133).
LVEFs derived by radionuclide angiography and by cardiac
catheterization were compared in the SAVE study, with high-
er values derived by catheterization (924). Radionuclear and
catheterization-derived LVEF were poorly correlated, but
lower values by either technique predicted a worse progno-
sis. In some circumstances, assessment of ventricular func-
tion by several techniques may be useful.
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Given the adverse clinical consequences of recurrent
infarction, it would be highly desirable to minimize the
chance of its occurrence after initial treatment for STEMI.
Routine referral for angiography of all patients after fibri-
nolytic therapy is intuitively attractive and supported indi-
rectly by retrospective analyses from trials of fibrinolytic
therapy that suggest that patients treated with PCI during the
index hospitalization had a lower risk of recurrent MI and a
lower 2-year mortality (512). However, previous randomized
trials testing a strategy of routine catheterization after fibri-
nolysis suggested that such an approach was deleterious
(480,503,505,516,1148). However, the previous trials were
conducted in an era during which aspirin was inconsistently
administered, high doses of UFH without monitoring of acti-
vated clotting time were used, and the interventional
catheters, radiographic imaging equipment, and supportive
antiplatelet agents were suboptimal. The Writing Committee
encourages contemporary research into the benefit of routine
catheterization versus watchful waiting after fibrinolytic
therapy in the contemporary era (1149,1149a). See Section
6.3.1.6.4.7.
7.11.1.7. Ambulatory ECG Monitoring for Ischemia
The value of ambulatory ECG monitoring in assessing
reversible myocardial ischemia and the risk of a subsequent
coronary event early after MI has been evaluated in a number
of studies (1150-1157). Up to 25% of patients will show
residual ischemia detected on ambulatory ECG monitoring.
Most episodes of transient myocardial ischemia are silent
and occur at rest or during times of low-level physical activ-
ity or mental stress (1158). During long-term follow-up stud-
ies, a number of investigators have reported that the presence
of ischemia detected by ambulatory ECG monitoring in the
postinfarction period is predictive of a subsequent poor out-
come and increases the risk of cardiac events (1150-1157).
One study found that the odds ratio for patients with ambu-
latory ischemia, compared with those without it, was 2.3 for
death or nonfatal MI at 1 year (1157). 
Despite the promising initial results with ambulatory ECG
monitoring, the totality of evidence does not support a gen-
eral statement about its role in patients with STEMI. Some
studies have shown that the results of ambulatory ECG mon-
itoring could be predicted from exercise test data
(1152,1155), whereas others have found that additional prog-
nostic information could be obtained by ambulatory ECG
monitoring in postinfarction patients (1153). At present, a
cost-effective strategy has not been developed to identify
patients who are at increased risk for ambulatory ischemia
and in whom ambulatory ECG monitoring might be more
helpful for stratification into high- and low-risk subgroups
for future coronary events.
7.11.1.8. Assessment of Ventricular Arrhythmias
Class IIb
Noninvasive assessment of the risk of ventricular
arrhythmias may be considered (including signal-
averaged ECG, 24-hour ambulatory monitoring,
by minimal exertion during recovery from STEMI.
(Level of Evidence: A)
2. Coronary arteriography should be performed for
intermediate- or high-risk findings on noninvasive
testing after STEMI (see Table 23 of the ACC/AHA
2002 Guideline Update for the Management of
Patients With Chronic Stable Angina) (71). (Level of
Evidence: B)
3. Coronary arteriography should be performed if the
patient is sufficiently stable before definitive therapy
of a mechanical complication of STEMI, such as acute
MR, VSR, pseudoaneurysm, or LV aneurysm. (Level
of Evidence: B)
4. Coronary arteriography should be performed in
patients with persistent hemodynamic instability.
(Level of Evidence: B)
5. Coronary arteriography should be performed in sur-
vivors of STEMI who had clinical heart failure during
the acute episode but subsequently demonstrated
well-preserved LV function. (Level of Evidence: C)
Class IIa
1. It is reasonable to perform coronary arteriography
when STEMI is suspected to have occurred by a mech-
anism other than thrombotic occlusion of an athero-
sclerotic plaque. This would include coronary
embolism, certain metabolic or hematological dis-
eases, or coronary artery spasm. (Level of Evidence: C)
2. Coronary arteriography is reasonable in STEMI
patients with any of the following: diabetes mellitus,
LVEF less than 0.40, CHF, prior revascularization, or
life-threatening ventricular arrhythmias. (Level of
Evidence: C)
Class IIb
Catheterization and revascularization may be consid-
ered as part of a strategy of routine coronary arteri-
ography for risk assessment after fibrinolytic therapy
(see Section 6.3.1.6.4.7). (Level of Evidence: B)
Class III
Coronary arteriography should not be performed in
survivors of STEMI who are thought not to be candi-
dates for coronary revascularization. (Level of
Evidence: A)
In contrast to noninvasive testing, coronary arteriography
provides detailed structural information to allow an assess-
ment of prognosis and to provide direction for appropriate
management. Indications for coronary arteriography are
interwoven with indications for possible therapeutic plans
such as PCI or CABG. All survivors of STEMI who are can-
didates for revascularization therapy with spontaneous
ischemia, intermediate- or high-risk findings on noninvasive
testing, hemodynamic or electrical instability, mechanical
defects, prior revascularization, or high-risk clinical features
should be considered for coronary arteriography.
Percutaneous coronary intervention or CABG may be con-
sidered in these patients if they are found to have significant
obstructive coronary artery disease (1145-1147). 
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Baroreceptor sensitivity also quantifies the influence of
parasympathetic tone on the heart. It is measured as the slope
of a regression line relating beat-to-beat heart rate change in
response to a change in blood pressure, often accomplished
by giving a small bolus of phenylephrine (1169). Reductions
in baroreflex sensitivity have been associated with an
increased susceptibility to arrhythmic events and sudden
death in experimental models and initial clinical reports
(1170-1172).
Finally, abnormalities in ventricular repolarization are
detectable by microvolt alterations of T-wave amplitude, or
T-wave alternans. In experimental preparations, the presence
of T-wave alternans was predictive of a lower fibrillation
threshold. Clinical studies have demonstrated that T-wave
alternans is associated with ventricular arrhythmias during
EP testing, as well as with clinically evident arrhythmias.
Microvolt T-wave alternans was subsequently shown to be
associated with inducible ventricular arrhythmias during pro-
grammed ventricular stimulation and spontaneous arrhyth-
mic events (1173,1174). 
The clinical applicability of these tests to the post-STEMI
patient is in a state of evolution. Although the negative pre-
dictive value of most of these tests taken in isolation is high
(generally greater than 90%), the positive predictive value is
unacceptably low (less than 30%). Whereas the positive pre-
dictive value of noninvasive testing for future arrhythmic
events can be modestly increased by combining several test
results, the therapeutic implications of positive findings are
unclear. Insufficient data are available to indicate whether
general therapies, such as beta-adrenoceptor blockade, ACE
inhibition, and revascularization procedures, or specific
interventions, such as treatment with amiodarone or an ICD,
targeted toward high-risk patients identified by a combina-
tion of noninvasive tests after MI can more favorably impact
mortality (1175). The widening indications for ICD implan-
tation in patients with LV dysfunction may encourage the use
of these studies to find the lowest-risk patients (i.e., those
without any high-risk markers whatsoever) to avoid ICD
implantation. Finally, it is difficult to justify the costs of the
routine use of these procedures in the absence of demon-
strated clinical benefits. Until these issues are resolved, these
tests are used only to support routine management and risk
assessment. 
7.12. Secondary Prevention
Class I
Patients who survive the acute phase of STEMI
should have plans initiated for secondary prevention
therapies. (Level of Evidence: A)
Secondary prevention therapies, unless contraindicated, are
an essential part of the management of all patients with
STEMI (Table 32) (68), regardless of sex (69,1176).
Inasmuch as atherosclerotic vascular disease is frequently
found in multiple vascular beds, the physician should search
heart rate variability, micro T-wave alternans, and T-
wave variability) in patients recovering from STEMI.
(Level of Evidence: B)
A number of noninvasive strategies have been used to try to
identify patients at high risk for arrhythmic events. Although
most of these measure some aspect of the excessive activa-
tion of the autonomic nervous system commonly observed in
high-risk patients with LV dysfunction, others measure
impulse conduction through the infarct zone. Thus, noninva-
sive determinants of arrhythmia risk encompass measure-
ment of changes in ventricular repolarization, alterations of
autonomic tone, and delayed and disordered myocardial con-
duction. 
The most frequently used techniques are signal-averaged or
high-resolution ECG, heart rate variability, baroreflex sensi-
tivity, and T-wave alternans. Signal-averaged electrocardiog-
raphy identifies delayed, fragmented conduction in the
infarct zone in the form of late potentials at the terminus of
the QRS complex and represents an anatomic substrate that
predisposes the patient to re-entrant VT. Kuchar et al. (1159)
reported that late potentials predict an increased incidence of
sudden death in the post-MI patient population. Gomes et al
(1160) found late potentials to be the best single predictor
when considering Holter monitoring and ejection fraction
and found that they contributed independently to a combined
index, although the positive predictive value of each was
poor. The filtered QRS duration was the most predictive fea-
ture of signal-averaged electrocardiography in a Cardiac
Arrhythmia Suppression Trial (CAST) substudy (1161).
More recent studies have shown that reperfusion therapy
reduces the incidence of late potentials after STEMI (1162).
In the setting of frequent use of fibrinolysis, the predictive
value of signal-averaged electrocardiography has been vari-
able (1163-1165).
Heart rate variability, an analysis of the beat-to-beat varia-
tion in cycle length, largely reflects the sympathovagal inter-
action that regulates heart rate. Heart rate variability can be
quantified in a number of ways, with either time- or frequen-
cy-domain parameters (1166). Low heart rate variability,
indicative of decreased vagal tone, is a predictor of increased
mortality, including sudden death, in patients after MI
(1166,1167) and may add significant prognostic information
to other parameters (1167). The Autonomic Tone and
Reflexes After Myocardial Infarction (ATRAMI) study
(1168) was a prospective multicenter study that enrolled
1284 patients with a recent (fewer than 28 days) MI.
Decreased heart rate variability was a significant and inde-
pendent predictor of cardiac mortality (hazard ratio 3.2, p
equals 0.005) (1168). 
The predictive value of heart rate variability after STEMI,
although significant, is modest when used alone. In combi-
nation with other techniques, its positive predictive accuracy
improves. The most practical, feasible, and cost-efficient
combination of noninvasive predictive tests with heart rate
variability remains to be determined. 
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adherence to practice guidelines for the management of
patients after STEMI is associated with significant reduc-
tions in short- and long-term mortality (1186).
7.12.1. Patient Education Before Discharge
Class I
1. Before hospital discharge, all STEMI patients should
be educated about and actively involved in planning
for adherence to the lifestyle changes and drug thera-
pies that are important for the secondary prevention
of cardiovascular disease. (Level of Evidence: B)
2. Post-STEMI patients and their family members
should receive discharge instructions about recogniz-
ing acute cardiac symptoms and appropriate actions
to take in response (i.e., calling 9-1-1 if symptoms are
unimproved or worsening 5 minutes after onset, or if
symptoms are unimproved or worsening 5 minutes
after 1 nitroglycerin dose sublingually) to ensure early
evaluation and treatment should symptoms recur.
(Level of Evidence: C)
3. Family members of STEMI patients should be advised
to learn about AEDs and CPR and be referred to a
CPR training program. Ideally, such training pro-
grams would have a social support component target-
ing family members of high-risk patients. (Level of
Evidence: C)
Once STEMI has occurred, secondary prevention, includ-
ing aggressive risk factor management through medical and
lifestyle therapy, is the mainstay of therapy. 
It is important for providers in the inpatient setting to com-
municate with the patient’s primary care provider to facilitate
coordination of care. The discharge summary should include
the patient’s medical, psychological, and functional status;
prescribed medication and lifestyle regimens; and the
patient's living/social support situation (1187).
Effective education is critical to enlist patients’ full partici-
pation in therapeutic regimens and secondary prevention
efforts and to minimize their natural concerns and anxieties.
It ideally leads to a patient who is better informed and more
satisfied with his or her care and who is also able to achieve
a better quality of life and improved survival (71,688,1188-
1190). In general, the outcomes of educational interventions
depend on the outcome studied (e.g., largest for knowledge
change, smallest for behavioral and psychological outcomes)
(692) and the strategies applied (688).
Principles of Patient Education. A thorough discussion of
the philosophies of and approaches to patient education is
beyond the scope of this guideline. There are useful reviews
on this topic (688,692,1191), including a few that focus on
ischemic heart disease (1192-1194). Well-designed educa-
tional programs can improve patients’ knowledge and in
some instances can improve outcomes (688,1195). These
approaches form the basis for commonly used educational
programs, such as those conducted before CABG (1196) and
after MI (690,1197). A variety of guidelines should be fol-
for symptoms or signs of peripheral vascular disease or cere-
brovascular disease in patients presenting with STEMI.
Approximately 70% of CHD deaths and 50% of MIs occur
in patients who have previously established coronary artery
disease (677). It is estimated that the likelihood of fatal and
nonfatal MI is 4 to 7 times higher in patients with apparent
coronary disease. The institution of secondary prevention
therapies and risk reduction strategies in patients recovering
from STEMI represents major opportunities to reduce the
toll of cardiovascular disease.
Smoking cessation, aggressive lipid lowering, control of
hypertension and diabetes, and prophylactic use of aspirin,
beta-blockers, and ACE inhibitors are key components of
secondary prevention that have a demonstrated benefit.
Dietary cholesterol contributes to elevations in LDL-C and
should be included in the list of dietary modifications (reduc-
tion in total calories, saturated fat, cholesterol, and salt and
increase in vegetables, fruits, and grain fiber) given to the
post-STEMI patient. These changes are both directly benefi-
cial and aid in hypertension control and lipid lowering. The
specifics of these therapies and recommendations for their
use are discussed in the following sections (68).
Secondary prevention services remain discouragingly
underutilized (1177) despite the compelling evidence for and
large magnitude of their benefits (1178-1180). The ACC and
AHA urge all healthcare providers to implement systems that
ensure the reliable identification of patients who can benefit
from secondary prevention interventions and to ensure that
these interventions occur (1181,69). Evidence exists that
lifestyle modifications (as discussed below), including regu-
lar physical exercise, weight reduction, cessation of cigarette
smoking, and stress reduction strategies, have a favorable
impact on blood coagulation, fibrinolysis, and platelet reac-
tivity, shifting the patient to a less atherogenic and pro-
thrombotic state (Table 32) (68,1182). Referral to outpatient
cardiac rehabilitation can aid in attainment of these goals
(1183,1184).
Many institutions have clinical pathways for improving
quality of care of patients with STEMI (205). Use of clinical
pathways or other management protocols in hospital settings
has resulted in improved adherence to therapy by CHD
patients and better cholesterol control. The Cardiac
Hospitalization Atherosclerosis Management Program
(CHAMP) focused on the initiation of therapy with aspirin,
beta-blockers, ACE inhibitors, statins, diet, and exercise in
persons with established CHD before hospital discharge
(1185). There was a significant increase in the use of aspirin,
beta-blockers, ACE inhibitors, and statin therapy. The pro-
gram used postdischarge follow-up visits to titrate the statin
dose to achieve an LDL-C level less than 100 mg/dL. One
year after discharge, 91% of patients were being treated with
cholesterol-lowering therapy, and 58% were at treatment
goals. These results suggest that the initiation of treatment
during hospitalization for CHD adds needed emphasis to the
importance of cholesterol-lowering treatment along with
other cardiac medications. There was also a reduction in
recurrent MI and 1-year mortality. Evidence exists that
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that travels with the patient) may provide consistency,
document material taught, identify goals that remain,
and promote independent study, an effective education
strategy (688,1191).
6. Although any planned teaching strategy is better than
none (688), computer-assisted instruction is the newest
approach to patient education. Patients without comput-
er access can be directed to a work station in the physi-
cian’s office, clinic, hospital education department/
library, or local library, where relevant pages can be
printed. A review of the literature on computer-based
approaches to patient education supports the use of com-
puter-based education as an effective strategy for trans-
fer of knowledge and skill development for patients
(1204). The World Wide Web is convenient for medical
personnel and patients with access to personal comput-
ers. The AHA maintains a Web site (http://www.ameri-
canheart.org) that presents detailed and practical dietary
recommendations and information about heart disease,
physical activity, heart attacks, and CPR. The NHLBI
Web site (http://www.nhlbi.nih.gov) has links to the
National High Blood Pressure Education Program,
NCEP, and the NHAAP’s “Act In Time to Heart Attack
Signs,” which have information for patients and profes-
sionals. Both the ACC’s “Guidelines Applied in
Practice” program (http://www.acc.org/gap/images/
Discharge.gif) and the AHA’s “Get With the Guidelines
Hospital Tool Kit” (http://www.americanheart.org/
downloadable/heart/1107_HospTool.pdf) provide dis-
charge information as part of a separate patient-specific
discharge form (Guidelines Applied in Practice) or
incorporated into a patient pathway (Get With the
Guidelines). The discharge information for patients
reviews and documents the important lifestyle changes
and drug therapies for the secondary prevention of car-
diovascular disease that are part of their discharge
instructions. An important issue currently receiving
attention is the issue of health literacy. Studies with
patients and the public have found average reading abil-
ities do not exceed the eighth-grade level (688,695). The
current recommendation is that materials be written at
the sixth-grade level to ensure that the maximum num-
ber of people can read and understand them.
7. Develop an action plan with the patient for their long-
term management. If it is necessary to convey a great
deal of information to patients about their condition, be
cognizant of the patient’s level of sophistication, readi-
ness to change, prior educational attainment, language
barriers, relevant clinical factors, and social support. A
realistic goal might be to motivate an internal change
that results in the patient’s desire to ask for information
on an important topic such as smoking cessation (691).
It may be counterproductive to attempt to coax a patient
into simultaneously changing several behaviors, such as
smoking, diet, and exercise, and taking (and purchasing)
multiple new medications. Achieving optimal adherence
often requires talking to patients to identify barriers to
lowed to help ensure that educational efforts are successful
(71):
1. Assess the patient’s baseline understanding. This not
only establishes a starting point for education but also
engages the patient. Healthcare providers are often sur-
prised at the idiosyncratic notions that patients have
about their own medical conditions and therapeutic
approaches (688,1198,1199).
2. Elicit the patient's desire for information. Adults prefer
to set their own agendas, and they learn better when they
can control the flow of information.
3. Use epidemiological and clinical evidence. As clinical
decision making becomes increasingly based on scien-
tific evidence, it is reasonable to share that evidence with
patients. Epidemiological data can assist in formulating
an approach to patient education, such as conveying
information on the major cardiovascular disease risk fac-
tors. Scientific evidence about the reduction in cardio-
vascular disease risk to be derived from risk factor mod-
ification/lowering can help persuade patients about the
effectiveness of various interventions.
4. Use allied professional personnel. Even though physi-
cians may feel constrained with the limited amount of
time available for a patient encounter, interpersonal con-
tact with and encouragement from physicians is never-
theless a vital component of the patient’s overall health
education. Medical encounters represent powerful
“teaching moments” for initiating discussion and shap-
ing perceptions and expectations, and they are perceived
as highly credible sources of information (1200,1201).
In many settings, trained health educators, many of
whom specialize in diabetes or cardiac disease, are avail-
able. Personnel from disciplines such as nursing, physi-
cal therapy, nutrition, pharmacy, and others can provide
reinforcement, more in-depth information, and ongoing
educational support and thus have much to offer patients
with ischemic heart disease (1202). Reimbursement for
educational activities by these allied providers is poor,
although this can also be accomplished as part of a car-
diac rehabilitation program for which funding is gener-
ally available. 
5. Use professionally prepared resources when available.
Studies have shown that combined teaching strategies,
including written and audiovisual materials in addition
to verbal instruction, group approaches, and enhanced
education methods, are the most effective in achieving
desired outcomes (688,692,1192). The decreasing
length of hospital stays has raised concern about ade-
quate opportunity for appropriate patient education
(369,697), although short educational sequences can
produce outcomes comparable to lengthy sessions (690).
Innovative presentation styles (e.g., programmed
instruction, audiovisual techniques, and health education
television programs) can produce benefits comparable to
individual educational sessions (1203). Use of a single
repository for all educational materials (e.g., a binder
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cous) fiber, and whole grains. Calorie intake should be
balanced with energy output to achieve and maintain
a healthy weight. (Level of Evidence: A)
2. A lipid profile should be performed, or obtained from
recent past records, for all STEMI patients, prefer-
ably after they have fasted and within 24 hours of
symptom onset. (Level of Evidence: C)
3. The target LDL-C level after STEMI should be sub-
stantially less than 100 mg/dL. (Level of Evidence: A) 
a. Patients with LDL-C 100 mg/dL or above should be
prescribed drug therapy on hospital discharge, with
preference given to statins. (Level of Evidence: A)
b. Patients with LDL-C less than 100 mg/dL or
unknown LDL-C levels should be prescribed statin
therapy on hospital discharge. (Level of Evidence: B)
4. Patients with non–high-density lipoprotein choles-
terol (HDL-C) levels less than 130 mg/dL who have
an HDL cholesterol level less than 40 mg/dL should
receive special emphasis on nonpharmacological
therapy (e.g., exercise, weight loss, and smoking ces-
sation) to increase HDL. (Level of Evidence: B)
Class IIa
1. It is reasonable to prescribe drug therapy at hospital
discharge to patients with non–HDL-C greater than
or equal to 130 mg/dL, with a goal of reducing
non–HDL-C to substantially less than 130 mg/dL.
(Level of Evidence: B)
2. It is reasonable to prescribe drugs such as niacin or
fibrate therapy to raise HDL-C levels in patients with
LDL-C less than 100 mg/dL and non–HDL-C less
than 130 mg/dL but HDL-C less than 40 mg/dL
despite dietary and other nonpharmacological thera-
py. Dietary-supplement niacin must not be used as a
substitute for prescription niacin, and over-the-count-
er niacin should be used only if approved and moni-
tored by a physician. (Level of Evidence: B)
3. It is reasonable to add drug therapy with either niacin
or a fibrate to diet regardless of LDL and HDL levels
when triglyceride levels are greater than 500 mg/dL.
In this setting, non–HDL-C (goal substantially less
than 130 mg/dL) should be the cholesterol target
rather than LDL-C. Dietary-supplement niacin must
not be used as a substitute for prescription niacin, and
over-the-counter niacin should be used only if
approved and monitored by a physician. (Level of
Evidence: B)
Early secondary prevention trials conducted before the use
of statin therapy, using the then-available drugs and diet to
lower cholesterol, demonstrated significant reductions of
25% in nonfatal MIs and 14% in fatal MIs (59).
Subsequently, a growing body of evidence derived mainly
from large randomized clinical trials of statin therapy has
firmly established the desirability of lowering atherogenic
serum lipids in patients who have recovered from a STEMI. 
compliance such as complex regimens and cost of med-
ications (1205) and addressing these barriers through
problem solving with the patient. 
8. Involve family members in educational efforts. It is
advisable and often essential to include family members
in educational efforts. Many activities require the partic-
ipation of family members; an example is meal prepara-
tion. Efforts to encourage smoking cessation, weight
loss, or increased physical activity may be enhanced by
enlisting the support of family members who can rein-
force the behavior and may themselves benefit from par-
ticipation.
9. Remind, repeat, and reinforce. Almost all learning dete-
riorates without reinforcement. At regular intervals, the
patients’ understanding should be reassessed, and key
information should be repeated as warranted. Feedback
is a powerful motivator, and patients should be congrat-
ulated for progress even when their ultimate goals are
not fully achieved. Even though the patient who has
reduced his or her use of cigarettes from 2 packs to 1
pack per day has not quit smoking, that 50% reduction
in exposure is important and may simply represent a
milestone on the path to complete cessation (688).
The secondary prevention targets for post-STEMI patients,
around which education and follow-up/management should
occur, are discussed in the following sections.
Within 6 years after a recognized heart attack, 18% of men
and 35% of women will have another heart attack (46); most
episodes of cardiac arrest occur within 18 months after hos-
pital discharge for STEMI (1206). Thus, it is critical that
patients and family members are educated in advance about
recognition of acute ischemic symptoms and the appropriate
action steps to take to ensure early evaluation and treatment
(see Section 3.3). Furthermore, patients who have had a
STEMI have a sudden death rate that is 4 to 6 times that of
the general population (46). Thus, family members of
patients with STEMI should be advised to learn CPR and
should be given community resources to obtain this training.
In addition, research has shown that patients whose family
members received a social support intervention in conjunc-
tion with being taught CPR reported better psychosocial
adjustment and less anxiety and hostility than those whose
families received CPR training only or CPR training with
risk factor education. Family members should be referred to
a CPR program that combines CPR training with social sup-
port (132,133). (See Section 4.2.) 
7.12.2. Lipid Management 
Class I
1. Dietary therapy that is low in saturated fat and cho-
lesterol (less than 7% of total calories as saturated fat
and less than 200 mg/d cholesterol) should be started
on discharge after recovery from STEMI. Increased
consumption of the following should be encouraged:
omega-3 fatty acids, fruits, vegetables, soluble (vis-
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tension to simvastatin 40 mg or placebo for a mean follow-
up of 5 years. The primary end point, total mortality, was sig-
nificantly reduced with statin treatment (1.8% ARD; 12%
RRR, p equals 0.0003). The advantages of simvastatin thera-
py were demonstrated in all important prespecified sub-
groups, including women, patients more than 75 years old,
diabetics, and individuals with baseline LDL-C of less than
100 mg/dL. The study supports the benefit of statin therapy
for all groups and argues for the use of statins among patients
with CHD and LDL-C values 100 to 129 mg/dL who had
previously been considered candidates for diet and lifestyle
changes to lower LDL-C before implementation of statin
therapy (59).
Approximately 25% of patients who have recovered from
STEMI demonstrate desirable total cholesterol values but a
low HDL-C fraction on a lipid profile. Low HDL-C is an
independent risk factor for development of coronary artery
disease (1214), and therefore a rationale exists for attempting
to raise HDL-C when it is found to be low in the patient with
coronary artery disease. The Veterans Affairs High-Density
Lipoprotein Cholesterol Intervention Trial (VA-HIT) (1215)
revealed that modification of other lipid risk factors can
reduce risk for CHD when LDL-C is in the range of 100 to
129 mg/dL. In this trial, male patients with a relatively low
LDL-C (mean 112 mg/dL) were treated with gemfibrozil for
5 years. Gemfibrozil therapy, which raised HDL-C and low-
ered triglycerides, reduced the primary end point of fatal and
nonfatal MI (4.4% ARD; 22% RRR) without significantly
lowering LDL-C levels. There was no evidence of an
increased risk of non-CHD mortality. This trial supports the
concept that when LDL-C is in the range of 100 to 129
mg/dL, the use of other lipid-modifying drugs (e.g., fibrates)
is a therapeutic option if the patient has a low HDL-C (less
than 40 mg/dL). 
The effect of hypertriglyceridemia is somewhat controver-
sial because in many cases, the triglyceride level varies
inversely with HDL-C levels. However, if hypertriglyc-
eridemia (triglyceride greater than 200 mg/dL) exists after
lifestyle changes such as diet and exercise and statin therapy
have been initiated, it is recommended that additional thera-
py be initiated to lower triglycerides for patients with estab-
lished CHD (59). In this setting, the target goal of therapy
should be non–HDL-C less than 130 mg/dL.
Diet and drug treatments available for the correction of
lipid abnormalities are as effective in the elderly as in the
young. Clinical trials have shown that such treatment can
reduce total mortality up to age 70 years (1207) and the rate
of recurrent coronary events up to age 75 years (1208). In
addition, the PROSPER trial (1208) studied the value of lipid
control for the prevention of initial coronary events in 5804
older persons (2804 men and 3000 women aged 70 to 82
years). Treatment with pravastatin 40 mg daily resulted in a
reduction in LDL-C by 34% and significantly reduced the
primary end point (CHD death, nonfatal MI, and fatal or non-
fatal stroke) over 3.2 years (2.1% ARD; 15% RRR). Unlike
previous trials involving elderly patients, the risk of stroke in
PROSPER was unaffected, possibly because of the relatively
The Scandinavian Simvastatin Survival Study (1207)
reported results in 4444 men and women with CHD and
moderate hypercholesterolemia observed over 5.4 years.
Coronary heart disease mortality was reduced by 42% and
total mortality by 30% among those receiving simvastatin
compared with placebo. The relative risk reduction seen in
this trial was similar among those with the lowest quartile
compared with the highest quartile of baseline serum LDL-
C. The CARE trial was a similar study in a population of
patients who had recovered from an earlier MI and whose
total cholesterol (mean 209 mg/dL) and LDL-C (mean 139
mg/dL) were essentially the same as the average for the gen-
eral US population. In this trial, 4159 patients were random-
ly assigned to either 40 mg of pravastatin a day or placebo.
After a median follow-up of 5 years, there was a significant
reduction in the primary end point of fatal CHD and nonfatal
confirmed MIs in the pravastatin cohort (3% ARD; 24%
RRR; p equals 0.003) (1208). 
The results of the large Long-Term Intervention With
Pravastatin in Ischemic Disease (LIPID) Study have been
reported for more than 9000 patients randomly assigned to
either placebo or 40 mg of pravastatin daily (1209). The trial
was conducted in patients with a prior history of MI or unsta-
ble angina. Patient age at time of entry ranged from 21 to 75
years. The LIPID trial was stopped prematurely because of
the efficacy of pravastatin in reducing major cardiovascular
events, including significant decreases in CHD deaths (1.9%
ARD; 24% RRR), total mortality rate (3.1% ARD; 22%
RRR), and stroke (0.8% ARD; 19% RRR). Benefit has also
been seen in patients with symptomatic coronary disease
who were treated with fluvastatin. In the Lescol in Severe
Atherosclerosis (LiSA) Study, patients with symptomatic
CHD and hypercholesterolemia who were given fluvastatin
had 71% fewer cardiac events than those in the placebo
group (1210).
The effect of cholesterol lowering combined with low-
intensity oral anticoagulation on late saphenous vein graft
status has also been investigated (1211). In an angiographic
trial attempting to reduce atherosclerosis in saphenous vein
grafts after CABG surgery, aggressive lowering of LDL to
less than 100 mg/dL with lovastatin 40 to 80 mg daily (and 8
g of cholestyramine daily, if needed), in addition to a Step I
AHA diet, achieved a significant reduction (2.7% ARD; 29%
RRR) in obstructive changes in the vein grafts at 4 to 5 years
compared with moderate lipid lowering to an LDL-C of 132
to 136 mg/dL (1211). There was no benefit of low-dose war-
farin therapy at 5 years. The results of 7.5-year follow-up
revealed significant reductions of 30% in revascularization
and 24% for the composite end point (death, nonfatal MI,
stroke, CABG, or PCI) in the group treated with aggressive
lipid-lowering therapy. The investigators concluded that the
study provided support for the NCEP recommendation that
LDL-C levels should be reduced to less than 100 mg/dL in
patients who have coronary artery disease (1212). 
The Heart Protection Study (1213) trial randomized more
than 20 000 men and women aged 40 to 80 years with coro-
nary disease, other vascular disease, diabetes, and/or hyper-
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benefits were observed in all important subgroups, including
men and women, young and old, and patients with and with-
out diabetes. These data support the early, intensive treatment
of patients with acute coronary syndromes to LDL-C goals
substantially less than 100 mg/dL with statin therapy. Patients
hospitalized with CHD who start lipid-lowering therapy
before discharge have been shown to be nearly 3 times as
likely to be taking medication at 6 months as those starting
therapy after discharge (1220).
7.12.3. Weight Management
Class I
1. Measurement of waist circumference and calculation
of body mass index are recommended. Desirable body
mass index range is 18.5 to 24.9 kg/m2. A waist cir-
cumference greater than 40 inches in men and 35
inches in women would result in evaluation for meta-
bolic syndrome and implementation of weight-reduc-
tion strategies. (Level of Evidence: B)
2. Patients should be advised about appropriate strate-
gies for weight management and physical activity
(usually accomplished in conjunction with cardiac
rehabilitation). (Level of Evidence: B)
3. A plan should be established to monitor the response
of body mass index and waist circumference to thera-
py (usually accomplished in conjunction with cardiac
rehabilitation). (Level of Evidence: B)
Obesity is a recognized major risk factor for cardiovascular
disease and an important component of the metabolic syn-
drome (59). The clinical criteria for the metabolic syndrome
include any 3 of the following: waist circumference greater
than 40 inches in men and greater than 35 inches in women;
triglycerides of at least 150 mg/dL; HDL-C less than 40
mg/dL in men or less than 50 mg/dL in women; blood pres-
sure greater than 130 mmHg systolic and greater than 85 mm
Hg diastolic; and fasting blood glucose of at least 110
mg/dL. The metabolic syndrome contributes significantly to
CHD risk. Its treatment has weight control and physical
activity as primary strategies. Because approximately 65% of
the US adult population is overweight or obese (1221), it is
suggested that this risk factor be carefully addressed as part
of the secondary prevention strategy for all patients after
STEMI. The suggested goal should be the achievement or
maintenance of a healthy weight, defined in the “Dietary
Guidelines for Americans” (1222) as a body mass index from
18.5 to 24.9 kg/m2. It is suggested that overweight patients be
instructed in a weight loss regimen as part of their cardiac
rehabilitation program after STEMI, with emphasis on the
importance of regular exercise and a lifelong prudent diet to
maintain healthy weight. Weight reduction enhances lower-
ing of other risk factors for cardiovascular disease, including
LDL-C, triglycerides, impaired glucose, and blood pressure.
An initial weight loss of 10% of body weight achieved over
6 months is a recommended target. The rate of weight loss
should be 1 to 2 pounds each week.
short duration of the trial. Among elderly patients, other risk
factors such as high blood pressure, cigarette smoking, and
diabetes are frequently present. Thus, it is especially impor-
tant in this group, as in younger patients, to develop compre-
hensive treatment programs, such as cardiac rehabilitation, to
address all risk factors that might contribute to future CHD
events in addition to treating their dyslipidemia. 
The early secondary prevention trials of statins specifically
excluded patients with STEMI in the acute phase. Thus,
although the data supporting the efficacy and benefit of statin
therapy for patients after STEMI are robust, statin therapy in
the early studies was started 4 to 6 months after STEMI.
Subsequent studies have addressed the potential benefits of
early initiation of statin therapy during hospitalization for
acute coronary syndrome. The results from several of these
studies, wherein statins were initiated during the hospital
phase of acute coronary syndromes, indicate improved car-
diovascular outcomes. The Lipid-Coronary Artery Disease
trial (1216) randomized 126 patients with acute coronary syn-
drome to early treatment with pravastatin with or without
cholestyramine or niacin therapy versus usual care. Treatment
initiated during hospitalization significantly reduced clinical
events at 2 years. The Myocardial Ischemia Reduction with
Aggressive Cholesterol Lowering (MIRACL) trial random-
ized 3086 patients admitted for acute coronary syndrome to
treatment with atorvastatin 80 mg per day or placebo within
96 hours after admission (1217). The primary end point of
death, nonfatal MI, resuscitated cardiac arrest, or recurrent
severe myocardial ischemia was reduced from 17.4% to
14.8% (p equals 0.048) by treatment with atorvastatin. The
major clinical benefits were fewer strokes and a lower risk of
severe recurrent ischemia among those treated with atorvas-
tatin. In the Swedish Registry of Cardiac Intensive Care of
nearly 20 000 patients, a 25% reduction in mortality at 1 year
was observed among patients when statin therapy was initiat-
ed before hospital discharge (1218). Early initiation of thera-
py has been recommended by the NCEP (59). The Pravastatin
or Atorvastatin Evaluation and Infection Therapy-
Thrombolysis in Myocardial Infarction 22 study (PROVE-IT-
TIMI 22) (1219) compared intensive lipid-lowering therapy
to moderate lipid-lowering therapy initiated within 10 days
after hospital admission in 4162 patients with acute coronary
syndrome. Lipid lowering to a goal of LDL-C less than 100
mg/dL (median 95 mg/dL) with pravastatin 40 mg per day
was compared with lipid-lowering to a goal of LDL-C less
than 70 mg/dL (median 62 mg/dL) with atorvastatin 80 mg
daily. After 2 years of therapy, the primary end point (death
due to any cause, MI, unstable angina requiring rehospital-
ization, coronary revascularization, and stroke) was 26.3%
for the group undergoing moderate lipid-lowering therapy
and 22.4% in the intensive lipid-lowering group, reflecting a
16% reduction in the hazard ratio favoring intensive lipid-
lowering therapy (p equals 0.005). Benefits were observed
within 30 days of initiation of therapy and occurred at all lev-
els of LDL-C, even among those patients with LDL-C less
than 100 mg/dL, although the greatest benefit was seen
among patients with LDL-C of 125 mg/dL or greater. The
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between nicotine patches and first-time MI (1233). Several
studies have suggested that nicotine replacement therapy
does not increase the risk for cardiovascular events, even in
people with underlying CHD (1234-1237), although the
studies had few or no patients with MI (1235-1237) and were
not designed (1235) or sufficiently powered (1234) to exam-
ine cardiovascular effects. Thus, routine use of these agents
is not recommended during hospitalization for STEMI
because of the sympathomimetic effects of the active ingre-
dient, nicotine. However, the dose of nicotine in gums and
patches is significantly lower than that found in cigarettes
and may be preferable to cigarette smoking if the patient is
experiencing acute withdrawal. Therefore, at the time of dis-
charge, if blood pressure and heart rate are stable, these
agents may be used in selected patients. Clonidine has been
shown to be effective in women but not men (1238); the rea-
son for this finding is unclear. Lobeline has not been shown
to have an advantage over placebo (1239-1241) but is again
under investigation. 
Bupropion has been shown to help smokers quit
(1242,1243). Nicotine intake is reinforced by activating the
central nervous system to release norepinephrine, dopamine,
and other neurotransmitters. Bupropion is a weak inhibitor of
the neuronal uptake of neurotransmitters. A study of 615 sub-
jects randomly assigned to take placebo or bupropion
achieved good initial quit rates with treatment augmented by
brief counseling at baseline, weekly counseling during treat-
ment, and intermittent counseling for up to 1 year (1244).
Seven weeks of treatment with bupropion was associated
with a smoking cessation rate of 28.8% (100 mg/d), 38.6%
(150 mg/d), and 44.2% (300 mg/d); 19.6% of subjects
assigned to placebo quit (p less than 0.001). At 1 year, 12.4%
of the placebo group and 19.6% (100 mg/d), 22.9% (150
mg/d), and 23.1% (300 mg/d) of the bupropion group
remained abstinent. The drug was well tolerated (37 [8%] of
462 stopped treatment prematurely because of headache,
insomnia, or dry mouth), although the study was insuffi-
ciently powered to detect an incidence of seizures known to
occur with related medications. It reduced the weight gain
common in smokers who quit. Bupropion appears to be a
valuable option for patients who need to quit smoking after
STEMI. In an actual large group-practice setting, the combi-
nation of slow-release bupropion and minimal or moderate
counseling was associated with 1-year quit rates of 24% and
33%, respectively (1243).
7.12.5. Antiplatelet Therapy
Class I
1. A daily dose of aspirin 75 to 162 mg orally should be
given indefinitely to patients recovering from STEMI.
(Level of Evidence: A)
2. If true aspirin allergy is present, preferably clopido-
grel (75 mg orally per day) or, alternatively, ticlopi-
dine (250 mg orally twice daily) should be substituted.
(Level of Evidence: C)
7.12.4. Smoking Cessation
Class I
1. Patients recovering from STEMI who have a history
of cigarette smoking should be strongly encouraged to
stop smoking and to avoid secondhand smoke.
Counseling should be provided to the patient and fam-
ily, along with pharmacological therapy (including
nicotine replacement and bupropion) and formal
smoking cessation programs as appropriate. (Level of
Evidence: B)
2. All STEMI patients should be assessed for a history of
cigarette smoking. (Level of Evidence: A)
Smoking cessation is essential for patients with STEMI.
Smoking triggers coronary spasm, reduces the anti-ischemic
effects of beta-adrenoceptor blockers, and doubles mortality
after STEMI (1223-1225). Smoking cessation reduces rates
of reinfarction and death within 1 year of quitting, but one
third to one half of patients with STEMI relapse within 6 to
12 months (1226). Because exposure to secondary cigarette
smoke has been identified as a risk factor, family members
who live in the same household should also be encouraged to
quit smoking to help reinforce the patient’s effort and to
decrease the risk of secondhand smoke (1227). 
The most effective strategies for encouraging quitting are
those that identify the patient's level or stage of readiness and
provide information, support, and, if necessary, pharma-
cotherapy targeted at the individual’s readiness and specific
needs (66,1228). Houston-Miller and Taylor (1229) advocate
a stepped approach to smoking cessation:
a. Provide a firm, unequivocal message to quit smoking
b. Determine whether the patient is willing to quit
c. Determine the best quitting method
d. Plan for problems associated with withdrawal
e. Set a quit date
f. Help the patient cope with urges to smoke
g. Provide additional help as needed
h. Follow-up by telephone call or visit
The stepwise strategies are summarized in Table 30 of the
ACC/AHA 2002 Guideline Update for the Management of
Patients with Chronic Stable Angina (71). 
The most effective pharmacological adjuncts for treating
nicotine dependence are nicotine replacement therapy and
bupropion in the sustained-release form. When these are
combined with behavioral counseling, the best treatment out-
comes have been reported (1230). Nicotine replacement ther-
apy (gum and patches) has been shown to increase smoking
cessation rates, particularly when combined with counseling
(1231). Nicotine replacement therapy can mitigate symptoms
of nicotine withdrawal in recovering patients (1232). A pop-
ulation-based case-control study did not find an association
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small increase in risk of cerebral hemorrhage, which is
masked by the beneficial effects of aspirin in patients with an
increased risk for thromboembolic stroke but becomes man-
ifest in healthy individuals at very low risk for this event. 
Aspirin and NSAIDs are among the most commonly con-
sumed drugs. An interaction between aspirin and ibuprofen
on platelet function has been demonstrated in an in vivo
model, with concomitant administration of ibuprofen (but
not rofecoxib, diclofenac, or acetaminophen) antagonizing
the irreversible platelet inhibition induced by aspirin (1252).
A subsequent epidemiological study demonstrated increased
all-cause and cardiovascular mortality in patients with car-
diovascular disease taking aspirin plus ibuprofen compared
with those taking aspirin alone, aspirin plus diclofenac, or
aspirin plus other NSAIDs (1253). The use of NSAIDs in
patients taking aspirin was also assessed in an observational
subgroup analysis of the Physician's Health Study (1254).
Regular (greater than 60 days per year) use of NSAIDs inhib-
ited the clinical benefits of aspirin, although intermittent use
(fewer than 59 days per year) had no effect. These findings
suggest that ibuprofen may limit the cardioprotective effects
of aspirin. Pending further data, clinicians should discourage
patients with cardiovascular disease who are taking aspirin
from using ibuprofen on a regular basis.
7.12.6. Inhibition of the Renin-Angiotensin-
Aldosterone System
Class I
1. An ACE inhibitor should be prescribed at discharge
for all patients without contraindications after
STEMI. (Level of Evidence: A)
2. Long-term aldosterone blockade should be prescribed
for post-STEMI patients without significant renal
dysfunction (creatinine should be less than or equal to
2.5 mg/dL in men and less than or equal to 2.0 mg/dL
in women) or hyperkalemia (potassium should be less
than or equal to 5.0 mEq/L) who are already receiving
therapeutic doses of an ACE inhibitor, have an LVEF
less than or equal to 0.40, and have either sympto-
matic heart failure or diabetes. (Level of Evidence: A)
3. An ARB should be prescribed at discharge to those
STEMI patients who are intolerant of an ACE
inhibitor and have either clinical or radiological signs
of heart failure and LVEF less than 0.40. Valsartan
and candesartan have established efficacy for this rec-
ommendation. (Level of Evidence: B)
Class IIa
In STEMI patients who tolerate ACE inhibitors, an
ARB can be useful as an alternative to ACE inhibitors
in the long-term management of STEMI patients, pro-
vided there are either clinical or radiological signs of
heart failure or LVEF less than 0.40. Valsartan and
candesartan have established efficacy for this recom-
mendation. (Level of Evidence: B)
3. If true aspirin allergy is present, warfarin therapy
with a target INR of 2.5 to 3.5 is a useful alternative to
clopidogrel in patients less than 75 years of age who
are at low risk for bleeding and who can be monitored
adequately for dose adjustment to maintain a target
INR range. (Level of Evidence: C)
Class III
Ibuprofen should not be used because it blocks the
antiplatelet effects of aspirin. (Level of Evidence: C)
On the basis of 12 randomized trials in 18788 patients with
prior infarction, the Antiplatelet Trialists’ Collaboration
reported a 25% reduction in the risk of recurrent infarction,
stroke, or vascular death in patients receiving prolonged
antiplatelet therapy (36 fewer events for every 1000 patients
treated) (263). No antiplatelet therapy has proved superior to
aspirin in this population, and daily doses of aspirin between
80 and 325 mg appear to be effective (1245). The CAPRIE
trial, which compared aspirin with clopidogrel in 19 185
patients at high risk for vascular events, demonstrated a
modest but significant reduction in serious vascular events
with clopidogrel compared with aspirin (0.51% ARD; 8.6%
RRR; p equals 0.043) (742). These data suggest clopidogrel
as the best alternative to aspirin in patients with true aspirin
allergy.
These compelling data suggest that all patients recovering
from STEMI should, in the absence of contraindications,
continue taking aspirin for an indefinite period (1246).
Clopidogrel or ticlopidine may be substituted in patients with
true aspirin allergy.
The use of warfarin therapy for secondary prevention of
vascular events in patients after STEMI is discussed in
Section 7.12.11. Large randomized trials have demonstrated
that oral anticoagulants, when given in adequate doses,
reduce the rates of adverse outcomes, at the cost of a small
increase in hemorrhagic events (1247-1249). In the Warfarin,
Aspirin, Reinfarction Study (WARIS II), warfarin without
aspirin in a dose intended to achieve an INR of 2.8 to 4.2
resulted in a significant reduction in a composite end point
(death, nonfatal reinfarction, or thromboembolic stroke)
compared with therapy with aspirin alone (16.7% versus
20.0%) (1247). Warfarin therapy resulted in a small but sig-
nificant increase in major, nonfatal bleeding compared with
therapy with aspirin alone (0.62% per year versus 0.17% per
year). Chronic therapy with warfarin after STEMI presents
an alternative to clopidogrel in patients with aspirin allergy.
A small increase in incidence of stroke in healthy men
treated with aspirin was reported in both the American physi-
cian and the British doctors primary prevention studies
(1250,1251). However, there has been no evidence of an
increased incidence of stroke in studies in which aspirin was
used for secondary prevention of coronary artery disease.
These secondary prevention trials clearly indicate that in
patients with clinical manifestations of atherosclerotic dis-
ease, aspirin reduces risk of stroke. It is likely that as a con-
sequence of its antihemostatic effect, aspirin produces a
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STEMI. The HOPE trial evaluated the effect of long-term (4
to 6 years) ACE inhibition therapy with ramipril 10 mg per
day in 9297 high-risk patients, 2480 of whom were women.
Fifty-two percent of the patients had a history of MI, and in
10%, the MI was within 1 year. Overall, there was a highly
significant reduction in the combined end point of MI,
stroke, and all-cause cardiovascular mortality (3.8% ARD;
22% RRR; p less than 0.001). Significant reductions were
seen for each individual component of the primary end point:
MI 2.4% ARD, RRR 20%; stroke 1.5% ARD, RRR 32%; and
death of any cause 1.8% ARD, RRR 16%. Importantly, the
study was performed in patients who were not known to have
low ejection fraction or heart failure. The European Trial on
Reduction of Cardiac Events With Perindopril in Stable
Coronary Artery Disease (EUROPA) evaluated the use of the
ACE inhibitor perindopril given 8 mg per day among 13 655
patients (age range 26 to 89 years, mean 60 years) with
known CHD but no history of clinical heart failure (1262).
Nearly two thirds (64%) of the patients had a history of pre-
vious MI (more than 3 months before screening). After a
mean follow-up of 4.2 years, treatment with perindopril was
associated with a significant reduction (2% ARD; 20% RRR;
p equals 0.0003) in the combined end point of nonfatal MI,
cardiovascular mortality and resuscitated cardiac arrest. The
benefit began to appear at 1 year and gradually progressed
throughout the trial. Patients in EUROPA all had CHD but a
lower risk than those in HOPE, in which the enrollment age
was 55 years or older and 39% had diabetes. In EUROPA,
nearly one third of the patients were younger than 55 years,
and fewer had diabetes and hypertension. Moreover, the ben-
efits of ACE inhibitor therapy with perindopril were
observed in spite of relatively high use of other secondary
prevention therapies such as platelet inhibitors (91%), lipid-
lowering medications (69%), and beta-blockers (63%).
Given the results of the HOPE trial and the secondary analy-
sis from the initial ACE inhibitor trials, ACE inhibitor thera-
py is recommended for all patients after STEMI unless oth-
erwise contraindicated.
The results of the VALIANT study evaluating the ARB val-
sartan are discussed in Section 7.4.3. The series of CHARM
studies (Candesartan in Heart Failure Assessment in
Reduction of Mortality, although focusing on the evaluation
of the ARB candesartan in patients with chronic heart failure,
provides information that can be extrapolated to the long-
term management of the STEMI patient, because 50% to
60% of the patients studied had ischemic heart disease as the
cause of heart failure. In patients with symptomatic heart
failure and LVEF 0.40 or less who were intolerant of ACE
inhibitors (CHARM-Alternative trial), candesartan (target
dose 32 mg once daily) was more effective than placebo in
preventing cardiovascular death or hospital admission for
heart failure (7% ARD; 23% RRR) (1263). In patients with
symptomatic heart failure and LVEF 0.40 or less who were
being treated with an ACE inhibitor (CHARM-Added trial),
candesartan (target dose 32 mg) was more effective than
placebo in preventing cardiovascular death or hospital admis-
sion for heart failure (4% ARD; 15% RRR) (1264). In
Class IIb
The combination of an ACE inhibitor and an ARB
may be considered in the long-term management of
STEMI patients with persistent symptomatic heart
failure and LVEF less than 0.40. (Level of Evidence: B)
The use of ACE inhibitors early in the acute phase of
STEMI and in the hospital management phase has been
described earlier in Sections 6.3.1.6.9.1 and 7.4.3. Through
their ability to interfere with ventricular remodeling, thereby
attenuating ventricular dilation over time, ACE inhibitors
improve clinical outcomes among patients with LV dysfunc-
tion (LVEF less than 0.40) after STEMI. The clinical result
is a lessened likelihood for development of CHF, recurrent
MI, and death. They are also of value in patients without clin-
ical evidence of CHF but with a history of previous MI, in
whom they have been shown to reduce cardiovascular mor-
tality, future MI, and cardiac arrest. 
These observations, coupled with experience in both the rat
model of STEMI (1255) and large randomized clinical trials
(585,1256,1257), have established that use of ACE inhibitors
begun after a patient has recovered from STEMI improves
long-term survival, provided the infarct was large and anteri-
or in location, and results in significant impairment of LV
contractility. Specifically, in the SAVE trial, patients took
captopril at a mean 11 days after onset of infarction, which
resulted in an approximate 20% reduction in mortality
(1256). The Acute Infarction Ramipril Efficacy (AIRE) trial,
in which patients who had been in clinical heart failure dur-
ing the first day of their infarct and then were randomly
assigned to either ramipril or placebo an average of 5 days
after onset of infarction, resulted in significant risk reduction
in all-cause mortality (6% ARD; 27% RRR) (1257).
Similarly, the TRACE trial, in which patients with LV dys-
function on echocardiogram were randomly assigned to
receive either trandolapril or placebo a median of 4 days after
onset of infarction, demonstrated a significant reduction in
mortality (7.6% ARD; 22% RRR) (1258). 
The SOLVD trial evaluated the ACE inhibitor enalapril in
4228 asymptomatic patients with LVEF less than 0.35, 80%
of whom had experienced a prior MI (1259). However,
randomization was performed considerably later on the aver-
age than in the SAVE and AIRE trials. This prevention arm
of the SOLVD trial revealed a trend toward improved mor-
tality but not a statistically significant difference (1260). On
the other hand, SOLVD did demonstrate a significant risk
reduction of 20% for the combined end points of death or
development of CHF requiring hospitalization. 
In secondary analyses of the initial ACE inhibitor trials, the
benefit of treatment appeared to be primarily in patients with
anterior infarctions or LVEF below 0.40. However, based on
post hoc analysis of the SAVE trial, in which the likelihood
of recurrent MI was reduced by approximately 25% in treat-
ed patients, studies were initiated to determine the benefits of
ACE inhibitor therapy among patients with known CHD but
no clinical evidence for CHF (1261). Compelling evidence
now supports the broad chronic use of ACE inhibitors after
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receive beta-blocker therapy. Treatment should begin
within a few days of the event, if not initiated acutely,
and continue indefinitely. (Level of Evidence: A)
2. Patients with moderate or severe LV failure should
receive beta-blocker therapy with a gradual titration
scheme. (Level of Evidence: B)
Class IIa
It is reasonable to prescribe beta-blockers to low-risk
patients after STEMI who have no contraindications
to that class of medications. (Level of Evidence: A)
The use of beta-blockers in the early phase of STEMI and
in hospital management is reviewed in Sections 6.3.1.6 and
7.4.1. The benefits of beta-blocker therapy in patients with-
out contraindications have been demonstrated with or with-
out reperfusion, initiated early or later in the clinical course,
and for all age groups. The greatest mortality benefit is seen
in patients with the greatest baseline risk: those with
impaired ventricular function or ventricular arrhythmias and
those who do not undergo reperfusion (1266,1267). The ben-
efits of beta-blocker therapy for secondary prevention are
well established (717,1012). In patients with moderate or
severe LV failure, beta-blocker therapy should be adminis-
tered with a gradual titration scheme (1268). Long-term beta-
blocker therapy should be administered to survivors of
STEMI who have subsequently undergone revascularization,
because there is evidence of a mortality benefit from their
use despite revascularization either with CABG surgery or
with PCI (1269).
Given these well-documented benefits, it is disturbing that
this therapy continues to be underused, especially in high-
risk groups such as the elderly (1270). Beta-blockers should
be prescribed for all high-risk patients provided no con-
traindications are present. In patients with an extremely good
prognosis (first STEMI, good ventricular function, no angi-
na, negative stress test, and no complex ventricular ectopy),
the effect of beta-blockers on survival will be less (1271).
However, beta-blockers are often prescribed for these
patients to minimize the likelihood of recurrent ischemic
symptoms and to help control surges of heart rate and blood
pressure with exertion.
Although relative contraindications may once have been
thought to preclude the use of beta-blockers in some patients,
evidence now suggests that the benefits of beta-blockers in
reducing reinfarctions and mortality may actually outweigh
the risks, even in patients with mild asthma not currently
active, insulin-dependent diabetes mellitus, chronic obstruc-
tive pulmonary disease, severe peripheral vascular disease,
PR interval greater than 0.24 seconds, and moderate LV fail-
ure. The use of beta-blockers in such patients requires moni-
toring to be certain that adverse events do not occur
(1270,1272,1273).
Some controversy exists as to how long patients should be
treated (1274). Data from large trials suggest that therapy
should be continued for at least 2 to 3 years (851,1275).
Thereafter, if the beta-blocker is well tolerated, such therapy
patients with symptomatic heart failure but with a preserved
LVEF (greater than 0.40; CHARM-Preserved trial), can-
desartan had no impact on cardiovascular death compared
with placebo but was associated with a trend toward fewer
admissions for heart failure (1265).
Given the extensive randomized trial and routine clinical
experience with ACE inhibitors, they remain the logical first
agent for inhibition of the renin-angiotensin-aldosterone sys-
tem in the long-term management of patients with STEMI
(726). The ARBs valsartan and candesartan should be admin-
istered over the long term to patients with STEMI with
symptomatic heart failure who are intolerant of ACE
inhibitors. As described in Section 7.4.3, the choice between
an ACE inhibitor and an ARB in patients who are tolerant of
ACE inhibitors over the long term will vary with individual
physician and patient preference, as well as cost and antici-
pated side-effect profile (726). 
The results of the most relevant clinical trials testing com-
binations of ACE inhibitors and ARBs have subtly different
but clinically relevant results. Whereas the CHARM-Added
(1264) trial demonstrated a reduction in the combined end
point of heart failure hospitalization and death over ACE
inhibition alone, the VALIANT study (725) reported that the
combination of captopril and valsartan was equivalent to
either alone, but with a greater number of adverse effects.
Thus, when combination ACE inhibition and angiotensin
receptor blockade is considered, the preferred ARB is can-
desartan. Although there is evidence that the combination of
an ACE inhibitor and an aldosterone inhibitor is effective at
reducing mortality and is well tolerated in patients with a
serum creatinine less than or equal to 2.5 mg/dL and serum
potassium concentration less than or equal to 5.0 mmol/L
(see Section 7.4.3), much less experience exists with the
combination of an ARB and an aldosterone inhibitor (24% of
2028 patients in the CHARM-Alternative trial) and the triple
combination of an ACE inhibitor, ARB, and an aldosterone
antagonist (17% of 2548 patients in the CHARM-Added
trial) (1263,1264).
The combination of an ACE inhibitor and an ARB (valsar-
tan 20 mg orally per day initially, titrated up to 160 mg oral-
ly twice per day, or candesartan 4 to 8 mg orally per day ini-
tially, titrated up to 32 mg orally per day) or an ACE inhibitor
and an aldosterone inhibitor may be considered for the long-
term management of patients with STEMI with symptomatic
heart failure and ejection fraction less than 0.40, provided the
serum creatinine is less than or equal to 2.5 mg/dL in men
and less than or equal to 2.0 mg/dL in women and serum
potassium concentration is less than or equal to 5.0 mEq/L.
(See Sections 7.4.3 and 7.6.4.)
7.12.7. Beta-Blockers
Class I
1. All patients after STEMI except those at low risk
(normal or near-normal ventricular function, success-
ful reperfusion, absence of significant ventricular
arrhythmias) and those with contraindications should
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should probably be continued in most patients, although data
are lacking.
7.12.8. Blood Pressure Control
Class I
1. Blood pressure should be treated with drug therapy to
less than 140/90 mmHg and to less than 130/80 mmHg
for patients with diabetes or chronic kidney disease.
(Level of Evidence: B)
2. Lifestyle modification (weight control, dietary
changes, physical activity, and sodium restriction)
should be initiated in all patients with blood pressure
greater than or equal to 120/80 mm Hg. (Level of
Evidence: B)
Class IIb
A target goal of 120/80 mm Hg for post-STEMI
patients may be reasonable. (Level of Evidence: C)
Class III
Short-acting dihydropyridine calcium channel block-
ing agents should not be used for the treatment of
hypertension. (Level of Evidence: B)
The Seventh Report of the Joint National Committee on
Prevention, Detection, Evaluation, and Treatment of High
Blood Pressure (JNC-7) (1276) recommends that patients be
treated after MI with ACE inhibitors, beta-blockers, and, if
necessary, aldosterone antagonists to a target blood pressure
of less than 140/90 mm Hg, or less than 130/80 mm Hg for
those with chronic kidney disease or diabetes (1276). Most
patients will require 2 or more drugs to reach goal, and when
the blood pressure is greater than 20/10 mm Hg above goal,
2 drugs should usually be used from the outset. The
Antihypertensive and Lipid-Lowering Treatment to Prevent
Heart Attack Trial (ALLHAT) (1277) demonstrated that an
antihypertensive regimen based on a thiazide diuretic was
equal to an ACE inhibitor– or long-acting calcium channel
blocker–based regimen in coronary outcomes and superior in
other outcomes (CHF, stroke). Most patients received a beta-
blocker in addition to the thiazide.
Beta-blockers reduce the risk for subsequent MI or sudden
cardiac death and are indicated in all patients after STEMI
absent specific contraindications; they may be especially
efficacious in patients with CHF. In general, beta-blockers
without intrinsic sympathomimetic activity should be used.
Beta-blockers are sufficiently important that they should be
withheld only for high-grade heart block, demonstrated intol-
erance, or other absolute contraindications. Most patients
with asthma are able to tolerate cardioselective beta-blockers
(1278). Because of the demonstrated effectiveness of thi-
azide diuretics for reducing adverse outcomes, they should
be strongly considered when a second or third agent is need-
ed. ACE inhibitors (or ARBs if ACE inhibitors are not toler-
ated) should be used long term for the treatment of hyper-
tension when LV dysfunction is present to prevent subse-
quent heart failure and mortality (1279). ACE inhibitors and
ARBs have been shown to favorably affect the progression of
diabetic and nondiabetic kidney disease but should be given
with careful attention to the development of hyperkalemia
(1276). Long-acting calcium channel blockers may be used
if other agents are not tolerated or are not sufficient to reach
blood pressure goal. Short-acting calcium antagonists should
not be used (636). 
JNC-7 emphasizes the importance of lifestyle modifica-
tions for all patients with blood pressure of 120/80 mmHg or
greater (1276). These modifications include: weight reduc-
tion if overweight or obese, consumption of a diet rich in
fruits and vegetables and low in total fat and saturated fat,
and reduction of sodium to no more than 2.4 g/d (1276). 
7.12.9. Diabetes Management
Class I
Hypoglycemic therapy should be initiated to achieve
HbA1C less than 7%. (Level of Evidence: B)
Class III
Thiazolidinediones should not be used in patients
recovering from STEMI who have New York Heart
Association class III or IV heart failure. (Level of
Evidence: B)
Tight glucose control in diabetics during and after STEMI
has been shown to lower acute and 1-year mortality rates
(602). Tight glucose control, defined as an HbA1C of less
than 7.0%, reduces microvascular disease and is strongly rec-
ommended, although further data are needed regarding its
specific benefits for macrovascular disease (1280). Control
of hyperglycemia has been shown to reduce diabetes-related
events, including MI (2.7% absolute reduction; 16% relative
reduction), for patients aged 25 to 65 years with newly
detected type 2 diabetes but without symptomatic macrovas-
cular disease (1280). 
Thiazolidinediones are frequently used as monotherapy or
in combination with other oral hypoglycemic agents, insulin,
and diet for control of diabetes. Although thiazolidinediones
may be helpful in combating insulin resistance and thereby
may improve vascular, neurohormonal, and myocardial func-
tion, their use may also be associated with fluid retention and
an increase in LV preload (1281) that is resistant to diuretics.
Therefore, thiazolidinediones should not be used in patients
recovering from STEMI who have New York Heart
Association class III or IV heart failure (1281,1282). 
7.12.10. Hormone Therapy
Class III
1. Hormone therapy with estrogen plus progestin should
not be given de novo to postmenopausal women after
STEMI for secondary prevention of coronary events.
(Level of Evidence: A)
2. Postmenopausal women who are already taking estro-
gen plus progestin at the time of a STEMI should not
continue hormone therapy. However, women who are
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CHD in the hormone therapy–assigned women in the latter
years of HERS did not persist during additional observation.
Hormone therapy did not reduce CHD events after 6.8 years.
The Estrogen Replacement and Atherosclerosis (ERA) trial
showed no effect of estrogen alone or estrogen plus proges-
terone on the progression of coronary artery disease, despite
favorable effects on lipids (1292). A small randomized con-
trolled trial of transdermal estradiol for women after non–ST-
elevation acute coronary syndrome showed no benefit, with
a trend toward excess events (1294). The Women's Health
Initiative (WHI) Hormone Trial (HT) includes a group of
women who have had hysterectomies (10 000) and receive
unopposed estrogen and women with intact uteruses who
receive the same estrogen plus progestin used in HERS
(1295-1297). Participants are not required to have CHD and
are generally younger than those in the HERS cohort. The
HT trial completed its enrollment of 27 348 women and
planned to report the results of the trial in 2005 after 9 years
of treatment. However, the data and safety monitoring board
recommended early termination of the combination of estro-
gen and progestin trial after 5.2 years’ average follow-up on
the basis of an excess of invasive breast cancer (HR 1.26,
1.00 to 1.59) and CHD (HR 1.29, 1.02 to 1.63), stroke (HR
1.41, 1.07 to 1.85), and pulmonary embolism (HR 2.13, 1.39
to 3.25) in study participants receiving active hormone
replacement therapy. The estrogen-only versus placebo trial
of the WHI study is continuing. In the Women’s
Angiographic Vitamin and Estrogen (WAVE) Trial, assign-
ment to conjugated equine estrogen, with or without prog-
estin, resulted in worsening of angiographic and clinical out-
comes (1298,1299). In a similar trial, WELL-HART
(Women's Estrogen-Progestin Lipid-Lowering Hormone
Atherosclerosis Regression Trial), there was no effect of 17-
beta-estradiol, with or without progestin, on angiographic
progression of disease (1299). Of note, no randomized trial
enrolled women within 3 to 6 months of an acute coronary
syndrome.
Inherited thrombophilias may increase the risk of thrombo-
sis due to estrogen (1300). However, none have been clearly
identified that would permit screening and exclusion of
women at excess risk. The role of selective estrogen receptor
modulators is yet to be defined (1291,1293,1301). On the
basis of WHI, HERS, and HERS II, postmenopausal women
should not receive combination estrogen and progestin ther-
apy for primary or secondary prevention of CHD
(1287,1293,1297). It is recommended that hormone therapy
be discontinued for women who have STEMI (1297).
However, women who are beyond 1 to 2 years after initiation
of HT and wish to continue it for another compelling indica-
tion should weigh the risks and benefits, recognizing a
greater risk of cardiovascular events. Hormone therapy
should not be continued while patients are on bedrest in the
hospital.
beyond 1 to 2 years after initiation of hormone thera-
py who wish to continue such therapy for another
compelling indication should weigh the risks and ben-
efits, recognizing a greater risk of cardiovascular
events. Hormone therapy should not be continued
while patients are on bedrest in the hospital. (Level of
Evidence: B)
Landmark randomized clinical trials have provided firm
evidence that combination estrogen and progestin replace-
ment therapy should not be used for either primary or sec-
ondary prevention of cardiovascular disease in women.
Observational studies (1283,1284) have been interpreted as
indicating that oral unopposed estrogen is effective in pri-
mary prevention of cardiovascular disease. Confounding fac-
tors such as compliance (1285), selection bias, and baseline
health in these studies make it difficult to be certain of the
effect of estrogen therapy alone.
Clinical trials have shown that estrogen given alone or in
combination with progestin improves the lipid profile and
lowers fibrinogen (1286). Favorable effects of estrogen on
the lipid profile would theoretically be expected to produce a
favorable result in preventing coronary atherosclerosis.
However, combining estrogen with a progestin (hormone
therapy) (1287) reduces the potential beneficial effect of
estrogen given alone on the lipid profile. In addition, hor-
mone therapy has been reported to increase high-sensitivity
C-reactive protein levels (1288).
The first large-scale, randomized, double-blind, placebo-
controlled trial that addressed the question of estrogen plus
progestin for secondary prevention of CHD in post-
menopausal women was published by Hulley et al. (1287) for
the Heart and Estrogen/progestin Replacement Study
(HERS) Research Group. Contrary to conventional wisdom
and several observational studies (1289-1292), this trial of
3763 postmenopausal women with established coronary dis-
ease and an average age of 66.7 years found no reduction in
overall risk for nonfatal MI or coronary death, nor any other
cardiovascular outcome, during an average of 4.1 years of
follow-up when comparing 0.625 mg of conjugated equine
estrogen plus 2.5 mg of medroxyprogesterone acetate in 1
tablet daily (1380 patients) to placebo (1383 patients). 
This lack of an overall effect occurred despite a net 11%
lower LDL-C level and a 10% higher HDL-C level in the
group given hormone therapy compared with the placebo
group (p less than 0.001). There was a statistically significant
time trend, however, with more primary coronary events in
the hormone therapy group than in the placebo group in year
1 and fewer in years 4 and 5. However, the latter was due to
nonfatal MI, because CHD deaths were similar in the 2
groups in years 4 and 5. More women in the hormone group
than in the placebo group experienced venous thromboem-
bolic events (34 versus 12; RR 2.89; 95% CI 1.50 to 5.58)
and gallbladder disease (84 versus 62; RR 1.38; 95% CI 1.00
to 1.92). HERS II extended the unblinded follow-up of the
HERS cohort (93% of survivors) for an additional 2.7 years
(total 6.8 years of observation) (1293). The lower rates of
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Several trials (1247-1249,1303-1305) have examined the
use of moderate- and high-intensity warfarin in secondary
prevention. Two of these trials, WARIS II and APRICOT
(Antithrombotics in the Prevention of Reocclusion In
Coronary Thrombolysis) II, were STEMI specific. In the
APRICOT II trial (1249), patients less than 75 years old with
STEMI received UFH, aspirin, and fibrinolytic therapy.
Those who achieved TIMI 3 flow were randomized to aspirin
alone (80 mg) or warfarin (INR 2 to 3) plus 80 mg of aspirin.
The combined group had fewer reocclusions (15% versus
28%; p less than 0.02) and a significant reduction in the com-
bined end points of death, MI, and revascularization (20%
ARD; 23% RRR; p less than 0.01) (Figure 37; Table 33)
(1248,1249,1303-1305).
The WARIS II study of 3630 subjects compared high-
intensity warfarin (INR 2.8 to 4.2) alone, medium-intensity
warfarin (INR 2 to 2.5) plus aspirin (75 mg), and aspirin
alone (160 mg) (1303). Patients were less than 75 years of
age. At follow-up in 4 years, the combined group had a lower
risk for an event (death, nonfatal reinfarction, thromboem-
bolic cerebral stroke) (3.3% ARD; 29% RRR; p equals 0.03)
and the high-intensity warfarin group had a lower risk (5%
ARD; 19% RRR; p equals 0.001) than the aspirin group.
There was no survival difference, and the benefit resulted
from a reduction in nonfatal MI and nonfatal thromboembol-
ic stroke. Bleeding was more common in the warfarin
groups, and approximately 35% of patients discontinued
warfarin therapy (Figure 37; Table 33) (1248,1249,1303-
1305).
In ASPECT (Anticoagulants in the Secondary Prevention
of Events in Coronary Thrombosis) II, aspirin (81 mg)
(1248) was compared with high-intensity anticoagulation
(INR 3 to 4) and with medium-intensity warfarin (INR 2 to
2.5) plus aspirin (1248) for secondary prevention in 999 sub-
jects (1308). Significantly fewer patients in the high-dose
warfarin and the combined regimen had death, MI, or stroke
than in the aspirin group (5%, 5%, and 9%, respectively).
Major bleeding was low in all groups. Minor bleeding was
higher in the combined group. However, almost 20% of the
warfarin and combined group discontinued therapy, and only
about 40% remained in the therapeutic range.
Although in these studies, medium-intensity warfarin plus
low-dose aspirin clearly reduced the rate of nonfatal rein-
farctions and nonfatal strokes, this was achieved at the
expense of increased bleeding and significant dropout rates.
Patients over 75 years of age have not been studied ade-
quately. Therefore, the Writing Committee wishes to make
no definitive recommendation in this age group at this time.
The high rate of discontinuation and the relatively large num-
ber of patients not on target remain problematic. Unless there
are indications for anticoagulation, at this time, the Writing
Committee reserves its current level IIa recommendation for
those patients under 75 years of age and not at risk of bleed-
ing who are at high risk for reinfarction or thromboembolic
events and who can be monitored reliably. For patients in
whom anticoagulation is indicated, warfarin (INR 2.5 to 3.5)
or medium-intensity warfarin (INR 2.0 to 3.0) plus aspirin
7.12.11. Warfarin Therapy
Class I
1. Warfarin should be given to aspirin-allergic post-
STEMI patients with indications for anticoagulation
as follows:
a. Without stent implanted (INR 2.5 to 3.5) (Level of
Evidence: B). 
b. With stent implanted and clopidogrel 75 mg/d
administered concurrently (INR 2.0 to 3.0) (Level
of Evidence: C)
2. Warfarin (INR 2.5 to 3.5) is a useful alternative to
clopidogrel in aspirin-allergic patients after STEMI
who do not have a stent implanted. (Level of
Evidence: B)
3. Warfarin (INR 2.0 to 3.0) should be prescribed for
post-STEMI patients with either persistent or parox-
ysmal AF. (Level of Evidence: A)
4. In post-STEMI patients with LV thrombus noted on
an imaging study, warfarin should be prescribed for
at least 3 months (Level of Evidence: B) and indefi-
nitely in patients without an increased risk of bleed-
ing. (Level of Evidence: C)
5. Warfarin alone (INR 2.5 to 3.5) or warfarin (INR 2.0
to 3.0) in combination with aspirin (75 to 162 mg)
should be prescribed in post-STEMI patients who
have no stent implanted and who have indications for
anticoagulation. (Level of Evidence: B)
Class IIa
1. In post-STEMI patients less than 75 years of age with-
out specific indications for anticoagulation who can
have their level of anticoagulation monitored reliably,
warfarin alone (INR 2.5 to 3.5) or warfarin (INR 2.0
to 3.0) in combination with aspirin (75 to 162 mg) can
be useful for secondary prevention. (Level of
Evidence: B)
2. It is reasonable to prescribe warfarin to post-STEMI
patients with LV dysfunction and extensive regional
wall-motion abnormalities. (Level of Evidence: A)
Class IIb
Warfarin may be considered in patients with severe
LV dysfunction, with or without CHF. (Level of
Evidence: C)
The indications for long-term anticoagulation after STEMI
remain controversial and are evolving. Although the use of
warfarin has been demonstrated to be cost-effective com-
pared with standard therapy without aspirin, the superior
safety, efficacy, and cost-effectiveness of aspirin has made it
the antithrombotic agent of choice for secondary prevention
(Figure 37; Table 33) (1248,1249,1302-1305). Two trials
failed to demonstrate a statistically significant reduction in
the combined end points of death, reinfarction, or stroke
using a regimen of low-dose aspirin in combination with
low-dose warfarin (INR less than 2) (1306,1307). 
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LV thrombus after STEMI had better outcomes and fewer
cerebral emboli when they underwent anticoagulation with
heparin and warfarin. Despite the absence of controlled stud-
ies, late thromboembolism was reduced in postinfarction
patients with LV aneurysm treated with warfarin in a number
of studies (1314-1316). A cohort analysis from the SOLVD
trial (1318) demonstrated that warfarin use was associated
with improved survival and reduced morbidity in post-MI
patients with LV dysfunction. Other studies and a Cochrane
review suggest that we be cautious in recommending war-
farin for this indication alone (1017,1319). Warfarin is indi-
cated in patients with persistent AF after STEMI, given the
results of multiple trials in other patients with AF (955,958).
7.12.12. Physical Activity
Class I
1. On the basis of assessment of risk, ideally with an
exercise test to guide the prescription, all patients
recovering from STEMI should be encouraged to
exercise for a minimum of 30 minutes, preferably
daily but at least 3 or 4 times per week (walking, jog-
ging, cycling, or other aerobic activity), supplemented
by an increase in daily lifestyle activities (e.g., walking
breaks at work, gardening, and household work).
(Level of Evidence: B)
(75 to 162 mg) may be used for secondary prevention. When
warfarin is used in combination with aspirin, an INR of 2.0
to 3.0 is acceptable with tight control, but the lower end of
the range is preferable (Figure 37). 
The use of clopidogrel and direct thrombin inhibitors in
STEMI remains to be studied more thoroughly. Although
definitive data are not available, the consensus of this
Writing Committee is that clopidogrel is preferred over war-
farin in aspirin-intolerant patients for secondary prevention
unless reasons for anticoagulation are present (Figure 37).
Patients who have undergone stenting may need to take
aspirin, clopidogrel, and warfarin (INR 2.0 to 3.0) if antico-
agulation is indicated (i.e., AF, LV thrombus, cerebral
emboli, or extensive regional wall-motion abnormality)
(Figure 37). In this situation, the Writing Committee believes
that clopidogrel may be stopped 1 month after a bare metal
stent is implanted and several months after a drug-eluting
stent is implanted (3 months after sirolimus and 6 months
after paclitaxel) because of the potential risk of bleeding with
warfarin and the antiplatelet agents (1309,1310). (See
Section 7.12.5.)
The previous ACC/AHA guidelines strongly recommended
the use of oral anticoagulants with an INR of 2.0 to 3.0 in
patients with a ventricular mural thrombus or a large akinet-
ic region of the LV for at least 3 months. In a meta-analysis
and other observational studies (1311-1317), patients with
Figure 37. Long-term antithrombotic therapy at hospital discharge after ST-elevation myocardial infarction (STEMI). ASA = aspirin; INR
= international normalized ratio; LOE = level of evidence. *Clopidogrel is preferred over warfarin because of increased risk of bleeding
and low patient compliance in warfarin trials. †For 12 months. ‡Discontinue clopidogrel 1 month after implantation of a bare metal stent
or several months after implantation of a drug-eluting stent (3 months after sirolimus and 6 months after paclitaxel) because of the
potential increased risk of bleeding with warfarin and 2 antiplatelet agents. Continue aspirin and warfarin long term if warfarin is indi-
cated for other reasons such as atrial fibrillation, LV thrombus, cerebral emboli, or extensive regional wall-motion abnormality. §An INR
of 2.0 to 3.0 is acceptable with tight control, but the lower end of this range is preferable. The combination of antiplatelet therapy and
warfarin may be considered in patients aged less than 75 years with low bleeding risk who can be monitored reliably.
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problematic. A prospective cohort study of more than 34 000
postmenopausal women suggested that an increase in dietary
vitamin E but not supplemental vitamin E was associated
with decreased cardiovascular risk (1330). In a randomized
trial involving 11 324 patients surviving recent (less than 3
months) MI, patients were assigned to treatment with the fol-
lowing: vitamin E (300 mg daily; n equals 2830); n-3
polyunsaturated fatty acids (1 g daily; n equals 2836); both
(n equals 2830); or neither (n equals 2828) for 3.5 years.
Treatment with n-3 polyunsaturated fatty acids but not vita-
min E significantly lowered the relative risk of the primary
end point (death, nonfatal MI, or stroke) by 10% (p equals
0.048) (1331). Thus, although dietary supplementation with
n-3 polyunsaturated fatty acids may have clinical benefits for
patients after STEMI, this trial failed to demonstrate a treat-
ment benefit for vitamin E. With regard to beta-carotene, sev-
eral prospective studies have convincingly shown a lack of
beneficial effect on cardiovascular disease (1332-1334), and
2 studies have indicated an increase in lung cancer with beta-
carotene treatment (1332,1333). 
There is even less evidence to support the use of water-sol-
uble enzymatic antioxidants for cardiovascular disease.
Although one study suggested reduced cardiovascular risk in
subjects taking supplemental vitamin C (1335), the majority
of other large epidemiological studies have not indicated a
benefit (1326-1328). Thus, routine use of vitamin C after
STEMI cannot be recommended. 
Despite promising experimental studies, recombinant
superoxide dismutase failed to reduce infarct size in a well-
controlled primary PCI trial (1336). One small study showed
a trend for reduced restenosis with vitamin E treatment after
coronary angioplasty (restenosis rate 35.5% for treatment
group versus 47.5% for placebo group; n equals 100, p
equals 0.06) (1337). A larger study evaluating the combina-
tion of vitamin E in association with omega-3 fatty acids 2
weeks before elective PCI showed no effect on the restenosis
rate (1338). 
Thus, there is no convincing evidence to support lipid- or
water-soluble antioxidant supplementation in patients after
STEMI or in patients with or without established coronary
disease (1338a). Because these agents are not harmless, the
growing practice of recommending antioxidant supplements
in these patients should be discouraged until the results of
ongoing, well-controlled studies become available and
unequivocally indicate a beneficial effect. An extensive
review of this subject has been published (1338).
8. LONG-TERM MANAGEMENT
8.1. Psychosocial Impact of STEMI
Class I
The psychosocial status of the patient should be eval-
uated, including inquiries regarding symptoms of
depression, anxiety, or sleep disorders and the social
support environment. (Level of Evidence: C)
2. Cardiac rehabilitation/secondary prevention pro-
grams, when available, are recommended for patients
with STEMI, particularly those with multiple modifi-
able risk factors and/or those moderate- to high-risk
patients in whom supervised exercise training is war-
ranted. (Level of Evidence: C)
Federal guidelines recommend that all Americans strive for
at least 30 minutes of moderate physical activity most days
of the week, preferably daily (1320). The 30 minutes can be
spread out over 2 or 3 segments during the day. For post-
patients with STEMI, daily walking can be encouraged
immediately after discharge. Physical activity is important in
efforts to lose weight because it increases energy expenditure
and plays an integral role in weight maintenance. Physical
activity reduces symptoms in patients with cardiovascular
disease and improves other cardiovascular disease risk fac-
tors. Beyond the instructions for daily exercise, patients
require specific instruction on those strenuous activities (e.g.,
heavy lifting, climbing stairs, yard work, household activi-
ties) that are permissible and those they should avoid. As
emphasized by the US Public Health Service, comprehensive
cardiac rehabilitation services include long-term programs
involving medical evaluation, prescribed exercise, cardiac
risk factor modification, education, and counseling (1184).
These programs are designed to limit the physiological and
psychological effects of cardiac illness, reduce the risk for
sudden death or reinfarction, control cardiac symptoms, sta-
bilize or reverse the atherosclerotic process, and enhance the
psychosocial and vocational status of selected patients.
Enrollment in a cardiac rehabilitation program after dis-
charge may enhance patient education and compliance with
the medical regimen and assist with the implementation of a
regular exercise program (1183,1322-1324). In addition to
aerobic training, mild- to moderate-resistance training is also
recommended. This can be started 2 to 4 weeks after aerobic
training has begun (1325).
7.12.13. Antioxidants
Class III
Antioxidant vitamins such as vitamin E and/or vita-
min C supplements should not be prescribed to
patients recovering from STEMI to prevent cardio-
vascular disease. (Level of Evidence: A)
Earlier observational data from epidemiological studies
suggested that an increased intake of lipid-soluble antioxi-
dant vitamins (vitamin E and beta-carotene) is associated
with reduced rates of cardiovascular events, including
STEMI (1326-1328). In support of these data, one random-
ized placebo-control study of vitamin E treatment in 2002
patients with documented coronary disease indicated a
reduction in nonfatal MI (27% ARD; 77% RRR) but no
effect on cardiovascular death or overall mortality (1329).
However, a midstudy change in the vitamin E dose and some
imbalance in the use of beta-adrenoceptor blockers in sub-
jects receiving vitamin E make interpretation of that study
e154
ACC - www.acc.org
AHA - www.americanheart.org
Antman et al. 2004
ACC/AHA Practice Guidelines
that the STEMI experience, with its sudden and unexpected
onset, dramatic changes in lifestyle, and the additive effort of
comorbid life events, is a relatively traumatic event and may
produce impaired coping during subsequent ischemic events
(1356).
Social integration and social support repeatedly have been
shown to influence outcomes after STEMI. Social integra-
tion refers to the existence of social ties (e.g., spouse, close
family members, or friends) and degree of participation in
group activities (e.g., family gatherings, religious affilia-
tions). Social support refers to the actual or perceived receipt
of information, materials, and/or emotional support. 
Mortality from all causes, including ischemic heart disease,
is lower in socially integrated individuals (1357). Recurrent
cardiac events are also significantly lower among persons
reporting high levels of social integration than among social-
ly isolated persons (1358,1359). When social support was
clearly defined and measured and the effect of depression
was controlled for, a large prospective trial (1360) demon-
strated that support did not directly predict post-MI mortali-
ty. However, high levels of support mitigated the effect of
depression on post-MI mortality. A randomized controlled
trial of a social support and depression management inter-
vention similarly did not demonstrate reduced mortality
(1355) but did significantly reduce social isolation.
The most effective social support interventions occur natu-
rally. The quality of the support provided is key; support has
been shown to facilitate treatment compliance, but only when
policing is minimized (1362). Overprotectiveness and with-
holding of information or worries, either of the patient by
family members or vice versa, is associated with worse out-
comes (1363,1364). Telephone follow-up, cardiac rehabilita-
tion, or other group events can be effective methods of sup-
port for socially isolated individuals (1365). 
Anxiety is prevalent among hospitalized patients with
STEMI but declines relatively rapidly after discharge to lev-
els typical of the general medical population (1366). Anxiety
is predictive of in-hospital recurrent ischemia and arrhyth-
mias after MI (707), and physicians’ and nurses’ subjective
judgments of patient anxiety are not accurate compared with
measurement on validated scales (709). At least one random-
ized controlled trial demonstrates that in-hospital anxiety and
depression can be reduced by a structured nursing support
intervention (714), and secondary analysis of a longer-term
trial suggests that both long-term psychosocial distress and
health outcomes may benefit (1367). Anxiety should be
assessed at the time of hospital discharge of patients hospi-
talized for STEMI. A number of studies have examined psy-
chological intervention programs designed to help post-MI
patients’ psychosocial and emotional adjustment. Two large
post-MI programs (1341,1368) failed to achieve positive
outcomes on psychological factors or prognosis. Some have
observed that the type of approach used with patients recov-
ering from MI varies in terms of its association with anxiety
reduction (1367,1369). Nevertheless, one meta-analysis
reported that the addition of psychosocial interventions to
standard treatment resulted in significantly less depression,
Class IIa
Treatment with cognitive-behavioral therapy and
selective serotonin reuptake inhibitors can be useful
for STEMI patients with depression that occurs in the
year after hospital discharge. (Level of Evidence: A)
Depression is a common consequence of STEMI, with
major depression occurring in 15% to 20% of patients with
STEMI and some degree of clinically significant depression
occurring in up to half (1339). Most studies have found
depression to be a significant independent predictor of post-
MI mortality (1340-1345), although others have not
(1346,1347). An ancillary follow-up study from the
ENRICHD trial (Enhancing Recovery in Coronary Heart
Disease) of a subsample of 358 depressed patients with an
acute MI compared with 408 nondepressed patients found
that the depressed patients were at higher risk for all-cause
mortality but not until nearly 12 months after the acute event.
Depression did not predict nonfatal recurrent infarction
(1348). The excess risk associated with depression soon after
STEMI remains significant for a longer time than previously
thought, and a dose-response relationship exists between
depression and mortality. The level of depression symptoms
at the time of STEMI admission is more closely linked to
long-term (5-year) survival than the level at 1 year, notably
so in patients with moderate to severe levels of depression.
Even minimal degrees of depression appear to confer risk,
and risk increases with degree of depression as measured on
the Beck Depression Inventory (1340). Depression markedly
decreases quality of life for post-STEMI patients
(1339,1346,1347,1349,1350) and is associated with substan-
tially greater costs (1341). Fatigue does not explain the
impact of STEMI in producing depression (1343), nor do
infarct size, LV function, or other physiological variables
predict the degree of depression (1345,1339). Depression
rather than physiological variables predicts failure to return
to usual activity and failure of social role resumption after
MI (1351). Depressed patients are less likely to complete
cardiac rehabilitation and less likely to adhere to important
lifestyle changes and medications. (1352,1353).
Treatment of depression with combined cognitive-behav-
ioral therapy and selective serotonin reuptake inhibitors
improves outcome in terms of depression symptoms and
social function (1350,1354,1355). A double-blind study
comparing sertraline and placebo found that sertraline was
associated with clinically meaningful improvement in multi-
ple quality-of-life domains in patients hospitalized with
acute coronary syndrome (74% of which was acute MI) in
the previous month who had recurrent depression (1350).
Although one randomized controlled trial showed no reduc-
tion in mortality or reinfarction (1355), a reanalysis suggest-
ed its follow-up was not long enough to demonstrate effect,
and indeed, depression was associated with mortality in that
study (1348). Therefore, it appears prudent to assess patients
with STEMI for depression during hospitalization and during
the first month after STEMI and to intervene and reassess
yearly in the first 5 years, as appropriate. There is evidence
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anxiety, morbidity, and mortality (1370). Psychosocial inter-
ventions in cardiac rehabilitation were found in another
review to improve the odds for mortality and recurrence of
nonfatal MI, but not necessarily with regard to females and
older participants (1369). A secondary analysis of a longer-
term trial suggests that both long-term psychosocial progno-
sis and health outcomes may improve in patients whose psy-
chological status improves (1367).
8.2. Cardiac Rehabilitation
Class I
Cardiac rehabilitation/secondary prevention pro-
grams, when available, are recommended for patients
with STEMI, particularly those with multiple modifi-
able risk factors and/or those moderate- to high-risk
patients in whom supervised exercise training is war-
ranted. (Level of Evidence: C)
Cardiac rehabilitation programs are designed to limit the
physiological and psychological effects of cardiac illness,
reduce the risk for sudden death or reinfarction, control car-
diac symptoms, stabilize or reverse the atherosclerotic
process, and enhance the psychosocial and vocational status
of selected patients (1184,1371,1372). Cardiac rehabilitation
is a comprehensive long-term program that involves medical
evaluation, prescribed exercise, cardiac risk factor modifica-
tion, education, and counseling (1184,1373). Cardiac reha-
bilitation can occur in a variety of settings, including super-
vised groups in a hospital, physician’s office, or community
facility. In clinically stable lower-risk patients, rehabilitation
can be undertaken independently, with regular guidance from
a cardiac rehabilitation healthcare professional (1184). The
exercise can be supervised or unsupervised and can involve a
stationary bicycle, treadmill, calisthenics, walking, or jog-
ging. Home exercise training programs have been shown to
be beneficial in certain low-risk patient groups. They offer
the advantages of convenience and low cost but lack the valu-
able elements of education and group interaction (1374).
The pooled effect estimate for total mortality for the exer-
cise-only intervention demonstrated a reduction in all-cause
mortality (random effects model OR 0.73 [0.54, 0.98]) com-
pared with usual care. Comprehensive cardiac rehabilitation
reduced all-cause mortality but to a lesser degree (OR 0.87
[0.71, 1.05]). Neither of the interventions had any effect on
the occurrence of nonfatal MI. The authors concluded that
exercise-based cardiac rehabilitation appeared to be effective
in reducing cardiac deaths but that it was still unclear
whether an exercise-only or a comprehensive cardiac reha-
bilitation intervention was more beneficial. The population
studied was predominantly male, middle-aged, and low risk.
The authors suggested that those who may have benefited
from the intervention were excluded owing to age, gender, or
comorbidity. The authors cautioned that the results were of
limited reliability because the quality of reporting in the
studies was generally poor, and there were high losses to fol-
low-up (1373). 
Cardiac rehabilitation comprising exercise training and
education, counseling, and behavioral interventions yielded
improvements in exercise tolerance with no significant car-
diovascular complications, improvements in symptoms
(decreased anginal pain and improved symptoms of heart
failure such as shortness of breath and fatigue), and improve-
ments in blood lipid levels; reduced cigarette smoking in
conjunction with a smoking cessation program; decreased
stress; and improved psychosocial well-being (1184). In
addition to reductions in total cholesterol and LDL-C,
increases in HDL levels have been reported (1197). 
Existing community studies reveal that fewer than one third
of patients with STEMI receive information or counseling
about cardiac rehabilitation before being discharged from the
hospital (1184,1375). Only 16% of patients in a study of 5
hospitals in 2 Michigan communities were referred to a car-
diac rehabilitation program at discharge, and only 26% of the
patients later interviewed in the community reported actual
participation in such a program. However, 54% of the
patients referred at discharge did participate at the time of
their follow-up interview (1375). Physician referral (to a car-
diologist/cardiac surgeon) was the most powerful predictor
of patient participation in a cardiac rehabilitation program. 
In a longitudinal study of the use of inpatient cardiac reha-
bilitation in 5204 Worcester, MA, residents hospitalized with
MI in 7 1-year periods between 1986 and 1997, patients not
referred to inpatient cardiac rehabilitation were less likely to
be prescribed effective cardiac medications and to undergo
risk factor modification counseling before discharge (1376).
Patient reasons for nonparticipation and noncompliance
include affordability of service, possible insurance coverage,
social support from a spouse or other caregiver, gender-spe-
cific attitudes, patient-specific internal factors such as anxi-
ety or poor motivation, and logistical and financial con-
straints, or a combination of these factors (1375,1377).
Women and the elderly have been reported to be referred less
frequently to cardiac rehabilitation programs, even though
they have been reported to derive benefit (1378-1380).
8.3. Follow-Up Visit With Medical Provider
Class I
1. A follow-up visit should delineate the presence or
absence of cardiovascular symptoms and functional
class. (Level of Evidence: C)
2. The patients’ list of current medications should be re-
evaluated in a follow-up visit, and appropriate titra-
tion of ACE inhibitors, beta-blockers, and statins
should be undertaken. (Level of Evidence: C)
3. The predischarge risk assessment and planned
workup should be reviewed and continued (Figure
36). This should include a check of LV function and
possibly Holter monitoring for those patients whose
early post-STEMI ejection fraction was 0.31 to 0.40 or
lower, in consideration of possible ICD use (Figure
32). (Level of Evidence: C)
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of return to work was not reported, but no adverse events
occurred as a result of this strategy (1384).
Disability. There is some evidence that a cardiac rehabilita-
tion program after STEMI contributes to reduction of mor-
tality and improved physical and emotional well-being (see
Section 8.2). Patients whose expectations for return to work
were addressed in rehabilitation returned to work at a signif-
icantly faster rate than the control group in a prospective
study (1385).
A low level of depressive symptoms before STEMI
increases the odds of recovery of functional status (1386).
Patients with high pre-STEMI functional independence
measurement have shorter length of stay and greater likeli-
hood of discharge to home (1387). Pre-STEMI peak aerobic
capacity and depression score are the best independent pre-
dictors of post-STEMI physical function. Women tend to
have lower physical function scores than men of similar age,
depression score, and comorbidity. Resting LVEF is not a
predictor of physical function score.
Patients’ cardiac functional states are not a strong predictor
of their probability of returning to work. Diabetes, older age,
Q-wave MI, and preinfarction angina are associated with
failure to resume full employment (1388). However, psycho-
logical variables such as trust, job security, patient feelings
about disability, expectations of recovery by both physician
and patient, and degree of somatizing are more predictive
(1389,1390). Physical requirements of the job play a role as
well (1388,1390).
To aid occupational physicians in making return-to-work
decisions, Froom et al. (1388) studied the incidence of post-
MI events at 1, 2, 4, 6, 9, and 12 months. The events includ-
ed cardiac death, recurrent infarction, CHF, and unstable
angina. They found that the incidence of events reached a
low steady state at 10 weeks.
Return to work can be determined by employer regulations
rather than by the patient’s medical condition. It behooves
the physician to provide data to prove that the patient’s job
does not impose a prohibitive risk for a cardiac event. An
example is the case of the Canadian bus drivers reported by
Kavanagh et al. (1391). The patients were evaluated with a
stress test. The physician and technologist studied the drivers
at work and showed that the cardiac stress values during driv-
ing were only half of the average values obtained in the stress
laboratory. The calculated risk of sudden cardiovascular inci-
dence causing injury or death to passengers, other road users,
and the drivers in the first year after recovery from an MI was
1 in 50 000 driving years. The bus drivers were allowed to
return to work after they satisfied the Canadian
Cardiovascular Society guidelines.
Women have entered the job market and are faced not only
with the gender difference but in procedure difference and
mortality. Covinsky et al. (1392) performed a mail survey
study of patients with MIs. Three months after discharge,
women reported worse physical and mental health and were
more likely to work less than before the MI. Similarly,
women were less likely to return to work than men.
4. The healthcare provider should review and emphasize
the principles of secondary prevention with the
patient and family members (Table 32) (68). (Level of
Evidence: C)
5. The psychosocial status of the patient should be eval-
uated in follow-up, including inquiries regarding
symptoms of depression, anxiety, or sleep disorders
and the social support environment. (Level of
Evidence: C)
6. In a follow-up visit, the healthcare provider should
discuss in detail issues of physical activity, return to
work, resumption of sexual activity, and travel,
including driving and flying. The MET values for var-
ious activities are provided as a resource (Table 34).
(Level of Evidence: C)
7. Patients and their families should be asked if they are
interested in CPR training after the patient is dis-
charged from the hospital. (Level of Evidence: C)
8. Providers should actively review the following issues
with patients and their families:
a. The patient’s heart attack risk. (Level of Evidence: C)
b. How to recognize symptoms of STEMI. (Level of
Evidence: C)
c. The advisability of calling 9-1-1 if symptoms are
unimproved or worsening after 5 minutes, despite
feelings of uncertainty about the symptoms and
fear of potential embarrassment. (Level of
Evidence: C)
d. A plan for appropriate recognition and response to
a potential acute cardiac event, including the phone
number to access EMS, generally 9-1-1. (Level of
Evidence: C)
9. It is reasonable that patients be referred to a struc-
tured cardiac rehabilitation program after hospital
discharge. (Level of Evidence: C)
A caring and supportive doctor-patient relationship is vital
to the well-being of the survivor and their families. It is com-
mon practice to see these patients 3 to 6 weeks after hospital
discharge to assess their progress. 
The physician should listen to the concerns of their patients
and their patients’ families and respond flexibly. Future
appointments should be scheduled and should reflect the
goals set for each individual patient in accordance with their
needs and current guidelines.
8.4. Return to Work and Disability
Return-to-work rates, which currently range from 63%
(1381) to 94% (1382), are difficult to influence because they
are confounded by factors such as job satisfaction, financial
stability, and company policies (1383). In PAMI-II, a study
of primary PTCA in low-risk patients with STEMI (i.e., age
less than 70 years, ejection fraction greater than 0.45, 1- or
2-vessel disease, and good PTCA result), patients were
encouraged to return to work at 2 weeks. The actual timing
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The current aggressive interventional treatment of STEMI
will have an impact on mortality, morbidity, and hospital
length of stay (696). It remains to be determined whether ear-
lier improvement in cardiac condition after STEMI will have
an effect on the rate of return to work because of the multi-
ple noncardiac factors that influence disability and return to
work.
8.5. Other Activities
In patients who desire to return to physically demanding
activities early, the safety of activity can be determined by
comparing performance on a graded exercise test with the
MET level required for the desired activity. Table 34 presents
energy levels, expressed in METs, required to perform a vari-
ety of common activities (1393). This and similar tables can
be helpful in translating a patient’s performance on a graded
exercise test into daily activities that may be undertaken with
reasonable safety. 
The physician should provide explicit advice about when to
return to previous levels of physical activity, sexual activity,
and employment. Daily walking can be encouraged immedi-
ately (1394). In stable patients without complications (class
I), sexual activity with the usual partner can be resumed
within 1 week to 10 days. Driving can begin 1 week after dis-
charge if the patient is judged to be in compliance with indi-
vidual state laws. Each state’s Department of Motor Vehicles
or its equivalent has mandated certain criteria, which vary
from state to state and must be met before operation of a
motor vehicle after serious illness (1395) These include such
caveats as the need to be accompanied and to avoid stressful
circumstances such as rush hour, inclement weather, night
driving, heavy traffic, and high speeds. For patients who have
experienced a complicated STEMI (one that required CPR or
was accompanied by hypotension, serious arrhythmias, high-
degree block, or CHF), driving should be delayed 2 to 3
weeks after symptoms have resolved. 
Most commercial aircraft are pressurized to 7500 to 8000
feet and therefore could cause hypoxia due to the reduced
alveolar oxygen tension. The maximum level of pressuriza-
tion is limited to 8000 feet (2440 meters) by Federal Aviation
Administration regulation (1396). Therefore, air travel with-
in the first 2 weeks of STEMI should be undertaken only if
there is no angina or dyspnea at rest or fear of flying. The
individual must have a companion, carry nitroglycerin, and
request airport transportation to avoid rushing (personal
communication, R.P. Gardner, PhD, November 2002). Air
travel for cardiac patients should gradually become safer.
Availability of an emergency medical kit and AED has been
mandated for April 12, 2004, (1398) in all aircraft that carry
at least approximately 30 passengers and have at least 1
flight attendant. 
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ED = emergency department
EMS = emergency medical services
EMT = emergency medical technician
EP = electrophysiology
EPHESUS = Eplerenone Post-Acute Myocardial 
Infarction Heart Failure Efficacy and
Survival Study
GIK = glucose-insulin-potassium
GISSI = Gruppo Italiano per lo Studio della 
Sopravvivenza nell’Infarto 
Miocardico 
GP = glycoprotein
GUSTO = Global Utilization of Strategies To 
Open occluded arteries
HDL-C = high-density lipoprotein cholesterol
HERO = Hirulog and Early Reperfusion or 
Occlusion trial
HERS = Heart and Estrogen/Progestin 
Replacement Study
HOPE = Heart Outcomes Prevention 
Evaluation
hsCRP = high-sensitivity C-reactive protein
IABP = intra-aortic balloon pump
ICD = implantable cardioverter defibrillator
ICH = intracranial hemorrhage
IMA = internal mammary artery
InTIME = Intravenous nPA for Treatment of 
Infarcting Myocardium Early
ISIS = International Study of Infarct 
Survival
IV = intravenous
JNC-7 = Seventh Joint National Committee on
High Blood Pressure
LAD = left anterior descending coronary 
artery
LBBB = left bundle-branch block
LDL-C = low-density lipoprotein cholesterol
LIPID = Long-Term Intervention With 
Pravastatin in Ischemic Disease
LMWH = low-molecular-weight heparin
LV = left ventricular, left ventricle
LVAD = left ventricular assist device
LVEF = left ventricular ejection fraction
MADIT = Multicenter Automatic Defibrillator 
Implantation Trial
MAGIC = Magnesium in Coronaries trial
MDPIT = Multicenter Diltiazem Postinfarction 
Trial
MET = metabolic equivalent
MI = myocardial infarction
MR = mitral regurgitation
MUSTT = Multicenter Unsustained Tachycardia
Trial
NASCET = North American Symptomatic 
Carotid Endarterectomy Trial
NCEP = National Cholesterol Education 
Program
NHAAP = National Heart Attack Alert Program
APPENDIX 3. ABBREVIATIONS
AAFP = American Academy of Family 
Physicians
ACC = American College of Cardiology
ACE = angiotensin converting enzyme
ACEP = American College of Emergency 
Physicians
ACLS = advanced cardiac life support
AED = automated external defibrillator
AF = atrial fibrillation
AFFIRM = Atrial Fibrillation Follow-up 
Investigation of Rhythm 
Management
AHA = American Heart Association
ALS = advanced life support
AMI = acute myocardial infarction
AMI-SK = Acute Myocardial Infarction-
Streptokinase
ARB = angiotensin receptor blocker
ARD = absolute risk difference
ASSENT = Assessment of the Safety and 
Efficacy of a New Thrombolytic 
Regimen
ATP III = Adult Treatment Panel III report
AV = atrioventricular
AVID = Antiarrhythmics Versus Implantable 
Defibrillators
bpm = beats per minute
CABG = coronary artery bypass graft surgery
CAPRICORN = Carvedilol Post-infarct Survival 
Controlled Evaluation
CAPRIE = Clopidogrel vs. Aspirin in Patients at 
Risk of Ischemic Events
CAPTIM = Comparison of Primary Angioplasty 
and Prehospital Thrombolysis in the 
Acute Phase of Myocardial 
Infarction
CARE = Cholesterol And Recurrent Events
CCP = Cooperative Cardiovascular Project
CCS = Canadian Cardiovascular Society
CCU = coronary care unit
CHD = coronary heart disease
CHF = congestive heart failure
CI = confidence interval
CK = creatine kinase
C-PORT = Cardiovascular Patient Outcomes 
Research Team
CPR = cardiopulmonary resuscitation
CT = computed tomography
CURE = Clopidogrel in Unstable angina to 
prevent Recurrent Events
DANAMI = DANish multicenter Trial in Acute 
Myocardial Infarction
DRS = Diltiazem Reinfarction Study
DVT = deep venous thrombosis
ECG = electrocardiogram
ECMO = extracorporeal membrane 
oxygenation
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NHLBI = National Heart, Lung, and Blood 
Institute
NRMI = National Registry of Myocardial 
Infarction
NS = not significant
NSTEMI = non–ST-elevation myocardial 
infarction
OR = odds ratio
PCI = percutaneous coronary intervention
PCWP = pulmonary capillary wedge pressure
PH = parenchymal hemorrhage
PRAGUE = PRimary Angioplasty in patients 
transferred from General community 
hospitals to specialized PTCA Units 
with or without Emergency throm-
bolysis
Primary 
care provider = physician, nurse practitioner, physi-
cian assistant
RBBB = right bundle-branch block
REACT = Rapid Early Action for Coronary 
Treatment
RR = relative risk
RRR = relative risk reduction
RV = right ventricular, right ventricle
SAVE = Survival and Ventricular Enlargement
SCD = sudden cardiac death
SHOCK = SHould we emergently revascularize 
Occluded Coronaries for cardiogenic 
shocK?
SPECT = single-photon emission computed 
tomography
STEMI = ST-elevation myocardial infarction
TEE = transesophageal echocardiography
TIA = transient ischemic attack
TIMI = thrombolysis in myocardial infarction
TIMI 0 = TIMI grade 0 flow, or no perfusion
TIMI 1 = TIMI grade 1 flow, or penetration 
without perfusion
TIMI 2 = TIMI grade 2 flow, or partial perfu-
sion
TIMI 3 = TIMI grade 3 flow, or complete per-
fusion
TLC = Therapeutic Lifestyle Changes
tPA = tissue plasminogen activator
TRACE = Trandolapril Cardiac Evaluation
UA = unstable angina
UFH = unfractionated heparin
VALIANT = Valsartan in Acute Myocardial 
Infarction Trial
VF = ventricular fibrillation
VSR = ventricular septal rupture
VT = ventricular tachycardia
WARIS = Warfarin-Aspirin Reinfarction Study
WHI = Women’s Health Initiative
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